<SEC-DOCUMENT>0001193125-22-260149.txt : 20221011
<SEC-HEADER>0001193125-22-260149.hdr.sgml : 20221011
<ACCEPTANCE-DATETIME>20221011062904
ACCESSION NUMBER:		0001193125-22-260149
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20221010
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221011
DATE AS OF CHANGE:		20221011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Orthofix Medical Inc.
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		221302186

	BUSINESS ADDRESS:	
		STREET 1:		3451 PLANO PARKWAY
		CITY:			LEWISVILLE
		STATE:			TX
		ZIP:			75056
		BUSINESS PHONE:		214-937-2000

	MAIL ADDRESS:	
		STREET 1:		3451 PLANO PARKWAY
		CITY:			LEWISVILLE
		STATE:			TX
		ZIP:			75056

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHOFIX INTERNATIONAL N V
		DATE OF NAME CHANGE:	19970708
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d345457d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ofix="http://www.orthofix.com/20221010" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-10-10_to_2022-10-10">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-10-10_to_2022-10-10">0000884624</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CurrentFiscalYearEndDate_duration_2022-10-10_to_2022-10-10" name="dei:CurrentFiscalYearEndDate" contextRef="duration_2022-10-10_to_2022-10-10">--12-31</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ofix-20221010.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-10-10_to_2022-10-10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000884624</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-10</xbrli:startDate> <xbrli:endDate>2022-10-10</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-10-10_to_2022-10-10">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of Earliest Event Reported): October&#160;11, 2022 (<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt:datemonthdayyearen">October 10, 2022</ix:nonNumeric>)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-10-10_to_2022-10-10">ORTHOFIX MEDICAL INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-10-10_to_2022-10-10">0-19961</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-10-10_to_2022-10-10">98-1340767</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation or organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-10-10_to_2022-10-10">3451 Plano Parkway</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-10-10_to_2022-10-10">Lewisville</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-10-10_to_2022-10-10">75056</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-10-10_to_2022-10-10">(214)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-10-10_to_2022-10-10">937-2000</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-10-10_to_2022-10-10">Common stock, $0.10 par value per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-10-10_to_2022-10-10">OFIX</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt-sec:exchnameen">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-10-10_to_2022-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Agreement and Plan of Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;10, 2022, Orthofix Medical Inc., a Delaware corporation (&#8220;Orthofix&#8221;) and Orca Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Orthofix (&#8220;Merger Sub&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with SeaSpine Holdings Corporation, a Delaware corporation (&#8220;SeaSpine&#8221;). The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into SeaSpine (the &#8220;Merger&#8221;), with SeaSpine continuing as the surviving company and a wholly-owned subsidiary of Orthofix following the transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, at the effective time and as a result of the Merger, each share of common stock of SeaSpine issued and outstanding immediately prior to the effective time of the Merger will be converted into the right to receive 0.4163 shares of common stock of Orthofix. In addition, at the effective time and as a result of the Merger, Orthofix will assume SeaSpine&#8217;s existing equity incentive plans in connection with the Merger, and outstanding SeaSpine equity awards will be automatically converted into Orthofix equity awards (on the same vesting schedule and other terms and conditions as existed prior to such conversion). The conversion of such equity awards will occur at the same exchange ratio as applies to SeaSpine common stock in the Merger, and the exercise price of converted SeaSpine stock options will also be correspondingly adjusted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Merger, Orthofix stockholders will own approximately 56.5% of the combined company on a fully diluted basis and SeaSpine stockholders will own approximately 43.5%. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, the board of directors of the combined company will consist of nine individuals, including five individuals who are nominees of the board of directors of Orthofix immediately prior to the effective time and four individuals who are nominees of the board of directors of SeaSpine immediately prior to the effective time. The Merger Agreement contemplates that Jon Serbousek will serve as Executive Chairman of the Board, and Keith Valentine will serve as President and Chief Executive Officer and as a member of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orthofix has agreed to take action necessary to list the Orthofix shares of common stock to be issued in connection with the Merger on the NASDAQ Global Select Market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each party&#8217;s obligation to implement the Merger is subject to certain customary conditions, including (i)&#160;the approval by Orthofix stockholders of the issuance of shares of Orthofix common stock in connection with the Merger; (ii)&#160;the adoption of the Merger Agreement by SeaSpine stockholders holding a majority of the outstanding shares of SeaSpine&#8217;s common stock; (iii)&#160;all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 having expired or been terminated and all mandatory waiting periods or required consents under any other applicable antitrust or competition laws having expired or been obtained; (iv)&#160;no law having been enacted or order issued that remains in effect and has the effect of enjoining or otherwise prohibiting the consummation of the Merger; (v)&#160;the truth and accuracy of the other party&#8217;s representations and warranties in the Merger Agreement, generally subject to a Material Adverse Effect (as defined in the Merger Agreement) standard; (vi)&#160;no Material Adverse Effect of the other party having occurred since the date of the Merger Agreement; and (vii)&#160;the performance in all material respects by the other party of all of its covenants and agreements under the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Orthofix and SeaSpine have made customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants that (i)&#160;each party will conduct its business in all material respects in the ordinary course consistent with past practice during the interim period between the execution of the Merger Agreement and the consummation of the Merger; (ii)&#160;each party will not engage in certain kinds of transactions or take certain actions during such period; (iii)&#160;each party will convene and hold a meeting of its stockholders for the purpose of considering the adoption of the Merger Agreement, in the case of SeaSpine, and for the purpose of approving the issuance of shares of Orthofix common stock in connection with the Merger, in the case of Orthofix; and (iv)&#160;the respective boards of directors will recommend, subject to certain exceptions, that, its stockholders adopt the Merger Agreement, in the case of SeaSpine, and its stockholders approve the issuance of shares of Orthofix common stock in connection with the Merger, in the case of Orthofix. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each party also has agreed not to (i)&#160;take certain actions to solicit proposals relating to alternative business combination transactions or (ii)&#160;subject to certain exceptions, including the receipt of a Superior Proposal (as such term is defined in the Merger Agreement), enter into discussions or an agreement concerning, or provide confidential information in connection with, any proposals for alternative business combination transactions. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement may be terminated by mutual written consent of Orthofix and SeaSpine. The Merger Agreement also contains certain termination rights, including, among others, the right of either party to terminate if (i)&#160;the Merger shall not have become effective by the date that is five (5)&#160;months following the date of the Merger Agreement (the &#8220;Termination Date&#8221;), subject to certain conditions, provided that the Termination Date may be extended by either party to the date that is eight (8)&#160;months following the date of the Merger Agreement if all conditions to consummate the Merger have been satisfied other than the condition requiring antitrust approvals are not received by the initial Termination Date; (ii)&#160;the Orthofix and/or SeaSpine stockholder approvals are not obtained; (iii)&#160;the other party breaches its representations and covenants and such breach would result in the closing conditions not being satisfied; or (iv)&#160;a governmental body shall have issued any final and <span style="white-space:nowrap">non-appealable</span> order or any applicable law shall have been enacted that has the effect of enjoining or otherwise prohibiting the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that Orthofix must pay SeaSpine a termination fee of $13,744,149 plus expenses not to exceed $2&#160;million if the Merger Agreement is terminated because (a)&#160;the Orthofix board of directors or committee thereof (i)&#160;makes an Orthofix Adverse Recommendation Change (as defined in the Merger Agreement), (ii)&#160;does not include its recommendation in the Joint Proxy Statement (as defined in the Merger Agreement), or (iii)&#160;publicly proposes to take any actions in clauses (i)&#160;and (ii); (b)&#160;Orthofix materially breaches the <span style="white-space:nowrap">non-solicitation</span> provisions of the Merger Agreement; or (c)&#160;Orthofix enters into a definitive agreement with respect to a Superior Proposal (as defined in the Merger Agreement) prior to obtaining the requisite Orthofix stockholder approval, and while in compliance with the <span style="white-space:nowrap">non-solicitation</span> provisions of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides that SeaSpine must pay Orthofix a termination fee of $10,582,995 plus expenses not to exceed $2&#160;million if the Merger Agreement is terminated because (a)&#160;the SeaSpine board of directors or committee thereof (i)&#160;makes a SeaSpine Adverse Recommendation Change (as defined in the Merger Agreement), (ii)&#160;does not include its recommendation in the Joint Proxy Statement (as defined in the Merger Agreement), or (iii)&#160;publicly proposes to take any actions in clauses (i)&#160;and (ii), (b)&#160;SeaSpine materially breaches the <span style="white-space:nowrap">non-solicitation</span> provisions of the Merger Agreement, or (c)&#160;SeaSpine enters into a definitive agreement with respect to a Superior Proposal (as defined in the Merger Agreement) prior to obtaining the requisite SeaSpine stockholder approval, and while in compliance with the <span style="white-space:nowrap">non-solicitation</span> provisions of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary of the principal terms of the Merger Agreement and the copy of the Merger Agreement filed as an exhibit to this report are intended to provide information regarding the terms of the Merger Agreement and are not intended to modify or supplement any factual disclosures about Orthofix in its public reports filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;). In particular, the Merger Agreement and related summary are not intended to be, and should not be relied upon as, disclosures regarding any facts and circumstances relating to Orthofix. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement includes customary representations, warranties and covenants of Orthofix, Merger Sub and SeaSpine made solely for the benefit of the parties to the Merger Agreement. The assertions embodied in those representations and warranties were made solely for purposes of the contract among Orthofix, Merger Sub and SeaSpine and may be subject to important qualifications and limitations agreed to by Orthofix, Merger Sub and SeaSpine in connection with the negotiated terms. Moreover, some of those representations and warranties may not be accurate or complete as of any specified date, may be subject to a contractual standard of materiality different from those generally applicable to Orthofix&#8217;s SEC filings or may have been used for purposes of allocating risk among Orthofix, Merger Sub and SeaSpine rather than establishing matters as facts. Investors are not third-party beneficiaries under the Merger Agreement and should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts of Orthofix, Merger Sub and SeaSpine or any of the respective subsidiaries or affiliates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is filed as Exhibit 2.1 hereto and incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.03</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;10, 2022, the Board of Directors of Orthofix approved an amendment and restatement (the &#8220;Amendment and Restatement&#8221;) of the Bylaws of Orthofix (the &#8220;Bylaws&#8221;), which became effective immediately. Among other things, the Amendment and Restatement: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provides that, unless the Company consents in writing to the selection of an alternative forum, the exclusive forum for legal actions arising under the Securities Act of 1933 will be federal court; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provides that if any action that is the subject of the forum provision in Section&#160;10 of the Bylaws is filed in a court other than the courts in the State of Delaware, the stockholder filing the suit will be deemed to have consented to the personal jurisdiction of state and federal courts in the State of Delaware in connection with any action brought to enforce the forum provision; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">confirms that the forum provision in Section&#160;10 of the Bylaws will not apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934 or any claim for which the federal courts of the United States have exclusive jurisdiction. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Amendment and Restatement is not complete and is qualified in its entirety by reference to the text of the Amendment and Restatement, marked to show the October&#160;10, 2022 changes, a copy of which is filed as Exhibit 3.1 hereto and the terms of which are incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;11, 2022, Orthofix and SeaSpine issued a joint press release announcing the execution of the Merger Agreement, a copy of which is filed as Exhibit 99.1 hereto and incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report contains statements which, to the extent they are not statements of historical or present fact, constitute &#8220;forward-looking statements&#8221; under the securities laws. From time to time, oral or written forward-looking statements may also be included in other information released to the public. These forward-looking statements are intended to provide Orthofix&#8217;s and SeaSpine&#8217;s respective management&#8217;s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. Forward-looking statements can be identified by the use of words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;expectations,&#8221; &#8220;plans,&#8221; &#8220;strategy,&#8221; &#8220;prospects,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;anticipate,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;see,&#8221; &#8220;guidance,&#8221; &#8220;outlook,&#8221; &#8220;confident,&#8221; &#8220;on track&#8221; and other words of similar meaning. Forward-looking statements may include, among other things, statements relating to future sales, earnings, cash flow, results of operations, uses of cash, tax rates, R&amp;D spend, other measures of financial performance, potential future plans, strategies or transactions, credit ratings and net indebtedness, other anticipated benefits of the proposed merger, including estimated synergies and cost savings resulting from the proposed merger, the expected timing of completion of the proposed merger, estimated costs associated with such transaction and other statements that are not historical facts. All forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Such risks, uncertainties and other factors include, without limitation: (1)&#160;the effect of economic conditions in the industries and markets in which Orthofix and SeaSpine operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, and the levels of market demand in the health care segments in which our products are purchased and utilized; (2)&#160;challenges in the development, regulatory approval, commercialization, reimbursement, market acceptance, performance and realization of the anticipated benefits of new products of the combined company; (3)&#160;the scope, nature, impact or timing of the proposed merger, including among other things the integration of the businesses and realization of synergies and opportunities for growth and innovation and incurrence of related costs and expenses; (4)&#160;future levels of indebtedness, capital spending and research and development spending; (5)&#160;future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6)&#160;delays and disruption in delivery of materials and services from suppliers; (7)&#160;cost reduction efforts and restructuring costs and savings; (8)&#160;new business and investment opportunities; (9)&#160;the ability to realize the intended benefits of organizational changes; (10)&#160;the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (11)&#160;the effect of changes in political conditions in the U.S. and other countries </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in which Orthofix, SeaSpine and the businesses of each operate, including the effect of changes in U.S. healthcare policies, on general market conditions in the near term and beyond; (12)&#160;the effect of changes in tax, regulatory and other laws and regulations in the U.S. and other countries in which Orthofix, SeaSpine and the businesses of each operate; (13)&#160;negative effects of the announcement or pendency of the proposed merger on the market price of Orthofix and/or SeaSpine&#8217;s respective common stock and/or on their respective financial performance; (14)&#160;the ability of the parties to receive the required regulatory approvals for the proposed merger (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction) and approvals of Orthofix&#8217;s and SeaSpine&#8217;s shareholders and to satisfy the other conditions to the closing of the merger on a timely basis or at all; (15)&#160;the occurrence of events that may give rise to a right of one or both of the parties to terminate the merger agreement; (16)&#160;risks relating to the value of the Orthofix shares to be issued in the proposed merger, significant transaction costs and/or unknown liabilities; (17)&#160;the possibility that the anticipated benefits from the proposed merger cannot be realized in full or at all or may take longer to realize than expected, including risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction; (18)&#160;risks associated with transaction-related litigation; (19)&#160;the possibility that costs or difficulties related to the integration of Orthofix&#8217;s and SeaSpine&#8217;s operations will be greater than expected; (20)&#160;the ability of the combined company to retain and hire key personnel; (21)&#160;the intended qualification of the merger as a <span style="white-space:nowrap">tax-free</span> reorganization to Orthofix and SeaSpine shareholders for U.S. federal income tax purposes; and (22)&#160;the impact of the proposed merger on the respective businesses of Orthofix and SeaSpine. There can be no assurance that the proposed merger will in fact be consummated in the manner described or at all. For additional information on identifying factors that may cause actual results to vary materially from those stated in forward-looking statements, see the reports of Orthofix and SeaSpine on Forms <span style="white-space:nowrap">10-K,</span> <span style="white-space:nowrap">10-Q</span> and <span style="white-space:nowrap">8-K</span> filed with or furnished to the SEC from time to time. Any forward-looking statement speaks only as of the date on which it is made, and Orthofix and SeaSpine assume no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Important Additional Information and Where to Find It </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction, Orthofix intends to file with the SEC a registration statement on Form <span style="white-space:nowrap">S-4,</span> which will include a document that serves as a prospectus of Orthofix and a joint proxy statement of Orthofix and SeaSpine (the &#8220;joint proxy statement/prospectus&#8221;). Each party also plans to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. A definitive joint proxy statement/prospectus will be sent to Orthofix&#8217;s shareholders and SeaSpine&#8217;s shareholders. Investors and securityholders may obtain a free copy of the joint proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by Orthofix and SeaSpine with the SEC at the SEC&#8217;s website at www.sec.gov. Copies of the documents filed by Orthofix with the SEC will be available free of charge on Orthofix&#8217;s website at http://ir.orthofix.com/ or by contacting Orthofix&#8217;s Investor Relations at (214) <span style="white-space:nowrap">937-3190.</span> Copies of the documents filed by SeaSpine with the SEC will be available free of charge on SeaSpine&#8217;s website at http://investor.seaspine.com/ or by contacting SeaSpine&#8217;s Investor Relations at (415) <span style="white-space:nowrap">937-5402.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orthofix and SeaSpine and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about directors and executive officers of Orthofix is available in the Orthofix proxy statement for its 2022 Annual Meeting, which was filed with the SEC on April&#160;27, 2022. Information about directors and executive officers of SeaSpine is available in the SeaSpine proxy statement for its 2022 Annual Meeting, which was filed with the SEC on April&#160;22, 2022. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. Investors may obtain free copies of these documents from Orthofix and SeaSpine as indicated above. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Offer or Solicitation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section&#160;10 of the Securities Act of 1933, as amended. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d345457dex21.htm">Agreement and Plan of Merger, dated as of October&#160;10, 2022, by and among Orthofix Medical Inc., Orca Merger Sub Inc. and SeaSpine Holdings Corporation* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d345457dex31.htm">Amended and Restated Bylaws of Orthofix Medical Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d345457dex991.htm">Joint Press Release of Orthofix Medical Inc. and SeaSpine Holdings Corporation, dated October&#160;11, 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The schedules to the Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(b)(2) of Regulation <span style="white-space:nowrap">S-K.</span> Orthofix will furnish copies of any such schedules to the SEC upon request. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October&#160;11, 2022 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:79%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="5"><span style="font-weight:bold">ORTHOFIX MEDICAL INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kimberley A. Elting</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Kimberley A. Elting</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President of Global Orthopedics; <br />Chief Legal and Development Officer</td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d345457dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and among </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORTHOFIX
MEDICAL INC., </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORCA MERGER SUB INC., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEASPINE HOLDINGS
CORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated October&nbsp;10, 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 1 DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Definitional Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 2 THE MERGER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Shares of Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.04</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.05</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effects of the Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Incorporation and Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.07</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Directors and Officers of the Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treatment of SeaSpine Shares, SeaSpine Equity Awards and Merger Sub Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing of SeaSpine Transfer Books</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exchange Fund; Exchange of Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interest; No Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Adjustments to Prevent Dilution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Corporate Governance Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF SEASPINE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Corporate Power</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorization; Valid and Binding Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capital Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.04</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.05</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Breach</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents, etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.07</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Reports; Disclosure Controls and Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Certain Developments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title to Properties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Contracts and Commitments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Data Privacy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Law; Permits; Anti-Corruption Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Compliance and Conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employment and Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FDA and Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokerage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.23</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Board Approval; Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.25</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Opinion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.26</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF ORTHOFIX AND MERGER SUB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Corporate Power</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorization; Valid and Binding Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capital Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.04</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.05</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Breach</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents, etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.07</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Reports; Disclosure Controls and Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Certain Developments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title to Properties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Contracts and Commitments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Data Privacy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Law; Permits; Anti-Corruption Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Compliance and Conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employment and Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FDA and Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokerage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.23</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Board Approval; Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.25</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Opinion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.26</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.27</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 5 COVENANTS RELATING TO CONDUCT OF BUSINESS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Covenants of SeaSpine</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Covenants of Orthofix</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 6 ADDITIONAL COVENANTS OF THE PARTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Investigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registration Statement and Proxy Statement for Shareholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Shareholders&#146; Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.04</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Non-Solicitation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.05</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Approvals; Additional Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination of SeaSpine ESPP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.07</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee and Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification of Officers and Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Public Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NASDAQ Listing of Additional Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Takeover Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Control of Other Party&#146;s Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Filing of Form S-8; Listing of Additional Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Loan Payoff</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SeaSpine Exchangeable Shares Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 7 CONDITIONS TO CLOSING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to All Parties&#146; Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Orthofix&#146;s and Merger Sub&#146;s Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to SeaSpine&#146;s Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 8 TERMINATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 9 MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.03</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.04</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Survival of Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.05</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.06</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Applicable Law; Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.07</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Jury Trial</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.08</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.09</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Specific Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 2.07 &#150; Directors and Officers of the Surviving Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 2.15 &#150; Corporate Governance Matters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule
6.05(a) &#150; Additional Antitrust Approvals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This AGREEMENT AND PLAN OF MERGER (this &#147;<U>Agreement</U>&#148;) is dated October&nbsp;10, 2022, by and among Orthofix Medical Inc., a
Delaware corporation (&#147;<U>Orthofix</U>&#148;), Orca Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Orthofix (&#147;<U>Merger Sub</U>&#148;), and SeaSpine Holdings Corporation, a Delaware corporation
(&#147;<U>SeaSpine</U>&#148;). Capitalized terms used and not otherwise defined herein have the meanings set forth in <U>ARTICLE 1</U> below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Orthofix Board and SeaSpine Board have deemed it advisable and in the best interests of their respective corporations and
stockholders that Orthofix and SeaSpine engage in the transactions contemplated by this Agreement, subject to the terms and conditions set forth herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Orthofix Board has unanimously: (a)&nbsp;approved and declared advisable this Agreement and the transactions contemplated by this
Agreement, including the Merger and the Orthofix Share Issuance, on the terms and subject to the conditions set forth in this Agreement; (b)&nbsp;determined that this Agreement and the transactions contemplated by this Agreement, including the
Merger and the Orthofix Share Issuance, are fair to, and in the best interests of, Orthofix and the Orthofix Stockholders; (c)&nbsp;resolved to recommend the approval of the Orthofix Share Issuance to the Orthofix Stockholders, on the terms and
subject to the conditions set forth in this Agreement (the &#147;<U>Orthofix Recommendation</U>&#148;); and (d)&nbsp;directed that the Orthofix Share Issuance be submitted to the Orthofix Stockholders for approval; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the SeaSpine Board has unanimously: (a)&nbsp;approved and declared advisable this Agreement and the transactions contemplated by this
Agreement, including the Merger, on the terms and subject to the conditions set forth in this Agreement; (b)&nbsp;determined that this Agreement and the transactions contemplated by this Agreement, including the Merger, are fair to, and in the best
interests of, SeaSpine and the SeaSpine Stockholders; (c)&nbsp;resolved to recommend the adoption of this Agreement to the SeaSpine Stockholders, on the terms and subject to the conditions set forth in this Agreement (the &#147;<U>SeaSpine
Recommendation</U>&#148;); and (d)&nbsp;directed that this Agreement be submitted to the SeaSpine Stockholders for adoption; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Merger Sub Board has unanimously: (a)&nbsp;approved and declared advisable this Agreement and the transactions contemplated by this Agreement, including the Merger, on the terms and subject to the conditions set forth in this Agreement;
(b)&nbsp;determined that this Agreement and the transactions contemplated by this Agreement, including the Merger, are fair to, and in the best interests of, Merger Sub and the sole stockholder of Merger Sub; (c)&nbsp;resolved to recommend the
adoption of this Agreement to the sole stockholder of Merger Sub, on the terms and subject to the conditions set forth in this Agreement; and (d)&nbsp;directed that this Agreement be submitted to the sole stockholder of Merger Sub for adoption; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, each of the parties intends that, for U.S. federal income tax purposes, this Agreement will constitute, and is hereby adopted
as, a &#147;plan of reorganization&#148; within the meaning of Section&nbsp;368 of the Code and the Treasury Regulations promulgated thereunder and the Merger will constitute a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of
the Code. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises, representations and warranties and mutual
covenants contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DEFINITIONS
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes hereof, the following terms, when used herein with initial capital
letters, shall have the respective meanings set forth herein: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acceptable Confidentiality Agreement</U>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;6.04(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>AcquireCo</U>&#148; means 7D Surgical ULC, a company amalgamated under the
laws of British Columbia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>AcquireCo Articles</U>&#148; means AcquireCo&#146;s Articles, as amended (including the Special Rights
and Restrictions set out in Schedule 1 thereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquisition Proposal</U>&#148; shall mean any <I>bona fide</I> proposal, offer
or inquiry, whether or not in writing, for any transaction or series of transactions (other than the transactions contemplated by this Agreement) involving the: (a)&nbsp;direct or indirect acquisition, exclusive license or purchase of a business or
assets that constitutes twenty percent (20%)&nbsp;or more of the consolidated net revenues, net income or the assets (based on the fair market value thereof) of such party and its Subsidiaries, taken as a whole, by any Person or group of Persons
(other than a party hereto or any of its Affiliates); (b)&nbsp;direct or indirect acquisition or purchase of twenty percent (20%)&nbsp;or more of any class of equity securities or capital stock of such party or any of its Subsidiaries whose business
constitutes twenty percent (20%)&nbsp;or more of the consolidated net revenues, net income or assets of such party and its Subsidiaries, taken as a whole, by any Person or group of Persons (other than a party hereto or any of its Affiliates); or
(c)&nbsp;merger, consolidation, restructuring, transfer of assets or other business combination, sale of shares of capital stock, tender offer, share exchange, exchange offer, recapitalization, stock repurchase program or other similar transaction
that if consummated would result in any Person or group of Persons (other than a party hereto or any of its Affiliates) beneficially owning twenty percent (20%)&nbsp;or more of any class of equity securities of such party or any of its Subsidiaries
whose business constitutes twenty percent (20%)&nbsp;or more of the consolidated net revenues, net income or assets of such party and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Action</U>&#148; means any claim, demand, notice, action, suit, arbitration, proceeding, audit or investigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Additional Antitrust Approvals</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.05(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; of any particular Person means any other Person controlling, controlled by or under common control with such
particular Person. For the purposes of this definition, &#147;controlling,&#148; &#147;controlled&#148; and &#147;control&#148; means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether
through the ownership of voting securities, contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; has the meaning set forth in the
Preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-Corruption Laws</U>&#148; means the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act
2010, and all other applicable anti-corruption/anti-bribery Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Antitrust Laws</U>&#148; means any antitrust, competition, or
trade regulation Laws that are designed or intended to prohibit, restrict, or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening competition through merger or acquisition, including the HSR Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Average Orthofix Stock Price</U>&#148; shall mean the volume weighted average
trading price per Orthofix Share on NASDAQ (as reported by Bloomberg L.P. or, if not reported therein, in another authoritative source mutually selected by the parties) for the five (5)&nbsp;consecutive Trading Days ending on (and including) the
Trading Day that is three Trading Days prior to the date of the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Book-Entry Share</U>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;2.09</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day that is not a Saturday, a Sunday or a day
on which banks are closed in New York, New York, Dallas, Texas or San Diego, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Capital Leases</U>&#148; means all
obligations for capital leases (determined in accordance with GAAP). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>CARES Act</U>&#148; means the Coronavirus Aid, Relief, and
Economic Security Act, H.R. 748, 116th Cong., 2d Sess. (signed into law on March&nbsp;27, 2020) and any similar or successor federal, state, local and foreign Law, including any applicable guidance (including IRS Notice <FONT
STYLE="white-space:nowrap">2020-65,</FONT> and IRS Notice <FONT STYLE="white-space:nowrap">2021-11)</FONT> issued thereunder or relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>CERCLA</U>&#148; means the Comprehensive Environmental Response, Compensation and Liability Act of 1980. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Certificate of Merger</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.04</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clean Team Agreement</U>&#148; means the Clean Team Confidentiality Agreement, effective as of August&nbsp;31, 2022, between Orthofix
and SeaSpine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.03</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.03</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidentiality Agreement</U>&#148; means the Confidentiality Agreement, dated February&nbsp;28, 2022, between Orthofix and SeaSpine.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contract</U>&#148; means any written, oral or other agreement, contract, subcontract, lease, binding understanding, obligation,
promise, instrument, indenture, mortgage, note, option, warranty, purchase order, license, sublicense, commitment or undertaking of any nature, which, in each case, is legally binding upon a party or on any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT></U>&#148; means
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and any mutations or variations thereof (including any directly related health conditions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures</U>&#148; means any quarantine, &#147;shelter in place,&#148; &#147;stay at
home,&#148; workforce reduction, social distancing, shut down, closure, sequester, safety or similar Law, directive, guidelines or recommendations promulgated by any Governmental Body, including the Centers for Disease Control and Prevention and the
World Health Organization, in each case, in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT> Response</U>&#148; means any
deviations from the ordinary course of business of a party or any of its Subsidiaries or any actions, inactions, activities or conduct of such party or any of its Subsidiaries, in each case, following the date of this Agreement that such party
reasonably and in good faith determines are reasonably necessary to comply with any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures or to mitigate, remedy, respond to or otherwise address the effects or impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> (including protecting the health or safety of any Person in response to <FONT STYLE="white-space:nowrap">COVID-19).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Defaulting Party</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.03(f)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>DGCL</U>&#148; means the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effect</U>&#148; has the meaning set forth in the definition of &#147;Material Adverse Effect.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Time</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.04</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Employees</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.07(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Laws</U>&#148; means all applicable federal, state, provincial, municipal, local and foreign Laws, statutes,
regulations, ordinances and bylaws that have the force or effect of law, and all judicial and administrative Orders and determinations that are binding upon SeaSpine or Orthofix, as applicable, and all policies, practices and guidelines of a
Governmental Body that have, or are determined to have, the force of law, concerning pollution or protection of the environment, including all those relating to the generation, handling, transportation, treatment, storage, disposal, distribution,
labeling, discharge, release, threatened release, control, or cleanup of any Hazardous Substances, as such of the foregoing are promulgated and in effect on or prior to the Closing Date, and all authorizations, licenses and permits issued or
required to be issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; means the Employee Retirement Income Security Act of 1974, or any successor
federal statute thereto and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA Affiliate</U>&#148; means any trade or
business (whether or not incorporated) which is, or has been, under common control, or treated as a single employer, with SeaSpine or Orthofix, as applicable, under Sections 414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, and the rules and regulations of the SEC promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Agency Agreement</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.10(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Agent</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.10(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Fund</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.10(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Ratio</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.08(a)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Shares</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.08(a)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Expenses</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.03(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA Fraud Policy</U>&#148; means the &#147;Fraud, Untrue Statements of Material
Facts, Bribery, and Illegal Gratuities&#148; Final Policy set forth in 56 Fed. Reg. 46,191 (September 10, 1991) and any amendments thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Forum</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;9.06(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fraud</U>&#148; means common law fraud that is committed with actual knowledge of falsity and with the intent to deceive or mislead
another; <U>provided</U>, <U>however</U>, that &#147;Fraud&#148; shall not include any fraud claim based on constructive knowledge, negligent misrepresentation, recklessness, or other similar theory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means U.S. generally accepted accounting principles as in effect on the date hereof, applied in a manner consistent
with SeaSpine&#146;s or Orthofix&#146;s past practice, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Body</U>&#148; means any federal, state,
provincial, local, municipal, foreign or other government or quasi-governmental authority or any department, minister, agency, commission, commissioner, board, subdivision, bureau, agency, instrumentality, court, arbitrator or other tribunal of any
of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Hazardous Substance</U>&#148; means petroleum, or any fraction thereof,
<FONT STYLE="white-space:nowrap">per-</FONT> and poly-fluoroalkyl substances or any hazardous substance as defined in CERCLA or any waste, material or substance that is regulated, defined, designated or otherwise determined to be dangerous,
hazardous, radioactive, explosive, toxic or a pollutant or contaminant under or pursuant to any Environmental Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Healthcare
Laws</U>&#148; means, to the extent related to the conduct of Orthofix&#146;s business or SeaSpine&#146;s business, as applicable, as of the date hereof, the following: (i)&nbsp;the Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.), the
Public Health Service Act (42 U.S.C. &#167; 201 et seq.), the coverage and reimbursement provisions of Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act) and other government healthcare programs,
including the Veterans Health Administration and the U.S. Department of Defense healthcare and contracting programs, the federal Anti-Kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Civil Monetary
Penalties Law (42 U.S.C. &#167; 1320a-7a), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the criminal false claims
statutes (18 U.S.C. &#167;&#167; 287 and 1001), the Program Fraud Civil Remedies Act of 1986 (31 U.S.C. &#167;3801, et seq.), the Federal Health Care Fraud Law (18 U.S.C. &#167; 1347), the Health Insurance Portability and Accountability Act of 1996
(42 U.S.C. &#167; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the
Sunshine/Open Payments Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> and any other U.S. federal or state Law that regulates the design, development, testing, studying, manufacturing, processing, storing, importing or
exporting, licensing, labeling or packaging, advertising, distributing, selling or marketing of biological, tissue or medical device products, or that is related to remuneration (including ownership) to or by physicians or other healthcare providers
(including kickbacks) or the disclosure or reporting of the same, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government healthcare programs, quality, safety, privacy, security,
licensure, accreditation or any other aspect of providing healthcare products or services; (ii)&nbsp;all equivalent or similar Laws in any jurisdiction applicable to either party or its Products; and (iii)&nbsp;all regulations promulgated pursuant
to such Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR Act</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and
regulations promulgated thereunder, and any successor to such statute, rules or regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indebtedness</U>&#148; means, with respect to any Person, without duplication:
(a)&nbsp;the principal, accreted value, accrued and unpaid interest, fees and prepayment premiums or penalties, unpaid fees or expenses and other monetary obligations in respect of (i)&nbsp;indebtedness of such Person for borrowed money and
(ii)&nbsp;indebtedness evidenced by notes, debentures, bonds, or other similar instruments for the payment of which such Person is liable; (b)&nbsp;all obligations of such Person issued or assumed as the deferred purchase price of property (other
than trade payables or accruals incurred in the ordinary course of business consistent with past practice); (c)&nbsp;all obligations of such Person for the reimbursement of any obligor on any letter of credit, banker&#146;s acceptance or similar
credit transaction; (d)&nbsp;all obligations of such Person under Capital Leases; (e)&nbsp;all obligations of the type referred to in clauses (a)&nbsp;through (d)&nbsp;of any Persons for the payment of which such Person is responsible or liable,
directly or indirectly, as obligor, guarantor, surety or otherwise, including guarantees of such obligations (but solely to the extent of such responsibility or liability); and (f)&nbsp;all obligations of the type referred to in clauses
(a)&nbsp;though (e)&nbsp;of other Persons secured by (or for which the holder of such obligations has an existing right, contingent or otherwise, to be secured by) any Lien on any property or asset of such Person (whether or not such obligation is
assumed by such Person);<U>&nbsp;provided</U>, <U>however</U>, that if such Person has not assumed any such obligations referred to in this clause (f), then the amount of Indebtedness of such Person for purposes of this clause (f)&nbsp;shall be
equal to the lesser of the amount of the obligations of the holder of such obligations and the fair market value of the assets of such Person which secure such obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indemnified Parties</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.08(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means all intellectual property and industrial rights arising in any jurisdiction throughout the
world including those arising from or in respect of the following: (i)&nbsp;all patents and applications therefor, including continuations, divisionals,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> or reissues of patent applications and patents issuing thereon; (ii)&nbsp;all trademarks, service marks, trade names, internet domain names,
service names, brand names and trade dress rights, and all applications, registrations and renewals thereof; (iii)&nbsp;copyrights and registrations and applications therefor, works of authorship and mask work rights; and (iv)&nbsp;data, databases,
trade secrets and <FONT STYLE="white-space:nowrap">know-how.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intentional and Material Breach</U>&#148; means any material
breach of this Agreement that is the consequence of any action or omission taken or omitted to be taken that the breaching party intentionally takes (or fails to take) and actually knows would, or would reasonably be expected to, be or cause a
material breach of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intervening Event</U>&#148; means any material event or development or material change in
circumstances first occurring, arising or coming to the attention of the SeaSpine Board or the Orthofix Board after the date of this Agreement to the extent that such event, development or change in circumstances (a)&nbsp;was neither known by the
SeaSpine Board or the Orthofix Board, as applicable, nor reasonably foreseeable by the SeaSpine Board or the Orthofix Board, as applicable, as of or prior to the date of this Agreement and (b)&nbsp;does not relate to an Acquisition Proposal or a
Superior Proposal or any inquiry or communications relating thereto; <U>provided</U>, <U>however</U>, that in no event shall the changes in the market price or trading volume of SeaSpine Shares or Orthofix Shares or the fact that a party fails to
meet, meets or exceeds internal or published projections, forecasts or revenue or earnings or other financial performance or results of operations predictions for any period be an Intervening Event (it being understood, however, that the underlying
causes of such change or fact shall not be excluded by this proviso). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Joint Proxy Statement</U>&#148; has the meaning set forth
in <U>Section</U><U></U><U>&nbsp;6.02</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>knowledge of Orthofix</U>&#148; or &#147;<U>Orthofix</U><U>&#146;</U><U>s
knowledge</U>&#148; shall mean, the actual knowledge of any of those individuals set forth in <U>Section</U><U></U><U>&nbsp;1.1</U> of the Orthofix Disclosure Letter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>knowledge of SeaSpine</U>&#148; or &#147;<U>SeaSpine&#146;s knowledge</U>&#148;
shall mean, the actual knowledge of any of those individuals set forth in <U>Section</U><U></U><U>&nbsp;1.1</U> of the SeaSpine Disclosure Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means any foreign or U.S. federal, state or local law (including common law), treaty, statute, code, Order, ordinance,
Permit, rule, regulation, guidance document or other requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body, including any Environmental Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liability</U>&#148; means, with respect to any Person, any liability or obligation of that Person of any kind, character or
description, whether known or unknown, absolute or contingent, accrued or unaccrued, asserted or unasserted, disputed or undisputed, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested,
executory, determined, determinable or otherwise, and whether or not the same is required to be accrued on the financial statements of that Person in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liens</U>&#148; means any lien, mortgage, security interest, pledge, encumbrance, deed of trust, security interest, claim, lease,
charge, option, preemptive right, right of first refusal, subscription right, easement, servitude, proxy, voting trust or agreement, transfer restriction under any shareholder or similar agreement, encumbrance or restriction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Effect</U>&#148; means any change, effect, event, circumstance, occurrence, state of facts or development (each, an
&#147;<U>Effect</U>&#148;) that has had, or would reasonably be expected to have, individually or in the aggregate with all other Effects, a material adverse effect on the business, financial condition or results of operations of a party and its
Subsidiaries, taken as a whole, other than any Effect arising out of or resulting from: (a)&nbsp;general business or economic conditions affecting the industry in which such party or any of its Subsidiaries operates, to the extent such Effect does
not disproportionately affect such party or any of its Subsidiaries relative to other participants in the industries in which such party and its Subsidiaries operate; (b)&nbsp;any national or international political or social conditions, including
the engagement by the U.S. in hostilities or the escalation thereof, whether or not pursuant to the declaration of a national emergency or war, or the occurrence or the escalation of any military or terrorist attack upon the U.S. (including any
internet or &#147;cyber&#148; attack or hacking), or any of its territories, possessions, or diplomatic or consular offices or upon any military installation, equipment or personnel of the U.S. or any similar event, or geopolitical conflict,
including Russia&#146;s invasion of Ukraine, and military and/or governmental responses thereto, including the effects of economic sanctions, reverse sanctions, boycotts, reverse boycotts, commercial, currency and banking restrictions, reductions or
cancellations in energy, technology or commercial product purchases, and the effects therefrom, in each case, to the extent such Effect does not disproportionately affect such party or any of its Subsidiaries relative to other participants in the
industries in which such party and its Subsidiaries operate; (c)&nbsp;any natural disaster, earthquake, hurricane, tsunami, tornado, flood, mudslide, wild fire or other natural disaster, changes in or effects in weather, meteorological conditions or
climate, explosion, fire, act of God or other force majeure event, to the extent such Effect does not disproportionately affect such party or any of its Subsidiaries relative to other participants in the industries in which such party and its
Subsidiaries operate; (d)&nbsp;any epidemic, disease outbreak or pandemic (including <FONT STYLE="white-space:nowrap">COVID-19</FONT> (and, for the avoidance of doubt, any loss of customers, suppliers, orders, Contracts or other business
relationships resulting from, or in connection with, <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures or such party&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> Response)),
public health emergency or widespread occurrence of infectious disease, to the extent such Effect does not disproportionately affect such party or any of its Subsidiaries relative to other participants in the industries in which such party and its
Subsidiaries operate; (e)&nbsp;financial, banking, or securities markets (including any disruption thereof and any decline in the price of any security or any market index), to the extent such Effect does not disproportionately affect such party or
any of its Subsidiaries relative to other participants in the industries in which such party and its Subsidiaries operate; (f)&nbsp;changes in GAAP, to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent such Effect does not disproportionately affect such party or any of its Subsidiaries relative to other participants in the industries in which such party and its Subsidiaries operate;
(g)&nbsp;changes in Laws, rules, regulations, Orders, or other binding directives issued by any Governmental Body, including any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures, to the extent such Effect does not disproportionately affect
such party or any of its Subsidiaries relative to other participants in the industries in which such party and its Subsidiaries operate; (h)&nbsp;the taking of any action expressly contemplated hereby or the other agreements contemplated hereby;
(i)&nbsp;the public announcement or the execution of this Agreement or the pendency or consummation of the Merger, including the impact thereof on relationships, contractual or otherwise, with customers, suppliers, licensors, distributors, partners,
providers and employees (provided that this clause (i)&nbsp;shall not apply to any representation or warranty of SeaSpine in <U>Section</U><U></U><U>&nbsp;3.05</U> or <U>Section</U><U></U><U>&nbsp;3.06</U> or of Orthofix in
<U>Section</U><U></U><U>&nbsp;4.05</U> or <U>Section</U><U></U><U>&nbsp;4.06</U> to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the
consummation of the Merger); (j) any failure, in and of itself, by either party to meet any internal or published projections, forecasts, estimates or predictions in respect of revenues, earnings or other financial metrics for any period (it being
understood that the facts or occurrences giving rise to or contributing to such failure may be taken into account in determining whether there has been or will be, a Material Adverse Effect unless otherwise excluded in this definition of
&#147;Material Adverse Effect&#148;); (k) any change, in and of itself, in the market price or trading volume of the securities of either party (it being understood that the facts or occurrences giving rise to or contributing to such change may be
taken into account in determining whether there has been or will be, a Material Adverse Effect unless otherwise excluded in this definition of &#147;Material Adverse Effect&#148;); (l) any litigation, claim or legal proceeding threatened or
initiated against Orthofix, Merger Sub, SeaSpine or any of their respective Subsidiaries, Affiliates, officers or directors, in each case, arising out of or relating to this Agreement or the transactions contemplated by this Agreement, and including
the impact of any of the foregoing on any relationships with customers, suppliers, licensors, distributors, partners, providers, employees or regulators; or (m)&nbsp;any adverse change in or effect on the business of the party that is cured by or on
behalf of the party before the earlier of the Closing Date and the date on which this Agreement is terminated pursuant to <U>ARTICLE 8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Measurement Date</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.03(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.02</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Consideration</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.08(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub</U>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub Board</U>&#148; means the board of directors of Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Tax Opinion</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.13(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Tax Representation Letters</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.13(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Misconduct Allegation</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.20</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>NASDAQ</U>&#148; means the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>New Plans</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.07(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;8.03(f)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan</U>&#148; means each Plan
that is subject to the Laws of a jurisdiction other than the U.S. (whether or not U.S. Law also applies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Old Plans</U>&#148;
has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.07(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any order, writ, injunction,
judgment or decree. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Organizational Documents</U>&#148; means the certificate of incorporation, articles of incorporation,
articles of association, bylaws or other charter or organizational documents of a company or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix</U>&#148;
has the meaning set forth in the Preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Adverse Recommendation Change</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.04(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Balance Sheet Date</U>&#148; means December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Board</U>&#148; means the board of directors of Orthofix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Disclosure Letter</U>&#148; has the meaning set forth in <U>ARTICLE 4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Employees</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.07(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Equity Plan</U>&#148; means Orthofix&#146;s Amended and Restated 2012 Long-Term Incentive Plan, as amended from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Inducement Plans</U>&#148; means (a)&nbsp;the Employee Inducement
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option Agreement between Orthofix and Jon Serbousek, dated August&nbsp;5, 2019, (b) the Employee Inducement Restricted Stock Unit Agreement between Orthofix and Jon Serbousek, dated
August&nbsp;5, 2019, and (c)&nbsp;the Inducement Grant <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option Agreement between Orthofix and Bradley R. Mason, dated March&nbsp;13, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Licenses</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.21(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Material Adverse Effect</U>&#148; means a Material Adverse Effect of Orthofix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Material Contract</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.12(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix-Nominated Directors</U>&#148; has the meaning set forth in <U>Schedule 2.15</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Notice of Change</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.04(f)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Option</U>&#148; means each option to acquire Orthofix Shares granted under an Orthofix Equity Plan or pursuant to a
stand-alone stock option agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Plan</U>&#148; means each Plan that Orthofix or any of its Subsidiaries maintains,
contributes to, is obligated to contribute to for the benefit of any current or former employee, officer, independent contractor or director of Orthofix or any of its Subsidiaries or with respect to which Orthofix or any of its Subsidiaries has or
may have any Liability, but excluding any plan, policy, program, arrangement or agreement in jurisdictions other than the U.S. solely to the extent the benefits provided thereunder are required to be provided by statute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Real Property</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.10(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Recommendation</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Registered Intellectual Property</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.13(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix RSU</U>&#148; means each restricted stock unit granted under an Orthofix Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix SEC Documents</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.07(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Share</U>&#148; means a share of common stock of Orthofix, $0.10 par value per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Share Issuance</U>&#148; means the issuance of Orthofix Shares in connection with the Merger as contemplated by this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix SPP</U>&#148; means Orthofix&#146;s Second Amended and Restated Stock Purchase Plan, as amended from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix SPP Purchase Rights</U>&#148; means rights to acquire Orthofix Shares under the Orthofix SPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Stockholde</U>r&#148; means a holder of Orthofix Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Stockholder Approval</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.24(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Stockholders&#146; Meeting</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.03(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Tax Counsel</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.13(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Orthofix Termination Fee</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.03(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permit</U>&#148; means any approval, clearance, authorization, certificate, consent, license, Order or permits or other similar
authorization of any Governmental Body or under any Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Liens</U>&#148; means: (a)&nbsp;statutory Liens for current
Taxes or other governmental charges not yet due and payable or the amount or validity of which is being contested in good faith by appropriate proceedings and for which adequate reserves are established in the consolidated financial statements of
SeaSpine or Orthofix, as applicable, in accordance with GAAP; (b)&nbsp;mechanics&#146;, carriers&#146;, workers&#146;, repairers&#146;, contractors&#146;, subcontractors&#146;, suppliers&#146; and similar statutory Liens arising or incurred in the
ordinary course of business consistent with past practice in respect of the construction, maintenance, repair or operation of assets for amounts which are not delinquent and which are not, individually or in the aggregate, significant;
(c)&nbsp;zoning, entitlement, building and other land use regulations imposed by governmental agencies having jurisdiction over the leased SeaSpine Real Property or Orthofix Real Property, as applicable, which are not violated by the current use and
operation of the leased SeaSpine Real Property or Orthofix Real Property, as applicable; (d)&nbsp;covenants, conditions, restrictions, easements and other similar matters of record affecting title to the leased SeaSpine Real Property or Orthofix
Real Property, as applicable, which do not materially impair the occupancy, marketability or use of such real property for the purposes for which it is currently used or proposed to be used in connection with SeaSpine&#146;s business or
Orthofix&#146;s business, as applicable; (e)&nbsp;matters that would be disclosed by an accurate current survey of the leased SeaSpine Real Property or Orthofix Real Property, which do not materially impair the occupancy, marketability or use of
such real property for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes for which it is currently used or proposed to be used in connection with SeaSpine&#146;s business or Orthofix&#146;s business, as applicable; (f)&nbsp;any other Liens (including any
immaterial imperfections or immaterial irregularities of title) that, in the aggregate, do not materially impair the occupancy, marketability or use of such real property for the purposes for which it is currently used or proposed to be used in
connection with SeaSpine&#146;s business or Orthofix&#146;s business, as applicable; (g)&nbsp;Liens arising under workers&#146; compensation, unemployment insurance and social security; and (h)&nbsp;purchase money Liens and Liens securing rental
payments under Capital Leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual, a partnership, a corporation, a limited liability company,
an unlimited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, any other entity, a governmental entity or any department, agency or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Personal Data</U>&#148; means any information in a party&#146;s or its Subsidiaries&#146; possession that identifies or could be used
to identify an individual, household or device including information that constitutes &#147;personal data,&#148; &#147;personal information&#148; or similar term as defined by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Plan</U>&#148; means an &#147;employee benefit plan&#148; within the meaning of Section&nbsp;3(3) of ERISA (whether or not subject to
ERISA) and any other compensation and benefit plan, policy, program, arrangement, agreement or payroll practice, whether written or unwritten, funded or unfunded, subject to ERISA or not and covering one or more Persons, including any stock
purchase, stock option, restricted stock, other equity-based, phantom equity, severance, separation, retention, employment, consulting, change in control, bonus, incentive, commission, deferred compensation, pension, supplemental retirement,
employee loan, health, dental, vision, workers&#146; compensation, collective bargaining, disability, life insurance, death benefit, welfare, vacation, paid time off, leave of absence, employee assistance, legal services, tuition assistance, fringe
benefit or other material benefit plan, policy, program, arrangement, agreement or payroll practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Period</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.01(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Products</U>&#148; means any product that SeaSpine or Orthofix, as applicable, has manufactured, distributed, marketed or sold, or is
manufacturing, distributing, marketing or selling and any products currently under preclinical or clinical development by SeaSpine or Orthofix, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.02</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representative</U>&#148; means any director, officer, employee, accountant, consultant, legal counsel, financial advisor, agent or
other representative of a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rollover Option</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.08</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine</U>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Adverse Recommendation Change</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.04(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Balance Sheet Date</U>&#148; means December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Board</U>&#148; means the board of directors of SeaSpine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Disclosure Letter</U>&#148; has the meaning set forth in <U>ARTICLE 3</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Exchangeable Share</U>&#148; means an &#147;Exchangeable Share&#148; as
defined in AcquireCo&#146;s Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Exchangeable Share Redemption</U>&#148; means a redemption pursuant to the
exercise of either a Retraction Call Right or Redemption Call Right (as such terms are defined in AcquireCo&#146;s Articles) of a SeaSpine Exchangeable Share in accordance with AcquireCo&#146;s Articles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Existing Loan Documents</U>&#148; means that certain Amended and Restated Credit Agreement, dated July&nbsp;27, 2018, among
SeaSpine Holdings Corporation and Project Maple Leaf Holdings ULC, as guarantors, and SeaSpine Orthopedics Corporation, SeaSpine, Inc., ISOTIS, Inc., SeaSpine Sales LLC, ISOTIS Orthobiologics, Inc., Theken Spine, LLC, SeaSpine Orthopedics
Intermediate Co, Inc., 7D Surgical USA Inc. and 7D Surgical ULC, as borrowers, the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent, and all other loan documents related thereto and entered into with respect
thereto, in each case, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Existing Loan Documents Termination</U>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;6.16</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Employees</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.07(a)</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Equity Plan</U>&#148; means SeaSpine&#146;s Amended and Restated 2015
Incentive Award Plan, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine ESPP</U>&#148; means SeaSpine&#146;s 2015 Employee Stock Purchase
Plan, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine ESPP Purchase Rights</U>&#148; means rights to acquire SeaSpine Shares under the
SeaSpine ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Inducement Plans</U>&#148; means, collectively, SeaSpine&#146;s 2018 Employment Inducement Incentive
Award Plan, as amended from time to time, and SeaSpine&#146;s 2020 Employment Inducement Incentive Award Plan, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Licenses</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.21(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Material Adverse Effect</U>&#148; means a Material Adverse Effect of SeaSpine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Material Contract</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.12(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine-Nominated Directors</U>&#148; has the meaning set forth in <U>Schedule 2.15</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Notice of Change</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.04(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Option</U>&#148; means each option to acquire SeaSpine Shares granted under a SeaSpine Equity Plan or pursuant to a
stand-alone stock option agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Plan</U>&#148; means each Plan that SeaSpine or any of its Subsidiaries maintains,
contributes to, is obligated to contribute to for the benefit of any current or former employee, officer, independent contractor or director of SeaSpine or any of its Subsidiaries or with respect to which SeaSpine or any of its Subsidiaries has or
may have any Liability, but excluding any plan, policy, program, arrangement or agreement in jurisdictions other than the U.S. solely to the extent the benefits provided thereunder are required to be provided by statute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Real Property</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.10(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Recommendation</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Registered Intellectual Property</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.13(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Restricted Share</U>&#148; means each restricted SeaSpine Share issued under a SeaSpine Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine RSU</U>&#148; means each restricted stock unit granted under a SeaSpine Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine SEC Documents</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.07(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Share</U>&#148; means a share of common stock of SeaSpine, $0.01 par value per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Share Certificate</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.09</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Stockholders</U>&#148; means all holders of SeaSpine Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Stockholder Approval</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.24(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Stockholders&#146; Meeting</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.03(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Support Agreement</U>&#148; means the Support Agreement, dated May&nbsp;20, 2020, among SeaSpine, AcquireCo, CallCo and the
Shareholder Representatives (as such term is defined therein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Tax Counsel</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.13(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SeaSpine Termination Fee</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;8.03(e)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, and the rules and regulations of the SEC promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SOX</U>&#148; shall mean the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means, with respect to any Person, any corporation, partnership, association, limited liability company,
unlimited liability company or other business entity of which: (a)&nbsp;if a corporation, a majority of the total voting power of shares of capital stock entitled (without regard to the occurrence of any contingency) to vote in the election of
directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof; or (b)&nbsp;if a partnership, association, limited
liability company, or other business entity, a majority of the partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by any Person or one or more Subsidiaries of that Person or a
combination thereof. For purposes hereof, a Person or Persons shall be deemed to have a majority ownership interest in a partnership, association, limited liability company or other business entity if such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Person or Persons are allocated a majority of partnership, association, limited liability company or other business entity gains or losses or otherwise control the managing director, managing
member, general partner or other managing Person of such partnership, association, limited liability company or other business entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Superior Proposal</U>&#148; means, with respect to a party hereto, any unsolicited <I>bona fide</I> written Acquisition Proposal with
respect to such party made by any Person or group of Persons (other than a party hereto or any of its Affiliates) to acquire, directly or indirectly, pursuant to a tender offer, exchange offer, merger, share exchange, consolidation or other business
combination, (a)&nbsp;fifty percent (50%)&nbsp;or more of the assets of such party and its Subsidiaries, taken as a whole, or (b)&nbsp;fifty percent (50%)&nbsp;or more of the equity securities of such party, in each case on terms which a majority of
the board of directors of such party determines in good faith (after consultation with such party&#146;s financial advisors and outside legal counsel and taking into account all relevant financial, legal and regulatory aspects of such Acquisition
Proposal and this Agreement, including any alternative transaction (including any modifications to the terms of this Agreement) proposed by any other party in response to such Superior Proposal, including any conditions to and expected timing of
consummation, and any risks of <FONT STYLE="white-space:nowrap">non-consummation,</FONT> of such Acquisition Proposal) to be more favorable from a financial point of view (taking into account the payment of the SeaSpine Termination Fee or Orthofix
Termination Fee, as applicable) to such party and its shareholders (in their capacity as shareholders) as compared to the transactions contemplated by this Agreement and to any alternative transaction (including any modifications to the terms of
this Agreement) proposed by any other party hereto pursuant to <U>Section</U><U></U><U>&nbsp;6.04</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Surviving
Corporation</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.02</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Takeover Law</U>&#148; means any
&#147;moratorium,&#148; &#147;control share acquisition,&#148; &#147;fair price,&#148; &#147;supermajority,&#148; &#147;affiliate transaction,&#148; or &#147;business combination&#148; statute or regulation or other similar antitakeover laws of a
state or any other Governmental Body, including Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax</U>&#148; or &#147;<U>Taxes</U>&#148; means:
(a)&nbsp;any and all federal, state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties,
capital stock, franchise, profits, withholding, social security (or similar, including FICA), unemployment, disability, real property, personal property, sales, use, transfer, registration, value-added, alternative or
<FONT STYLE="white-space:nowrap">add-on</FONT> minimum, estimated, or other tax of any kind or any charge of any kind in the nature of (or similar to) taxes whatsoever, including any interest, penalty, or addition thereto, in each case whether
disputed or not; and (b)&nbsp;any Liability for the payment of any amounts of the type described in clause (a)&nbsp;of this definition as a result of being a member of an affiliated, consolidated, combined or unitary group for any period, as a
result of any tax sharing or tax allocation agreement, arrangement or understanding, or as a result of being liable for another Person&#146;s taxes as a transferee or successor, by Contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Returns</U>&#148; means any return, report, election, designation, information return or other document (including schedules or
any related or supporting information) filed or required to be filed with any Governmental Body or other authority in connection with the determination, assessment or collection of any Tax or the administration of any Laws, regulations or
administrative requirements relating to any Tax, including all information returns relating to Taxes of third parties, any claims for refund of Taxes and any amendments or supplements to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Termination Date</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.01(d)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; shall mean a day on which Orthofix Shares are traded on NASDAQ. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Treasury Regulations</U>&#148; means the regulations promulgated under the Code, as
such regulations may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>U.S.</U>&#148; means the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>WARN</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.20</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.02&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Definitional Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;All references in this Agreement to Exhibits, Schedules, the SeaSpine Disclosure Letter, the Orthofix Disclosure
Letter, Articles, Sections, subsections and other subdivisions refer to the corresponding Exhibits, Schedules, Disclosure Schedules, Articles, Sections, subsections and other subdivisions of or to this Agreement unless expressly provided otherwise.
Titles appearing at the beginning of any Articles, Sections, subsections or other subdivisions of this Agreement are for convenience only, do not constitute any part of this Agreement, and will be disregarded in construing the language hereof. All
references in this Agreement to &#147;days&#148; refer to &#147;calendar days&#148; unless otherwise specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits, Schedules, the SeaSpine Disclosure Letter and the Orthofix Disclosure Letter to this Agreement are
attached hereto and by this reference incorporated herein for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The words &#147;this
Agreement,&#148; &#147;herein,&#148; &#147;hereby,&#148; &#147;hereunder&#148; and &#147;hereof,&#148; and words of similar import, refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The words
&#147;this Article,&#148; &#147;this Section&#148; and &#147;this subsection,&#148; and words of similar import, refer only to the Article, Section or subsection hereof in which such words occur. The words &#147;either,&#148; &#147;or,&#148;
&#147;neither,&#148; &#147;nor&#148; and &#147;any&#148; are not exclusive. The word &#147;including&#148; (in its various forms) means including without limitation. The word &#147;extent&#148; in the phrase &#147;to the extent&#148; shall mean the
degree to which a subject or other thing extends, and such phrase shall not mean simply &#147;if.&#148; All references to &#147;$&#148; and &#147;dollars&#148; shall be deemed to refer to U.S. currency unless otherwise specifically provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Any definition of or reference to any agreement, instrument, benefit plan or other document or any Law in this
Agreement shall be construed as referring to such agreement, instrument or other document or Law as from time to time amended, supplemented or otherwise modified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Pronouns in masculine, feminine or neuter genders shall be construed to state and include any other gender, and
words, terms and titles (including terms defined herein) in the singular form shall be construed to include the plural and vice versa, unless the context otherwise requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against
the drafting party shall not be applied in the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;The phrases
&#147;provided to,&#148; &#147;furnished to,&#148; &#147;made available&#148; and phrases of similar import when used herein, unless the context otherwise requires, shall mean that a copy of the information or material referred to has been
(i)&nbsp;provided to the party to whom such information or material is to be provided, including by means of being provided for review in the virtual data room (including the clean room contained therein) set up by SeaSpine or Orthofix, as
applicable, in connection with the transactions contemplated by this Agreement or (ii)&nbsp;has been publicly filed with the SEC, in each case, at least twenty-four (24)&nbsp;hours prior to the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>THE MERGER </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Shares of Merger Sub</U>. Merger Sub is a corporation incorporated under the Laws of the State of Delaware and
is a constituent company in the Merger. Orthofix beneficially owns 100% of the outstanding capital stock of Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.02&nbsp;&nbsp;&nbsp;&nbsp;<U>The Merger</U>. Upon the terms and subject to the conditions of this Agreement, in accordance with the DGCL, at
the Effective Time, Merger Sub shall be merged with and into SeaSpine (the &#147;<U>Merger</U>&#148;). At the Effective Time, the separate corporate existence of Merger Sub shall cease, and SeaSpine shall continue as the surviving corporation (the
&#147;<U>Surviving Corporation</U>&#148;). The Surviving Corporation shall continue to exist under the Laws of the State of Delaware, with all its rights, privileges, immunities, powers and franchises, unaffected by the Merger except as set forth in
this <U>ARTICLE 2</U>. Immediately following the Effective Time, but subject to <U>Section</U><U></U><U>&nbsp;2.10(b)</U>, the Surviving Corporation shall be a wholly-owned subsidiary of Orthofix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.03&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>. The closing of the Merger (the &#147;<U>Closing</U>&#148;) shall be held remotely by exchange of
documents and signatures (or their electronic counterparts) at a date and time to be specified by the parties, which shall be no later than the third Business Day after satisfaction or (to the extent permitted by applicable Law) waiver of the
conditions set forth in <U>ARTICLE 7</U> (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or (to the extent permitted by applicable Law) waiver of such conditions) (such date the
&#147;<U>Closing Date</U>&#148;), unless another date or time is mutually agreed upon in writing by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.04&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective Time</U>. Subject to the provisions of this Agreement, at the Closing, the parties shall cause a
certificate of merger (the &#147;<U>Certificate of Merger</U>&#148;) to be executed, acknowledged and filed with the Secretary of State of the State of Delaware in accordance with the relevant provisions of the DGCL and shall make all other filings
and recordings required under the DGCL with respect to the Merger. The Merger shall become effective at such time as the Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or at such later date or time as
may be agreed by Orthofix and SeaSpine in writing and specified in the Certificate of Merger in accordance with the DGCL (the effective time of the Merger being referred to herein as the &#147;<U>Effective Time</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.05&nbsp;&nbsp;&nbsp;&nbsp;<U>Effects of the Merger</U>. The Merger shall have the effects set forth in this Agreement and in the applicable
provisions of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.06&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate of Incorporation and Bylaws</U>. At the Effective Time, the parties
shall take all necessary actions so that, at or immediately prior to the Effective Time, (a)&nbsp;the certificate of incorporation of SeaSpine shall, by virtue of the Merger, but subject to <U>Section</U><U></U><U>&nbsp;6.08</U>, be amended and
restated in its entirety to read as the certificate of incorporation of Merger Sub in effect immediately prior to the Effective Time, except that all references therein to Merger Sub shall be deemed to be references to the Surviving Corporation,
until thereafter changed or amended as provided therein or by applicable Law; <U>provided</U>, <U>however</U>, that Article I thereof shall read as follows: &#147;The name of the Corporation is SeaSpine Holdings Corporation&#148; and
(b)&nbsp;subject to <U>Section</U><U></U><U>&nbsp;6.08</U>, the bylaws of Merger Sub, as in effect immediately prior to the Effective Time, shall be the bylaws of the Surviving Corporation, except that all references therein to Merger Sub shall be
deemed to be references to the Surviving Corporation, until thereafter modified, changed or amended as provided therein or by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.07&nbsp;&nbsp;&nbsp;&nbsp;<U>Directors and Officers of the Surviving Corporation</U>. From and after the Effective Time, the Persons listed
on <U>Schedule 2.07</U> shall be the initial directors and executive officers of the Surviving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation, each to hold office in accordance with the terms set forth in the certificate of incorporation and bylaws of the Surviving Corporation until their respective successors shall have
been duly elected, appointed, designated or qualified, or until their earlier death, resignation or removal in accordance with the certificate of incorporation and bylaws of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.08&nbsp;&nbsp;&nbsp;&nbsp;<U>Treatment of SeaSpine Shares, SeaSpine Equity Awards</U><U> and Merger Sub Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;At the Effective Time, by virtue of the Merger and without any further action on the part of Orthofix, Merger Sub,
SeaSpine or any holder of shares thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;each SeaSpine Share held as of the Effective Time by
Orthofix, Merger Sub, any direct or indirect wholly-owned Subsidiary of SeaSpine or Orthofix or by SeaSpine as treasury shares (collectively, the &#147;<U>Excluded Shares</U>&#148;), shall be canceled and retired and shall cease to exist, and no
consideration shall be delivered in exchange therefor; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;subject to
<U>Section</U><U></U><U>&nbsp;2.08(b)</U>, <U>Section</U><U></U><U>&nbsp;2.08(c)</U> and <U>Section</U><U></U><U>&nbsp;2.13</U>, each SeaSpine Share outstanding immediately prior to the Effective Time, including shares outstanding pursuant to
<U>Section</U><U></U><U>&nbsp;2.08(b)(i)</U> below and SeaSpine Shares issuable in connection with a SeaSpine Exchangeable Share Redemption (other than the Excluded Shares) shall be canceled and converted into the right to receive 0.4163 fully paid
and nonassessable Orthofix Shares (such ratio, as such number may be adjusted in accordance with this <U>ARTICLE&nbsp;2</U>, the &#147;<U>Exchange Ratio</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">The aggregate number of Orthofix Shares issuable pursuant to <U>Section</U><U></U><U>&nbsp;2.08(a)(ii)</U>, including shares
outstanding pursuant to <U>Section</U><U></U><U>&nbsp;2.08(b)(i)</U>, and <U>Section</U><U></U><U>&nbsp;2.08(b)(ii)</U> is referred to as the &#147;<U>Merger Consideration</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Merger shall be deemed to constitute a &#147;Change in Control&#148; for purposes of each of the SeaSpine
Equity Plan and the SeaSpine Inducement Plans and all awards granted respectively thereunder, and it is the intent of the parties that all &#147;Options&#148; as defined in the SeaSpine Equity Plan and the SeaSpine Inducement Plans, respectively,
will be treated in accordance with Section&nbsp;12.2(d)(i) of the SeaSpine Equity Plan and Section&nbsp;11.2(d)(i) of the SeaSpine Inducement Plans, respectively. Accordingly, as of immediately prior to the Effective Time and subject to
<U>Section</U><U></U><U>&nbsp;2.13</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;each SeaSpine Restricted Share award that is then
outstanding shall automatically, without any action on the part of the holder thereof, be converted into an award of restricted Orthofix Shares with the same terms and conditions that applied to such SeaSpine Restricted Share award immediately prior
to the Effective Time, including applicable vesting conditions (which, for the avoidance of doubt, shall include any rights accruing under the SeaSpine Equity Plan or SeaSpine Inducement Plan, as applicable, as a result of the occurrence of a Change
in Control), relating to a number of Orthofix Shares equal to the product, rounded down to the nearest whole number of Orthofix Shares, of (A)&nbsp;the number of shares of SeaSpine Shares subject to such SeaSpine Restricted Share award immediately
prior to the Effective Time and (B)&nbsp;the Exchange Ratio; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;each SeaSpine RSU award that is
then outstanding shall automatically, without any action on the part of the holder thereof, be converted into an award of restricted stock units of Orthofix with the same terms and conditions that applied to such SeaSpine RSU award immediately prior
to the Effective Time, including applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
vesting conditions (which, for the avoidance of doubt, shall include any rights accruing under the SeaSpine Equity Plan or SeaSpine Inducement Plan, as applicable, as a result of the occurrence
of a Change in Control), relating to a number of Orthofix Shares equal to the product, rounded down to the nearest whole number of Orthofix Shares, of (A)&nbsp;the number of shares of SeaSpine Shares subject to such SeaSpine RSU award immediately
prior to the Effective Time and (B)&nbsp;the Exchange Ratio; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;each SeaSpine Option that is
then outstanding (each, a &#147;<U>Rollover Option</U>&#148;) shall automatically, without any action on the part of the holder thereof, be converted into an option to acquire Orthofix Shares at an adjusted exercise price per share (as detailed
below), subject to the same terms and conditions as were applicable to such SeaSpine Option immediately prior to the Effective Time (which, for the avoidance of doubt, shall include any rights accruing under the SeaSpine Equity Plan or SeaSpine
Inducement Plan, as applicable, as a result of the occurrence of a Change in Control (as defined therein)), including applicable vesting conditions; accordingly, effective as of the Effective Time: (A)&nbsp;each such Rollover Option shall be
exercisable solely for Orthofix Shares; (B)&nbsp;the number of Orthofix Shares subject to each Rollover Option shall be determined by multiplying the number of shares of SeaSpine Shares subject to the SeaSpine Option by the Exchange Ratio and
rounding down to the nearest whole number of Orthofix Shares; and (C)&nbsp;the per share exercise price for the Orthofix Shares issuable upon exercise of such Rollover Option shall be determined by dividing the per share exercise price for the
shares of SeaSpine Shares subject to the SeaSpine Option, as in effect immediately prior to the Effective Time, by the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;the parties shall take all actions that SeaSpine determines are necessary or desirable to
effectuate the provisions of this <U>Section</U><U></U><U>&nbsp;2.08(b)</U>, including obtaining board or committee consents or adopting or assuming a SeaSpine Equity Plan and/or SeaSpine Inducement Plan, as applicable, by Orthofix. Orthofix shall
provide SeaSpine, and SeaSpine shall provide Orthofix, with drafts of, and a reasonable opportunity to comment upon, all resolutions, option agreements and other written actions as may be required to effectuate the provisions of this
<U>Section</U><U></U><U>&nbsp;2.08(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing and for the avoidance of doubt, the first sentence of this
<U>Section</U><U></U><U>&nbsp;2.08(b) </U>shall not be interpreted to affect whether or not the Merger will be deemed a &#147;change in control,&#148; &#147;change of control&#148; or similar phrase for any purpose other than as specifically stated
in such sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of this Agreement, no fractional Orthofix Shares shall
be issued in connection with the Merger, no dividends or distributions of Orthofix shall relate to such fractional share interests, no certificates for any such fractional shares shall be issued, and such fractional share interests shall not entitle
the owner thereof to vote or to any rights as an Orthofix Stockholder. Any SeaSpine Stockholder who would otherwise be entitled to receive a fraction of an Orthofix Share pursuant to the Merger (after taking into account all SeaSpine Shares held
immediately prior to the Effective Time by such holder) shall, in lieu of such fraction of a share and upon surrender of such SeaSpine Share Certificate or Book-Entry Shares, be paid in cash the dollar amount (rounded to the nearest whole cent),
without interest and subject to any required Tax withholding, determined by multiplying such fraction by the Average Orthofix Stock Price. No such holder shall be entitled to dividends, voting rights or any other rights in respect of any fractional
Orthofix Share that would otherwise have been issuable as part of the Merger Consideration. The parties acknowledge that payment of the cash consideration in lieu of issuing fractional Orthofix Shares was not separately <FONT
STYLE="white-space:nowrap">bargained-for</FONT> consideration but merely represents a mechanical rounding off for purposes of avoiding the expense and inconvenience to Orthofix that would otherwise be caused by the issuance of fractional Orthofix
Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;All calculations performed pursuant to the terms of this
Agreement shall be calculated to four decimal places (0.0001). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;At the Effective Time, by virtue of the Merger
and without any action on the part of Orthofix, Merger Sub, SeaSpine or any holder of shares thereof, all shares of common stock of Merger Sub outstanding immediately prior to the Effective Time shall be converted into and become one validly issued,
fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of common stock, par value $0.01 per share, of the Surviving Corporation and shall constitute the only outstanding share of common stock of the Surviving Corporation, which
share shall be held by Orthofix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;In accordance with Section&nbsp;262 of the DGCL, no appraisal rights shall be
available to SeaSpine Stockholders in connection with the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.09&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing of SeaSpine Transfer Books</U>.
At the Effective Time: (a)(i)&nbsp;each certificate formerly representing any SeaSpine Share (other than an Excluded Share) (&#147;<U>SeaSpine Share Certificate</U>&#148;) and (ii)&nbsp;each uncertificated SeaSpine Share (&#147;<U>Book-Entry
</U><U>Share</U>&#148;) formerly representing any SeaSpine Share (other than an Excluded Share) shall cease to be outstanding and (other than any Excluded Shares) shall represent only the right to receive Orthofix Shares (and cash in lieu of any
fractional Orthofix Shares) as contemplated by <U>Section</U><U></U><U>&nbsp;2.08</U> and any dividends or other distributions to which the holders thereof are entitled pursuant to <U>Section</U><U></U><U>&nbsp;2.13</U> and all holders of SeaSpine
Share Certificates or Book-Entry Shares shall cease to have any rights as shareholders of SeaSpine; and (b)&nbsp;the stock transfer books of SeaSpine shall be closed with respect to all SeaSpine Shares outstanding immediately prior to the Effective
Time. No further transfer of any such SeaSpine Shares shall be made on such stock transfer books after the Effective Time. If after the Effective Time, a valid certificate previously representing any SeaSpine Shares is presented to the Exchange
Agent, to the Surviving Corporation or to Orthofix, such SeaSpine Share Certificate shall be cancelled and shall be exchanged as provided in this <U>ARTICLE 2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange Fund; Exchange of Certificates</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Prior to the Closing Date, Orthofix and SeaSpine shall mutually select a bank or trust company, which may be the
transfer agent for the Orthofix Shares, to act as exchange agent in the Merger (the &#147;<U>Exchange Agent</U>&#148;), and, not later than the Effective Time, Orthofix shall enter into an agreement with such bank or trust company, which agreement
shall be reasonably acceptable to SeaSpine (the &#147;<U>Exchange Agency Agreement</U>&#148;), for the payment of the Merger Consideration as provided in <U>Section</U><U></U><U>&nbsp;2.08</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix shall issue and deliver, prior to or concurrent with the Effective Time to the Exchange Agent solely for
the account and benefit of the former SeaSpine Stockholders, (i)&nbsp;the maximum number of Orthofix Shares that have become issuable pursuant to <U>Section</U><U></U><U>&nbsp;2.08(a)(ii)</U>, including shares outstanding pursuant to
<U>Section</U><U></U><U>&nbsp;2.082.08(b)(i), </U>and <U>Section</U><U></U><U>&nbsp;2.082.08(b)(ii)</U> for delivery to the Merger Consideration recipients entitled thereto (such Orthofix Shares being the &#147;<U>Exchange Fund</U>&#148;) and
(ii)&nbsp;cash sufficient to make payments in lieu of fractional shares in accordance with <U>Section</U><U></U><U>&nbsp;2.08(c)</U> for delivery to the Merger Consideration recipients entitled thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;At the Effective Time and without any action on the part of any holder, all Book-Entry Shares shall be deemed
surrendered to the Exchange Agent and Orthofix shall cause the Exchange Agent to: (i)&nbsp;deliver to each holder of Book-Entry Shares that number of uncertificated whole Orthofix Shares that the holder is entitled to receive pursuant to this
<U>ARTICLE 2</U> and cancel such Book-Entry Shares; and (ii)&nbsp;mail to each holder of Book-Entry Shares a check in the amount of any cash payable in respect of such holder&#146;s Book-Entry Shares pursuant to
<U>Section</U><U></U><U>&nbsp;2.08(c)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;As promptly as reasonably practicable after the Effective Time,
but in any event within five (5)&nbsp;Business Days thereafter, Orthofix shall cause the Exchange Agent to mail to the record holders of SeaSpine Share Certificates: (i)&nbsp;a notice advising such holder of the effectiveness of the Merger;
(ii)&nbsp;a letter of transmittal in customary form and containing such provisions as Orthofix and SeaSpine may reasonably specify (including a provision confirming that delivery of SeaSpine Share Certificates shall be effected, and risk of loss and
title to the SeaSpine Shares shall pass, only upon delivery of such SeaSpine Share Certificates to the Exchange Agent); and (iii)&nbsp;instructions for use in effecting the surrender of the SeaSpine Share Certificates in exchange for the Orthofix
Shares, as provided in <U>Section</U><U></U><U>&nbsp;2.08(a)</U>. Upon surrender of a SeaSpine Share Certificate to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably
required by the Exchange Agent or Orthofix, (A)&nbsp;the holder of such SeaSpine Share Certificate shall be entitled to receive in exchange a certificate or evidence of shares in book entry form representing the number of whole Orthofix Shares that
such holder has the right to receive pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;2.08(a)</U> (and cash in lieu of any fractional Orthofix Shares pursuant to <U>Section</U><U></U><U>&nbsp;2.08(c)</U>) and (B)&nbsp;the SeaSpine Share
Certificate so surrendered shall immediately be canceled. Until surrendered as contemplated by this <U>Section</U><U></U><U>&nbsp;2.10(d)</U>, each SeaSpine Share Certificate shall be deemed, from and after the Effective Time, to represent only the
right to receive Orthofix Shares (and cash in lieu of any fractional Orthofix Shares pursuant to <U>Section</U><U></U><U>&nbsp;2.08(c)</U>) as contemplated by this <U>ARTICLE 2</U> and any distribution or dividend with respect to Orthofix Shares,
the record date for which is after the Effective Time. In the event of a transfer of ownership of SeaSpine Shares that is not registered in the transfer records of SeaSpine, a certificate or evidence of shares in book-entry form representing the
proper number of Orthofix Shares may be issued to a Person other than the Person in whose name the SeaSpine Share Certificate so surrendered is registered if such SeaSpine Share Certificate shall be properly endorsed or otherwise be in proper form
for transfer, and the Person requesting such issuances shall pay any transfer or other Taxes required by reason of the issuance of the Orthofix Shares to a person other than the registered holder of such SeaSpine Shares or establish to the
satisfaction of Orthofix that such Taxes have been paid or are not applicable. If any SeaSpine Share Certificate shall have been lost, stolen or destroyed, Orthofix may, in its discretion and as a condition precedent to the issuance of any
certificate or evidence of shares in book-entry form representing Orthofix Shares, require the owner of such lost, stolen or destroyed SeaSpine Share Certificate to provide an appropriate affidavit and to deliver a bond (in such sum as Orthofix may
reasonably direct) as indemnity against any claim that may be made against the Exchange Agent, Orthofix, or the Surviving Corporation with respect to such SeaSpine Share Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;All Orthofix Shares to be issued and delivered to the Exchange Agent pursuant to this
<U>Section</U><U></U><U>&nbsp;2.10</U> shall be deemed issued and outstanding as of the Effective Time, and whenever a dividend or other distribution is declared by Orthofix in respect of Orthofix Shares, the record date for which is at or after the
Effective Time, that declaration shall include dividends or other distributions in respect of all Orthofix Shares issuable pursuant to this Agreement. No dividends or other distributions declared or made with respect to the Orthofix Shares with a
record date after the Effective Time shall be paid to the holder of an unsurrendered SeaSpine Share Certificate with respect to the Orthofix Shares that such holder has the right to receive pursuant to the Merger until such holder surrenders such
SeaSpine Share Certificate in accordance with this <U>Section</U><U></U><U>&nbsp;2.10</U>. All such dividends and other distributions shall be paid by Orthofix to the Exchange Agent after deduction of any applicable Taxes and shall be included in
the Exchange Fund, in each case until the surrender of such SeaSpine Share Certificate in accordance with this <U>Section</U><U></U><U>&nbsp;2.10</U>. Subject to the effect of applicable Laws, following surrender of any such SeaSpine Share
Certificate there shall be paid to the recordholder thereof, without interest, (i)&nbsp;at the time of such surrender, the dividends or other distributions with a record date after the Effective Time theretofore
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payable with respect to such Orthofix Shares and not paid and (ii)&nbsp;at the appropriate payment date, the dividends or other distributions payable with respect to such Orthofix Shares with a
record date after the Effective Time but with a payment date subsequent to surrender. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Any portion of the
Exchange Fund that remains undistributed to holders of SeaSpine Share Certificates as of the date one (1)&nbsp;year after the Closing Date shall be delivered to Orthofix upon demand, and any holders of SeaSpine Share Certificates who have not
theretofore surrendered their SeaSpine Share Certificates to the Exchange Agent in accordance with this <U>Section</U><U></U><U>&nbsp;2.10(f)</U>, as well as any holders of Book-Entry Shares who have not theretofore cashed any check payable to them
in accordance with <U>Section</U><U></U><U>&nbsp;2.08(c)</U>, shall thereafter look only to Orthofix for satisfaction of their claims for Orthofix Shares, cash in lieu of fractional Orthofix Shares and any dividends or distributions with respect to
Orthofix Shares, subject to applicable abandoned property law, escheat law or similar Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Neither Orthofix,
nor the Surviving Corporation shall be liable to any current or former SeaSpine Stockholder or to any other Person with respect to any Orthofix Shares (or dividends or distributions with respect thereto), or for any cash amounts, properly delivered
to any public official in compliance with any applicable abandoned property law, escheat law or similar Law. If any SeaSpine Share Certificate shall not have been surrendered prior to five (5)&nbsp;years after the Closing Date (or immediately prior
to such earlier date on which any Orthofix Shares or any dividends or other distributions payable to the holder of such SeaSpine Share Certificate would otherwise escheat to or become the property of any Governmental Body), any Orthofix Shares
issuable upon the surrender of, or any dividends or other distributions in respect of, such SeaSpine Share Certificate shall, to the extent permitted by applicable Law, become the property of Orthofix, free and clear of all claims or interest of any
Person previously entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U>. Each of SeaSpine, Orthofix, Merger Sub and the
Surviving Corporation (as applicable) shall be entitled to deduct or withhold such amounts as it determines, in its sole discretion, are necessary to cover all required withholdings from the amounts payable (including Orthofix Shares deliverable)
under this Agreement in accordance with the Code and any other applicable Law, and the Exchange Agent shall be entitled to so deduct or withhold to the extent it is entitled as set forth in the general instructions in the letter of transmittal. Any
such withheld or deducted amount shall be timely paid over to the appropriate Governmental Body and treated as though such amount had been paid to the Person in respect of whom such withholding was required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest; No Liability</U>. All payments made pursuant to this <U>ARTICLE 2</U> shall be without interest.
Neither Orthofix, Merger Sub nor the Surviving Corporation shall be liable to any Person in respect of any cash or securities delivered to a public official pursuant to any applicable abandoned property law, escheat law or similar Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments to Prevent Dilution</U>. Without limiting the other provisions of this Agreement, in the event that
SeaSpine changes the number of SeaSpine Shares issued and outstanding prior to the Effective Time (other than pursuant to the issuance of SeaSpine Shares to holders of SeaSpine Exchangeable Shares pursuant to the exchange, redemption or retraction
of SeaSpine Exchangeable Shares pursuant to AcquireCo&#146;s Articles and the SeaSpine Support Agreement) or Orthofix changes the number of Orthofix Shares issued and outstanding prior to the Effective Time, in either case, as a result of a
reclassification, stock split (including a reverse stock split), stock dividend or distribution, recapitalization, merger, subdivision, issuer tender or exchange offer, or other similar transaction, the consideration paid in accordance with this
Agreement, including the Exchange Ratio, shall be equitably adjusted to reflect such change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Further Action</U>. If, at any time after the Effective Time,
any further action is determined by Orthofix or SeaSpine to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to rights and property of Merger Sub
and SeaSpine, the officers and directors of Orthofix shall be further authorized to take such action. Orthofix and the Surviving Corporation also shall take such further actions as may be necessary or desirable to ensure that the Exchange Agent
sends out the letters of transmittal to SeaSpine Stockholders and issues certificates or evidence of shares in book-entry form representing Orthofix Shares to such shareholders in accordance with <U>Section</U><U></U><U>&nbsp;2.10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate Governance Matters</U>. The Orthofix Board shall take all necessary corporate action, to the extent
within its power and authority, to cause the following to occur as of the Effective Time: (a)&nbsp;the directors constituting the Orthofix Board shall be as set forth in <U>Schedule 2.15</U>, subject to such individuals&#146; willingness to serve;
(b)&nbsp;the composition of the committees of the Orthofix Board shall be as set forth in <U>Schedule 2.15</U>, subject to such individuals&#146; willingness to serve; and (c)&nbsp;the executive officers of Orthofix shall be as set forth in
<U>Schedule 2.15</U>, subject to such individuals&#146; willingness to serve. In the event any designee identified on <U>Schedule 2.15</U> becomes unwilling to serve as of the Effective Time, a replacement for such designee shall be determined in
accordance with the provisions of <U>Schedule 2.15</U> hereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>REPRESENTATIONS AND WARRANTIES OF SEASPINE </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as disclosed in (a)&nbsp;the SeaSpine SEC Documents furnished or filed prior to the date hereof (excluding any disclosures in any risk
factors section or otherwise relating to forward-looking statements to the extent that they are cautionary, predictive or forward-looking in nature) or (b)&nbsp;the confidential disclosure letter delivered by SeaSpine to Orthofix prior to the
execution and delivery of this Agreement (the &#147;<U>SeaSpine Disclosure Letter</U>&#148;) to the extent it makes reference to the particular Section or subsection of this Agreement to which exception is being taken (or to the extent that it is
reasonably apparent from the face of such disclosure that such disclosure also qualifies or applies to another Section or subsection of this Agreement), SeaSpine represents and warrants to Orthofix as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization and Corporate Power</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine is a corporation duly organized, validly existing and in good standing under the Laws of the State of
Delaware, with full corporate power and authority to enter into this Agreement and perform its obligations hereunder. Each of the Subsidiaries of SeaSpine is a corporation or other entity duly organized and validly existing under the Laws of the
jurisdiction of its incorporation or organization. Each of SeaSpine and its Subsidiaries has all requisite corporate power and authority necessary to own, lease and operate its properties and to carry on its business as it is now being conducted.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each of SeaSpine and its Subsidiaries has all authorizations, licenses and permits, necessary to own, lease
and operate its properties and to carry on its business as it is now being conducted, except where the failure to hold such authorizations, licenses and permits would not have a SeaSpine Material Adverse Effect. Each of SeaSpine and its Subsidiaries
is duly qualified or authorized to do business and is in good standing in every jurisdiction (to the extent such concept exists in such jurisdiction) in which its ownership of property or the conduct of its business as now conducted requires it to
qualify, except where the failure to be so qualified, authorized or in good standing would not have a SeaSpine Material Adverse Effect. True and complete copies of the certificate of incorporation and bylaws of SeaSpine, as in effect as of the date
hereof, have been heretofore made available to Orthofix. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.02&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization; Valid and Binding Agreement</U>. Subject to
obtaining the SeaSpine Stockholder Approval, the execution, delivery and performance of this Agreement by SeaSpine and each other agreement, document, instrument or certificate contemplated hereby to be executed, delivered and performed by SeaSpine
and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all requisite action on the part of SeaSpine, and no other corporate approvals on SeaSpine&#146;s part are necessary to authorize the
execution, delivery or performance of this Agreement. Assuming that this Agreement is a valid and binding obligation of Orthofix and Merger Sub, this Agreement constitutes a valid and binding obligation of SeaSpine, enforceable in accordance with
its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance, reorganization or moratorium Laws, other similar Laws affecting creditors&#146; rights or general principles of equity affecting the
availability of specific performance and other equitable remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.03&nbsp;&nbsp;&nbsp;&nbsp;<U>Capital Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The authorized capital stock of SeaSpine consists of 120,000,000 SeaSpine Shares and 15,000,000 shares of preferred
stock, $0.01 par value per share, of which, as of October&nbsp;7, 2022 (the &#147;<U>Measurement Date</U>&#148;), 37,202,800 SeaSpine Shares (which amount, for clarity, includes 147,443 unvested SeaSpine Restricted Shares) and 0 shares of preferred
stock were issued and outstanding. Between the Measurement Date and the date of this Agreement, there have been no issuances or grants of SeaSpine Shares, SeaSpine Options, SeaSpine Restricted Shares, SeaSpine RSUs or SeaSpine ESPP Purchase Rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;3.03(b)</U> of the SeaSpine Disclosure Letter sets forth a true and complete
list as of the Measurement Date of the outstanding SeaSpine Shares, SeaSpine Options, SeaSpine Restricted Shares, SeaSpine RSUs and SeaSpine ESPP Purchase Rights (assuming that all participants in the SeaSpine ESPP as of the date hereof were to
continue to participate through the next regularly scheduled exercise date under the SeaSpine ESPP), including, with respect to each SeaSpine Option, SeaSpine RSU award and SeaSpine ESPP Purchase Right, the number of SeaSpine Shares issuable
thereunder or with respect thereto, the holder thereof and the exercise price (if any), and SeaSpine has granted no other such awards since the Measurement Date and prior to the date of this Agreement. In addition, 1,298,648 SeaSpine Exchangeable
Shares are outstanding for which 1,248,648 SeaSpine Shares are, as of the date hereof, issuable upon the exchange, redemption or retraction of SeaSpine Exchangeable Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;All of the outstanding SeaSpine Shares have been duly authorized and validly issued and are fully paid, <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and free of preemptive or similar rights. All of the issued and outstanding SeaSpine Shares were issued in compliance in all material respects with all applicable Laws concerning the issuance of
securities. Except as set forth in <U>Section</U><U></U><U>&nbsp;3.03(b)</U> of the SeaSpine Disclosure Letter, SeaSpine does not have any other equity securities or securities containing any equity features authorized, issued or outstanding, and
there are no agreements, options, warrants or other rights or arrangements existing or outstanding which provide for the sale or issuance of any of the foregoing by SeaSpine. Except as set forth in <U>Section</U><U></U><U>&nbsp;3.03(b)</U> of the
SeaSpine Disclosure Letter, there are no outstanding (i)&nbsp;shares of capital stock or other equity interests or voting securities of SeaSpine, (ii)&nbsp;securities convertible or exchangeable, directly or indirectly, into capital stock of
SeaSpine, (iii)&nbsp;options, warrants, purchase rights, subscription rights, preemptive rights, conversion rights, exchange rights, calls, puts, rights of first refusal or other Contracts that require SeaSpine to issue, sell or otherwise cause to
become outstanding or to acquire, repurchase or redeem capital stock of SeaSpine, (iv)&nbsp;stock appreciation, phantom stock, profit participation or similar rights with respect to SeaSpine or (v)&nbsp;bonds, debentures, notes or other Indebtedness
of SeaSpine having the right to vote (or convertible into or exercisable for securities having the right to vote) on any matters on which stockholders of SeaSpine may vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;All of the outstanding SeaSpine Options, SeaSpine Restricted
Shares, SeaSpine RSUs and SeaSpine ESPP Purchase Rights have been duly authorized by all necessary corporate action and were granted in accordance with the terms of all applicable Plans and applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;There are no stockholder agreements or voting trusts or other agreements or understandings to which SeaSpine is a
party with respect to the voting, or restricting the transfer, of the capital stock or any other equity interest of SeaSpine. SeaSpine has not granted any preemptive rights, anti-dilutive rights or rights of first refusal, registration rights or
similar rights with respect to its shares of capital stock that are in effect. No shares of capital stock of SeaSpine are held by any Subsidiary of SeaSpine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there is no stockholder rights plan, &#147;poison pill&#148; antitakeover plan or
similar device in effect to which SeaSpine or any of its Subsidiaries is subject, a party to or otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.04&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>. All of the outstanding shares of capital stock or equivalent equity interests of each of
SeaSpine&#146;s Subsidiaries are owned of record and beneficially, directly or indirectly, by SeaSpine free and clear of all material Liens, pledges, security interests or other encumbrances (other than Permitted Liens). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.05&nbsp;&nbsp;&nbsp;&nbsp;<U>No Breach</U>. Except with respect to clauses (b)&nbsp;and (c)&nbsp;for any conflicts, violations, breaches,
defaults or other occurrences which would not constitute a SeaSpine Material Adverse Effect, the execution, delivery and performance of this Agreement by SeaSpine and, subject to obtaining the SeaSpine Stockholder Approval, the consummation of the
transactions contemplated hereby do not (a)&nbsp;conflict with or violate SeaSpine&#146;s or any of its Subsidiaries&#146; Organizational Documents, (b)&nbsp;assuming all consents, approvals, authorizations and other actions described in
<U>Section</U><U></U><U>&nbsp;3.06</U> have been obtained and all filings and obligations described in <U>Section</U><U></U><U>&nbsp;3.06</U> have been made, conflict with or violate any Law, statute, rule or regulation or Order, judgment or decree
to which SeaSpine or its Subsidiaries or any of their properties or assets is subject, or (c)&nbsp;conflict with or result in any material breach of, constitute a material default under, result in a material violation of, give rise to a right of
termination, cancellation or acceleration under, give rise to any penalties, repayment obligations, special assessments or additional payments under, result in the creation of any Lien upon any assets of SeaSpine or any of its Subsidiaries, or
require any authorization, consent, waiver, approval, filing, exemption or other action by or notice to any court, other Governmental Body or other third party, under the provisions of any SeaSpine Material Contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.06&nbsp;&nbsp;&nbsp;&nbsp;<U>Consents, etc.</U> Except as may be required by (a)&nbsp;the HSR Act and any other applicable Antitrust Laws,
(b)&nbsp;the Exchange Act, (c)&nbsp;the Securities Act, (d)&nbsp;U.S. state securities Laws, (e)&nbsp;NASDAQ and (f)&nbsp;the DGCL, in each case, which requirements have or will be made in connection with the transactions contemplated hereby,
(i)&nbsp;none of SeaSpine or any of its Subsidiaries is required to submit any notice, report or other filing with any Governmental Body in connection with the execution, delivery or performance by it of this Agreement or the consummation of the
transactions contemplated hereby and (ii)&nbsp;no consent, approval or authorization of any Governmental Body or any other party or Person is required to be obtained by SeaSpine or any of its Subsidiaries in connection with its execution, delivery
and performance of this Agreement or the consummation of the transactions contemplated hereby, except for those consents, approvals and authorizations the failure of which to obtain would not, individually or in the aggregate, reasonably be expected
to have a SeaSpine Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.07&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC Reports; Disclosure Controls and Procedures</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine has filed or furnished all reports, schedules, forms, statements and other documents (including exhibits
and other information incorporated by reference therein) with the SEC required to be filed or furnished by SeaSpine since January&nbsp;1, 2020 (the &#147;<U>SeaSpine SEC Documents</U>&#148;). As of their respective filing dates or, if amended prior
to the date of this Agreement, as of the date of (and giving effect to) the last such amendment: (i)&nbsp;each of the SeaSpine SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act
(as the case may be), and the requirements of SOX, each as in effect on the date so filed or furnished, and (ii)&nbsp;none of the SeaSpine SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of the date of this Agreement, there are no outstanding or unresolved comments received from
the SEC with respect to any of the SeaSpine SEC Documents, and, to the knowledge of SeaSpine, none of the SeaSpine SEC Documents is the subject of any outstanding SEC comment or investigation. No Subsidiary of SeaSpine is required to file reports
with the SEC pursuant to the requirements of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements
(including all related notes and schedules) of SeaSpine and its consolidated Subsidiaries contained in the SeaSpine SEC Documents: (i)&nbsp;complied as to form in all material respects with the published rules and regulations of the SEC applicable
thereto; (ii)&nbsp;were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited statements, as permitted by Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> of the SEC, and except that the unaudited financial statements may not have contained notes and were subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments); and
(iii)&nbsp;fairly presented in all material respects the consolidated financial position of SeaSpine and its consolidated Subsidiaries as of the respective dates thereof and the consolidated results of operations and cash flows of SeaSpine and its
consolidated Subsidiaries for the periods covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine maintains a system of &#147;internal
control over financial reporting&#148; (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> of the Exchange Act) sufficient to provide reasonable assurance (i)&nbsp;that
transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP, consistently applied, (ii)&nbsp;that transactions are executed only in accordance with the authorization of management and
(iii)&nbsp;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of SeaSpine&#146;s properties or assets. Since January&nbsp;1, 2020, none of SeaSpine, SeaSpine&#146;s independent accountants, the SeaSpine
Board or its audit committee has received any oral or written notification of any (A) &#147;significant deficiency&#148; in the internal controls over financial reporting of SeaSpine, (B) &#147;material weakness&#148; in the internal controls over
financial reporting of SeaSpine, or (C)&nbsp;fraud, whether or not material, that involves management or other employees of SeaSpine or its Subsidiaries who have a significant role in the internal controls over financial reporting of SeaSpine. Since
January&nbsp;1, 2020, any material change in internal control over financial reporting required to be disclosed in any SeaSpine SEC Document has been so disclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The &#147;disclosure controls and procedures&#148; (as defined in Rules
<FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> of the Exchange Act) utilized by SeaSpine are reasonably designed to ensure that all information (both financial and <FONT
STYLE="white-space:nowrap">non-financial)</FONT> required to be disclosed by SeaSpine in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and
forms of the SEC and that all such information required to be disclosed is accumulated and communicated to the management of SeaSpine, as appropriate, to allow timely decisions regarding required disclosure and to enable the chief executive officer
and chief financial officer of SeaSpine to make the certifications required under the Exchange Act with respect to such reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Since the SeaSpine Balance Sheet Date, (i)&nbsp;neither SeaSpine
nor any of its Subsidiaries nor, to the knowledge of SeaSpine, any director, officer, employee, auditor, accountant or representative of SeaSpine or any of its Subsidiaries has received or otherwise obtained knowledge of any material complaint,
allegation, assertion or claim, whether written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of SeaSpine or any of its Subsidiaries or their respective internal accounting controls, including any
material complaint, allegation, assertion or claim that SeaSpine or any of its Subsidiaries has engaged in questionable accounting or auditing practices, and (ii)&nbsp;to the knowledge of SeaSpine, no attorney representing SeaSpine or any of its
Subsidiaries, whether or not employed by SeaSpine or any of its Subsidiaries, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation, by SeaSpine or any of its Subsidiaries or any of their
officers, directors, employees or agents to any director or executive officer of SeaSpine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine is in
material compliance with the applicable listing and corporate governance rules and regulations of NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.08&nbsp;&nbsp;&nbsp;&nbsp;<U>No Undisclosed Liabilities</U>. Except (a)&nbsp;as and to the extent disclosed or reserved against on the
unaudited consolidated balance sheet of SeaSpine as of June&nbsp;30, 2022, included in the SeaSpine SEC Documents; (b)&nbsp;as incurred after the date thereof in the ordinary course of business consistent with past practice or (c)&nbsp;as set forth
in <U>Section</U><U></U><U>&nbsp;3.08</U> of the SeaSpine Disclosure Letter, SeaSpine, together with its Subsidiaries, does not have any liabilities or obligations of any nature, whether known or unknown, absolute, accrued, contingent or otherwise
and whether due or to become due, in each case required by GAAP to be reflected or reserved against in the consolidated balance sheet of SeaSpine and its Subsidiaries prepared in accordance therewith (or disclosed in the notes to such balance
sheet), that, individually or in the aggregate, have or would reasonably be expected to have a SeaSpine Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.09&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Certain Developments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Since the SeaSpine Balance Sheet Date, there has not been any SeaSpine Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly contemplated by this Agreement, since the SeaSpine Balance Sheet Date, each of SeaSpine and its
Subsidiaries has carried on and operated its business in all material respects in the ordinary course of business consistent with past practice, and none of them has: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;amended or modified its Organizational Documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;sold, leased, assigned, transferred or purchased any material tangible assets, in each case in a
single or related series of transactions, except in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;issued, sold, redeemed or transferred any of its capital stock or other equity securities,
securities convertible into its capital stock or other equity securities or warrants, options or other rights to acquire its capital stock or other equity securities, or any bonds or debt securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;declared or paid any dividend or other distribution of the assets of SeaSpine; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;made or approved any material changes in its Plans or made any material changes in wages, salary, or
other compensation, including severance, with respect to its current or former officers, directors or executive employees other than increases in base salaries and wages that are consistent with past practices or as required by applicable Law or any
SeaSpine Plan; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;paid, loaned or advanced (other than the payment
of compensation and benefits in the ordinary course of business consistent with past practice or the payment, advance or reimbursement of business expenses in the ordinary course of business consistent with past practice or 401(k) plan loans) any
amounts to, or sold, transferred or leased any of its assets to, or entered into any other transactions with, any of its Affiliates, or made any loan to, or entered into any other transaction with, any of its directors or officers outside the
ordinary course of business or other than at arm&#146;s length; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;except as required by
applicable Law, adopted or materially amended any SeaSpine Plans; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;hired or terminated any of
its officers or employees with fixed annual compensation in excess of $350,000, with respect to <FONT STYLE="white-space:nowrap">non-officer</FONT> employees, other than in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;commenced or settled any Action in which the amount in dispute is in excess of $1,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;made any material change in accounting principles, methods, procedures or policies, except as
required by GAAP; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;made, changed or revoked any material Tax election, or settled or
compromised any material Tax claim or liabilities, or filed any substantially amended material Tax Return; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;authorized, proposed, entered into or agreed to enter into any plan of liquidation,
dissolution or other reorganization or (ii)&nbsp;authorized, proposed, entered into or agreed to enter into any merger, consolidation or business combination with any Person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;except in the ordinary course of business consistent with past practice, incurred or discharged
any Indebtedness; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;other than spinal or orthopedic implant set and instrument purchases, made
capital expenditures individually in excess of $500,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp;suffered any material damage,
destruction or loss, whether or not covered by insurance; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;sold, assigned, transferred,
abandoned or allowed to lapse or expire any material Intellectual Property rights or other intangible assets owned, used or licensed by SeaSpine or any of its Subsidiaries in connection with any product of SeaSpine or any of its Subsidiaries or the
operation of any of their businesses; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;been subject to any written claim or written threat of
infringement, misappropriation or other violation by or against SeaSpine or any of its Subsidiaries of Intellectual Property rights of SeaSpine or any of its Subsidiaries or a third party; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii)&nbsp;&nbsp;&nbsp;&nbsp;materially reduced the amount of any
insurance coverage provided by existing insurance policies; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix)&nbsp;&nbsp;&nbsp;&nbsp;committed to do or take any of
the actions described in the foregoing clauses (i)&nbsp;through (xviii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Title to Properties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine and its Subsidiaries have sufficient title to, or hold pursuant to valid and enforceable leases or other
comparable contract rights, all of the personal property and other tangible assets necessary for the conduct of the business of SeaSpine and its Subsidiaries, taken as a whole, as currently conducted, in each case free and clear of any Liens (other
than Permitted Liens), except where the failure to do so would not constitute a SeaSpine Material Adverse Effect. To SeaSpine&#146;s knowledge, all such items of tangible personal property are in normal operating condition and repair (ordinary wear
and tear excepted) and have been maintained in accordance with normal industry practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine does not
own any real property. The leased real property described in <U>Section</U><U></U><U>&nbsp;3.10(b)</U> of the SeaSpine Disclosure Letter (the &#147;<U>SeaSpine Real Property</U>&#148;) constitutes all of the real property used, occupied or leased by
SeaSpine or its Subsidiaries. The SeaSpine Real Property leases are in full force and effect, and SeaSpine holds a valid and existing leasehold interest in the SeaSpine Real Property under each such applicable lease. Neither SeaSpine nor, to
SeaSpine&#146;s knowledge, any other party to the applicable SeaSpine Real Property leases is in default in any material respect under any of such leases. No event has occurred which, if not remedied, would result in a default by SeaSpine in any
material respect under the SeaSpine Real Property leases, and, to SeaSpine&#146;s knowledge, no event has occurred which, if not remedied, would result in a default by any party other than SeaSpine in any material respect under the SeaSpine Real
Property leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;SeaSpine and its Subsidiaries have timely filed (taking into account any applicable extensions) all
material Tax Returns required to be filed by them, (ii)&nbsp;such Tax Returns are complete and correct in all material respects, (iii)&nbsp;SeaSpine and its Subsidiaries have paid all material Taxes as due and payable (whether or not shown on any
Tax Return) and, (iv)&nbsp;as of the SeaSpine Balance Sheet Date, any Liability of SeaSpine or any of its Subsidiaries for accrued Taxes not yet due and payable, or which are being contested in good faith through appropriate proceedings, has been
provided for in the financial statements of SeaSpine in accordance with applicable accounting practices and procedures. Since the SeaSpine Balance Sheet Date, neither SeaSpine nor any of its Subsidiaries has incurred any material Liability for Taxes
outside the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;No claim has been made in writing by any Governmental Body in a
jurisdiction where SeaSpine or any of its Subsidiaries do not file Tax Returns that such Person is or may be subject to taxation by that jurisdiction. There are no material Liens for Taxes (other than Taxes not yet due and payable) upon any of the
assets of SeaSpine or any of its Subsidiaries. SeaSpine and its Subsidiaries have withheld and paid all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor,
creditor, shareholder or other third party. Neither SeaSpine nor any of its Subsidiaries has been a party to any &#147;reportable transaction&#148; as defined in Section&nbsp;6707A(c)(1) of the Code and Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;No material
<FONT STYLE="white-space:nowrap">non-U.S.,</FONT> federal, state or local Tax audits or administrative or judicial Tax proceedings are pending or being conducted with respect to SeaSpine or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;(A) There is no outstanding request for any extension of time for
SeaSpine or any of its Subsidiaries to pay any material Tax or file any material Tax Return, other than any such request made in the ordinary course of business, and (B)&nbsp;there has been no waiver or extension of any applicable statute of
limitations for the assessment or collection of any material Tax of SeaSpine or any of its Subsidiaries that is currently in force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Neither SeaSpine nor any of its Subsidiaries is a party to or bound by any Tax allocation, sharing or similar
agreement (other than any commercial agreement entered into in the ordinary course of business that does not relate primarily to Taxes). Neither SeaSpine nor any of its Subsidiaries (i)&nbsp;has been a member of an affiliated group filing a
combined, consolidated or unitary Tax Return (other than a group the common parent of which was SeaSpine) or (ii)&nbsp;has Liability for the Taxes of any Person (other than SeaSpine or its Subsidiaries) under Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law), as a transferee or successor, by Contract, or otherwise (other than any commercial agreements
entered into in the ordinary course of business that do not relate primarily to Taxes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Neither SeaSpine nor
any of its Subsidiaries has been a &#147;distributing corporation&#148; or a &#147;controlled corporation&#148; within the meaning of Section&nbsp;355(a)(1)(A) of the Code (or any similar provision of state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Neither SeaSpine nor any of its Subsidiaries will be
required to include any material item of income in, or exclude any material item of deduction or loss from, taxable income, or make any material adjustment under Section&nbsp;481(a) of the Code, for any taxable period (or portion thereof) ending
after the Closing Date as a result of any: (i)&nbsp;change in or improper use of any method of accounting for any taxable period ending on or prior to the Closing Date; (ii)&nbsp;&#147;closing agreement&#148; as described in Section&nbsp;7121 of the
Code (or any corresponding or similar provision of state, local or other Law) executed prior to the Closing Date; (iii)&nbsp;installment sale or open transaction disposition made on or prior to the Closing Date; (iv)&nbsp;prepaid amount received or
deferred revenue accrued outside the ordinary course of business on or prior to the Closing Date; (v)&nbsp;election under Section&nbsp;108(i) of the Code; or (vi)&nbsp;the application of Section&nbsp;965 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;Neither SeaSpine nor any of its Subsidiaries has taken advantage of any relief or Tax deferral provisions or any
carryback of net operating losses or similar Tax items related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> for Tax purposes whether federal, state, local or foreign, including the CARES Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Neither SeaSpine nor any of its Subsidiaries has knowledge of any facts, or has taken or plans to take any action
that would reasonably be expected to prevent or impede the Merger from qualifying as a &#147;reorganization&#148; within the meaning of Section&nbsp;368 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Contracts and Commitments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;As of the date hereof, none of SeaSpine or any of its Subsidiaries is a party to or bound by any: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&#147;material contract&#148; (as such term is defined in Item&nbsp;601(b)(10) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> of the SEC) with respect to SeaSpine or any of its Subsidiaries that was required to be, but has not been, filed with the SEC with SeaSpine&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, or any SeaSpine SEC Documents filed after the date of filing of such Form <FONT STYLE="white-space:nowrap">10-K</FONT> until the date hereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Contract (A)&nbsp;relating to the disposition or
acquisition by SeaSpine or any of its Subsidiaries of a material amount of assets (1)&nbsp;after the date of this Agreement, other than in the ordinary course of business consistent with past practice, or (2)&nbsp;prior to the date hereof, which
contains any material ongoing obligations (including indemnification, <FONT STYLE="white-space:nowrap">&#147;earn-out&#148;</FONT> or other contingent obligations) that are still in effect that are reasonably likely, under any of them, to result in
liabilities to SeaSpine and its Subsidiaries in excess of $500,000 or (B)&nbsp;pursuant to which SeaSpine or any of its Subsidiaries will acquire any material ownership interest in any other person or other business enterprise other than
SeaSpine&#146;s Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;collective bargaining agreement or Contract with any labor
union, trade organization or other employee representative body (other than any statutorily mandated agreement in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Contract establishing any joint ventures, partnerships or similar arrangements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;Contract (A)&nbsp;prohibiting or materially limiting the right of SeaSpine or any of its
Subsidiaries to compete in any line of business or to conduct business with any Person or in any geographical area, (B)&nbsp;obligating SeaSpine or any of its Subsidiaries to purchase or otherwise obtain any product or service exclusively from a
single party or sell any product or service exclusively to a single party or (C)&nbsp;under which any Person has been granted the right to manufacture, sell, market or distribute any product of SeaSpine or any of its Subsidiaries on an exclusive
basis to any Person or group of Persons or in any geographical area but excluding any distribution, sales representative, sales agent or similar agreement under which SeaSpine or any of its Subsidiaries has granted a Person an exclusive geographical
area and under which SeaSpine paid commissions less than $1,000,000 to such Person in 2021 or from whom SeaSpine received less than $2,000,000 from the sale of product to said Person in 2021; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Contract pursuant to which SeaSpine or any of its Subsidiaries (A)&nbsp;licenses any material
Intellectual Property from another Person that is used by SeaSpine or one of its Subsidiaries in the conduct of its business as currently conducted that could reasonably require payment by SeaSpine or any of its Subsidiaries of royalties or license
fees exceeding $250,000 in any twelve (12)&nbsp;month period, or (B)&nbsp;licenses Intellectual Property owned by SeaSpine or any of its Subsidiaries to another Person, except <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted in
the ordinary course of business consistent with past practice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;mortgages, indentures,
guarantees, loans or credit agreements, security agreements or other Contracts relating to the borrowing of money or extension of credit of $1,000,000 or more, other than (A)&nbsp;accounts receivables and payables and (B)&nbsp;loans to direct or
indirect wholly-owned Subsidiaries, in each case in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;Contract providing for any guaranty by SeaSpine or any of its Subsidiaries of third-party
obligations (under which SeaSpine or any of its Subsidiaries has continuing obligations as of the date hereof) of $500,000 or more, other than any guaranty by SeaSpine or any of its Subsidiaries&#146; of obligations of SeaSpine or any of its
Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;Contract between SeaSpine, on the one hand, and
any Affiliate of SeaSpine (other than a Subsidiary of SeaSpine), on the other hand; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;Contract
containing a right of first refusal, right of first negotiation or right of first offer in favor of a party other than SeaSpine or its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;Contract under which SeaSpine and SeaSpine&#146;s Subsidiaries are expected to make annual
expenditures, excluding sales commissions, or receive annual revenues in excess of $2,000,000 during the current or a subsequent fiscal year; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;Contract to enter into any Contract of the type described in the foregoing clauses
(i)&nbsp;through (xi). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix has been given access to a true and correct copy of all written SeaSpine
Material Contracts, together with all material amendments, waivers or other changes thereto, and a correct and complete written summary setting forth the terms and conditions of each oral SeaSpine Material Contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Except as would not, individually or in the aggregate, reasonably be expected to have a SeaSpine Material Adverse
Effect, (i)&nbsp;SeaSpine is not in default under any Contract listed, or required to be listed, in <U>Section</U><U></U><U>&nbsp;3.12(a)</U> of the SeaSpine Disclosure Letter (each, a &#147;<U>SeaSpine Material Contract</U>&#148; and, collectively,
the &#147;<U>SeaSpine Material Contracts</U>&#148;) and (ii)&nbsp;to SeaSpine&#146;s knowledge, as of the date hereof, the parties other than SeaSpine or any of its Subsidiaries to each of the SeaSpine Material Contracts is not in default
thereunder. Each SeaSpine Material Contract is legal and in full force and effect and is valid, binding and enforceable against SeaSpine and its Subsidiaries (to the extent party thereto) and, to SeaSpine&#146;s knowledge, each other party thereto.
As of the date hereof, no party to any SeaSpine Material Contract has given any written notice, or to the knowledge of SeaSpine, any notice (whether or not written) of termination or cancellation of any SeaSpine Material Contract or that it intends
to seek to terminate or cancel any SeaSpine Material Contract (whether as a result of the transactions contemplated hereby or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;All of the patents, domain names, registered trademarks and service marks, registered copyrights and applications
for any of the foregoing, that are currently owned by SeaSpine or any of its Subsidiaries (collectively, &#147;<U>SeaSpine Registered Intellectual Property</U>&#148;) are set forth in <U>Section</U><U></U><U>&nbsp;3.13</U> of the SeaSpine Disclosure
Letter. One or more of SeaSpine and its Subsidiaries owns and possesses all right, title and interest in and to each item of the Intellectual Property owned by SeaSpine or any of its Subsidiaries free and clear of all Liens other than Permitted
Liens. To the knowledge of SeaSpine, the Intellectual Property owned by SeaSpine or its Subsidiaries, together with any Intellectual Property licensed to SeaSpine or its Subsidiaries constitutes all Intellectual Property used in and material to or
otherwise necessary for SeaSpine&#146;s or its Subsidiaries&#146; manufacture or sale of its Products or operation of the business of SeaSpine and its Subsidiaries. To the knowledge of SeaSpine, no Person is currently infringing, misappropriating,
diluting or otherwise violating, or has previously within the past four (4)&nbsp;years infringed, misappropriated, diluted or otherwise violated, any material Intellectual Property owned by SeaSpine or any of its Subsidiaries. No Person has provided
written notice of a claim or pending Action or, to the knowledge of SeaSpine, threatened a claim or Action, challenging the ownership, validity, enforceability or scope of any SeaSpine Registered Intellectual Property, and no item of SeaSpine
Registered Intellectual Property is the subject of any outstanding Order, injunction, judgment, decree or ruling enacted, adopted, promulgated or applied by a Governmental Body or arbitrator of which SeaSpine has received written notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;To SeaSpine&#146;s knowledge, SeaSpine and its Subsidiaries,
their Products and the business of SeaSpine and its Subsidiaries as currently conducted, does not infringe, misappropriate, dilute or otherwise violate any Intellectual Property owned by another Person and has not infringed, misappropriated, diluted
or otherwise violated any Intellectual Property owned by another Person within the past four (4)&nbsp;years. SeaSpine and its Subsidiaries have not, within the past four (4)&nbsp;years, received any charge, complaint, claim, demand, notice or other
communication alleging any infringement, misappropriation, dilution or other violation (including any claim that SeaSpine or a Subsidiary must license or refrain from using any Intellectual Property of another Person in order to avoid infringement,
misappropriation, dilution or other violation) of the Intellectual Property of another Person, and there is no pending Action (or to the knowledge of SeaSpine, threatened Action), claim, or suit alleging any such infringement, misappropriation,
dilution or violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine and its Subsidiaries have taken commercially reasonable efforts to protect and
preserve their rights in all Intellectual Property owned by SeaSpine or any of its Subsidiaries. To the knowledge of SeaSpine, all employees, contractors and consultants who have created Intellectual Property used in the conduct of the business of
SeaSpine or a Subsidiary as currently conducted have either (i)&nbsp;assigned to one or more of SeaSpine or its Subsidiaries all of their rights therein, to the full extent permitted by Law and to the extent such rights would not automatically vest
with SeaSpine or one of its Subsidiaries by operation of Law or (ii)&nbsp;with respect to consultants and contractors, have granted SeaSpine or its Subsidiaries sufficient rights in such Intellectual Property to conduct the business of SeaSpine and
its Subsidiaries as currently conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Data Privacy</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine and its Subsidiaries (i)&nbsp;maintain commercially reasonable policies and procedures regarding the
security, privacy, transfer and use of Personal Data that are designed to protect Personal Data from unauthorized access, use or disclosure, and (ii)&nbsp;except as would not, individually or in the aggregate, reasonably be expected to have a
SeaSpine Material Adverse Effect, since January&nbsp;1, 2018, have been in compliance with all of SeaSpine&#146;s and its Subsidiaries&#146; published and written policies, as applicable, governing the security, privacy, transfer and use of Personal
Data and applicable Laws governing data privacy and data security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;To SeaSpine&#146;s knowledge, since
January&nbsp;1, 2018, (i) none of SeaSpine or any of its Subsidiaries has experienced any confirmed unauthorized access, acquisition, theft, destruction or compromise of any Personal Data, which, individually or in the aggregate, has had a SeaSpine
Material Adverse Effect and (ii)&nbsp;there has not been any unauthorized intrusions or breaches of security into any SeaSpine information technology system used in the operation of the businesses of SeaSpine and its Subsidiaries, which,
individually or in the aggregate, has had a SeaSpine Material Adverse Effect. To SeaSpine&#146;s knowledge, since January&nbsp;1, 2018, no third-party processing Personal Data on behalf SeaSpine has experienced a security breach affecting Personal
Data of SeaSpine or its Subsidiaries, which, individually or in the aggregate, has had a SeaSpine Material Adverse Effect. Neither SeaSpine, its Subsidiaries, nor any third party acting at SeaSpine&#146;s direction or authorization has paid any
perpetrator of any actual or threatened security incident or cyber-attack, including a ransomware attack or a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attack. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To SeaSpine&#146;s knowledge, since January&nbsp;1, 2018, none of SeaSpine or any of its Subsidiaries has been
under investigation by any state, federal, or foreign jurisdiction regarding its protection, storage, use, disclosure, and transfer of Personal Data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To SeaSpine&#146;s knowledge, since January&nbsp;1, 2018, none of
SeaSpine or any of its Subsidiaries has received any material written claim, complaint, inquiry or notice from any governmental, regulatory or self-regulatory authority or entity, or any data subject, related to SeaSpine&#146;s or its
Subsidiaries&#146; collection, processing, use, storage, security, and/or disclosure of Personal Data, alleging that any of these activities are in violation of any applicable Laws governing data privacy and data security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>. There are no Actions pending, or to SeaSpine&#146;s knowledge, threatened, against SeaSpine or
any of its Subsidiaries, at law or in equity, or before or by any Governmental Body, and SeaSpine and its Subsidiaries are not subject to or in violation of any outstanding judgment, Order or decree of any court or Governmental Body, in each case,
that would, individually or in the aggregate, have a SeaSpine Material Adverse Effect. This <U>Section</U><U></U><U>&nbsp;3.15</U> shall not apply to Taxes, with respect to which exclusively the representations and warranties in
<U>Section</U><U></U><U>&nbsp;3.11</U> shall apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.16&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. <U>Section</U><U></U><U>&nbsp;3.16</U>
of the SeaSpine Disclosure Letter lists each material insurance policy maintained by SeaSpine or any of its Subsidiaries or, to SeaSpine&#146;s knowledge, under which SeaSpine is a named insured or otherwise the principal beneficiary of coverage,
including the policy number and the period, type and amount of coverage. All such insurance policies are in full force and effect and shall continue in effect until the Closing Date. Such insurance policies are sufficient, in all material respects
in the aggregate, with the operation of SeaSpine&#146;s or its Subsidiaries&#146; business for the industry in which it operates. SeaSpine is not in default with respect to its obligations under any such insurance policies and, to SeaSpine&#146;s
knowledge, there is no threatened termination of, or threatened premium increase with respect to, any of such policies, other than in connection with SeaSpine&#146;s annual renewal process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.17&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;3.17</U> of the SeaSpine Disclosure Letter lists all current SeaSpine Plans (other
than (i)&nbsp;immaterial <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plans that are otherwise SeaSpine Plans or (ii)&nbsp;any <FONT STYLE="white-space:nowrap">at-will</FONT> employment agreement or any services agreement terminable upon 30
days&#146; notice or less, in either case that does not provide for severance, notice of termination (or pay in lieu), change of control, retention or bonus pay or similar benefits (other than continuation coverage or other entitlements required by
Law)). Each SeaSpine Plan that is intended to meet the requirements to be qualified under Section&nbsp;401(a) of the Code has received a favorable determination letter or is covered by a favorable opinion letter from the Internal Revenue Service
that remains current to the effect that the form of such SeaSpine Plan is so qualified, and SeaSpine is not aware of any facts or circumstances that would reasonably be expected to jeopardize the qualification of such SeaSpine Plan. The SeaSpine
Plans comply in form and in operation in all material respects with the requirements of the Code, ERISA and other applicable Law; and SeaSpine has not become subject to any material Liability by reason of (i)&nbsp;a failure to provide any notice,
(ii)&nbsp;a failure to make any contribution to a SeaSpine Plan intended to be qualified under Section&nbsp;401(a) of the Code within the time prescribed for the contribution under ERISA, or (iii)&nbsp;a breach of fiduciary duty or prohibited
transaction under ERISA or any other applicable Law, in each case with respect to a SeaSpine Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each current material SeaSpine Plan, SeaSpine has made available true and complete copies of the following (as applicable) prior to the date hereof: (i)&nbsp;the plan document, including all amendments thereto or, with respect to any
unwritten plan, a summary of all material terms thereof; (ii)&nbsp;the summary plan description along with all summaries of material modifications thereto; (iii)&nbsp;all related trust instruments or other funding-related documents; (iv)&nbsp;a copy
of the most recent financial statements for the plan; (v)&nbsp;a copy of all material correspondence with any Governmental Body relating to a SeaSpine Plan received or sent within the last two years and (vi)&nbsp;the most recent determination or
opinion letter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Except as would not reasonably be expected to have, individually
or in the aggregate, a SeaSpine Material Adverse Effect, with respect to the SeaSpine Plans, (i)&nbsp;all required contributions to, and premiums payable in respect of, such SeaSpine Plan have been made or, to the extent not required to be made on
or before the date hereof, have been properly accrued on SeaSpine&#146;s financial statements in accordance with GAAP, and (ii)&nbsp;there are no Actions, audits, suits or claims pending or, to SeaSpine&#146;s knowledge, threatened, other than
routine claims for benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Neither SeaSpine nor any of its ERISA Affiliates has at any time in the past six
(6)&nbsp;years sponsored or contributed to, or has or has had any Liability or obligation in respect of any SeaSpine Plan (including any &#147;multiemployer plan&#148; (as defined in Section&nbsp;3(37) or Section&nbsp;4001(a)(3) of ERISA)) that is
or was at any relevant time subject to Title IV of ERISA or Section&nbsp;412 of the Code. None of the SeaSpine Plans obligates SeaSpine or its Subsidiaries to provide a current or former employee or other service provider (or any spouse or dependent
thereof) any life insurance or medical or health benefits after his or her termination of employment with SeaSpine or any of its Subsidiaries, other than as required under Part 6 of Subtitle B of Title I of ERISA, Section&nbsp;4980B of the Code or
any other Law and coverage through the end of the month of termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise
contemplated by this Agreement, neither the execution or delivery of this Agreement, nor the consummation of the transactions contemplated hereby, will, either individually or together with the occurrence of some other event (including a termination
of employment or service), (i)&nbsp;result in any payment (including severance, bonus or other similar payment) becoming due to any Person, (ii)&nbsp;increase or otherwise enhance any benefits or compensation otherwise payable under any SeaSpine
Plan, (iii)&nbsp;result in the acceleration of the time of payment or vesting of any benefits under any SeaSpine Plan, (iv)&nbsp;require SeaSpine or its Subsidiaries to set aside any assets to fund any benefits under a SeaSpine Plan or result in the
forgiveness in whole or in part of any outstanding loans made by SeaSpine to any Person, (v)&nbsp;limit the ability to amend or terminate any SeaSpine Plan or related trust or (vi)&nbsp;result in the payment of any &#147;excess parachute
payment&#148; within the meaning of Section&nbsp;280G of the Code or in the imposition of an excise Tax under Section&nbsp;4999 of the Code or Section&nbsp;409A of the Code (or, in either case, any corresponding provision of state, local or foreign
Tax law). SeaSpine has no obligation to pay any <FONT STYLE="white-space:nowrap">gross-up</FONT> in respect of any Tax under Section&nbsp;4999 of the Code or Section&nbsp;409A of the Code (or, in either case, any corresponding provision of state,
local or foreign Tax law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;With respect to each SeaSpine Plan that is a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan, and except as would not reasonably be expected to have, individually or in the aggregate, a SeaSpine Material Adverse Effect, the fair market value of the assets of each funded <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Plan, the liability of each insurer for any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Plan funded through insurance or the book reserve established for any
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan, together with any accrued contributions, is sufficient to procure or provide for the benefits determined on an ongoing basis (actual or contingent) with respect to all current or former
participants under such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan according to the actuarial assumptions and valuation most recently used to determine employer contributions to such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan,
and none of the contemplated transactions will cause such assets, insurance obligations or book reserves to be less than such benefit obligations. Each such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan required to be registered has been
registered and has been maintained in all material respects in good standing with each applicable Governmental Body. No SeaSpine Plan that is a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan is a defined benefit pension plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.18&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Law; Permits; </U><U>Anti-Corruption Laws</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine and each of its Subsidiaries hold all Permits required to operate their respective businesses as they are
being conducted as of the date hereof, and all of such Permits are in full force and effect, except where the failure to obtain or have any such Permit would, individually or in the aggregate, not reasonably be expected to have a SeaSpine Material
Adverse Effect, and no proceeding is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pending or, to the knowledge of SeaSpine, threatened to revoke, suspend, cancel, terminate or adversely modify any such Permit. Neither SeaSpine nor any of its Subsidiaries is in material
violation of, or in default under, any Law, in each case applicable to SeaSpine or any of its Subsidiaries or any of their respective assets and properties. Notwithstanding the foregoing, this <U>Section</U><U></U><U>&nbsp;3.18</U> shall not apply
to Taxes, employee benefit plans, environmental matters, labor and employment matters or regulatory matters, which are the subjects exclusively of the representations and warranties in <U>Section</U><U></U><U>&nbsp;3.11</U>,
<U>Section</U><U></U><U>&nbsp;3.17</U>, <U>Section</U><U></U><U>&nbsp;3.19</U>, <U>Section</U><U></U><U>&nbsp;3.20</U> and <U>Section</U><U></U><U>&nbsp;3.21</U>, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine and its Subsidiaries are, and since January&nbsp;1, 2018 have been, in compliance in all material respects
with Anti-Corruption Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, none of SeaSpine or its Subsidiaries nor, to the
knowledge of SeaSpine, any director, officer, employee or agent of SeaSpine, has directly or indirectly used, offered, authorized, promised, provided, paid, requested, or received, whether directly or indirectly through a third party, on behalf of
SeaSpine or its Subsidiaries or in connection with their business, any bribes, kickbacks, gifts, or anything else of value, regardless of form or amount, to any Person for any improper purpose, including for obtaining or retaining business or
securing an improper business advantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, neither SeaSpine nor its Subsidiaries, to
SeaSpine&#146;s knowledge, have been or are currently under any internal or Governmental Body review, investigation, inspection, or examination relating to their compliance with Anti-Corruption Laws, or have received any written notice or other
communication from any Governmental Body regarding a violation of, or failure to comply with, any Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, SeaSpine and its Subsidiaries have not, to their knowledge, been and are not now under
any administrative, civil, or criminal investigation, prosecution, or indictment, and neither SeaSpine nor its Subsidiaries are party to any legal actions involving alleged false statements, false claims or other improprieties relating to their
compliance with Anti-Corruption Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, SeaSpine and its Subsidiaries have
maintained an adequate system or systems of internal controls reasonably designed to ensure compliance with all Anti-Corruption Laws and prevent and detect violations of Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, neither SeaSpine nor any of its Subsidiaries has made any disclosure (voluntary or
otherwise) to any Governmental Body with respect to any alleged irregularity, misstatement or omission or other potential violation or liability arising under or relating to any Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.19&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental Compliance and Conditions</U>. Except for matters that would not, individually or in the
aggregate, reasonably be expected to have a SeaSpine Material Adverse Effect: (a)&nbsp;each of SeaSpine and its Subsidiaries is and has been in compliance with all Environmental Laws; (b)&nbsp;each of SeaSpine and its Subsidiaries holds, and is and
has been in compliance with, all authorizations, licenses and Permits required under Environmental Laws to operate its business at the SeaSpine Real Property as presently conducted; (c)&nbsp;none of SeaSpine or any of its Subsidiaries has received
any notice from any Governmental Body or third party regarding any actual or alleged violation of Environmental Laws or any Liabilities or potential Liabilities for investigation costs, cleanup costs, response costs, corrective action costs,
personal injury, property damage, natural resources damages or attorneys&#146; fees under Environmental Laws; (d)&nbsp;no Hazardous Substance has ever been released, generated, treated, contained, handled, used, manufactured, processed, buried,
disposed of, deposited or stored by SeaSpine or on, under or about any of the real property occupied or used by SeaSpine. SeaSpine has not disposed of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or released or allowed or permitted the release of any Hazardous Substance at any real property, including the SeaSpine Real Property, so as to give rise to Liability for investigation costs,
cleanup costs, response costs, corrective action costs, personal injury, property damage, natural resources damages or attorney fees under CERCLA or any other Environmental Laws; and (e)&nbsp;to SeaSpine&#146;s knowledge, there are no and have never
been any Hazardous Substances present on, at, in or under any real property currently or formerly owned, leased or used by SeaSpine for which SeaSpine has, or may have, Liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.20&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment and Labor Matters</U>. SeaSpine has made available a true and complete listing of all current
SeaSpine employees and contractors, including for each: (a)&nbsp;their work location; (b)&nbsp;date of hire; (c)&nbsp;annual base salary (or hourly wage rate, or other method of compensation as applicable); (d) job title or description of services;
and (e)&nbsp;employment or engagement status (e.g., as applicable, full-time or part-time employee, contractor, <FONT STYLE="white-space:nowrap">non-exempt</FONT> or exempt classification under the Fair Labor Standards Act or similar applicable
Laws). SeaSpine is not a party to or bound by any collective bargaining agreement or other agreement with a labor union, works council or other employee representative body (other than any statutorily mandated agreement in <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions), and there are no such agreements which pertain to employees of SeaSpine in existence or in negotiation. No employees of SeaSpine are represented by a labor union, works council or other
employee representative body (other than any statutorily mandated representation in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions). SeaSpine has not experienced any strike or material grievance, claim of unfair labor practices, or
other collective bargaining dispute within the past two (2)&nbsp;years. SeaSpine will not incur any notice, consultation or consent obligations with respect to any labor union, works council or other employee representative body in connection with
the execution of this Agreement or the consummation of the transactions contemplated hereby. There are no, and for the past four (4)&nbsp;years there have been no, Actions or any material disputes pending or threatened between SeaSpine and any of
its employees or independent contractors. To SeaSpine&#146;s knowledge, there are no, and for the past four (4)&nbsp;years there have been no Actions or any material disputes pending or threatened (i)&nbsp;by or before any Governmental Body
affecting SeaSpine concerning employment matters and (ii)&nbsp;there is no current campaign being conducted to solicit cards from or otherwise organize employees of SeaSpine or to authorize a labor union, works council or other employee
representative body to request that the National Labor Relations Board (or any other Governmental Body) certify or otherwise recognize such a body with respect to employees of SeaSpine, and SeaSpine has not been subject to an application by a labor
union, works council or other employee representative body to be declared a common or related employer under labor relations legislation. SeaSpine is in compliance in all material respects with all Laws relating to the employment of labor, including
all such Laws relating to wages, hours, civil and/or human rights, harassment, discrimination and/or retaliation in employment, reasonable accommodation, unfair competition, affirmative action, pay equity, employment equity, workers&#146;
compensation, safety and health, worker classification (including employee-independent contractor classification and the proper classification of employees as exempt employees and <FONT STYLE="white-space:nowrap">non-exempt</FONT> employees), the
Worker Adjustment and Retraining Notification Act (&#147;<U>WARN</U>&#148;) and any similar foreign, state, provincial or local &#147;mass layoff&#148; or &#147;plant closing&#148; Law. No allegation, complaint, charge or claim (formal or otherwise)
of sexual or racial harassment, sexual assault, sexual or racial misconduct, sex/gender or racial discrimination or similar behavior (a &#147;<U>Misconduct Allegation</U>&#148;) has been made at any time within the past four (4)&nbsp;years against
any Person who is or was an officer, director, manager or supervisory-level employee of SeaSpine in such person&#146;s capacity as such or, to the knowledge of SeaSpine, in any other capacity, nor are any Misconduct Allegations pending or, to the
knowledge of SeaSpine, threatened, nor is there any reasonable basis for such a Misconduct Allegation. Within the past four (4)&nbsp;years, SeaSpine has not entered into any settlement agreement, tolling agreement,
<FONT STYLE="white-space:nowrap">non-disparagement</FONT> agreement, confidentiality agreement or <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, or any Contract or provision similar to any of the foregoing relating directly or
indirectly to any Misconduct Allegation against SeaSpine or any person who is or was an officer, director, manager, employee or independent contractor of SeaSpine. There has been no &#147;mass layoff&#148; or &#147;plant closing&#148; (as defined by
WARN or any similar foreign, state, provincial or local Laws) with respect to SeaSpine within the six (6)&nbsp;months prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Closing Date. As of the date hereof, to SeaSpine&#146;s knowledge, no current executive, key employee or group of employees has given notice of termination of employment or otherwise
disclosed plans to SeaSpine or any of its Subsidiaries to terminate employment with SeaSpine or any of its Subsidiaries within the next twelve (12)&nbsp;months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.21&nbsp;&nbsp;&nbsp;&nbsp;<U>FDA and Regulatory Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as has not and would not reasonably be expected to have, individually or in the aggregate, a SeaSpine
Material Adverse Effect, SeaSpine is, and since December&nbsp;31, 2018, has been, in compliance with all Healthcare Laws applicable to SeaSpine and its Products, including requirements relating to design, clinical and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> research and/or testing, product approval or clearance, premarketing notification, labeling, advertising and promotion, <FONT STYLE="white-space:nowrap">record-keeping,</FONT> adverse event or
medical device reporting, reporting of corrections and removals, current good tissue practice (GTP), and current good manufacturing practice (GMP) for biological, tissue, and medical device products, and no officer, director, manager or managing
director of SeaSpine, or to the knowledge of SeaSpine, any other Person, has engaged in any act on behalf of SeaSpine that violates any Healthcare Law. To SeaSpine&#146;s knowledge, any contract manufacturers assisting in the manufacture of the
Products or Product components are, and, since December&nbsp;31, 2018, have been, in compliance with the FDA&#146;s establishment registration and product listing requirements to the extent required by applicable Healthcare Laws insofar as they
pertain to the manufacture of Products or Product components for SeaSpine, except as has not and would not reasonably be expected to have, individually or in the aggregate, a SeaSpine Material Adverse Effect. SeaSpine has not received any written
notification of any pending or threatened claim, subpoena, civil investigative demand, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other Action from any Governmental Body, including the Centers for
Medicare&nbsp;&amp; Medicaid Services and the U.S. Department of Health and Human Services Office of Inspector General, the U.S. Department of Justice, any U.S. Attorney&#146;s Office or state Attorney General, or any comparable state or federal
Governmental Body, or any other Person, alleging potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or Liability of, SeaSpine under any Healthcare Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine holds such Permits of Governmental Bodies required for the conduct of its business as currently conducted,
including those Permits necessary to permit the design, development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, manufacture, labeling, sale, importation, exportation, storage, shipment, distribution and promotion of
its Products in jurisdictions where it currently conducts such activities with respect to each Product (collectively, the &#147;<U>SeaSpine </U><U>Licenses</U>&#148;), except to the extent where the failure to hold such Permits would not,
individually or in the aggregate, be reasonably expected to have a SeaSpine Material Adverse Effect. SeaSpine has fulfilled and performed all of its obligations with respect to each SeaSpine License and is in material compliance with all terms and
conditions of each SeaSpine License, and, to SeaSpine&#146;s knowledge, no event has occurred which allows, or after notice or lapse of time would allow, revocation, suspension or termination thereof or would result in any other impairment of the
rights of the holder of any SeaSpine License, except to the extent where the failure to be in material compliance would not, individually or in the aggregate, be reasonably expected to have a SeaSpine Material Adverse Effect. SeaSpine has not
received any written information or notification from the FDA or any other Governmental Body with jurisdiction over the design, clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research and/or testing, labeling, advertising,
promotion, marketing, sale, use, handling and control, safety, efficacy, reliability, distribution or manufacturing of biological, tissue, or medical device products which would reasonably be expected to lead to the denial of any application for
marketing approval, licensure or clearance currently pending before the FDA or any other Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;All material filings, reports, documents, claims, submissions and notices submitted or required to be filed,
maintained or furnished to the FDA, CMS, state or other Governmental Bodies have been so timely submitted, filed, maintained or furnished and were complete and correct in all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material respects on the date filed (or were corrected in or supplemented by a subsequent filing), including all claims, statements, adverse event reports, medical device reports, reports of
recalls, corrections and removals with regard to the Products and any transparency reports. All applications, notifications, submissions, information, claims, reports, filings and other data and conclusions derived therefrom utilized as the basis
for, or submitted in connection with, any and all requests for a SeaSpine License from the FDA or other Governmental Body relating to SeaSpine or its businesses or the Products, when submitted to the FDA or any other Governmental Body, whether oral,
written or electronically delivered, were true, accurate and complete in all material respects as of the date of submission. Any necessary or required updates, changes, corrections or modifications to such applications, notifications, submissions,
information, claims, reports, filings and other data have been submitted to the FDA or other Governmental Body and as so updated, changed, corrected or modified remain true, accurate and complete in all material respects and do not materially
misstate any of the statements or information included therein or omit to state a material fact necessary to make the statements therein not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine has not received any written notice or other communication from the FDA or any other Governmental Body
contesting the regulatory classification, licensure, <FONT STYLE="white-space:nowrap">pre-market</FONT> clearance or approval of, the uses of or the labeling and promotion of any of the Products. No manufacturing site which assists in the
manufacture of the Products or Product components (whether SeaSpine-owned or operated or that of a contract manufacturer for any Products or Product components) has been subject to a Governmental Body (including the FDA) shutdown or import or export
detention, refusal or prohibition. Neither SeaSpine nor, to SeaSpine&#146;s knowledge, any manufacturing site which assists in the manufacture of any material Products or material Product components (whether SeaSpine-owned or operated or that of a
contract manufacturer for the Products or Product components) has received, since December&nbsp;31, 2018, any FDA Form 483 or other Governmental Body notice of inspectional observations or adverse findings, &#147;warning letters,&#148;
&#147;untitled letters&#148; or similar correspondence or notice from the FDA or other Governmental Body alleging, observing or asserting noncompliance with any applicable Healthcare Laws or SeaSpine Licenses or alleging a lack of safety or
effectiveness from the FDA or any other Governmental Body, and, to SeaSpine&#146;s knowledge, there is no such Action or proceeding pending or threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The FDA has not mandated that SeaSpine recall any of its Products. There are no voluntary recalls of any of
SeaSpine&#146;s Products contemplated by SeaSpine or pending. Since December&nbsp;31, 2018, there have been no recalls (either voluntary or involuntary), field notifications, field corrections, market withdrawals or replacements, warnings,
&#147;dear doctor&#148; letters, investigator notices, safety alerts or other notices of action relating to an alleged lack of safety, efficacy or regulatory compliance of any Product or Product component, or seizures ordered or adverse regulatory
actions taken (or, to SeaSpine&#146;s knowledge, threatened) by the FDA or any Governmental Body with respect to any of the Products or Product components or any facilities where Products or Product components are developed, designed, tested,
manufactured, assembled, processed, packaged or stored. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on
<U>Section</U><U></U><U>&nbsp;3.21(f)</U> of the SeaSpine Disclosure Letter, there are no clinical trials that are being conducted as of the date hereof by or on behalf of, or sponsored by, SeaSpine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine is not the subject of any pending or, to the knowledge of SeaSpine, threatened investigation regarding
SeaSpine or the Products by the FDA pursuant to the FDA Fraud Policy. Neither SeaSpine nor, to the knowledge of SeaSpine, any officer, employee, agent or distributor of SeaSpine has made an untrue statement of material fact to the FDA or any other
Governmental Body, failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Body or committed an act, made a statement or failed to make a statement that, at the time such disclosure was made, would reasonably
be expected to provide a basis for the FDA or any other Governmental Body to invoke the FDA Fraud Policy or any similar policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;All of SeaSpine&#146;s and its Subsidiaries&#146; contracts,
participation in joint ventures and other business relationships with potential customers, prescribers, physicians or other healthcare professionals, distributors, patients, or other sources of orders or referrals, including any consulting, speaker,
development, sponsorship, grant and royalty agreements with, and training events for, physicians, other healthcare professionals or providers, governmental representatives or healthcare entities or organizations, comply in all material respects with
all Healthcare Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;None of SeaSpine, SeaSpine&#146;s Subsidiaries or, to the knowledge of SeaSpine, any of
their respective officers, directors, managers, managing directors, employees, agents, or distributors is excluded from participation in any federal healthcare program as that term is defined by 42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(f),</FONT> is debarred under 21 U.S.C. &#167; 335a, or is restricted or prohibited from participation in any healthcare, procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> program or
reimbursement system authorized, funded, administered or sponsored by any Governmental Body. None of SeaSpine, SeaSpine&#146;s Subsidiaries or, to the knowledge of SeaSpine, any of their officers, directors, managers, managing directors, employees,
agents, or distributors (i)&nbsp;has engaged in, been charged with or been investigated for any conduct that would reasonably be expected to result in exclusion from any federal healthcare program or debarment or any other sanction under similar
foreign, state, or local applicable Law, or (ii)&nbsp;has otherwise engaged in any activities that would reasonably be expected to provide cause for civil, criminal or administrative penalties or sanctions or mandatory or permissive exclusion or
debarment under any Healthcare Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine has operated since December&nbsp;31, 2018, a compliance program
having all the elements of an effective compliance program identified in the Compliance Program Guidance for Pharmaceutical Manufacturers, 68 Fed. Reg. 23731 (May 5, 2003) issued by the Office of Inspector General for U.S. Department of Health and
Human Services. There are no outstanding compliance complaints or reports, ongoing internal compliance investigations, or outstanding compliance corrective actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.22&nbsp;&nbsp;&nbsp;&nbsp;<U>Brokerage</U>. Other than Piper Sandler&nbsp;&amp; Co., no Person will be entitled to, any brokerage
commissions, finders&#146; fees or similar compensation in connection with the transactions contemplated hereby based on any arrangement or agreement made by or on behalf of SeaSpine or any of its Subsidiaries. Orthofix has been given access to a
true and correct copy of all Contracts entitling any person to any brokerage commissions, finders&#146; fees or similar compensation in connection with the transactions contemplated hereby based on any arrangement or agreement made by or on behalf
of SeaSpine, together with all amendments, waivers or other changes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.23&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>. None of the
information supplied or to be supplied by or on behalf of SeaSpine for inclusion or incorporation by reference in (a)&nbsp;the Registration Statement will, at the time the Registration Statement is filed with the SEC and becomes effective under the
Securities Act or (b)&nbsp;the Joint Proxy Statement will, at the time the Joint Proxy Statement is mailed to the SeaSpine Stockholders, or at the time of the SeaSpine Stockholders&#146; Meeting, contain any untrue statement of a material fact, or
omit to state any material fact required to be stated therein, necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading or necessary in order to correct any statement of a material
fact in any earlier communication with respect to the solicitation of proxies for the SeaSpine Stockholders&#146; Meeting which has become false or misleading. The Joint Proxy Statement will comply as to form in all material respects with the
applicable provisions of the Exchange Act and the rules and regulations promulgated by the SEC thereunder. Notwithstanding the foregoing, SeaSpine makes no representation or warranty with respect to any information supplied by or to be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplied by Orthofix that is included or incorporated by reference in the Joint Proxy Statement. The representations and warranties contained in this <U>Section</U><U></U><U>&nbsp;3.23</U> will
not apply to statements or omissions included in the Registration Statement or Joint Proxy Statement upon information furnished to SeaSpine in writing by Orthofix specifically for use therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.24&nbsp;&nbsp;&nbsp;&nbsp;<U>Board Approval; Vote Required</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The SeaSpine Board, by resolutions duly adopted by a unanimous vote of all of the members of the SeaSpine Board at
a meeting duly called and held, has duly (i)&nbsp;approved and declared advisable this Agreement and the transactions contemplated by this Agreement, including the Merger, on the terms and subject to the conditions set forth in this Agreement,
(ii)&nbsp;determined that this Agreement and the transactions contemplated by this Agreement, including the Merger, are fair to, and in the best interests of, SeaSpine and the SeaSpine Stockholders, (iii)&nbsp;resolved to recommend the adoption of
this Agreement to the SeaSpine Stockholders, on the terms and subject to the conditions set forth in this Agreement, and (iv)&nbsp;directed that this Agreement be submitted to the SeaSpine Stockholders for adoption, and, subject to
<U>Section</U><U></U><U>&nbsp;6.04</U>, such resolutions have not been rescinded, modified or withdrawn in any way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of the holders of a majority of all outstanding SeaSpine Shares entitled to vote thereon (the
&#147;<U>SeaSpine Stockholder Approval</U>&#148;) is necessary to adopt this Agreement. Other than the SeaSpine Stockholder Approval, no other corporate proceeding is necessary to authorize the execution, delivery or performance of this Agreement
and the transactions contemplated thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The SeaSpine Board has taken all actions necessary to ensure that
the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL are inapplicable to the execution, delivery and performance of this Agreement and any of the transactions and other agreements contemplated hereby. No
Takeover Law applies or purports to apply to the Merger, this Agreement or any of the transactions or other agreements contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.25&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion</U>. The SeaSpine Board has received the written opinion of Piper Sandler&nbsp;&amp; Co., to the effect
that, as of the date of such opinion, and based upon and subject to the various assumptions and limitations set forth therein, the Exchange Ratio is fair, from a financial point of view, to the holders of SeaSpine Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.26&nbsp;&nbsp;&nbsp;&nbsp;<U>No Other Representations and Warranties</U>. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN
<U>ARTICLE&nbsp;3</U> OF THIS AGREEMENT (AS MODIFIED BY THE SEASPINE DISCLOSURE LETTER), SEASPINE MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, AND SEASPINE HEREBY DISCLAIMS ANY SUCH REPRESENTATION OR WARRANTY WITH RESPECT TO THE EXECUTION
AND DELIVERY OF THIS AGREEMENT AND THE CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. IN CONNECTION WITH ORTHOFIX&#146;S INVESTIGATION OF SEASPINE, ORTHOFIX HAS RECEIVED FROM OR ON BEHALF OF SEASPINE CERTAIN PROJECTIONS, INCLUDING
PROJECTED STATEMENTS OF OPERATING REVENUES AND INCOME FROM OPERATIONS OF SEASPINE AND CERTAIN BUSINESS PLAN INFORMATION OF SEASPINE. SEASPINE MAKES NO REPRESENTATIONS OR WARRANTIES WHATSOEVER WITH RESPECT TO SUCH ESTIMATES, PROJECTIONS AND OTHER
FORECASTS AND PLANS (INCLUDING THE REASONABLENESS OF THE ASSUMPTIONS UNDERLYING SUCH ESTIMATES, PROJECTIONS AND FORECASTS). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>REPRESENTATIONS AND WARRANTIES OF ORTHOFIX AND MERGER SUB </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as disclosed in (a)&nbsp;the Orthofix SEC Documents furnished or filed prior to the date hereof (excluding any disclosures in any risk
factors section or otherwise relating to forward-looking statements to the extent that they are cautionary, predictive or forward-looking in nature) or (b)&nbsp;the confidential disclosure letter delivered by Orthofix to SeaSpine prior to the
execution and delivery of this Agreement (the &#147;<U>Orthofix Disclosure Letter</U>&#148;) to the extent it makes reference to the particular Section or subsection of this Agreement to which exception is being taken (or to the extent that it is
reasonably apparent from the face of such disclosure that such disclosure also qualifies or applies to another Section or subsection of this Agreement), Orthofix represents and warrants to SeaSpine as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization and Corporate Power</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix is a corporation duly organized, validly existing and in good standing under the Laws of the State of
Delaware, with full corporate power and authority to enter into this Agreement and perform its obligations hereunder. Each of the Subsidiaries of Orthofix is a corporation or other entity duly organized and validly existing under the Laws of the
jurisdiction of its incorporation or organization. Each of Orthofix and its Subsidiaries has all requisite corporate power and authority necessary to own, lease and operate its properties and to carry on its business as it is now being conducted.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each of Orthofix and its Subsidiaries has all authorizations, licenses and permits, necessary to own, lease
and operate its properties and to carry on its business as it is now being conducted, except where the failure to hold such authorizations, licenses and permits would not have an Orthofix Material Adverse Effect. Each of Orthofix and its
Subsidiaries is duly qualified or authorized to do business and is in good standing in every jurisdiction (to the extent such concept exists in such jurisdiction) in which its ownership of property or the conduct of its business as now conducted
requires it to qualify, except where the failure to be so qualified, authorized or in good standing would not have an Orthofix Material Adverse Effect. True and complete copies of the certificate of incorporation and bylaws of Orthofix, as in effect
as of the date hereof, have been heretofore made available to SeaSpine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.02&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization; Valid and Binding
Agreement</U>. Subject to obtaining the Orthofix Stockholder Approval and the adoption of this Agreement by the sole stockholder of Merger Sub, the execution, delivery and performance of this Agreement by Orthofix and Merger Sub and each other
agreement, document, instrument or certificate contemplated hereby to be executed, delivered and performed by Orthofix and Merger Sub and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by
all requisite action on the part of Orthofix and Merger Sub, and no other corporate approvals on Orthofix&#146;s or Merger Sub&#146;s part are necessary to authorize the execution, delivery or performance of this Agreement. Assuming that this
Agreement is a valid and binding obligation of SeaSpine, this Agreement constitutes a valid and binding obligation of Orthofix and Merger Sub, enforceable in accordance with its terms, except as enforceability may be limited by applicable
bankruptcy, insolvency, fraudulent conveyance, reorganization or moratorium Laws, other similar Laws affecting creditors&#146; rights or general principles of equity affecting the availability of specific performance and other equitable remedies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.03&nbsp;&nbsp;&nbsp;&nbsp;<U>Capital Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The authorized capital stock of Orthofix consists of 50,000,000 Orthofix Shares, of which, as of the Measurement
Date, 20,007,065 Orthofix Shares were issued and outstanding. Between the Measurement Date and the date of this Agreement, there have been no issuances or grants of Orthofix Shares, Orthofix Options, Orthofix RSUs or Orthofix SPP Purchase Rights.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;4.03(b)</U> of the Orthofix
Disclosure Letter sets forth a true and complete list as of the Measurement Date of the outstanding Orthofix Shares, Orthofix Options, Orthofix RSUs and Orthofix SPP Purchase Rights (assuming that all participants in the Orthofix SPP as of the date
hereof were to continue to participate through the next regularly scheduled exercise date under the Orthofix SPP), including, with respect to each Orthofix Option, Orthofix RSU award and Orthofix SPP Purchase Right, the number of Orthofix Shares
issuable thereunder or with respect thereto, the holder thereof and the exercise price (if any), and Orthofix has granted no other such awards since the Measurement Date and prior to the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;All of the outstanding Orthofix Shares have been duly authorized and validly issued and are fully paid, <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and free of preemptive or similar rights. All of the issued and outstanding Orthofix Shares were issued in compliance in all material respects with all applicable Laws concerning the issuance of
securities. Except as set forth in <U>Section</U><U></U><U>&nbsp;4.03(b)</U> of the Orthofix Disclosure Letter, Orthofix does not have any other equity securities or securities containing any equity features authorized, issued or outstanding, and
there are no agreements, options, warrants or other rights or arrangements existing or outstanding which provide for the sale or issuance of any of the foregoing by Orthofix. Except as set forth in <U>Section</U><U></U><U>&nbsp;4.03(b)</U> of the
Orthofix Disclosure Letter, there are no outstanding (i)&nbsp;shares of capital stock or other equity interests or voting securities of Orthofix, (ii)&nbsp;securities convertible or exchangeable, directly or indirectly, into capital stock of
Orthofix, (iii)&nbsp;options, warrants, purchase rights, subscription rights, preemptive rights, conversion rights, exchange rights, calls, puts, rights of first refusal or other Contracts that require Orthofix to issue, sell or otherwise cause to
become outstanding or to acquire, repurchase or redeem capital stock of Orthofix, (iv)&nbsp;stock appreciation, phantom stock, profit participation or similar rights with respect to Orthofix or (v)&nbsp;bonds, debentures, notes or other Indebtedness
of Orthofix having the right to vote (or convertible into or exercisable for securities having the right to vote) on any matters on which stockholders of Orthofix may vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;All of the outstanding Orthofix Options, Orthofix RSUs and Orthofix SPP Purchase Rights have been duly authorized
by all necessary corporate action and were granted in accordance with the terms of all applicable Plans and applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;There are no stockholder agreements or voting trusts or other agreements or understandings to which Orthofix is a
party with respect to the voting, or restricting the transfer, of the capital stock or any other equity interest of Orthofix. Orthofix has not granted any preemptive rights, anti-dilutive rights or rights of first refusal, registration rights or
similar rights with respect to its shares of capital stock that are in effect. No shares of capital stock of Orthofix are held by any Subsidiary of Orthofix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there is no stockholder rights plan, &#147;poison pill&#148; antitakeover plan or
similar device in effect to which Orthofix or any of its Subsidiaries is subject, a party to or otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.04&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>. All of the outstanding shares of capital stock or equivalent equity interests of each of
Orthofix&#146;s Subsidiaries are owned of record and beneficially, directly or indirectly, by Orthofix free and clear of all material Liens, pledges, security interests or other encumbrances (other than Permitted Liens). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.05&nbsp;&nbsp;&nbsp;&nbsp;<U>No Breach</U>. Except with respect to clauses (b)&nbsp;and
(c)&nbsp;for any conflicts, violations, breaches, defaults or other occurrences which would not constitute an Orthofix Material Adverse Effect, the execution, delivery and performance of this Agreement by Orthofix and, subject to obtaining the
Orthofix Stockholder Approval, the consummation of the transactions contemplated hereby do not (a)&nbsp;conflict with or violate Orthofix&#146;s or any of its Subsidiaries&#146; Organizational Documents, (b)&nbsp;assuming all consents, approvals,
authorizations and other actions described in <U>Section</U><U></U><U>&nbsp;4.06</U> have been obtained and all filings and obligations described in <U>Section</U><U></U><U>&nbsp;4.06</U> have been made, conflict with or violate any Law, statute,
rule or regulation or Order, judgment or decree to which Orthofix or its Subsidiaries or any of their properties or assets is subject, or (c)&nbsp;conflict with or result in any material breach of, constitute a material default under, result in a
material violation of, give rise to a right of termination, cancellation or acceleration under, give rise to any penalties, repayment obligations, special assessments or additional payments under, result in the creation of any Lien upon any assets
of Orthofix or any of its Subsidiaries, or require any authorization, consent, waiver, approval, filing, exemption or other action by or notice to any court, other Governmental Body or other third party, under the provisions of any Orthofix Material
Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.06&nbsp;&nbsp;&nbsp;&nbsp;<U>Consents, etc.</U> Except as may be required by (a)&nbsp;the HSR Act and any other applicable
Antitrust Laws, (b)&nbsp;the Exchange Act, (c)&nbsp;the Securities Act, (d)&nbsp;U.S. state securities Laws, (e)&nbsp;NASDAQ and (f)&nbsp;the DGCL, in each case, which requirements have or will be made in connection with the transactions
contemplated hereby, (i)&nbsp;none of Orthofix or any of its Subsidiaries is required to submit any notice, report or other filing with any Governmental Body in connection with the execution, delivery or performance by it of this Agreement or the
consummation of the transactions contemplated hereby and (ii)&nbsp;no consent, approval or authorization of any Governmental Body or any other party or Person is required to be obtained by Orthofix or any of its Subsidiaries in connection with its
execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby, except for those consents, approvals and authorizations the failure of which to obtain would not, individually or in the aggregate,
reasonably be expected to have an Orthofix Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.07&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC Reports; Disclosure Controls and
Procedures</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix has filed or furnished all reports, schedules, forms, statements and other documents
(including exhibits and other information incorporated by reference therein) with the SEC required to be filed or furnished by Orthofix since January&nbsp;1, 2020 (the &#147;<U>Orthofix SEC Documents</U>&#148;). As of their respective filing dates
or, if amended prior to the date of this Agreement, as of the date of (and giving effect to) the last such amendment: (i)&nbsp;each of the Orthofix SEC Documents complied in all material respects with the applicable requirements of the Securities
Act or the Exchange Act (as the case may be), and the requirements of SOX, each as in effect on the date so filed or furnished, and (ii)&nbsp;none of the Orthofix SEC Documents contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of the date of this Agreement, there are no outstanding or unresolved
comments received from the SEC with respect to any of the Orthofix SEC Documents, and, to the knowledge of Orthofix, none of the Orthofix SEC Documents is the subject of any outstanding SEC comment or investigation. No Subsidiary of Orthofix is
required to file reports with the SEC pursuant to the requirements of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The consolidated
financial statements (including all related notes and schedules) of Orthofix and its consolidated Subsidiaries contained in the Orthofix SEC Documents: (i)&nbsp;complied as to form in all material respects with the published rules and regulations of
the SEC applicable thereto; (ii)&nbsp;were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited statements,
as permitted by Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of the SEC, and except that the unaudited financial statements may not have contained notes and were subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT>
adjustments); and (iii)&nbsp;fairly presented in all material respects the consolidated financial position of Orthofix and its consolidated Subsidiaries as of the respective dates thereof and the consolidated results of operations and cash flows of
Orthofix and its consolidated Subsidiaries for the periods covered thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix maintains a system of &#147;internal control over
financial reporting&#148; (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> of the Exchange Act) sufficient to provide reasonable assurance (i)&nbsp;that transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP, consistently applied, (ii)&nbsp;that transactions are executed only in accordance with the authorization of management and (iii)&nbsp;regarding prevention
or timely detection of the unauthorized acquisition, use or disposition of Orthofix&#146;s properties or assets. Since January&nbsp;1, 2020, none of Orthofix, Orthofix&#146;s independent accountants, the Orthofix Board or its audit committee has
received any oral or written notification of any (A) &#147;significant deficiency&#148; in the internal controls over financial reporting of Orthofix, (B) &#147;material weakness&#148; in the internal controls over financial reporting of Orthofix,
or (C)&nbsp;fraud, whether or not material, that involves management or other employees of Orthofix or its Subsidiaries who have a significant role in the internal controls over financial reporting of Orthofix. Since January&nbsp;1, 2020, any
material change in internal control over financial reporting required to be disclosed in any Orthofix SEC Document has been so disclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The &#147;disclosure controls and procedures&#148; (as defined in Rules
<FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> of the Exchange Act) utilized by Orthofix are reasonably designed to ensure that all information (both financial and <FONT
STYLE="white-space:nowrap">non-financial)</FONT> required to be disclosed by Orthofix in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and
forms of the SEC and that all such information required to be disclosed is accumulated and communicated to the management of Orthofix, as appropriate, to allow timely decisions regarding required disclosure and to enable the chief executive officer
and chief financial officer of Orthofix to make the certifications required under the Exchange Act with respect to such reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Since the Orthofix Balance Sheet Date, (i)&nbsp;neither Orthofix nor any of its Subsidiaries nor, to the knowledge
of Orthofix, any director, officer, employee, auditor, accountant or representative of Orthofix or any of its Subsidiaries has received or otherwise obtained knowledge of any material complaint, allegation, assertion or claim, whether written or
oral, regarding the accounting or auditing practices, procedures, methodologies or methods of Orthofix or any of its Subsidiaries or their respective internal accounting controls, including any material complaint, allegation, assertion or claim that
Orthofix or any of its Subsidiaries has engaged in questionable accounting or auditing practices, and (ii)&nbsp;to the knowledge of Orthofix, no attorney representing Orthofix or any of its Subsidiaries, whether or not employed by Orthofix or any of
its Subsidiaries, has reported evidence of a material violation of securities Laws, breach of fiduciary duty or similar violation, by Orthofix or any of its Subsidiaries or any of their officers, directors, employees or agents to any director or
executive officer of Orthofix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix is in material compliance with the applicable listing and corporate
governance rules and regulations of NASDAQ. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.08&nbsp;&nbsp;&nbsp;&nbsp;<U>No Undisclosed Liabilities</U>. Except (a)&nbsp;as and to the
extent disclosed or reserved against on the unaudited consolidated balance sheet of Orthofix as of June&nbsp;30, 2022, included in the Orthofix SEC Documents; (b)&nbsp;as incurred after the date thereof in the ordinary course of business consistent
with past practice or (c)&nbsp;as set forth in <U>Section</U><U></U><U>&nbsp;4.08</U> of the Orthofix Disclosure Letter, Orthofix, together with its Subsidiaries, does not have any liabilities or obligations of any nature, whether known or unknown,
absolute, accrued, contingent or otherwise and whether due or to become due, in each case required by GAAP to be reflected or reserved against in the consolidated balance sheet of Orthofix and its Subsidiaries prepared in accordance therewith (or
disclosed in the notes to such balance sheet), that, individually or in the aggregate, have or would reasonably be expected to have an Orthofix Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.09&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Certain Developments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Since the Orthofix Balance Sheet Date, there has not been any Orthofix Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly contemplated by this Agreement, since the Orthofix Balance Sheet Date, each of Orthofix and its
Subsidiaries has carried on and operated its business in all material respects in the ordinary course of business consistent with past practice, and none of them has: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;amended or modified its Organizational Documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;sold, leased, assigned, transferred or purchased any material tangible assets, in each case in a
single or related series of transactions, except in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;issued, sold, redeemed or transferred any of its capital stock or other equity securities,
securities convertible into its capital stock or other equity securities or warrants, options or other rights to acquire its capital stock or other equity securities, or any bonds or debt securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;declared or paid any dividend or other distribution of the assets of Orthofix; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;made or approved any material changes in its Plans or made any material changes in wages, salary or
other compensation, including severance, with respect to its current or former officers, directors or executive employees other than increases in base salaries and wages that are consistent with past practices or as required by applicable Law or any
Orthofix Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;paid, loaned or advanced (other than the payment of compensation and benefits
in the ordinary course of business consistent with past practice or the payment, advance or reimbursement of business expenses in the ordinary course of business consistent with past practice or 401(k) plan loans) any amounts to, or sold,
transferred or leased any of its assets to, or entered into any other transactions with, any of its Affiliates, or made any loan to, or entered into any other transaction with, any of its directors or officers outside the ordinary course of business
or other than at arm&#146;s length; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;except as required by applicable Law, adopted or
materially amended any Orthofix Plans; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;hired or terminated any of its officers or employees
with fixed annual compensation in excess of $350,000, with respect to <FONT STYLE="white-space:nowrap">non-officer</FONT> employees, other than in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;commenced or settled any Action in which the amount in dispute is in excess of $1,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;made any material change in accounting principles, methods, procedures or policies, except as
required by GAAP; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;made, changed or revoked any material Tax
election, or settled or compromised any material Tax claim or liabilities, or filed any substantially amended material Tax Return; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;authorized, proposed, entered into or agreed to enter into any plan of liquidation,
dissolution or other reorganization or (ii)&nbsp;authorized, proposed, entered into or agreed to enter into any merger, consolidation or business combination with any Person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;except in the ordinary course of business consistent with past practice, incurred or discharged
any Indebtedness; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;other than spinal or orthopedic implant set and instrument purchases, made
capital expenditures individually in excess of $500,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp;suffered any material damage,
destruction or loss, whether or not covered by insurance; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;sold, assigned, transferred,
abandoned or allowed to lapse or expire any material Intellectual Property rights or other intangible assets owned, used or licensed by Orthofix or any of its Subsidiaries in connection with any product of Orthofix or any of its Subsidiaries or the
operation of any of their businesses; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;been subject to any written claim or written threat of
infringement, misappropriation or other violation by or against Orthofix or any of its Subsidiaries of Intellectual Property rights of Orthofix or any of its Subsidiaries or a third party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii)&nbsp;&nbsp;&nbsp;&nbsp;materially reduced the amount of any insurance coverage provided by existing insurance policies;
or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix)&nbsp;&nbsp;&nbsp;&nbsp;committed to do or take any of the actions described in the foregoing clauses
(i)&nbsp;through (xviii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Title to Properties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix and its Subsidiaries have sufficient title to, or hold pursuant to valid and enforceable leases or other
comparable contract rights, all of the personal property and other tangible assets necessary for the conduct of the business of Orthofix and its Subsidiaries, taken as a whole, as currently conducted, in each case free and clear of any Liens (other
than Permitted Liens), except where the failure to do so would not constitute an Orthofix Material Adverse Effect. To Orthofix&#146;s knowledge, all such items of tangible personal property are in normal operating condition and repair (ordinary wear
and tear excepted) and have been maintained in accordance with normal industry practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Orthofix Owned
Real Property and leased real property described in <U>Section</U><U></U><U>&nbsp;4.10(b)</U> of the Orthofix Disclosure Letter (the &#147;<U>Orthofix Real Property</U>&#148;) constitutes all of the real property owned, used, occupied or leased by
Orthofix or its Subsidiaries. The Orthofix Real Property leases are in full force and effect, and Orthofix holds a valid and existing leasehold interest in the Orthofix Real Property under each such applicable lease. Neither Orthofix nor, to
Orthofix&#146;s knowledge, any other party to the applicable Orthofix Real Property leases is in default in any material respect under any of such leases. No event has occurred which, if not remedied, would result in a default by Orthofix in any
material respect under the Orthofix Real Property leases, and, to Orthofix&#146;s knowledge, no event has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occurred which, if not remedied, would result in a default by any party other than Orthofix in any material respect under the Orthofix Real Property leases. Orthofix or an Orthofix Subsidiary has
good and marketable fee simple title (or the equivalent in any applicable foreign jurisdiction) to each real property owned by Orthofix or an Orthofix Subsidiary (such real property, collectively, the &#147;<U>Orthofix Owned Real
Property</U>&#148;), free and clear of all Liens (other than Permitted Liens), except as has not been and would not reasonably be expected to have, individually or in the aggregate, an Orthofix Material Adverse Effect. Since January&nbsp;1, 2021,
neither Orthofix nor any Orthofix Subsidiary has received written notice of any pending condemnation proceeding with respect to any Orthofix Owned Real Property, and, to the knowledge of Orthofix, no such proceeding is threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Orthofix and its Subsidiaries have timely filed (taking into account any applicable extensions) all
material Tax Returns required to be filed by them, (ii)&nbsp;such Tax Returns are complete and correct in all material respects, (iii)&nbsp;Orthofix and its Subsidiaries have paid all material Taxes as due and payable (whether or not shown on any
Tax Return) and, (iv)&nbsp;as of the Orthofix Balance Sheet Date, any Liability of Orthofix or any of its Subsidiaries for accrued Taxes not yet due and payable, or which are being contested in good faith through appropriate proceedings, has been
provided for in the financial statements of Orthofix in accordance with applicable accounting practices and procedures. Since the Orthofix Balance Sheet Date, neither Orthofix nor any of its Subsidiaries has incurred any material Liability for Taxes
outside the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;No claim has been made in writing by any Governmental Body in a
jurisdiction where Orthofix or any of its Subsidiaries do not file Tax Returns that such Person is or may be subject to taxation by that jurisdiction. There are no material Liens for Taxes (other than Taxes not yet due and payable) upon any of the
assets of Orthofix or any of its Subsidiaries. Orthofix and its Subsidiaries have withheld and paid all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor,
creditor, shareholder or other third party. Neither Orthofix nor any of its Subsidiaries has been a party to any &#147;reportable transaction&#148; as defined in Section&nbsp;6707A(c)(1) of the Code and Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;No material
<FONT STYLE="white-space:nowrap">non-U.S.,</FONT> federal, state or local Tax audits or administrative or judicial Tax proceedings are pending or being conducted with respect to Orthofix or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;There is no outstanding request for any extension of time for Orthofix or any of its Subsidiaries to pay
any material Tax or file any material Tax Return, other than any such request made in the ordinary course of business, and (B)&nbsp;there has been no waiver or extension of any applicable statute of limitations for the assessment or collection of
any material Tax of Orthofix or any of its Subsidiaries that is currently in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Neither Orthofix nor any
of its Subsidiaries is a party to or bound by any Tax allocation, sharing or similar agreement (other than any commercial agreement entered into in the ordinary course of business that does not relate primarily to Taxes). Neither Orthofix nor any of
its Subsidiaries (i)&nbsp;has been a member of an affiliated group filing a combined, consolidated or unitary Tax Return (other than a group the common parent of which was Orthofix) or (ii)&nbsp;has Liability for the Taxes of any Person (other than
Orthofix or its Subsidiaries) under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law), as a transferee or successor,
by Contract, or otherwise (other than any commercial agreements entered into in the ordinary course of business that do not relate primarily to Taxes). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Neither Orthofix nor any of its Subsidiaries has been a
&#147;distributing corporation&#148; or a &#147;controlled corporation&#148; within the meaning of Section&nbsp;355(a)(1)(A) of the Code (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Neither Orthofix nor any of its Subsidiaries will be required to include any material item of income in, or exclude
any material item of deduction or loss from, taxable income, or make any material adjustment under Section&nbsp;481(a) of the Code, for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i)&nbsp;change in or
improper use of any method of accounting for any taxable period ending on or prior to the Closing Date; (ii)&nbsp;&#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any corresponding or similar provision of state, local
or other Law) executed prior to the Closing Date; (iii)&nbsp;installment sale or open transaction disposition made on or prior to the Closing Date; (iv)&nbsp;prepaid amount received or deferred revenue accrued outside the ordinary course of business
on or prior to the Closing Date; (v)&nbsp;election under Section&nbsp;108(i) of the Code; or (vi)&nbsp;the application of Section&nbsp;965 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;Neither Orthofix nor any of its Subsidiaries has taken advantage of any relief or Tax deferral provisions or any
carryback of net operating losses or similar Tax items related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> for Tax purposes whether federal, state, local or foreign, including the CARES Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Neither Orthofix nor any of its Subsidiaries has knowledge of any facts, or has taken or plans to take any action
that would reasonably be expected to prevent or impede the Merger from qualifying as a &#147;reorganization&#148; within the meaning of Section&nbsp;368 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Contracts and Commitments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;As of the date hereof, none of Orthofix or any of its Subsidiaries is a party to or bound by any: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&#147;material contract&#148; (as such term is defined in Item&nbsp;601(b)(10) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> of the SEC) with respect to Orthofix or any of its Subsidiaries that was required to be, but has not been, filed with the SEC with Orthofix&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, or any Orthofix SEC Documents filed after the date of filing of such Form <FONT STYLE="white-space:nowrap">10-K</FONT> until the date hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Contract (A)&nbsp;relating to the disposition or acquisition by Orthofix or any of its Subsidiaries
of a material amount of assets (1)&nbsp;after the date of this Agreement, other than in the ordinary course of business consistent with past practice, or (2)&nbsp;prior to the date hereof, which contains any material ongoing obligations (including
indemnification, <FONT STYLE="white-space:nowrap">&#147;earn-out&#148;</FONT> or other contingent obligations) that are still in effect that are reasonably likely, under any of them, to result in liabilities to Orthofix and its Subsidiaries in
excess of $500,000 or (B)&nbsp;pursuant to which Orthofix or any of its Subsidiaries will acquire any material ownership interest in any other person or other business enterprise other than Orthofix&#146;s Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;collective bargaining agreement or Contract with any labor union, trade organization or other
employee representative body (other than any statutorily mandated agreement in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Contract establishing any joint ventures, partnerships or similar arrangements; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;Contract (A)&nbsp;prohibiting or materially
limiting the right of Orthofix or any of its Subsidiaries to compete in any line of business or to conduct business with any Person or in any geographical area, (B)&nbsp;obligating Orthofix or any of its Subsidiaries to purchase or otherwise obtain
any product or service exclusively from a single party or sell any product or service exclusively to a single party or (C)&nbsp;under which any Person has been granted the right to manufacture, sell, market or distribute any product of Orthofix or
any of its Subsidiaries on an exclusive basis to any Person or group of Persons or in any geographical area but excluding any distribution, sales representative, sales agent or similar agreement under which Orthofix or any of its Subsidiaries has
granted a Person an exclusive geographical area and under which Orthofix paid commissions less than $1,000,000 to such Person in 2021 or from whom Orthofix received less than $2,000,000 from the sale of product to said Person in 2021; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Contract pursuant to which Orthofix or any of its Subsidiaries (A)&nbsp;licenses any material
Intellectual Property from another Person that is used by Orthofix or one of its Subsidiaries in the conduct of its business as currently conducted that could reasonably require payment by Orthofix or any of its Subsidiaries of royalties or license
fees exceeding $250,000 in any twelve (12)&nbsp;month period, or (B)&nbsp;licenses Intellectual Property owned by Orthofix or any of its Subsidiaries to another Person, except <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted in
the ordinary course of business consistent with past practice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;mortgages, indentures,
guarantees, loans or credit agreements, security agreements or other Contracts relating to the borrowing of money or extension of credit of $1,000,000 or more, other than (A)&nbsp;accounts receivables and payables and (B)&nbsp;loans to direct or
indirect wholly-owned Subsidiaries, in each case in the ordinary course of business consistent with past practice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;Contract providing for any guaranty by Orthofix or any of its Subsidiaries of third-party
obligations (under which Orthofix or any of its Subsidiaries has continuing obligations as of the date hereof) of $500,000 or more, other than any guaranty by Orthofix or any of its Subsidiaries&#146; of obligations of Orthofix or any of its
Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;Contract between Orthofix, on the one hand, and any Affiliate of Orthofix (other
than a Subsidiary of Orthofix), on the other hand; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;Contract containing a right of first
refusal, right of first negotiation or right of first offer in favor of a party other than Orthofix or its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;Contract under which Orthofix and Orthofix&#146;s Subsidiaries are expected to make annual
expenditures, excluding sales commissions, or receive annual revenues in excess of $2,000,000 during the current or a subsequent fiscal year; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;Contract to enter into any Contract of the type described in the foregoing clauses
(i)&nbsp;through (xi). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine has been given access to a true and correct copy of all written Orthofix
Material Contracts, together with all material amendments, waivers or other changes thereto, and a correct and complete written summary setting forth the terms and conditions of each oral Orthofix Material Contract. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Except as would not, individually or in the aggregate, reasonably
be expected to have an Orthofix Material Adverse Effect, (i)&nbsp;Orthofix is not in default under any Contract listed, or required to be listed, in <U>Section</U><U></U><U>&nbsp;4.12(a)</U> of the Orthofix Disclosure Letter (each, a
&#147;<U>Orthofix Material Contract</U>&#148; and, collectively, the &#147;<U>Orthofix Material Contracts</U>&#148;) and (ii)&nbsp;to Orthofix&#146;s knowledge, as of the date hereof, the parties other than Orthofix or any of its Subsidiaries to
each of the Orthofix Material Contracts is not in default thereunder. Each Orthofix Material Contract is legal and in full force and effect and is valid, binding and enforceable against Orthofix and its Subsidiaries (to the extent party thereto)
and, to Orthofix&#146;s knowledge, each other party thereto. As of the date hereof, no party to any Orthofix Material Contract has given any written notice, or to the knowledge of Orthofix, any notice (whether or not written) of termination or
cancellation of any Orthofix Material Contract or that it intends to seek to terminate or cancel any Orthofix Material Contract (whether as a result of the transactions contemplated hereby or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;All of the patents, domain names, registered trademarks and service marks, registered copyrights and applications
for any of the foregoing, that are currently owned by Orthofix or any of its Subsidiaries (collectively, &#147;<U>Orthofix Registered Intellectual Property</U>&#148;) are set forth in <U>Section</U><U></U><U>&nbsp;4.13</U> of the Orthofix Disclosure
Letter. One or more of Orthofix and its Subsidiaries owns and possesses all right, title and interest in and to each item of the Intellectual Property owned by Orthofix or any of its Subsidiaries free and clear of all Liens other than Permitted
Liens. To the knowledge of Orthofix, the Intellectual Property owned by Orthofix or its Subsidiaries, together with any Intellectual Property licensed to Orthofix or its Subsidiaries constitutes all Intellectual Property used in and material to or
otherwise necessary for Orthofix&#146;s or its Subsidiaries&#146; manufacture or sale of its Products or operation of the business of Orthofix and its Subsidiaries. To the knowledge of Orthofix, no Person is currently infringing, misappropriating,
diluting or otherwise violating, or has previously within the past four (4)&nbsp;years infringed, misappropriated, diluted or otherwise violated, any material Intellectual Property owned by Orthofix or any of its Subsidiaries. No Person has provided
written notice of a claim or pending Action or, to the knowledge of Orthofix, threatened a claim or Action, challenging the ownership, validity, enforceability or scope of any Orthofix Registered Intellectual Property, and no item of Orthofix
Registered Intellectual Property is the subject of any outstanding Order, injunction, judgment, decree or ruling enacted, adopted, promulgated or applied by a Governmental Body or arbitrator of which Orthofix has received written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;To Orthofix&#146;s knowledge, Orthofix and its Subsidiaries, their Products and the business of Orthofix and its
Subsidiaries as currently conducted, does not infringe, misappropriate, dilute or otherwise violate any Intellectual Property owned by another Person and has not infringed, misappropriated, diluted or otherwise violated any Intellectual Property
owned by another Person within the past four (4)&nbsp;years. Orthofix and its Subsidiaries have not, within the past four (4)&nbsp;years, received any charge, complaint, claim, demand, notice or other communication alleging any infringement,
misappropriation, dilution or other violation (including any claim that Orthofix or a Subsidiary must license or refrain from using any Intellectual Property of another Person in order to avoid infringement, misappropriation, dilution or other
violation) of the Intellectual Property of another Person, and there is no pending Action (or to the knowledge of SeaSpine, threatened Action), claim, or suit alleging any such infringement, misappropriation, dilution or violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix and its Subsidiaries have taken commercially reasonable efforts to protect and preserve their rights in
all Intellectual Property owned by Orthofix or any of its Subsidiaries. To the knowledge of Orthofix, all employees, contractors and consultants who have created Intellectual Property used in the conduct of the business of Orthofix or a Subsidiary
as currently conducted have either (i)&nbsp;assigned to one or more of Orthofix or its Subsidiaries all of their rights therein, to the full extent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permitted by Law and to the extent such rights would not automatically vest with Orthofix or one of its Subsidiaries by operation of Law or (ii)&nbsp;with respect to consultants and contractors,
have granted Orthofix or its Subsidiaries sufficient rights in such Intellectual Property to conduct the business of Orthofix and its Subsidiaries as currently conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Data Privacy</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix and its Subsidiaries (i)&nbsp;maintain commercially reasonable policies and procedures regarding the
security, privacy, transfer and use of Personal Data that are designed to protect Personal Data from unauthorized access, use or disclosure, and (ii)&nbsp;except as would not, individually or in the aggregate, reasonably be expected to have an
Orthofix Material Adverse Effect, since January&nbsp;1, 2018, have been in compliance with all of Orthofix&#146;s and its Subsidiaries&#146; published and written policies, as applicable, governing the security, privacy, transfer and use of Personal
Data and applicable Laws governing data privacy and data security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;To Orthofix&#146;s knowledge, since
January&nbsp;1, 2018, (i) none of Orthofix or any of its Subsidiaries has experienced any confirmed unauthorized access, acquisition, theft, destruction or compromise of any Personal Data, which, individually or in the aggregate, has had an Orthofix
Material Adverse Effect and (ii)&nbsp;there has not been any unauthorized intrusions or breaches of security into any Orthofix information technology system used in the operation of the businesses of Orthofix and its Subsidiaries, which,
individually or in the aggregate, has had an Orthofix Material Adverse Effect. To Orthofix&#146;s knowledge, since January&nbsp;1, 2018, no third-party processing Personal Data on behalf Orthofix has experienced a security breach affecting Personal
Data of Orthofix or its Subsidiaries, which, individually or in the aggregate, has had an Orthofix Material Adverse Effect. Neither Orthofix, its Subsidiaries, nor any third party acting at Orthofix&#146;s direction or authorization has paid any
perpetrator of any actual or threatened security incident or cyber-attack, including a ransomware attack or a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attack. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To Orthofix&#146;s knowledge, since January&nbsp;1, 2018, none of Orthofix or any of its Subsidiaries has been
under investigation by any state, federal, or foreign jurisdiction regarding its protection, storage, use, disclosure, and transfer of Personal Data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To Orthofix&#146;s knowledge, since January&nbsp;1, 2018, none of Orthofix or any of its Subsidiaries has received
any material written claim, complaint, inquiry or notice from any governmental, regulatory or self-regulatory authority or entity, or any data subject, related to the Orthofix&#146;s or its Subsidiaries&#146; collection, processing, use, storage,
security, and/or disclosure of Personal Data, alleging that any of these activities are in violation of any applicable Laws governing data privacy and data security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>. There are no Actions pending, or to Orthofix&#146;s knowledge, threatened, against Orthofix or
any of its Subsidiaries, at law or in equity, or before or by any Governmental Body, and Orthofix and its Subsidiaries are not subject to or in violation of any outstanding judgment, Order or decree of any court or Governmental Body, in each case,
that would, individually or in the aggregate, have an Orthofix Material Adverse Effect. This <U>Section</U><U></U><U>&nbsp;4.15</U> shall not apply to Taxes, with respect to which exclusively the representations and warranties in
<U>Section</U><U></U><U>&nbsp;4.11</U> shall apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.16&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. <U>Section</U><U></U><U>&nbsp;4.16</U>
of the Orthofix Disclosure Letter lists each material insurance policy maintained by Orthofix or any of its Subsidiaries or, to Orthofix&#146;s knowledge, under which Orthofix is a named insured or otherwise the principal beneficiary of coverage,
including the policy number and the period, type and amount of coverage. All such insurance policies are in full force and effect and shall continue in effect until the Closing Date. Such insurance policies are sufficient, in all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material respects in the aggregate, with the operation of Orthofix&#146;s or its Subsidiaries&#146; business for the industry in which it operates. Orthofix is not in default with respect to its
obligations under any such insurance policies and, to Orthofix&#146;s knowledge, there is no threatened termination of, or threatened premium increase with respect to, any of such policies, other than in connection with Orthofix&#146;s annual
renewal process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.17&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;4.17</U> of the Orthofix Disclosure Letter lists all current Orthofix Plans (other
than (i)&nbsp;immaterial <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plans that are otherwise Orthofix Plans or (ii)&nbsp;any <FONT STYLE="white-space:nowrap">at-will</FONT> employment agreement or any services agreement terminable upon 30
days&#146; notice or less, in either case that does not provide for severance, notice of termination (or pay in lieu), change of control, retention or bonus pay or similar benefits (other than continuation coverage or other entitlements required by
Law)). Each Orthofix Plan that is intended to meet the requirements to be qualified under Section&nbsp;401(a) of the Code has received a favorable determination letter or is covered by a favorable opinion letter from the Internal Revenue Service
that remains current to the effect that the form of such Orthofix Plan is so qualified, and Orthofix is not aware of any facts or circumstances that would reasonably be expected to jeopardize the qualification of such Orthofix Plan. The Orthofix
Plans comply in form and in operation in all material respects with the requirements of the Code, ERISA and other applicable Law; and Orthofix has not become subject to any material Liability by reason of (i)&nbsp;a failure to provide any notice,
(ii)&nbsp;a failure to make any contribution to an Orthofix Plan intended to be qualified under Section&nbsp;401(a) of the Code within the time prescribed for the contribution under ERISA, or (iii)&nbsp;a breach of fiduciary duty or prohibited
transaction under ERISA or any other applicable Law, in each case with respect to an Orthofix Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each current material Orthofix Plan, Orthofix has made available true and complete copies of the following (as applicable) prior to the date hereof: (i)&nbsp;the plan document, including all amendments thereto or, with respect to any
unwritten plan, a summary of all material terms thereof; (ii)&nbsp;the summary plan description along with all summaries of material modifications thereto; (iii)&nbsp;all related trust instruments or other funding-related documents; (iv)&nbsp;a copy
of the most recent financial statements for the plan; (v)&nbsp;a copy of all material correspondence with any Governmental Body relating to an Orthofix Plan received or sent within the last two years and (vi)&nbsp;the most recent determination or
opinion letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Except as would not reasonably be expected to have, individually or in the aggregate, an
Orthofix Material Adverse Effect, with respect to the Orthofix Plans, (i)&nbsp;all required contributions to, and premiums payable in respect of, such Orthofix Plan have been made or, to the extent not required to be made on or before the date
hereof, have been properly accrued on Orthofix&#146;s financial statements in accordance with GAAP, and (ii)&nbsp;there are no Actions, audits, suits or claims pending or, to Orthofix&#146;s knowledge, threatened, other than routine claims for
benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Neither Orthofix nor any of its ERISA Affiliates has at any time in the past six (6)&nbsp;years
sponsored or contributed to, or has or has had any Liability or obligation in respect of any Orthofix Plan (including any &#147;multiemployer plan&#148; (as defined in Section&nbsp;3(37) or Section&nbsp;4001(a)(3) of ERISA)) that is or was at any
relevant time subject to Title IV of ERISA or Section&nbsp;412 of the Code. None of the Orthofix Plans obligates Orthofix or its Subsidiaries to provide a current or former employee or other service provider (or any spouse or dependent thereof) any
life insurance or medical or health benefits after his or her termination of employment with Orthofix or any of its Subsidiaries, other than as required under Part 6 of Subtitle B of Title I of ERISA, Section&nbsp;4980B of the Code or any other Law
and coverage through the end of the month of termination of employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise contemplated by this Agreement, neither the
execution or delivery of this Agreement, nor the consummation of the transactions contemplated hereby, will, either individually or together with the occurrence of some other event (including a termination of employment or service), (i)&nbsp;result
in any payment (including severance, bonus or other similar payment) becoming due to any Person, (ii)&nbsp;increase or otherwise enhance any benefits or compensation otherwise payable under any Orthofix Plan, (iii)&nbsp;result in the acceleration of
the time of payment or vesting of any benefits under any Orthofix Plan, (iv)&nbsp;require Orthofix or its Subsidiaries to set aside any assets to fund any benefits under an Orthofix Plan or result in the forgiveness in whole or in part of any
outstanding loans made by Orthofix to any Person, (v)&nbsp;limit the ability to amend or terminate any Orthofix Plan or related trust or (vi)&nbsp;result in the payment of any &#147;excess parachute payment&#148; within the meaning of
Section&nbsp;280G of the Code or in the imposition of an excise Tax under Section&nbsp;4999 of the Code or Section&nbsp;409A of the Code (or, in either case, any corresponding provision of state, local or foreign Tax law). Orthofix has no obligation
to pay any <FONT STYLE="white-space:nowrap">gross-up</FONT> in respect of any Tax under Section&nbsp;4999 of the Code or Section&nbsp;409A of the Code (or, in either case, any corresponding provision of state, local or foreign Tax law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;With respect to each Orthofix Plan that is a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan, and except as
would not reasonably be expected to have, individually or in the aggregate, an Orthofix Material Adverse Effect, the fair market value of the assets of each funded <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan, the liability of each insurer
for any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Plan funded through insurance or the book reserve established for any <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan, together with any accrued contributions, is sufficient to procure
or provide for the benefits determined on an ongoing basis (actual or contingent) with respect to all current or former participants under such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan according to the actuarial assumptions and
valuation most recently used to determine employer contributions to such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan, and none of the contemplated transactions will cause such assets, insurance obligations or book reserves to be less than
such benefit obligations. Each such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan required to be registered has been registered and has been maintained in all material respects in good standing with each applicable Governmental Body. No
Orthofix Plan that is a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Plan is a defined benefit pension plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.18&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Law; Permits; </U><U>Anti-Corruption Laws</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix and each of its Subsidiaries hold all Permits required to operate their respective businesses as they are
being conducted as of the date hereof, and all of such Permits are in full force and effect, except where the failure to obtain or have any such Permit would, individually or in the aggregate, not reasonably be expected to have an Orthofix Material
Adverse Effect, and no proceeding is pending or, to the knowledge of Orthofix, threatened to revoke, suspend, cancel, terminate or adversely modify any such Permit. Neither Orthofix nor any of its Subsidiaries is in material violation of, or in
default under, any Law, in each case applicable to Orthofix or any of its Subsidiaries or any of their respective assets and properties. Notwithstanding the foregoing, this <U>Section</U><U></U><U>&nbsp;4.18</U> shall not apply to Taxes, employee
benefit plans, environmental matters, labor and employment matters or regulatory matters, which are the subjects exclusively of the representations and warranties in <U>Section</U><U></U><U>&nbsp;4.11</U>, <U>Section</U><U></U><U>&nbsp;4.17</U>,
<U>Section</U><U></U><U>&nbsp;4.19</U>, <U>Section</U><U></U><U>&nbsp;4.20</U> and <U>Section</U><U></U><U>&nbsp;4.21</U>, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix and its Subsidiaries are, and since January&nbsp;1, 2018 have been, in compliance in all material respects
with Anti-Corruption Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, none of Orthofix or its Subsidiaries nor, to the
knowledge of Orthofix, any director, officer, employee or agent of Orthofix, has directly or indirectly used, offered, authorized, promised, provided, paid, requested, or received, whether directly or indirectly through a third party, on behalf of
Orthofix or its Subsidiaries or in connection with their business, any bribes, kickbacks, gifts, or anything else of value, regardless of form or amount, to any Person for any improper purpose, including for obtaining or retaining business or
securing an improper business advantage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, neither Orthofix nor its
Subsidiaries, to their knowledge, have been or are currently under any internal or Governmental Body review, investigation, inspection, or examination relating to their compliance with Anti-Corruption Laws, or have received any written notice or
other communication from any Governmental Body regarding a violation of, or failure to comply with, any Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, Orthofix and its Subsidiaries have not, to their knowledge, been and are not now under
any administrative, civil, or criminal investigation, prosecution, or indictment, and neither Orthofix nor its Subsidiaries are party to any legal actions involving alleged false statements, false claims or other improprieties relating to their
compliance with Anti-Corruption Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, Orthofix and its Subsidiaries have
maintained an adequate system or systems of internal controls reasonably designed to ensure compliance with all Anti-Corruption Laws and prevent and detect violations of Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2018, neither Orthofix nor any of its Subsidiaries has made any disclosure (voluntary or
otherwise) to any Governmental Body with respect to any alleged irregularity, misstatement or omission or other potential violation or liability arising under or relating to any Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.19&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental Compliance and Conditions</U>. Except for matters that would not, individually or in the
aggregate, reasonably be expected to have an Orthofix Material Adverse Effect: (a)&nbsp;each of Orthofix and its Subsidiaries is and has been in compliance with all Environmental Laws; (b)&nbsp;each of Orthofix and its Subsidiaries holds, and is and
has been in compliance with, all authorizations, licenses and Permits required under Environmental Laws to operate its business at the Orthofix Real Property as presently conducted; (c)&nbsp;none of Orthofix or any of its Subsidiaries has received
any notice from any Governmental Body or third party regarding any actual or alleged violation of Environmental Laws or any Liabilities or potential Liabilities for investigation costs, cleanup costs, response costs, corrective action costs,
personal injury, property damage, natural resources damages or attorneys&#146; fees under Environmental Laws; (d)&nbsp;no Hazardous Substance has ever been released, generated, treated, contained, handled, used, manufactured, processed, buried,
disposed of, deposited or stored by Orthofix or on, under or about any of the real property occupied or used by Orthofix. Orthofix has not disposed of or released or allowed or permitted the release of any Hazardous Substance at any real property,
including the Orthofix Real Property, so as to give rise to Liability for investigation costs, cleanup costs, response costs, corrective action costs, personal injury, property damage, natural resources damages or attorney fees under CERCLA or any
other Environmental Laws; and (e)&nbsp;to Orthofix&#146;s knowledge, there are no and have never been any Hazardous Substances present on, at, in or under any real property currently or formerly owned, leased or used by Orthofix for which Orthofix
has, or may have, Liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.20&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment and Labor Matters</U>. Orthofix has made available a true and
complete listing of all current Orthofix employees and contractors, including for each: (a)&nbsp;their work location; (b)&nbsp;date of hire; (c)&nbsp;annual base salary (or hourly wage rate, or other method of compensation as applicable); (d) job
title or description of services; and (e)&nbsp;employment or engagement status (e.g., as applicable, full-time or part-time employee, contractor, <FONT STYLE="white-space:nowrap">non-exempt</FONT> or exempt classification under the Fair Labor
Standards Act or similar applicable Laws). Orthofix is not a party to or bound by any collective bargaining agreement or other agreement with a labor union, works council or other employee representative body (other than any statutorily mandated
agreement in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions), and there are no such agreements which pertain to employees of Orthofix in existence or in negotiation. No employees of Orthofix are represented by a labor union, works
council or other employee representative body (other than any statutorily mandated representation in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions). Orthofix has not experienced any strike or material grievance, claim of unfair
labor practices, or other collective bargaining dispute within the past </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
two (2)&nbsp;years. Orthofix will not incur any notice, consultation or consent obligations with respect to any labor union, works council or other employee representative body in connection with
the execution of this Agreement or the consummation of the transactions contemplated hereby. There are no, and for the past four (4)&nbsp;years there have been no, Actions or any material disputes pending or threatened between Orthofix and any of
its employees or independent contractors. To Orthofix&#146;s knowledge, there are no, and for the past four (4)&nbsp;years there have been no Actions or any material disputes pending or threatened (i)&nbsp;by or before any Governmental Body
affecting Orthofix concerning employment matters and (ii)&nbsp;there is no current campaign being conducted to solicit cards from or otherwise organize employees of Orthofix or to authorize a labor union, works council or other employee
representative body to request that the National Labor Relations Board (or any other Governmental Body) certify or otherwise recognize such a body with respect to employees of Orthofix, and Orthofix has not been subject to an application by a labor
union, works council or other employee representative body to be declared a common or related employer under labor relations legislation. Orthofix is in compliance in all material respects with all Laws relating to the employment of labor, including
all such Laws relating to wages, hours, civil and/or human rights, harassment, discrimination and/or retaliation in employment, reasonable accommodation, unfair competition, affirmative action, pay equity, employment equity, workers&#146;
compensation, safety and health, worker classification (including employee-independent contractor classification and the proper classification of employees as exempt employees and <FONT STYLE="white-space:nowrap">non-exempt</FONT> employees), WARN
and any similar foreign, state, provincial or local &#147;mass layoff&#148; or &#147;plant closing&#148; Law. No Misconduct Allegation has been made at any time within the past four (4)&nbsp;years against any Person who is or was an officer,
director, manager or supervisory-level employee of Orthofix in such person&#146;s capacity as such or, to the knowledge of Orthofix, in any other capacity, nor are any Misconduct Allegations pending or, to the knowledge of Orthofix, threatened, nor
is there any reasonable basis for such a Misconduct Allegation. Within the past four (4)&nbsp;years, Orthofix has not entered into any settlement agreement, tolling agreement, <FONT STYLE="white-space:nowrap">non-disparagement</FONT> agreement,
confidentiality agreement or <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, or any Contract or provision similar to any of the foregoing relating directly or indirectly to any Misconduct Allegation against Orthofix or any person
who is or was an officer, director, manager, employee or independent contractor of Orthofix. There has been no &#147;mass layoff&#148; or &#147;plant closing&#148; (as defined by WARN or any similar foreign, state, provincial or local Laws) with
respect to Orthofix within the six (6)&nbsp;months prior to the Closing Date. As of the date hereof, to Orthofix&#146;s knowledge, no current executive, key employee or group of employees has given notice of termination of employment or otherwise
disclosed plans to Orthofix or any of its Subsidiaries to terminate employment with Orthofix or any of its Subsidiaries within the next twelve (12)&nbsp;months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.21&nbsp;&nbsp;&nbsp;&nbsp;<U>FDA and Regulatory Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as has not and would not reasonably be expected to have, individually or in the aggregate, an Orthofix
Material Adverse Effect, Orthofix is, and since December&nbsp;31, 2018, has been, in compliance with all Healthcare Laws applicable to Orthofix and its Products, including requirements relating to design, clinical and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> research and/or testing, product approval or clearance, premarketing notification, labeling, advertising and promotion, <FONT STYLE="white-space:nowrap">record-keeping,</FONT> adverse event or
medical device reporting, reporting of corrections and removals, current good tissue practice (GTP), and current good manufacturing practice (GMP) for biological, tissue, and medical device products, and no officer, director, manager or managing
director of Orthofix, or to the knowledge of Orthofix, any other Person, has engaged in any act on behalf of Orthofix that violates any Healthcare Law. To Orthofix&#146;s knowledge, any contract manufacturers assisting in the manufacture of the
Products or Product components are, and, since December&nbsp;31, 2018, have been, in compliance with the FDA&#146;s establishment registration and product listing requirements to the extent required by applicable Healthcare Laws insofar as they
pertain to the manufacture of Products or Product components for Orthofix, except as has not and would not reasonably be expected to have, individually or in the aggregate, an Orthofix Material Adverse Effect. Orthofix has not received any written
notification of any pending or threatened claim, subpoena, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
civil investigative demand, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other Action from any Governmental Body, including the Centers for Medicare&nbsp;&amp;
Medicaid Services and the U.S. Department of Health and Human Services Office of Inspector General, the U.S. Department of Justice, any U.S. Attorney&#146;s Office or state Attorney General, or any comparable state or federal Governmental Body, or
any other Person, alleging potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or Liability of, Orthofix under any Healthcare Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix holds such Permits of Governmental Bodies required for the conduct of its business as currently conducted,
including those Permits necessary to permit the design, development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, manufacture, labeling, sale, importation, exportation, storage, shipment, distribution and promotion of
its Products in jurisdictions where it currently conducts such activities with respect to each Product (collectively, the &#147;<U>Orthofix </U><U>Licenses</U>&#148;), except to the extent where the failure to hold such Permits would not,
individually or in the aggregate, be reasonably expected to have an Orthofix Material Adverse Effect. Orthofix has fulfilled and performed all of its obligations with respect to each Orthofix License and is in material compliance with all terms and
conditions of each Orthofix License, and, to Orthofix&#146;s knowledge, no event has occurred which allows, or after notice or lapse of time would allow, revocation, suspension or termination thereof or would result in any other impairment of the
rights of the holder of any Orthofix License, except to the extent where the failure to be in material compliance would not, individually or in the aggregate, be reasonably expected to have an Orthofix Material Adverse Effect. Orthofix has not
received any written information or notification from the FDA or any other Governmental Body with jurisdiction over the design, clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> research and/or testing, labeling, advertising,
promotion, marketing, sale, use, handling and control, safety, efficacy, reliability, distribution or manufacturing of biological, tissue, or medical device products which would reasonably be expected to lead to the denial of any application for
marketing approval, licensure or clearance currently pending before the FDA or any other Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;All material filings, reports, documents, claims, submissions and notices submitted or required to be filed,
maintained or furnished to the FDA, CMS, state or other Governmental Bodies have been so timely submitted, filed, maintained or furnished and were complete and correct in all material respects on the date filed (or were corrected in or supplemented
by a subsequent filing), including all claims, statements, adverse event reports, medical device reports, reports of recalls, corrections and removals with regard to the Products and any transparency reports. All applications, notifications,
submissions, information, claims, reports, filings and other data and conclusions derived therefrom utilized as the basis for, or submitted in connection with, any and all requests for an Orthofix License from the FDA or other Governmental Body
relating to Orthofix or its businesses or the Products, when submitted to the FDA or any other Governmental Body, whether oral, written or electronically delivered, were true, accurate and complete in all material respects as of the date of
submission. Any necessary or required updates, changes, corrections or modifications to such applications, notifications, submissions, information, claims, reports, filings and other data have been submitted to the FDA or other Governmental Body and
as so updated, changed, corrected or modified remain true, accurate and complete in all material respects and do not materially misstate any of the statements or information included therein or omit to state a material fact necessary to make the
statements therein not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix has not received any written notice or other communication from
the FDA or any other Governmental Body contesting the regulatory classification, licensure, <FONT STYLE="white-space:nowrap">pre-market</FONT> clearance or approval of, the uses of or the labeling and promotion of any of the Products. No
manufacturing site which assists in the manufacture of the Products or Product components (whether Orthofix-owned or operated or that of a contract manufacturer for any Products or Product components) has been subject to a Governmental Body
(including the FDA) shutdown or import or export detention, refusal or prohibition. Neither Orthofix nor, to Orthofix&#146;s knowledge, any manufacturing site which assists in the manufacture of any material Products or material Product components
(whether </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Orthofix-owned or operated or that of a contract manufacturer for the Products or Product components) has received, since December&nbsp;31, 2018, any FDA Form&nbsp;483 or other Governmental Body
notice of inspectional observations or adverse findings, &#147;warning letters,&#148; &#147;untitled letters&#148; or similar correspondence or notice from the FDA or other Governmental Body alleging, observing or asserting noncompliance with any
applicable Healthcare Laws or Orthofix Licenses or alleging a lack of safety or effectiveness from the FDA or any other Governmental Body, and, to Orthofix&#146;s knowledge, there is no such Action or proceeding pending or threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The FDA has not mandated that Orthofix recall any of its Products. There are no voluntary recalls of any of
Orthofix&#146;s Products contemplated by Orthofix or pending. Since December&nbsp;31, 2018, there have been no recalls (either voluntary or involuntary), field notifications, field corrections, market withdrawals or replacements, warnings,
&#147;dear doctor&#148; letters, investigator notices, safety alerts or other notices of action relating to an alleged lack of safety, efficacy or regulatory compliance of any Product or Product component, or seizures ordered or adverse regulatory
actions taken (or, to Orthofix&#146;s knowledge, threatened) by the FDA or any Governmental Body with respect to any of the Products or Product components or any facilities where Products or Product components are developed, designed, tested,
manufactured, assembled, processed, packaged or stored. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on
<U>Section</U><U></U><U>&nbsp;4.21(f)</U> of the Orthofix Disclosure Letter, there are no clinical trials that are being conducted as of the date hereof by or on behalf of, or sponsored by, Orthofix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix is not the subject of any pending or, to the knowledge of Orthofix, threatened investigation regarding
Orthofix or the Products by the FDA pursuant to the FDA Fraud Policy. Neither Orthofix nor, to the knowledge of Orthofix, any officer, employee, agent or distributor of Orthofix has made an untrue statement of material fact to the FDA or any other
Governmental Body, failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Body or committed an act, made a statement or failed to make a statement that, at the time such disclosure was made, would reasonably
be expected to provide a basis for the FDA or any other Governmental Body to invoke the FDA Fraud Policy or any similar policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;All of Orthofix&#146;s and its Subsidiaries&#146; contracts, participation in joint ventures and other business
relationships with potential customers, prescribers, physicians or other healthcare professionals, distributors, patients, or other sources of orders or referrals, including any consulting, speaker, development, sponsorship, grant and royalty
agreements with, and training events for, physicians, other healthcare professionals or providers, governmental representatives or healthcare entities or organizations, comply in all material respects with all Healthcare Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;None of Orthofix, Orthofix&#146;s Subsidiaries or, to the knowledge of Orthofix, any of their respective officers,
directors, managers, managing directors or employees is excluded from participation in any federal healthcare program as that term is defined by 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(f),</FONT> is debarred under 21 U.S.C. &#167;
335a, or is restricted or prohibited from participation in any healthcare, procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> program or reimbursement system authorized, funded, administered or sponsored by any Governmental Body.
None of Orthofix, Orthofix&#146;s Subsidiaries or, to the knowledge of Orthofix, any of their officers, directors, managers, managing directors, employees, agents, or distributors (i)&nbsp;has engaged in, been charged with or been investigated for
any conduct that would reasonably be expected to result in exclusion from any federal healthcare program or debarment or any other sanction under similar foreign, state, or local applicable Law, or (ii)&nbsp;has otherwise engaged in any activities
that would reasonably be expected to provide cause for civil, criminal or administrative penalties or sanctions or mandatory or permissive exclusion or debarment under any Healthcare Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix has operated since December&nbsp;31, 2018, a compliance
program having all the elements of an effective compliance program identified in the Compliance Program Guidance for Pharmaceutical Manufacturers, 68 Fed. Reg. 23731 (May 5, 2003) issued by the Office of Inspector General for U.S. Department of
Health and Human Services. There are no outstanding compliance complaints or reports, ongoing internal compliance investigations, or outstanding compliance corrective actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.22&nbsp;&nbsp;&nbsp;&nbsp;<U>Brokerage</U>. Other than Perella Weinberg Partners LP, no Person will be entitled to, any brokerage
commissions, finders&#146; fees or similar compensation in connection with the transactions contemplated hereby based on any arrangement or agreement made by or on behalf of Orthofix or any of its Subsidiaries. SeaSpine has been given access to a
true and correct copy of all Contracts entitling any person to any brokerage commissions, finders&#146; fees or similar compensation in connection with the transactions contemplated hereby based on any arrangement or agreement made by or on behalf
of Orthofix, together with all amendments, waivers or other changes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.23&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>. None of the
information supplied or to be supplied by or on behalf of Orthofix for inclusion or incorporation by reference in (a)&nbsp;the Registration Statement will, at the time the Registration Statement is filed with the SEC and becomes effective under the
Securities Act or (b)&nbsp;the Joint Proxy Statement will, at the time the Joint Proxy Statement is mailed to the Orthofix Stockholders, or at the time of the Orthofix Stockholders&#146; Meeting, contain any untrue statement of a material fact, or
omit to state any material fact required to be stated therein, necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading or necessary in order to correct any statement of a material
fact in any earlier communication with respect to the solicitation of proxies for the Orthofix Stockholders&#146; Meeting which has become false or misleading. The Joint Proxy Statement will comply as to form in all material respects with the
applicable provisions of the Exchange Act and the rules and regulations promulgated by the SEC thereunder. Notwithstanding the foregoing, Orthofix makes no representation or warranty with respect to any information supplied by or to be supplied by
SeaSpine that is included or incorporated by reference in the Joint Proxy Statement. The representations and warranties contained in this <U>Section</U><U></U><U>&nbsp;4.23</U> will not apply to statements or omissions included in the Registration
Statement or Joint Proxy Statement upon information furnished to Orthofix in writing by SeaSpine specifically for use therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.24&nbsp;&nbsp;&nbsp;&nbsp;<U>Board Approval; Vote Required</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Orthofix Board, by resolutions duly adopted by a unanimous vote of all of the members of the Orthofix Board at
a meeting duly called and held, has duly (i)&nbsp;approved and declared advisable this Agreement and the transactions contemplated by this Agreement, including the Merger and the Orthofix Share Issuance, on the terms and subject to the conditions
set forth in this Agreement, (ii)&nbsp;determined that this Agreement and the transactions contemplated by this Agreement, including the Merger and the Orthofix Share Issuance, are fair to, and in the best interests of, Orthofix and the Orthofix
Stockholders, (iii)&nbsp;resolved to recommend the approval of the Orthofix Share Issuance to the Orthofix Stockholders, on the terms and subject to the conditions set forth in this Agreement, and (iv)&nbsp;directed that the Orthofix Share Issuance
be submitted to the Orthofix Stockholders for approval, and, subject to <U>Section</U><U></U><U>&nbsp;6.04</U>, such resolutions have not been rescinded, modified or withdrawn in any way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of a majority in voting power of the outstanding Orthofix Shares present in person or
represented by proxy at the Orthofix Stockholders&#146; Meeting and entitled to vote on the proposal to approve the Orthofix Share Issuance (the &#147;<U>Orthofix Stockholder Approval</U>&#148;) is necessary to approve the Orthofix Share Issuance.
Other than the Orthofix Stockholder Approval, no other corporate proceeding is necessary to authorize the execution, delivery or performance of this Agreement and the transactions contemplated thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Orthofix Board has taken all actions necessary to ensure that
the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL are inapplicable to the execution, delivery and performance of this Agreement and any of the transactions and other agreements contemplated hereby. No
Takeover Law applies or purports to apply to the Merger, this Agreement or any of the transactions or other agreements contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.25&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion</U>. Prior to the execution of this Agreement, the Orthofix Board has received an opinion from Perella
Weinberg Partners LP to the effect that, as of the date thereof and based upon and subject to the various assumptions and limitations set forth therein, the Exchange Ratio provided for in the Merger is fair, from a financial point of view, to
Orthofix. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.26&nbsp;&nbsp;&nbsp;&nbsp;<U>Merger Sub</U>. Merger Sub was organized solely for the purpose of entering into this Agreement
and consummating the transactions contemplated hereby and has not engaged in any activities or business and has incurred no liabilities or obligations whatsoever, in each case other than those incident to its organization and the execution of this
Agreement and the consummation of the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:2%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.27&nbsp;&nbsp;&nbsp;&nbsp;<U>No Other
Representations and Warranties</U>. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN <U>ARTICLE&nbsp;4</U> OF THIS AGREEMENT (AS MODIFIED BY THE ORTHOFIX DISCLOSURE LETTER), ORTHOFIX MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY,
AND ORTHOFIX HEREBY DISCLAIMS ANY SUCH REPRESENTATION OR WARRANTY WITH RESPECT TO THE EXECUTION AND DELIVERY OF THIS AGREEMENT AND THE CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. IN CONNECTION WITH SEASPINE&#146;S INVESTIGATION
OF ORTHOFIX, SEASPINE HAS RECEIVED FROM OR ON BEHALF OF ORTHOFIX CERTAIN PROJECTIONS, INCLUDING PROJECTED STATEMENTS OF OPERATING REVENUES AND INCOME FROM OPERATIONS OF ORTHOFIX AND CERTAIN BUSINESS PLAN INFORMATION OF ORTHOFIX. ORTHOFIX MAKES NO
REPRESENTATIONS OR WARRANTIES WHATSOEVER WITH RESPECT TO SUCH ESTIMATES, PROJECTIONS AND OTHER FORECASTS AND PLANS (INCLUDING THE REASONABLENESS OF THE ASSUMPTIONS UNDERLYING SUCH ESTIMATES, PROJECTIONS AND FORECASTS). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 5 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>COVENANTS RELATING
TO CONDUCT OF BUSINESS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Covenants of SeaSpine</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except (i)&nbsp;as set forth in <U>Section</U><U></U><U>&nbsp;5.01(a)</U> of the SeaSpine Disclosure Letter,
(ii)&nbsp;as required by applicable Law, (iii)&nbsp;as expressly required by this Agreement, (iv)&nbsp;with the prior written consent of Orthofix (which consent shall not be unreasonably delayed, withheld or conditioned), or (v)&nbsp;for the taking
of any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Response, from the date hereof until the earlier of the Effective Time or the date this Agreement is validly terminated in accordance with <U>ARTICLE 8</U> (the &#147;<U><FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Period</U>&#148;), SeaSpine and its Subsidiaries shall conduct the business and operations of SeaSpine and its Subsidiaries, taken as a whole, in all material respects in the ordinary course of business
consistent with past practice. During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, SeaSpine shall, promptly upon learning of the same, notify Orthofix (A)&nbsp;of any change, occurrence, effect, condition, fact, event or
circumstance known to SeaSpine that is reasonably likely, individually or taken together with all other changes, occurrences, effects, conditions, facts, events and circumstances known to SeaSpine, to result in a SeaSpine Material Adverse Effect and
(B)&nbsp;any matter reasonably likely to constitute a failure by SeaSpine of any of the conditions contained in <U>Section</U><U></U><U>&nbsp;7.02(a)</U> or <U>Section</U><U></U><U>&nbsp;7.02(b)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except (i)&nbsp;as set forth on
<U>Section</U><U></U><U>&nbsp;5.01(b)</U> of the SeaSpine Disclosure Letter, (ii)&nbsp;as required by applicable Law, (iii)&nbsp;as expressly required by this Agreement, (iv)&nbsp;with the prior written consent of Orthofix (which consent shall not
be unreasonably delayed, withheld or conditioned) or (v)&nbsp;for the taking of any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Response, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, SeaSpine shall not and shall not
permit any of its Subsidiaries, without the prior written consent of Orthofix (which consent shall not be unreasonably delayed, withheld or conditioned), to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;(X)&nbsp;declare, set aside or pay any dividends on or make other distributions in respect of any of
its capital stock or shares or (Y)&nbsp;other than pursuant to the issuance of SeaSpine Shares to holders of SeaSpine Exchangeable Shares pursuant to the exchange, redemption or retraction of SeaSpine Exchangeable Shares pursuant to AcquireCo&#146;s
Articles and the SeaSpine Support Agreement, directly or indirectly redeem, repurchase or otherwise acquire any shares of its capital stock or any SeaSpine Options, SeaSpine RSUs, SeaSpine Restricted Shares or SeaSpine ESPP Purchase Rights with
respect thereto except, in each case: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;for the declaration and payment of dividends by a direct
or indirect wholly-owned Subsidiary of SeaSpine solely to its parent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;in connection with
intercompany purchases of capital stock or share capital among one or more of SeaSpine and its Subsidiaries; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;for the purpose of fulfilling its obligations under the SeaSpine ESPP, to the extent consistent
with past practice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;other than pursuant to the issuance of SeaSpine Shares to holders of
SeaSpine Exchangeable Shares pursuant to the exchange, redemption or retraction of SeaSpine Exchangeable Shares pursuant to AcquireCo&#146;s Articles and the SeaSpine Support Agreement, (A)&nbsp;issue, sell, pledge, dispose of or encumber, or
authorize the issuance, sale, pledge, disposition or encumbrance of (1)&nbsp;any shares of beneficial interests, capital stock or other ownership interest in SeaSpine or any of its Subsidiaries, (2)&nbsp;any securities convertible into or
exchangeable or exercisable for any such shares or ownership interest or (3)&nbsp;any rights, warrants or options to acquire or with respect to any such shares of beneficial interest, capital stock, ownership interest or convertible or exchangeable
securities; or (B)&nbsp;take any action to cause to be exercisable any otherwise unexercisable option under any existing share option plan except, in each case of clause (A)&nbsp;or (B) hereof, (I)&nbsp;for issuances of SeaSpine Shares in respect of
(x)&nbsp;any exercise of SeaSpine Options outstanding on the date hereof or (y)&nbsp;the exercise of any SeaSpine ESPP Purchase Rights under the terms of a SeaSpine ESPP as in effect on the date hereof, (II)&nbsp;for the issuance or sale of SeaSpine
Shares pursuant to the exercise of SeaSpine Options or the vesting of or delivery of shares under SeaSpine RSUs, in accordance with their terms as of the date hereof or (III)&nbsp;for transactions solely between or among SeaSpine and its
wholly-owned Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;except as required by a SeaSpine Plan or as otherwise required by
applicable Law: (A)&nbsp;increase the compensation or other benefits payable or provided to any of SeaSpine&#146;s or any of its Subsidiaries&#146; officers, directors, independent contractors, leased personnel or, except in the ordinary course of
business consistent with past practice (including as a result of promotions), employees; (B)&nbsp;enter into, materially amend or terminate any employment termination, change of control, severance, retention or other Contract with any current or
former employee, independent contractor or leased </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
personnel of SeaSpine or any of its Subsidiaries (exclusive of (1)&nbsp;agreements entered into with any newly hired employees or replacements or as a result of promotions, in each case,
consistent with past practice, or (2)&nbsp;employment agreements terminable on less than thirty (30)&nbsp;days&#146; notice without payment or penalty); (C)&nbsp;establish, adopt, enter into, materially amend or terminate any SeaSpine Plan for the
benefit of any current or former officers, employees, independent contractors, leased personnel or any of their beneficiaries (exclusive of (1)&nbsp;agreements entered into with any newly hired employees or replacements or as a result of promotions,
in each case, consistent with past practice, or (2)&nbsp;employment agreements terminable on less than thirty (30)&nbsp;days&#146; notice without payment or penalty) or (D)&nbsp;enter into or amend any collective bargaining agreement or other
agreement with a union or labor organization; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;amend, or propose to amend, or permit the
adoption of any material amendment to any of the Organizational Documents of SeaSpine or any of its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;effect a recapitalization, reclassification of shares, stock split, reverse stock split or similar
transaction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;adopt a plan of complete or partial liquidation, dissolution, consolidation,
restructuring or recapitalization of SeaSpine or any of its &#147;significant subsidiaries,&#148; as defined in Rule <FONT STYLE="white-space:nowrap">1-02(w)</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;make any capital expenditure except for (A)&nbsp;expenditures required by existing Contracts,
(B)&nbsp;expenditures made in the ordinary course of business consistent with past practice or (C)&nbsp;expenditures made in response to any emergency or accident, whether caused by war, terrorism, weather events, public health events, outages or
otherwise (whether or not covered by insurance); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;acquire or agree to acquire, by merging or
consolidating with, by purchasing an equity interest in or a portion of the material assets of any business or any corporation, partnership, association or other business organization or division thereof, or otherwise acquire or agree to acquire any
material assets of any other Person, except for (A)&nbsp;the purchase of assets from suppliers or vendors in the ordinary course of business or (B)&nbsp;transactions with a value less than $1,000,000 in any single instance or $2,500,000 in the
aggregate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;except in the ordinary course of business consistent with past practice,
(A)&nbsp;incur any Indebtedness for borrowed money or guarantee any such Indebtedness of another Person, issue or sell any debt securities or warrants or other rights to acquire any debt securities, guarantee any debt securities of another Person,
renew or extend any existing credit or loan arrangements, enter into any &#147;keep well&#148; or other agreement to maintain any financial condition of another Person or enter into any agreement or arrangement having the economic effect of any of
the foregoing, except for (1)&nbsp;intercompany transactions or arrangements among one or more of SeaSpine and its Subsidiaries, (2)&nbsp;agreements or arrangements or borrowings incurred under SeaSpine&#146;s or any of its Subsidiaries&#146;
existing credit facilities and (3)&nbsp;short-term Indebtedness incurred in the ordinary course of business consistent with past practice; (B)&nbsp;make any loans or advances to any other Person other than intercompany transactions or arrangements
among one or more of SeaSpine and its Subsidiaries or (C)&nbsp;make any capital contributions to, or investments in, any other Person except for intercompany transactions or arrangements among one or more of SeaSpine and its Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;enter into any Contract that would materially
restrict, after the Effective Time, Orthofix and its Subsidiaries (including the Surviving Corporation and its Subsidiaries) with respect to engaging or competing in any line of business or in any geographic area; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;except in the ordinary course of business consistent with past practice, sell, transfer, assign,
mortgage, encumber or otherwise dispose of any assets with a fair market value in excess of $1,000,000 in the aggregate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;commence, pay, discharge, settle, compromise or satisfy any pending or threatened litigation,
arbitration, proceedings or claims other than any monetary settlement entered in the ordinary course of business consistent with past practice in an amount less than $1,000,000 in any single instance or $1,000,000 in the aggregate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;change any of its financial or Tax accounting methods or practices in any respect, except as
required by GAAP or Law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;make, change or revoke any material Tax election with
respect to SeaSpine or any of its Subsidiaries, (B)&nbsp;file any material amended Tax Return or claim for refund of material Taxes with respect to SeaSpine or any of its Subsidiaries, (C)&nbsp;enter into any &#147;closing agreement&#148; as
described in Section&nbsp;7121 of the Code (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law) affecting any material Tax Liability or refund of material Taxes with respect to SeaSpine
or any of its Subsidiaries, (D)&nbsp;extend or waive the application of any statute of limitations regarding the assessment or collection of any material Tax with respect to SeaSpine or any of its Subsidiaries, (E)&nbsp;settle or compromise any
material Tax Liability or refund of material Taxes with respect to SeaSpine or any of its Subsidiaries or (F)&nbsp;take, prior to the Effective Time, any action that would reasonably be expected to prevent or impede the Merger from qualifying as a
&#147;reorganization&#148; within the meaning of Section&nbsp;368 of the Code; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp;other than in
the ordinary course of business consistent with past practice, waive, release or assign any rights or claims under, or renew (other than automatic renewals), modify or terminate (other than termination by natural expiration), any SeaSpine Material
Contract (other than intercompany transactions, agreements or arrangements among one or more of SeaSpine and its Subsidiaries), in any material respect in a manner which taken as a whole is adverse to SeaSpine and its Subsidiaries or which could
prevent or materially delay the consummation of the Merger or the other transactions contemplated hereby past the Termination Date (or any extension thereof); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;cease to maintain with financially responsible insurance companies insurance in such amounts and
against such risks and losses as are customary for the nature of the property so insured and for companies engaged in the respective businesses of SeaSpine and its Subsidiaries, to the extent available on commercially reasonable terms; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;agree or commit to take any of the actions described in clauses (i)&nbsp;through (xvi)&nbsp;of
this <U>Section</U><U></U><U>&nbsp;5.01(b)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.02&nbsp;&nbsp;&nbsp;&nbsp;<U>Covenants of Orthofix</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except (i)&nbsp;as set forth in <U>Section</U><U></U><U>&nbsp;5.02(a)</U> of the Orthofix Disclosure Letter,
(ii)&nbsp;as required by applicable Law, (iii)&nbsp;as expressly required by this Agreement, (iv)&nbsp;with the prior written consent of SeaSpine (which consent shall not be unreasonably delayed, withheld or conditioned), or (v)&nbsp;for the taking
of any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Response, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Orthofix and its Subsidiaries shall conduct the business and operations of Orthofix and its Subsidiaries, taken
as a whole, in all material respects in the ordinary course of business consistent with past practice. During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Orthofix shall, promptly upon learning of the same, notify SeaSpine
(A)&nbsp;of any change, occurrence, effect, condition, fact, event or circumstance known to Orthofix that is reasonably likely, individually or taken together with all other changes, occurrences, effects, conditions, facts, events and circumstances
known to Orthofix, to result in an Orthofix Material Adverse Effect and (B)&nbsp;any matter reasonably likely to constitute a failure by Orthofix of any of the conditions contained in <U>Section</U><U></U><U>&nbsp;7.03(a)</U> or
<U>Section</U><U></U><U>&nbsp;7.03(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except (i)&nbsp;as set forth on
<U>Section</U><U></U><U>&nbsp;5.02(b)</U> of the Orthofix Disclosure Letter, (ii)&nbsp;as required by applicable Law, (iii)&nbsp;as expressly required by this Agreement, (iv)&nbsp;with the prior written consent of SeaSpine (which consent shall not
be unreasonably delayed, withheld or conditioned) or (v)&nbsp;for the taking of any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Response, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Orthofix shall not and shall not
permit any of its Subsidiaries, without the prior written consent of SeaSpine (which consent shall not be unreasonably delayed, withheld or conditioned), to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;(X)&nbsp;declare, set aside or pay any dividends on or make other distributions in respect of any of
its capital stock or shares or (Y)&nbsp;directly or indirectly redeem, repurchase or otherwise acquire any shares of its capital stock or any Orthofix Options, Orthofix RSUs or Orthofix SPP Purchase Rights with respect thereto except, in each case:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;for the declaration and payment of dividends by a direct or indirect wholly-owned Subsidiary
of Orthofix solely to its parent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;in connection with intercompany purchases of capital stock
or share capital among one or more of SeaSpine and its Subsidiaries; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;for the purpose of
fulfilling its obligations under the Orthofix SPP, to the extent consistent with past practice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;(A) issue, sell, pledge, dispose of or encumber, or authorize the issuance, sale, pledge,
disposition or encumbrance of (1)&nbsp;any shares of beneficial interests, capital stock or other ownership interest in Orthofix or any of its Subsidiaries, (2)&nbsp;any securities convertible into or exchangeable or exercisable for any such shares
or ownership interest or (3)&nbsp;any rights, warrants or options to acquire or with respect to any such shares of beneficial interest, capital stock, ownership interest or convertible or exchangeable securities; or (B)&nbsp;take any action to cause
to be exercisable any otherwise unexercisable option under any existing share option plan except, in each case of clause (A)&nbsp;or (B) hereof, (I)&nbsp;for issuances of Orthofix Shares in respect of (x)&nbsp;any exercise of Orthofix Options
outstanding on the date hereof or (y)&nbsp;the exercise of any Orthofix SPP Purchase Rights under the terms of the Orthofix SPP as in effect on the date hereof, (II)&nbsp;for the issuance or sale of Orthofix Shares pursuant to the exercise of
Orthofix Options or the vesting of or delivery of shares under Orthofix RSUs, in accordance with their terms as of the date hereof or (III)&nbsp;for transactions solely between or among Orthofix and its wholly-owned Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;except as required by an Orthofix Plan or as
otherwise required by applicable Law: (A)&nbsp;increase the compensation or other benefits payable or provided to any of Orthofix&#146;s or any of its Subsidiaries&#146; officers, directors, independent contractors, leased personnel or, except in
the ordinary course of business consistent with past practice (including as a result of promotions), employees; (B)&nbsp;enter into, materially amend or terminate any employment termination, change of control, severance, retention or other Contract
with any current or former employee, independent contractor or leased personnel of Orthofix or any of its Subsidiaries (exclusive of (1)&nbsp;agreements entered into with any newly hired employees or replacements or as a result of promotions, in
each case, consistent with past practice, or (2)&nbsp;employment agreements terminable on less than thirty (30)&nbsp;days&#146; notice without payment or penalty); (C)&nbsp;establish, adopt, enter into, materially amend or terminate any Orthofix
Plan for the benefit of any current or former officers, employees, independent contractors, leased personnel or any of their beneficiaries (exclusive of (1)&nbsp;agreements entered into with any newly hired employees or replacements or as a result
of promotions, in each case, consistent with past practice, or (2)&nbsp;employment agreements terminable on less than thirty (30)&nbsp;days&#146; notice without payment or penalty) or (D)&nbsp;enter into or amend any collective bargaining agreement
or other agreement with a union or labor organization; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;amend, or propose to amend, or permit
the adoption of any material amendment to any of the Organizational Documents of Orthofix or any of its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;effect a recapitalization, reclassification of shares, stock split, reverse stock split or similar
transaction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;adopt a plan of complete or partial liquidation, dissolution, consolidation,
restructuring or recapitalization of Orthofix or any of its &#147;significant subsidiaries,&#148; as defined in Rule <FONT STYLE="white-space:nowrap">1-02(w)</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;make any capital expenditure except for (A)&nbsp;expenditures required by existing Contracts,
(B)&nbsp;made in the ordinary course of business consistent with past practice or (C)&nbsp;expenditures made in response to any emergency or accident, whether caused by war, terrorism, weather events, public health events, outages or otherwise
(whether or not covered by insurance); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;acquire or agree to acquire, by merging or
consolidating with, by purchasing an equity interest in or a portion of the material assets of any business or any corporation, partnership, association or other business organization or division thereof, or otherwise acquire or agree to acquire any
material assets of any other Person, except for (A)&nbsp;the purchase of assets from suppliers or vendors in the ordinary course of business or (B)&nbsp;transactions with a value less than $1,000,000 in any single instance or $2,500,000 in the
aggregate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;except in the ordinary course of business consistent with past practice,
(A)&nbsp;incur any Indebtedness for borrowed money or guarantee any such Indebtedness of another Person, issue or sell any debt securities or warrants or other rights to acquire any debt securities, guarantee any debt securities of another Person,
renew or extend any existing credit or loan arrangements, enter into any &#147;keep well&#148; or other agreement to maintain any financial condition of another Person or enter into any agreement or arrangement having the economic effect of any of
the foregoing, except for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
(1)&nbsp;intercompany transactions or arrangements among one or more of Orthofix and its Subsidiaries, (2)&nbsp;agreements or arrangements or borrowings incurred under Orthofix&#146;s or any of
its Subsidiaries&#146; existing credit facilities, and (3)&nbsp;short-term Indebtedness incurred in the ordinary course of business consistent with past practice; (B)&nbsp;make any loans or advances to any other Person other than intercompany
transactions or arrangements among one or more of Orthofix and its Subsidiaries or (C)&nbsp;make any capital contributions to, or investments in, any other Person except for intercompany transactions or arrangements among one or more of Orthofix and
its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;enter into any Contract that would materially restrict, after the Effective
Time, Orthofix and its Subsidiaries (including the Surviving Corporation and its Subsidiaries) with respect to engaging or competing in any line of business or in any geographic area; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;except in the ordinary course of business consistent with past practice, sell, transfer, assign,
mortgage, encumber or otherwise dispose of any assets with a fair market value in excess of $1,000,000 in the aggregate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;commence, pay, discharge, settle, compromise or satisfy any pending or threatened litigation,
arbitration, proceedings or claims other than any monetary settlement entered in the ordinary course of business consistent with past practice in an amount less than $1,000,000 in any single instance or $1,000,000 in the aggregate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;change any of its financial or Tax accounting methods or practices in any respect, except as
required by GAAP or Law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;make, change or revoke any material Tax election with
respect to Orthofix or any of its Subsidiaries, (B)&nbsp;file any material amended Tax Return or claim for refund of material Taxes with respect to Orthofix or any of its Subsidiaries, (C)&nbsp;enter into any &#147;closing agreement&#148; as
described in Section&nbsp;7121 of the Code (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law) affecting any material Tax Liability or refund of material Taxes with respect to Orthofix
or any of its Subsidiaries, (D)&nbsp;extend or waive the application of any statute of limitations regarding the assessment or collection of any material Tax with respect to Orthofix or any of its Subsidiaries, (E)&nbsp;settle or compromise any
material Tax Liability or refund of material Taxes with respect to Orthofix or any of its Subsidiaries or (F)&nbsp;take, prior to the Effective Time, any action that would reasonably be expected to prevent or impede the Merger from qualifying as a
&#147;reorganization&#148; within the meaning of Section&nbsp;368 of the Code; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp;other than in
the ordinary course of business consistent with past practice, waive, release or assign any rights or claims under, or renew (other than automatic renewals), modify or terminate (other than termination by natural expiration), any Orthofix Material
Contract (other than intercompany transactions, agreements or arrangements among one or more of Orthofix and its Subsidiaries), in any material respect in a manner which taken as a whole is adverse to Orthofix and its Subsidiaries or which could
prevent or materially delay the consummation of the Merger or the other transactions contemplated hereby past the Termination Date (or any extension thereof); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;cease to maintain with financially responsible insurance companies insurance in such amounts and
against such risks and losses as are customary for the nature of the property so insured and for companies engaged in the respective businesses of Orthofix and its Subsidiaries, to the extent available on commercially reasonable terms; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;agree or commit to take any of the actions
described in clauses (i)&nbsp;through (xvi)&nbsp;of this <U>Section</U><U></U><U>&nbsp;5.02(b)</U>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 6 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ADDITIONAL COVENANTS OF THE PARTIES </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Investigation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each of SeaSpine and Orthofix shall afford to the other party and to the Representatives of such other party
reasonable access during normal business hours, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, to its and its Subsidiaries&#146; personnel, facilities and properties, Contracts, commitments, books and records and any reports,
schedules or other documents filed or received by it pursuant to the requirements of applicable Law and with such additional financing, operating and other data and information regarding it and its Subsidiaries, as the other party or any of its
Representatives may reasonably request in connection with their activities in order to facilitate the completion of the transactions contemplated by this Agreement. Notwithstanding the foregoing, neither SeaSpine nor Orthofix nor their respective
Subsidiaries shall be required to provide the access or information contemplated by this <U>Section</U><U></U><U>&nbsp;6.01</U> if it would (i)&nbsp;unreasonably disrupt the operations of such party or any of its Subsidiaries, (ii)&nbsp;cause a
violation of any agreement to which such party or any of its Subsidiaries is a party (provided, that Orthofix or SeaSpine, as the case may be, has used commercially reasonable efforts to find an alternative way to provide the access or information
contemplated by this <U>Section</U><U></U><U>&nbsp;6.01</U>), (iii) cause a risk of a loss of privilege to such party or any of its Subsidiaries, (iv)&nbsp;constitute a violation of any applicable Law or (v)&nbsp;otherwise disclose competitively
sensitive material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The parties hereby agree that all information provided to them or their respective
Representatives in connection with this Agreement and the consummation of the transactions contemplated by this Agreement shall be deemed to be Evaluation Material, as such term is used in, and shall be treated in accordance with, the
Confidentiality Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.02&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Statement and Proxy Statement for Shareholder Approval</U>. As
soon as reasonably practicable following the execution of this Agreement, (a)&nbsp;Orthofix and SeaSpine shall jointly prepare a joint proxy statement (the &#147;<U>Joint Proxy Statement</U>&#148;) in preliminary form, which shall contain each of
the Orthofix Recommendation and SeaSpine Recommendation (unless, in either case, an Orthofix Adverse Recommendation Change or a SeaSpine Adverse Recommendation Change, as applicable, has occurred), and (b)&nbsp;Orthofix shall prepare and file with
the SEC (i)&nbsp;a registration statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> in which the Joint Proxy Statement shall be included and (ii)&nbsp;a prospectus relating to the Orthofix Shares to be offered and sold pursuant to this
Agreement and the Merger (such registration statement together with the amendments and supplements thereto, the &#147;<U>Registration Statement</U>&#148;). Each of Orthofix and SeaSpine shall use its reasonable best efforts to have the Registration
Statement declared effective under the Securities Act as promptly as practicable after such filing and to keep the Registration Statement effective as long as necessary to consummate the transactions contemplated by this Agreement, including the
Merger. Each of Orthofix and SeaSpine shall use its respective reasonable best efforts to mail the Joint Proxy Statement to its respective shareholders as promptly as practicable after the Registration Statement is declared effective under the
Securities Act. Orthofix shall use reasonable best efforts to take any action required to be taken under any applicable state securities Laws and other applicable Laws in connection with the issuance of Orthofix Shares pursuant to this Agreement,
and each party shall furnish all information concerning SeaSpine, Orthofix and the holders of capital stock of SeaSpine and Orthofix, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable, as may be reasonably requested by another party in connection with any such action or the preparation, filing or distribution of the Joint Proxy Statement. No filing of, or amendment
or supplement to, or material correspondence to the SEC or its staff with respect to, the Registration Statement shall be made by Orthofix, or with respect to the Joint Proxy Statement, shall be made by SeaSpine, Orthofix or any of their respective
Subsidiaries, without providing the other party a reasonable opportunity to review and comment thereon; <U>provided</U>, <U>however</U>, that this obligation shall not apply with respect to information relating to a SeaSpine Adverse Recommendation
Change or an Orthofix Adverse Recommendation Change. Orthofix shall advise SeaSpine, promptly after it receives notice thereof, of the time when the Registration Statement has become effective or any supplement or amendment has been filed, the
issuance of any stop order, the suspension of the qualification of the Orthofix Shares issuable in connection with the Merger for offering or sale in any jurisdiction, or any request by the SEC for amendment of the Registration Statement or comments
thereon and responses thereto or requests by the SEC for additional information. Each of Orthofix and SeaSpine shall advise the other, promptly after it receives notice thereof, of any request by the SEC for the amendment of the Joint Proxy
Statement or comments thereon and responses thereto or requests by the SEC for additional information. If at any time prior to the Effective Time any information relating to SeaSpine or Orthofix, or any of their respective Affiliates, officers or
directors, is discovered by SeaSpine or Orthofix which should be set forth in an amendment or supplement to either the Registration Statement or the Joint Proxy Statement so that any of such documents would not include any misstatement of a material
fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party which discovers such information shall promptly notify the other parties hereto and
an appropriate amendment or supplement describing such information shall be promptly filed with the SEC, after the other party has had a reasonable opportunity to review and comment thereon, and, to the extent required by applicable Law,
disseminated to either Orthofix Stockholders or SeaSpine Stockholders, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.03&nbsp;&nbsp;&nbsp;&nbsp;<U>Shareholders</U><U>&#146;</U><U> Meetings</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine shall take any and all actions necessary in accordance with applicable Law and SeaSpine&#146;s
Organizational Documents to duly give notice of, convene and hold a meeting of the SeaSpine Stockholders, to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, for the purpose of
obtaining the SeaSpine Stockholder Approval (the &#147;<U>SeaSpine Stockholders</U><U>&#146;</U><U> Meeting</U>&#148;). Subject to <U>Sections</U><U></U><U>&nbsp;6.04(b)</U> and <U>6.04(c)</U>, SeaSpine shall, through the SeaSpine Board, recommend
that the SeaSpine Stockholders adopt this Agreement and shall use reasonable best efforts to solicit from the SeaSpine Stockholders proxies in favor of the adoption of this Agreement and to take all other actions necessary or advisable to secure the
SeaSpine Stockholder Approval. Subject to <U>Sections</U><U></U><U>&nbsp;6.04(b)</U> and <U>6.04(c)</U> and the remainder of this <U>Section</U><U></U><U>&nbsp;6.03(a)</U>, SeaSpine may only postpone or adjourn the SeaSpine Stockholders&#146;
Meeting (i)&nbsp;to solicit additional proxies for the purpose of obtaining the SeaSpine Stockholder Approval, (ii)&nbsp;for the absence of a quorum and/or (iii)&nbsp;to allow reasonable additional time for the filing and/or mailing of any
supplemental or amended disclosure that SeaSpine has determined, after consultation with outside legal counsel, is reasonably likely to be required under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed
by SeaSpine Stockholders prior to the SeaSpine Stockholders&#146; Meeting, provided<I> </I>that without the prior written consent of Orthofix (not to be unreasonably withheld, conditioned or delayed), (A)&nbsp;no single such adjournment or
postponement pursuant to clauses&nbsp;(i), (ii) or (iii)&nbsp;shall be for more than ten (10)&nbsp;Business Days, except as may be required by applicable Law and (B)&nbsp;all such adjournments and postponements together shall not cause the date of
the SeaSpine Stockholders&#146; Meeting to be less than five (5)&nbsp;Business Days prior to the Termination Date. Subject to <U>Sections</U><U></U><U>&nbsp;6.04(b)</U> and <U>6.04(c)</U>, SeaSpine may and shall postpone or adjourn the SeaSpine
Stockholders&#146; Meeting up to two (2)&nbsp;times for up to ten (10)&nbsp;Business Days each time upon the reasonable request of Orthofix. SeaSpine shall use reasonable efforts to, on a daily basis during the ten (10)&nbsp;Business Days prior to
the date of the SeaSpine </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholders&#146; Meeting, advise Orthofix as to the aggregate number of SeaSpine Shares entitled to vote at the SeaSpine Stockholders&#146; Meeting for which proxies have been received by
SeaSpine with respect to the SeaSpine Stockholder Approval and the number of such proxies authorizing the holder thereof to vote in favor of the SeaSpine Stockholder Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix shall take any and all actions necessary in accordance with applicable Law and Orthofix&#146;s
Organizational Documents to duly give notice of, convene and hold a meeting of the Orthofix Stockholders, to be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act, for the purpose of
obtaining the Orthofix Stockholder Approval (the &#147;<U>Orthofix Stockholders</U><U>&#146;</U><U> Meeting</U>&#148;). Subject to <U>Sections</U><U></U><U>&nbsp;6.04(e)</U> and <U>6.04(f)</U>, Orthofix shall, through the Orthofix Board, recommend
that the Orthofix Stockholders approve the Orthofix Share Issuance and shall use reasonable best efforts to solicit from the Orthofix Stockholders proxies in favor of approval of the Orthofix Share Issuance and to take all other actions necessary or
advisable to secure the Orthofix Stockholder Approval. Subject to <U>Sections</U><U></U><U>&nbsp;6.04(e)</U> and <U>6.04(f)</U> and the remainder of this <U>Section</U><U></U><U>&nbsp;6.03(b)</U>, Orthofix may only postpone or adjourn the Orthofix
Stockholders&#146; Meeting (i)&nbsp;to solicit additional proxies for the purpose of obtaining the Orthofix Stockholder Approval, (ii)&nbsp;for the absence of a quorum and/or (iii)&nbsp;to allow reasonable additional time for the filing and/or
mailing of any supplemental or amended disclosure that Orthofix has determined, after consultation with outside legal counsel, is reasonably likely to be required under applicable Law and for such supplemental or amended disclosure to be
disseminated and reviewed by Orthofix Stockholders prior to the Orthofix Stockholders&#146; Meeting, provided<I> </I>that without the prior written consent of SeaSpine (not to be unreasonably withheld, conditioned or delayed), (A)&nbsp;no single
such adjournment or postponement pursuant to clauses&nbsp;(i), (ii) or (iii)&nbsp;shall be for more than ten (10)&nbsp;Business Days, except as may be required by applicable Law and (B)&nbsp;all such adjournments and postponements together shall not
cause the date of the Orthofix Stockholders&#146; Meeting to be less than five (5)&nbsp;Business Days prior to the Termination Date. Subject to <U>Sections</U><U></U><U>&nbsp;6.04(e)</U> and <U>6.04(f)</U>, Orthofix may and shall postpone or adjourn
the Orthofix Stockholders&#146; Meeting up to two (2)&nbsp;times for up to ten (10)&nbsp;Business Days each time upon the reasonable request of SeaSpine. Orthofix shall use reasonable efforts to, on a daily basis during the ten (10)&nbsp;Business
Days prior to the date of the Orthofix Stockholders&#146; Meeting, advise SeaSpine as to the aggregate number of Orthofix Shares entitled to vote at the Orthofix Stockholders&#146; Meeting for which proxies have been received by Orthofix with
respect to the Orthofix Stockholder Approval and the number of such proxies authorizing the holder thereof to vote in favor of the Orthofix Stockholder Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine and Orthofix shall use their reasonable best efforts to hold the SeaSpine Stockholders&#146; Meeting and
the Orthofix Stockholders&#146; Meeting on the same date and as soon as practicable after the date of this Agreement (but after the Registration Statement is declared effective). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Except with the prior written consent of SeaSpine and Orthofix, the only matters to be voted upon at each of the
SeaSpine Stockholders&#146; Meeting and the Orthofix Stockholders&#146; Meeting are (i)&nbsp;adoption of this Agreement, in the case of the SeaSpine Stockholders&#146; Meeting, and the Orthofix Share Issuance, in the case of the Orthofix
Stockholders&#146; Meeting, (ii)&nbsp;any adjournment or postponement of the SeaSpine Stockholders&#146; Meeting or the Orthofix Stockholders&#146; Meeting, as applicable and/or (iii)&nbsp;any other matters that are required by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.04&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine agrees that, except as expressly contemplated hereby, neither it nor any of its Subsidiaries shall, and
SeaSpine shall, and shall cause its Subsidiaries to, instruct its and their respective Representatives not to, directly or indirectly (i)&nbsp;initiate, seek or solicit, or knowingly encourage or facilitate (including by way of furnishing <FONT
STYLE="white-space:nowrap">non-public</FONT> information) or take any other action that is reasonably expected to promote, directly or indirectly, any inquiries or the making or submission of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposal that constitutes, or would reasonably be expected to lead to, an Acquisition Proposal with respect to SeaSpine; (ii)&nbsp;participate or engage in discussions or negotiations with, or
disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information or data relating to SeaSpine or any of its Subsidiaries or afford access to the properties, books or records of SeaSpine or any of its Subsidiaries to any Person or group of
Persons (or any of their Affiliates or Representatives) that has made an Acquisition Proposal with respect to SeaSpine or (iii)&nbsp;enter into any agreement, including any letter of intent, memorandum of understanding, agreement in principle,
merger agreement, acquisition agreement or other similar agreement, with respect to an Acquisition Proposal with respect to SeaSpine (other than an Acceptable Confidentiality Agreement permitted pursuant to this
<U>Section</U><U></U><U>&nbsp;6.04</U>). SeaSpine shall, and shall cause its Subsidiaries and instruct its and their respective Representatives to, promptly upon the execution of this Agreement cause to be terminated any solicitation, encouragement,
discussion or negotiation with or involving any Person or group of Persons, or any of their Affiliates (other than Orthofix and/or its Affiliates), conducted heretofore by SeaSpine or any Subsidiary thereof or any of its or their respective
Representatives, with respect to an Acquisition Proposal or which could reasonably be expected to lead to an Acquisition Proposal, and, in connection therewith, SeaSpine shall immediately discontinue access by any Person or group of Persons, and any
of their Affiliates (other than Orthofix and its Affiliates), to any data room (virtual or otherwise) established by SeaSpine or its Representatives for such purpose. Within ten (10)&nbsp;Business Days from the date hereof, SeaSpine shall request
the return or destruction of all confidential, <FONT STYLE="white-space:nowrap">non-public</FONT> information provided to third parties that have entered into confidentiality agreements with SeaSpine or any Subsidiary thereof since January&nbsp;1,
2022, relating to an Acquisition Proposal. Notwithstanding anything to the contrary in this Agreement, prior to obtaining the SeaSpine Stockholder Approval, SeaSpine and the SeaSpine Board may take any actions described in clause (ii)&nbsp;of this
<U>Section</U><U></U><U>&nbsp;6.04(a)</U> with respect to a third party if (A)&nbsp;SeaSpine receives a written Acquisition Proposal with respect to SeaSpine from such third party (and such Acquisition Proposal was not initiated, sought, solicited,
knowingly encouraged or facilitated in violation of this <U>Section</U><U></U><U>&nbsp;6.04</U>) and (B)&nbsp;such proposal constitutes, or the SeaSpine Board determines in good faith that such proposal would reasonably be expected to lead to, a
Superior Proposal with respect to SeaSpine, provided that, SeaSpine may deliver <FONT STYLE="white-space:nowrap">non-public</FONT> information to such third party only pursuant to a confidentiality agreement containing terms no less favorable to
SeaSpine with respect to confidentiality than the terms of the Confidentiality Agreement (including with respect to any standstill agreement or similar provisions) (an &#147;<U>Acceptable Confidentiality Agreement</U>&#148;) and so long as it sends
a copy of such Acceptable Confidentiality Agreement to Orthofix promptly following its execution. Nothing contained in this <U>Section</U><U></U><U>&nbsp;6.04</U> shall prohibit SeaSpine or the SeaSpine Board from (1)&nbsp;taking and disclosing to
the SeaSpine Stockholders a position with respect to an Acquisition Proposal with respect to SeaSpine pursuant to Rules <FONT STYLE="white-space:nowrap">14d-9</FONT> and <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> promulgated under the Exchange
Act or from making any similar disclosure, if the SeaSpine Board has reasonably determined in good faith that the failure to do so would be reasonably likely to be a breach of its fiduciary duties to the SeaSpine Stockholders or (2)&nbsp;directing
any Person (or the Representatives of that Person) who makes an Acquisition Proposal regarding SeaSpine to the provisions of this <U>Section</U><U></U><U>&nbsp;6.04</U>,&nbsp;provided that this sentence shall not permit the SeaSpine Board to make a
SeaSpine Adverse Recommendation Change, except to the extent permitted by <U>Section</U><U></U><U>&nbsp;6.04(b)</U> or <U>Section</U><U></U><U>&nbsp;6.04(c)</U>. Without limiting the foregoing, it is understood that any violation of the restrictions
contained in this <U>Section</U><U></U><U>&nbsp;6.04(a)</U> by any of SeaSpine&#146;s or its Subsidiaries&#146; respective Representatives shall be deemed to be a breach of this <U>Section</U><U></U><U>&nbsp;6.04(a)</U> by SeaSpine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Neither the SeaSpine Board nor any committee thereof shall directly or indirectly (i)&nbsp;withhold, withdraw (or
amend, qualify or modify in a manner adverse to Orthofix or Merger Sub), or publicly propose to withdraw (or amend, qualify or modify in a manner adverse to Orthofix or Merger Sub), the approval, recommendation or declaration of advisability by the
SeaSpine Board or any such committee of the transactions contemplated by this Agreement, (ii)&nbsp;propose publicly to recommend, adopt or approve any Acquisition Proposal with respect to SeaSpine, (iii)&nbsp;fail to publicly reaffirm or <FONT
STYLE="white-space:nowrap">re-publish</FONT> the SeaSpine Recommendation within five (5)&nbsp;Business Days of being requested by Orthofix to do so (or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if earlier, at least two (2)&nbsp;Business Days prior to the SeaSpine Stockholders&#146; Meeting), or (iv)&nbsp;fail to send to the SeaSpine Stockholders, within ten (10)&nbsp;Business Days after
the commencement of a tender or exchange offer relating to the SeaSpine Shares (or if earlier, at least two (2)&nbsp;Business Days prior to the SeaSpine Stockholders&#146; Meeting), a statement disclosing that SeaSpine recommends rejection of such
tender or exchange offer and reaffirming the SeaSpine Recommendation (any action described in this sentence being referred to as a &#147;<U>SeaSpine Adverse Recommendation Change</U>&#148;). For the avoidance of doubt, a change of the SeaSpine
Recommendation to &#147;neutral&#148; is a SeaSpine Adverse Recommendation Change. Notwithstanding the foregoing, at any time prior to obtaining the SeaSpine Stockholder Approval, and subject to SeaSpine&#146;s compliance at all times with the
provisions of this <U>Section</U><U></U><U>&nbsp;6.04</U> and <U>Section</U><U></U><U>&nbsp;6.03</U>, in response to a Superior Proposal with respect to SeaSpine that has not been withdrawn and did not result from a breach of
<U>Section</U><U></U><U>&nbsp;6.04(a)</U>, the SeaSpine Board may make a SeaSpine Adverse Recommendation Change; <U>provided</U>, <U>however</U>, that unless the SeaSpine Stockholders&#146; Meeting is scheduled to occur within the next ten
(10)&nbsp;Business Days, SeaSpine shall not be entitled to exercise its right to make a SeaSpine Adverse Recommendation Change in response to a Superior Proposal with respect to SeaSpine (x)&nbsp;until five (5)&nbsp;Business Days after SeaSpine
provides written notice to Orthofix advising Orthofix that the SeaSpine Board has received a Superior Proposal, specifying the material terms and conditions of such Superior Proposal, identifying the Person or group of Persons making such Superior
Proposal and including copies of all documents pertaining to such Superior Proposal; (y)&nbsp;if during such five (5)&nbsp;Business Day period, Orthofix irrevocably proposes any alternative transaction (including any modifications to the terms of
this Agreement), unless the SeaSpine Board determines in good faith, after good faith negotiations between SeaSpine and Orthofix (if such negotiations are requested by Orthofix) during such five (5)&nbsp;Business Day period (after and taking into
account all financial, legal and regulatory terms and conditions of such alternative transaction proposal and expected timing of consummation and the relative risks of <FONT STYLE="white-space:nowrap">non-consummation</FONT> of the alternative
transaction proposal and the Superior Proposal) that such alternative transaction proposal is not at least as favorable to SeaSpine and its shareholders as the Superior Proposal and (z)&nbsp;unless the SeaSpine Board determines that the failure to
make a SeaSpine Adverse Recommendation Change would be a breach of its fiduciary obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the first sentence of <U>Section</U><U></U><U>&nbsp;6.04(b)</U>, at any time prior to obtaining the SeaSpine Stockholder Approval, in connection with any Intervening Event, the SeaSpine Board may make a SeaSpine Adverse Recommendation Change, after
the SeaSpine Board (i)&nbsp;determines in good faith that the failure to make such SeaSpine Adverse Recommendation Change would be a breach of its fiduciary duties to the SeaSpine Stockholders, (ii)&nbsp;determines in good faith that the reasons for
making such SeaSpine Adverse Recommendation Change are independent of and unrelated to any pending Acquisition Proposal with respect to SeaSpine and (iii)&nbsp;provides written notice to Orthofix (a &#147;<U>SeaSpine Notice of Change</U>&#148;)
advising Orthofix that the SeaSpine Board is contemplating making a SeaSpine Adverse Recommendation Change and specifying the material facts and information constituting the basis for such contemplated determination; <U>provided</U>, <U>however</U>,
that, unless the SeaSpine Stockholders&#146; Meeting is scheduled to occur within the next five (5)&nbsp;Business Days, (x)&nbsp;the SeaSpine Board may not make such SeaSpine Adverse Recommendation Change until the fifth (5<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day after receipt by Orthofix of a SeaSpine Notice of Change and (y)&nbsp;during such five (5)&nbsp;Business Day period, at the request of Orthofix, SeaSpine shall negotiate in good faith
with respect to any changes or modifications to this Agreement which would allow the SeaSpine Board not to make such SeaSpine Adverse Recommendation Change, consistent with its fiduciary duties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix agrees that, except as expressly contemplated hereby, neither it nor any of its Subsidiaries shall, and
Orthofix shall, and shall cause its Subsidiaries to, instruct its and their respective Representatives not to, directly or indirectly (i)&nbsp;initiate, seek or solicit, or knowingly encourage or facilitate (including by way of furnishing <FONT
STYLE="white-space:nowrap">non-public</FONT> information) or take any other action that is reasonably expected to promote, directly or indirectly, any inquiries or the making or submission of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposal that constitutes, or would reasonably be expected to lead to, an Acquisition Proposal with respect to Orthofix; (ii)&nbsp;participate or engage in discussions or negotiations with, or
disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information or data relating to Orthofix or any of its Subsidiaries or afford access to the properties, books or records of Orthofix or any of its Subsidiaries to any Person or group of
Persons (or any of their Affiliates or Representatives) that has made an Acquisition Proposal with respect to Orthofix or (iii)&nbsp;enter into any agreement, including any letter of intent, memorandum of understanding, agreement in principle,
merger agreement, acquisition agreement or other similar agreement, with respect to an Acquisition Proposal with respect to Orthofix (other than an Acceptable Confidentiality Agreement permitted pursuant to this
<U>Section</U><U></U><U>&nbsp;6.04</U>). Orthofix shall, and shall cause its Subsidiaries and instruct its and their respective Representatives to, promptly upon the execution of this Agreement cause to be terminated any solicitation, encouragement,
discussion or negotiation with or involving any Person or group of Persons, or any of their Affiliates (other than SeaSpine and/or its Affiliates), conducted heretofore by Orthofix or any Subsidiary thereof or any of its or their respective
Representatives, with respect to an Acquisition Proposal or which could reasonably be expected to lead to an Acquisition Proposal, and, in connection therewith, Orthofix shall immediately discontinue access by any Person or group of Persons, and any
of their Affiliates (other than SeaSpine and its Affiliates), to any data room (virtual or otherwise) established by Orthofix or its Representatives for such purpose. Within ten (10)&nbsp;Business Days from the date hereof, Orthofix shall request
the return or destruction of all confidential, <FONT STYLE="white-space:nowrap">non-public</FONT> information provided to third parties that have entered into confidentiality agreements with Orthofix or any Subsidiary thereof since January&nbsp;1,
2022, relating to an Acquisition Proposal. Notwithstanding anything to the contrary in this Agreement, prior to obtaining the Orthofix Stockholder Approval, Orthofix and the Orthofix Board may take any actions described in clause (ii)&nbsp;of this
<U>Section</U><U></U><U>&nbsp;6.04(d)</U> with respect to a third party if (A)&nbsp;Orthofix receives a written Acquisition Proposal with respect to Orthofix from such third party (and such Acquisition Proposal was not initiated, sought, solicited,
knowingly encouraged or facilitated in violation of this <U>Section</U><U></U><U>&nbsp;6.04</U>) and (B)&nbsp;such proposal constitutes, or the Orthofix Board determines in good faith that such proposal would reasonably be expected to lead to, a
Superior Proposal with respect to Orthofix, provided that, Orthofix may deliver <FONT STYLE="white-space:nowrap">non-public</FONT> information to such third party only pursuant to an Acceptable Confidentiality Agreement (but in relation to Orthofix
rather than SeaSpine) and so long as it sends a copy of such Acceptable Confidentiality Agreement to SeaSpine promptly following its execution. Nothing contained in this <U>Section</U><U></U><U>&nbsp;6.04</U> shall prohibit Orthofix or the Orthofix
Board from (1)&nbsp;taking and disclosing to the Orthofix Stockholders a position with respect to an Acquisition Proposal with respect to Orthofix pursuant to Rules <FONT STYLE="white-space:nowrap">14d-9</FONT> and
<FONT STYLE="white-space:nowrap">14e-2(a)</FONT> promulgated under the Exchange Act or from making any similar disclosure, if the Orthofix Board has reasonably determined in good faith that the failure to do so would be reasonably likely to be a
breach of its fiduciary duties to the Orthofix Stockholders or (2)&nbsp;directing any Person (or the Representatives of that Person) who makes an Acquisition Proposal regarding Orthofix to the provisions of this
<U>Section</U><U></U><U>&nbsp;6.04</U>, provided that this sentence shall not permit the Orthofix Board to make an Orthofix Adverse Recommendation Change, except to the extent permitted by <U>Section</U><U></U><U>&nbsp;6.04(e)</U> or
<U>Section</U><U></U><U>&nbsp;6.04(f)</U>. Without limiting the foregoing, it is understood that any violation of the restrictions contained in this <U>Section</U><U></U><U>&nbsp;6.04(d)</U> by any of Orthofix&#146;s or its Subsidiaries&#146;
respective Representatives shall be deemed to be a breach of this <U>Section</U><U></U><U>&nbsp;6.04(d)</U> by Orthofix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Orthofix Board nor any committee thereof shall directly or indirectly (i)&nbsp;withhold, withdraw (or
amend, qualify or modify in a manner adverse to SeaSpine) or publicly propose to withdraw (or amend, qualify or modify in a manner adverse to SeaSpine), the approval, recommendation or declaration of advisability by the Orthofix Board or any such
committee of the transactions contemplated by this Agreement including the issuance of Orthofix Shares in the Merger, (ii)&nbsp;propose publicly to recommend, adopt or approve any Acquisition Proposal with respect to Orthofix, (iii)&nbsp;fail to
publicly reaffirm or <FONT STYLE="white-space:nowrap">re-publish</FONT> the Orthofix Recommendation within five (5)&nbsp;Business Days of being requested by SeaSpine to do so (or if earlier, at least two (2)&nbsp;Business Days prior to the SeaSpine
Stockholders&#146; Meeting), or (iv)&nbsp;fail to send to the SeaSpine Stockholders, within ten (10)&nbsp;Business Days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
after the commencement of a tender or exchange offer relating to the SeaSpine Shares (or if earlier, at least two (2)&nbsp;Business Days prior to the SeaSpine Stockholders&#146; Meeting), a
statement disclosing that SeaSpine recommends rejection of such tender or exchange offer and reaffirming the SeaSpine Recommendation (any action described in this sentence being referred to as a &#147;<U>Orthofix Adverse Recommendation
Change</U>&#148;). For the avoidance of doubt, a change of the Orthofix Recommendation to &#147;neutral&#148; is an Orthofix Adverse Recommendation Change. Notwithstanding the foregoing, at any time prior to obtaining the Orthofix Stockholder
Approval, and subject to Orthofix&#146;s compliance at all times with the provisions of this <U>Section</U><U></U><U>&nbsp;6.04</U> and <U>Section</U><U></U><U>&nbsp;6.03</U>, in response to a Superior Proposal with respect to Orthofix that has not
been withdrawn and did not result from a breach of <U>Section</U><U></U><U>&nbsp;6.04(d)</U>, the Orthofix Board may make an Orthofix Adverse Recommendation Change; <U>provided</U>, <U>however</U>, that unless the Orthofix Stockholders&#146; Meeting
is scheduled to occur within the next ten (10)&nbsp;Business Days, Orthofix shall not be entitled to exercise its right to make an Orthofix Adverse Recommendation Change in response to a Superior Proposal with respect to Orthofix (x)&nbsp;until five
(5)&nbsp;Business Days after Orthofix provides written notice to SeaSpine advising SeaSpine that the Orthofix Board has received a Superior Proposal, specifying the material terms and conditions of such Superior Proposal, identifying the Person or
group of Persons making such Superior Proposal and including copies of all documents pertaining to such Superior Proposal; (y)&nbsp;if during such five (5)&nbsp;Business Day period, SeaSpine irrevocably proposes any alternative transaction
(including any modifications to the terms of this Agreement), unless the Orthofix Board determines in good faith, after good faith negotiations between Orthofix and SeaSpine (if such negotiations are requested by SeaSpine) during such five
(5)&nbsp;Business Day period (after and taking into account all financial, legal and regulatory terms and conditions of such alternative transaction proposal and expected timing of consummation and the relative risks of <FONT
STYLE="white-space:nowrap">non-consummation</FONT> of the alternative transaction proposal and the Superior Proposal) that such alternative transaction proposal is not at least as favorable to Orthofix and its shareholders as the Superior Proposal
and (z)&nbsp;unless the Orthofix Board determines that the failure to make an Orthofix Adverse Recommendation Change would be a breach of its fiduciary obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the first sentence of <U>Section</U><U></U><U>&nbsp;6.04(e)</U>, at any time prior to obtaining the
Orthofix Stockholder Approval, in connection with any Intervening Event, the Orthofix Board may make an Orthofix Adverse Recommendation Change, after the Orthofix Board (i)&nbsp;determines in good faith that the failure to make such Orthofix Adverse
Recommendation Change would be a breach of its fiduciary duties to the Orthofix Stockholders, (ii)&nbsp;determines in good faith that the reasons for making such Orthofix Adverse Recommendation Change are independent of and unrelated to any pending
Acquisition Proposal with respect to SeaSpine and (iii)&nbsp;provides written notice to SeaSpine (a &#147;<U>Orthofix Notice of Change</U>&#148;) advising SeaSpine that the Orthofix Board is contemplating making an Orthofix Adverse Recommendation
Change and specifying the material facts and information constituting the basis for such contemplated determination; <U>provided</U>, <U>however</U>, that, unless the Orthofix Stockholders&#146; Meeting is scheduled to occur within the next five
(5)&nbsp;Business Days, (x)&nbsp;the Orthofix Board may not make such Orthofix Adverse Recommendation Change until the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Business Day after receipt by SeaSpine of an Orthofix Notice of
Change and (y)&nbsp;during such five (5)&nbsp;Business Day period, at the request of SeaSpine, Orthofix shall negotiate in good faith with respect to any changes or modifications to this Agreement which would allow the Orthofix Board not to make
such Orthofix Adverse Recommendation Change, consistent with its fiduciary duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;The parties agree that in
addition to the obligations of SeaSpine and Orthofix set forth in paragraphs (a)&nbsp;through (f)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.04</U>, as promptly as practicable after receipt thereof (and in any event, within one (1)&nbsp;Business
Day), SeaSpine or Orthofix, as applicable, shall advise Orthofix or SeaSpine, respectively, in writing of any request for information or any Acquisition Proposal with respect to such party received from any Person or group of Persons, or any
inquiry, discussions or negotiations with respect to any Acquisition Proposal with respect to such party, and the terms and conditions of such request, Acquisition Proposal, inquiry, discussions or negotiations, and SeaSpine or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Orthofix, as applicable, shall promptly (and in any event, within one (1)&nbsp;Business Day) provide to Orthofix or SeaSpine, respectively, copies of any written materials received by SeaSpine or
Orthofix, as applicable, in connection with any of the foregoing and the identity of the Person or group of Persons making any such request, Acquisition Proposal or inquiry or with whom any discussions or negotiations are taking place. Each of
SeaSpine and Orthofix agrees that it shall simultaneously provide to the other any <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning itself or its Subsidiaries provided to any other Person or group of Persons in connection
with any Acquisition Proposal which was not previously provided to the other. SeaSpine and Orthofix shall keep Orthofix and SeaSpine, respectively, fully informed of the status of any Acquisition Proposals (including the identity of the parties and
price involved and any changes to any material terms and conditions thereof). Each of SeaSpine and Orthofix agrees not to release, or permit any of its Affiliates to release, any Person from, or waive any provisions of, any confidentiality or
standstill agreement to which it is a party or fail to enforce, to the fullest extent permitted under applicable Law, any such standstill or similar agreement to which it is a party; <U>provided, however,</U> that, if either the SeaSpine Board or
Orthofix Board determines in good faith after consultation with SeaSpine&#146;s or Orthofix&#146;s outside legal counsel, as applicable, that the failure to waive (or amend or modify) a particular standstill provision, or other provision with
similar effect, could reasonably be expected to be a breach of its directors&#146; fiduciary duties under applicable Law, SeaSpine or Orthofix, as the case may be, may, with prior written notice to the other party, waive (or amend or modify) such
standstill provision, or other provision with similar effect, solely to the extent necessary to permit the applicable Person (if it has not been solicited in violation of this <U>Section</U><U></U><U>&nbsp;6.04</U>) to make an Acquisition Proposal.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.05&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory Approvals; Additional Agreements</U>.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine and Orthofix shall promptly prepare and file, as soon as reasonably practical and in any event no
later than ten (10)&nbsp;Business Days after the date of this Agreement, with the U.S. Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice Notification and Report Forms required pursuant to the HSR Act for the
consummation of the transactions contemplated by this Agreement. In addition, Orthofix, with SeaSpine&#146;s reasonable cooperation and collaboration, shall use reasonable best efforts to file, as promptly as reasonably practicable following the
date of this Agreement, all initial filings, notifications, submissions (or, initial draft notifications, or <FONT STYLE="white-space:nowrap">pre-filings,</FONT> in each case if customary) required to complete the transactions contemplated by this
Agreement pursuant to any other applicable Antitrust Law promulgated by a Government Body in the jurisdictions set forth in <U>Schedule 6.05(a)</U> (collectively, the &#147;<U>Additional Antitrust Approvals</U>&#148;). Orthofix shall pay all filing
fees required by the HSR Act and any other applicable merger notification or control Laws in connection with such filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix and SeaSpine each shall promptly (i)&nbsp;supply the other with any information reasonably required in
order to effectuate the filings described in this <U>Section</U><U></U><U>&nbsp;6.05</U>, (ii)&nbsp;supply additional information reasonably required by a Governmental Body and, (iii)&nbsp;subject to applicable legal limitations and the instructions
of any Governmental Body, keep each other apprised of the status of matters relating to the completion of the transactions contemplated by this Agreement, including promptly furnishing the other with copies of communications received from any
Governmental Body. Neither Orthofix nor SeaSpine shall independently participate in any meeting, or engage in any substantive conversation, with any Governmental Body in connection with such filings without using commercially reasonable efforts to
give the other prior notice of the meeting or conversation and, unless prohibited by such Governmental Body, a reasonable opportunity to attend or participate. The parties shall reasonably consult and cooperate with one another and permit the other
party or its counsel to review in advance any proposed written communication by such party to any Governmental Body in connection with any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted
by or on behalf of any party in connection with proceedings under or relating to any other Antitrust Laws in connection with the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Each of SeaSpine and Orthofix shall (i)&nbsp;give the other party
prompt notice of the commencement or written threat of commencement of any legal proceeding by or before any Governmental Body with respect to the transactions contemplated by this Agreement, (ii)&nbsp;keep the other party informed as to the status
of any such legal proceeding or threat and (iii)&nbsp;reasonably cooperate with each other and use reasonable best efforts to contest and resist any such action or proceeding and to have vacated, lifted, reversed or overturned any decree, judgment,
injunction or other order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the conditions and upon the terms of this Agreement, each of Orthofix and SeaSpine shall use reasonable
best efforts (subject to, and in accordance with, applicable Law) to take promptly, or cause to be taken promptly, all actions, and to do promptly, or cause to be done, and to assist and cooperate with the other parties in doing, all things
necessary, proper or advisable under applicable Laws to carry out the intent and purposes of this Agreement and to consummate the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, subject to the
conditions and upon the terms of this Agreement, each party to this Agreement shall use reasonable best efforts (i)&nbsp;to cooperate with the other party, execute and deliver such further documents, certificates, agreements and instruments and take
such other actions as may be reasonably requested by the other party to evidence or reflect the transactions contemplated by this Agreement (including the execution and delivery of all documents, certificates, agreements and instruments reasonably
necessary for all filings hereunder); (ii)&nbsp;to give all notices required to be made and given by such party in connection with the transactions contemplated by this Agreement and (iii)&nbsp;to obtain each approval, consent, ratification,
permission and waiver of authorization required to be obtained from a Governmental Body or a party to any material Contract; <U>provided</U>, that, notwithstanding anything to the contrary contained in this Agreement, in no event shall
(A)&nbsp;SeaSpine or Orthofix or any of their respective Subsidiaries be required to pay any fee, penalty or other consideration to any third party for any approval, consent, ratification, permission or waiver of authorization required to be
obtained from parties to any material Contracts or (B)&nbsp;the receipt of any such approval, consent, ratification, permission or waiver of authorization required to be obtained from parties to any material Contracts be a condition to any
party&#146;s obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this Agreement,
neither Orthofix nor SeaSpine, by itself or on behalf of any of its Subsidiaries or Affiliates, (A)&nbsp;is required to divest, sell, dispose of, or license or agree to divest, sell, dispose of, or license any assets, businesses, rights or
operations and (B)&nbsp;shall, without the prior written consent of the other, offer or agree to divest, sell, dispose of, or license any assets, businesses, rights or operations, in the case of each of (A)&nbsp;and (B), in order to satisfy the
conditions in <U>Section</U><U></U><U>&nbsp;7.01(d)</U> and <U>Section</U><U></U><U>&nbsp;7.01(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.06&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of SeaSpine ESPP</U>. SeaSpine shall take all actions necessary to (a)&nbsp;provide that no
Offering Period (as defined in the SeaSpine ESPP) shall commence under the SeaSpine ESPP following the date hereof, (b)&nbsp;provide that the Offering Period in effect on the date hereof under the SeaSpine ESPP shall terminate upon the earlier of
(i)&nbsp;the date that is four (4)&nbsp;Trading Days prior to the Effective Time or (ii)&nbsp;the date on which such Offering Period would otherwise end, and that no additional Offering Periods shall commence under the SeaSpine ESPP after the date
hereof, (c)&nbsp;provide that an Exercise Date (as defined in the SeaSpine ESPP) shall occur under the SeaSpine ESPP upon the earlier of (i)&nbsp;the date that is four (4)&nbsp;Trading Days prior to the Effective Time or (ii)&nbsp;the date on which
such Offering Period would otherwise end, (d)&nbsp;provide that no individual participating in the SeaSpine ESPP shall be permitted to increase his or her rate of payroll contributions thereunder from the rate in effect as of the date hereof,
(e)&nbsp;provide that no individual who is not participating in the SeaSpine ESPP as of the date hereof may commence participation in the SeaSpine ESPP following the date hereof and (f)&nbsp;terminate the SeaSpine ESPP as of immediately prior to the
Effective Time. Any SeaSpine Shares acquired after the date hereof under the SeaSpine ESPP shall be treated as outstanding SeaSpine Shares for purposes of <U>Section</U><U></U><U>&nbsp;2.08(a)(ii)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.07&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee and Labor Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;With respect to the compensation and benefits to be provided after the Effective Time in respect of individuals who
are employees of SeaSpine or its Subsidiaries as of the Effective Time (the &#147;<U>SeaSpine Employees</U>&#148;) and to individuals who are employees of Orthofix or its Subsidiaries as of the Effective Time (the &#147;<U>Orthofix
Employees</U>&#148; and, together with SeaSpine Employees, the &#147;<U>Employees</U>&#148;) who are not represented by a union or labor organization with respect to the terms and conditions of their employment nor employed pursuant to the terms of
a collective bargaining agreement, SeaSpine and Orthofix have agreed that, consistent with the current practices of SeaSpine and Orthofix, the Surviving Corporation and Orthofix shall seek, after the Effective Time, to attract and retain superior
quality executive, managerial, technical and administrative personnel in every market in which they conduct activities and will generally implement compensation and benefit plans and policies necessary or appropriate to achieve this objective. It is
the specific intention that, in each of the markets in which they operate, the compensation and benefit programs of the Surviving Corporation and Orthofix (i)&nbsp;will be competitive with those provided generally in their industry, both with
respect to the type and variety of programs as well as the level of benefits afforded, and (ii)&nbsp;will treat similarly-situated SeaSpine Employees and Orthofix Employees on a substantially comparable basis, taking into account all relevant
factors, including duties, geographic location, tenure, qualifications and abilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;For all purposes under
the employee benefit plans of Orthofix and its Subsidiaries providing benefits to any Employees after the Effective Time (the &#147;<U>New Plans</U>&#148;), each SeaSpine Employee shall be credited with his or her years of service with SeaSpine and
its Subsidiaries before the Effective Time for purposes of vesting, benefits eligibility and level of benefits, and each Orthofix Employee shall be credited with his or her years of service with Orthofix and its Subsidiaries before the Effective
Time for such purposes, in each case, to the same extent as such Employee was entitled, before the Effective Time, to credit for such service under any similar SeaSpine Plan or Orthofix Plan, as applicable;&nbsp;provided,&nbsp;however, that such
service crediting shall not be required (i)&nbsp;to the extent it would result in a duplication of benefits or (ii)&nbsp;to the extent SeaSpine Employees and Orthofix Employees are equally affected without regard to whether employment before the
Effective Time was with SeaSpine and its Subsidiaries or Orthofix and its Subsidiaries (for example, in the event a New Plan is adopted for SeaSpine Employees and Orthofix Employees under which no participants receive credit for service before the
effective date of the New Plan). In addition, and without limiting the generality of the foregoing provisions of this paragraph (b), Orthofix shall make commercially reasonable efforts to provide that (A)&nbsp;each Employee shall be immediately
eligible to participate, without any waiting time, in any and all New Plans to the extent coverage under such New Plan replaces coverage under a comparable SeaSpine Plan or Orthofix Plan in which such Employee participated immediately before the
Effective Time (such plans, collectively, the &#147;<U>Old Plans</U>&#148;), and (B)&nbsp;for purposes of each New Plan providing medical, dental, pharmaceutical and/or vision benefits to any Employee,
<FONT STYLE="white-space:nowrap">pre-existing</FONT> condition exclusions and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">actively-at-work</FONT></FONT> requirements of such New Plan are waived for such Employee and his or her
covered dependents, and any eligible expenses incurred by such Employee and his or her covered dependents during the portion of the plan year of the Old Plan ending on the date such Employee&#146;s participation in the corresponding New Plan begins
are taken into account under such New Plan for purposes of satisfying all deductible, coinsurance and maximum <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> requirements applicable to such Employee and
his or her covered dependents for the applicable plan year as if such amounts had been paid in accordance with such New Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Merger shall be deemed to constitute a &#147;Corporate Transaction&#148; and &#147;Change in Control&#148; for
purposes of each of the Orthofix Equity Plan and the Orthofix Inducement Plans </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and all awards granted respectively thereunder, and it is the intent of the parties that awards under such respective Plans shall be continued, and that all awards under the Orthofix Equity Plan
will be treated in accordance with Section&nbsp;17.4(b) of the Orthofix Equity Plan. Notwithstanding the foregoing and for the avoidance of doubt, the preceding sentence shall not be interpreted to affect whether or not the Merger will be deemed a
&#147;change in control,&#148; &#147;change of control&#148; or similar phrase for any purpose other than as specifically stated in the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this <U>Section</U><U></U><U>&nbsp;6.07</U> shall not be construed to prevent the termination of
employment of any Employee or the amendment or termination of any particular SeaSpine Plan or Orthofix Plan, to the extent permitted by its terms as in effect immediately before the Effective Time. Notwithstanding anything in this Agreement to the
contrary, no provision of this Agreement is intended to, or does, constitute the establishment or adoption of, or amendment to, any SeaSpine Plan or Orthofix Plan, and no Person participating in any such Plan shall have any claim or cause of action,
under ERISA or otherwise, in respect of the provisions of this Agreement as it relates to any such plan or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.08&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification of Officers and Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix agrees that all rights to indemnification and exculpation from liabilities, including advancement of
expenses, for acts or omissions occurring at or prior to the Effective Time now existing in favor of the current or former directors or officers of SeaSpine (the &#147;<U>Indemnified Parties</U>&#148;) as provided in SeaSpine&#146;s Amended and
Restated Certificate of Incorporation (as amended), SeaSpine&#146;s Amended and Restated Bylaws (as amended), or any indemnification Contract between such directors or officers and SeaSpine (in each case, as in effect on, and, in the case of any
indemnification Contracts, to the extent made available to Orthofix prior to, the date of this Agreement) shall survive the Merger and shall continue in full force and effect. For a period of six (6)&nbsp;years from the Effective Time, the Surviving
Corporation shall, and Orthofix shall cause the Surviving Corporation to, maintain in effect the exculpation, indemnification and advancement of expenses equivalent to the provisions of SeaSpine&#146;s Amended and Restated Certificate of
Incorporation (as amended), and SeaSpine&#146;s Amended and Restated Bylaws (as amended), as in effect immediately prior to the Effective Time with respect to acts or omissions occurring prior to the Effective Time and shall not amend, repeal or
otherwise modify any such provisions in any manner that would adversely affect the rights thereunder of any Indemnified Party; <U>provided</U>, <U>however</U>, that all rights to indemnification with respect to any claim made for indemnification
within such period shall continue until the disposition of such Action or resolution of such claim. From and after the Effective Time, Orthofix shall guarantee and stand surety for, and shall cause the Surviving Corporation to honor, in accordance
with their respective terms, each of the covenants contained in this <U>Section</U><U></U><U>&nbsp;6.08</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Prior to or at the Effective Time, SeaSpine shall purchase a six (6)-year prepaid &#147;tail&#148; policy, with
terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under SeaSpine&#146;s existing policies of directors&#146; and officers&#146; liability insurance and fiduciary liability insurance, with
respect to matters arising on or before the Effective Time (including in connection with this Agreement and the transactions or actions contemplated by this Agreement), and Orthofix shall cause such policy to be maintained in full force and effect,
for its full term, and cause all obligations thereunder to be honored by the Surviving Corporation;<U>&nbsp;provided</U>, <U>however</U>,&nbsp;that SeaSpine shall not pay or agree to pay, and the Surviving Corporation shall not be required to pay,
in excess of 300% of the last annual premium paid by SeaSpine prior to the date of this Agreement in respect of such &#147;tail&#148; policy. Should SeaSpine be unable to purchase a <FONT STYLE="white-space:nowrap">6-year</FONT> tail policy for
fiduciary liability, SeaSpine shall purchase the longest tail period available, which shall be deemed to satisfy this <U>Section</U><U></U><U>&nbsp;6.08(b)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The covenants contained in this
<U>Section</U><U></U><U>&nbsp;6.08</U> are intended to be for the benefit of, and shall be enforceable by, each of the Indemnified Parties and their respective heirs and shall not be deemed exclusive of any other rights to which any such person is
entitled, whether pursuant to applicable Law, Contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If Orthofix or the Surviving Corporation
or any of their respective successors or assigns (i)&nbsp;shall consolidate with or merge into any other corporation or entity and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii)&nbsp;shall
transfer all or substantially all of its properties and assets to any individual, corporation or other entity, then, and in each such case, proper provisions shall be made so that the successors and assigns of Orthofix or the Surviving Corporation
shall assume all of the obligations set forth in this <U>Section</U><U></U><U>&nbsp;6.08</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.09&nbsp;&nbsp;&nbsp;&nbsp;<U>Public
Disclosure</U>. The initial press release relating to this Agreement shall be a joint press release in form and substance acceptable to each party, and thereafter Orthofix and SeaSpine shall consult with each other before issuing, and provide each
other the reasonable opportunity to review and comment upon, any press release or other public statements with respect to the Merger or the other transactions contemplated hereby; <U>provided</U>, <U>however</U>, that subject to compliance by the
parties in all respects with the terms of <U>Section</U><U></U><U>&nbsp;6.04</U> of this Agreement, no such opportunity to review and comment shall be required in connection with a SeaSpine Adverse Recommendation Change (or any responses thereto) or
an Orthofix Adverse Recommendation Change (or any responses thereto). No provision of this Agreement shall prohibit either SeaSpine or Orthofix from issuing any press release or public statement in the event of a SeaSpine Adverse Recommendation
Change or an Orthofix Adverse Recommendation Change in compliance in all respects with the terms of <U>Section</U><U></U><U>&nbsp;6.04</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10&nbsp;&nbsp;&nbsp;&nbsp;<U>NASDAQ Listing of Additional Shares</U>. Orthofix shall, in accordance with the requirements of NASDAQ, file
with NASDAQ a Listing of Additional Shares Notice covering the Orthofix Shares to be issued to SeaSpine Stockholders pursuant to this Agreement (including, for the avoidance of doubt, Orthofix Shares issuable with respect to the SeaSpine Restricted
Shares, SeaSpine RSUs and SeaSpine Options), as promptly as reasonably practicable after the date of this Agreement, and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Takeover Laws</U>. If any Takeover Law may become, or may purport to be, applicable to the transactions
contemplated by this Agreement, each of Orthofix and SeaSpine shall, and shall cause the members of its board of directors to, to the extent permissible under applicable Law, grant such approvals and take such actions, in accordance with the terms
of this Agreement, as are necessary so that the transactions contemplated by this Agreement may be consummated as promptly as practicable following the date hereof, and in any event prior to the Termination Date, on the terms and conditions
contemplated hereby and otherwise, and to the extent permissible under applicable Law, take such actions as are necessary to eliminate the effect of any Takeover Law on any of the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Section</U><U></U><U>&nbsp;16</U>. Orthofix shall, prior to the Effective Time, cause the Orthofix Board to
approve the issuance of Orthofix Shares in connection with the Merger with respect to any employees of SeaSpine who, as a result of their relationship with Orthofix as of or following the Effective Time, are subject or will become subject to the
reporting requirements of Section&nbsp;16 of the Exchange Act to the extent necessary for such issuance to be an exempt acquisition pursuant to SEC Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> Prior to the Effective Time, SeaSpine shall cause
the SeaSpine Board shall approve the disposition of SeaSpine equity securities (including derivative securities) in connection with the Merger by those directors and officers of SeaSpine subject to the reporting requirements of Section&nbsp;16 of
the Exchange Act to the extent necessary for such disposition to be an exempt disposition pursuant to SEC Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;None of the parties shall (and each party shall cause its respective Subsidiaries not to) take any action (or
knowingly fail to take any action) which action (or failure to act) would or would reasonably be expected to prevent or impede the Merger from qualifying as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. The
parties shall treat, for U.S. federal income tax purposes, the Merger as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code and no party shall take any position for Tax purposes inconsistent therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;From and after the date of this Agreement and until the Closing, Orthofix, on the one hand, and SeaSpine, on the
other hand, shall cooperate with each other and each shall use its reasonable best efforts to obtain: (i)&nbsp;in the case of Orthofix, a written opinion, in form and substance reasonably satisfactory to Orthofix, of Hogan Lovells US LLP (or other
nationally recognized tax counsel reasonably acceptable to Orthofix, which shall include DLA Piper LLP) (&#147;<U>Orthofix Tax Counsel</U>&#148;); and (ii)&nbsp;in the case of SeaSpine, a written opinion, in form and substance reasonably
satisfactory to SeaSpine, of DLA Piper LLP (or other nationally recognized tax counsel reasonably acceptable to SeaSpine, which shall include Hogan Lovells US LLP) (&#147;<U>SeaSpine Tax Counsel</U>&#148;) (each such opinion referred to in clauses
(i)&nbsp;and (ii), a &#147;<U>Merger Tax Opinion</U>&#148;). Each Merger Tax Opinion shall be dated as of the Closing Date, and (a)&nbsp;be to the effect that, on the basis of customary representations, assumptions and undertakings set forth or
referred to in such opinion and in the related Merger Tax Representation Letters, the Merger will qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, and (b)&nbsp;will address any supplemental matter
reasonably requested by both Orthofix and SeaSpine to be included in such opinion. Each of Orthofix, SeaSpine, and Merger Sub shall deliver to Orthofix Tax Counsel and SeaSpine Tax Counsel for purposes of the Merger Tax Opinions a representation
letter dated as of the Closing Date (and, if requested, dated as of the date the Registration Statement shall have been declared effective by the SEC or such other date(s) as determined necessary by Orthofix Tax Counsel and SeaSpine Tax Counsel in
connection with the filing of the registration statement or its exhibits) containing customary representations, assumptions and undertakings, reasonably satisfactory in form and substance to Orthofix Tax Counsel and SeaSpine Tax Counsel (the
&#147;<U>Merger Tax Representation Letters</U>&#148;). Orthofix will promptly notify SeaSpine if, before the Closing, (i)&nbsp;it knows or has reason to believe that Orthofix is no longer able to obtain the Merger Tax Opinion from Orthofix Tax
Counsel, or (ii)&nbsp;the terms of this Agreement would need to be amended in order to facilitate receipt of such opinion. SeaSpine will promptly notify Orthofix if, before the Closing, (A)&nbsp;it knows or has reason to believe that SeaSpine is no
longer able to obtain the Merger Tax Opinion from SeaSpine Tax Counsel, or (B)&nbsp;the terms of this Agreement would need to be amended in order to facilitate receipt of such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.14&nbsp;&nbsp;&nbsp;&nbsp;<U>No Control of Other Party</U><U>&#146;</U><U>s Business</U>. Nothing contained in this Agreement shall give
SeaSpine, directly or indirectly, the right to control or direct Orthofix&#146;s operations or give Orthofix, directly or indirectly, the right to control or direct SeaSpine&#146;s operations prior to the Effective Time. Prior to the Effective Time,
each of SeaSpine and Orthofix shall exercise, consistent with the terms and conditions of this Agreement, complete control and supervision over its respective operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing of Form <FONT STYLE="white-space:nowrap">S-8;</FONT> Listing of Additional Shares</U>. Orthofix shall
file no later than five (5)<U></U> days after the Closing Date, a registration statement on Form<U></U> <FONT STYLE="white-space:nowrap">S-8</FONT><U></U>&nbsp;(or any successor form) with respect to the Orthofix Shares issuable with respect to
SeaSpine Restricted Shares, SeaSpine RSUs and SeaSpine Options pursuant to Section<U></U>&nbsp;2.08(b), and shall use reasonable best efforts to maintain the effectiveness of such registration statement or registration statements (and maintain the
current status of the prospectus or prospectuses contained therein) for so long such SeaSpine Restricted Shares, SeaSpine RSUs and SeaSpine Options remain outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.16&nbsp;&nbsp;&nbsp;&nbsp;<U>Loan Payoff</U>. SeaSpine shall use reasonable best efforts
to deliver all notices and take all other actions, in each case to the extent reasonably requested by Orthofix, that are reasonably necessary to facilitate the termination at Closing of all commitments in respect of the SeaSpine Existing Loan
Documents, the repayment in full at the Closing of all obligations in respect of the indebtedness thereunder, and the release on or promptly following the Closing of any Liens securing such indebtedness and guarantees in connection therewith. In
furtherance thereof, at the written request of Orthofix, SeaSpine shall use its reasonable best efforts to arrange for the receipt and delivery to Orthofix, at least three (3)&nbsp;Business Days prior to the Closing, of a customary payoff letter
executed from the holders (or agent on behalf of such holders) of Indebtedness under the SeaSpine Existing Loan Documents, in form and substance reasonably satisfactory to Orthofix, in which the payee shall agree that upon payment of the amounts
specified in such payoff letter: (i)&nbsp;all outstanding payment obligations of SeaSpine and its Subsidiaries arising under the SeaSpine Existing Loan Documents shall be repaid, discharged and extinguished in full on the Closing Date; (ii)&nbsp;all
Liens in connection therewith shall be terminated, discharged and released; and (iii)&nbsp;the payee shall take all actions reasonably requested by Orthofix (or shall allow SeaSpine or Orthofix to take all actions) to evidence and record such
termination, discharge and release of Liens as promptly as practicable after the Closing (the &#147;<U>SeaSpine Existing Loan Documents Termination</U>&#148;). Notwithstanding anything to the contrary contained herein, (x)&nbsp;in no event shall
this Section&nbsp;6.16 require SeaSpine or any of its Subsidiaries to cause the SeaSpine Existing Loan Documents Termination unless the Closing shall have occurred and (y)&nbsp;Orthofix shall provide, or cause to be provided, all funds required to
effect the SeaSpine Existing Loan Documents Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.17&nbsp;&nbsp;&nbsp;&nbsp;<U>SeaSpine Exchangeable Shares Notice</U>. Prior to
the Closing, SeaSpine shall, in accordance with AcquireCo&#146;s Articles, (a)&nbsp;provide written notice to each holder of SeaSpine Exchangeable Shares that a mandatory redemption of all outstanding SeaSpine Exchangeable Shares shall occur in
connection with the Merger and (b)&nbsp;effect a SeaSpine Exchangeable Share Redemption and the issuance of SeaSpine Shares in connection therewith and with respect to all outstanding SeaSpine Exchangeable Shares contingent upon, and as of
immediately prior to, the Effective Time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 7 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CONDITIONS TO CLOSING </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions to All Parties</U><U>&#146;</U><U> Obligations</U>. The obligations of Orthofix and SeaSpine to
consummate the transactions contemplated by this Agreement are subject to the satisfaction (or waiver by Orthofix and SeaSpine), at or prior to the Closing, of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Orthofix Stockholder Approval shall have been attained; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the SeaSpine Stockholder Approval shall have been attained; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;the Registration Statement shall have become effective under the Securities Act and shall remain in effect, and
shall not be the subject of any stop order or any Action by the SEC seeking a stop order; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;any waiting
period (and any extension thereof) applicable to the transactions contemplated by this Agreement under the HSR Act shall have expired or been terminated, and (ii)&nbsp;any mandatory waiting period or required consent under any other applicable
Antitrust Laws shall have expired or been obtained, except where the failure to observe such waiting period or obtain a consent referred to in this clause (ii)&nbsp;would not reasonably be expected to delay or prevent the consummation of the Merger
or have a material adverse effect on the expected benefits of the Merger to SeaSpine and Orthofix, taken as a whole; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;no Governmental Body of competent jurisdiction shall have issued
or entered any Order after the date of this Agreement, and no applicable Law shall have been enacted or promulgated after the date of this Agreement, in each case, that (whether temporary or permanent) is then in effect and has the effect of
enjoining or otherwise prohibiting the consummation of the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.02&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions to
Orthofix</U><U>&#146;</U><U>s and Merger Sub</U><U>&#146;</U><U>s Obligations</U>. The obligations of Orthofix and Merger Sub to consummate the transactions contemplated by this Agreement are subject to the satisfaction (or waiver by Orthofix), at
or prior to the Closing, of the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the representations and warranties contained in
<U>Section</U><U></U><U>&nbsp;3.01(a)</U>, <U>Section</U><U></U><U>&nbsp;3.02</U>, <U>Section</U><U></U><U>&nbsp;3.22</U> and <U>Section</U><U></U><U>&nbsp;3.24</U> shall be true and correct in all material respects as of the Closing Date as though
made on the Closing Date (except to the extent such representations and warranties expressly relate to a specific date or the date of this Agreement, in which case such representations and warranties, shall be true and correct in all material
respects as of such date), (ii) the representations and warranties contained in <U>Section</U><U></U><U>&nbsp;3.03</U> shall be true and correct in all respects as of the Closing Date as though made on the Closing Date (except to the extent such
representations and warranties expressly relate to a specific date or the date of this Agreement, in which case such representations and warranties, shall be true and correct in all respects as of such date), except where a failure of such
representations and warranties to be true or correct is <I>de minimis</I> in nature, (iii)&nbsp;the representations and warranties contained in <U>Section</U><U></U><U>&nbsp;3.09(a)</U> shall be true and correct in all respects as of the Closing
Date as though made on the Closing Date and (iv)&nbsp;the representations and warranties contained in <U>ARTICLE 3</U> of this Agreement (other than those contained in the sections set forth in the preceding clauses (i), (ii) and (iii)) shall be
true and correct (without giving effect to any limitation as to &#147;materiality,&#148; &#147;Material Adverse Effect&#148; or any similar limitation set forth therein) in all respects as of the Closing Date as though made on the Closing Date
(except to the extent such representations and warranties expressly relate to a specific date or the date of this Agreement, in which case such representations and warranties shall be true and correct in all respects as of such date), except where
the failure to be so true and correct does not have, and would not reasonably be expected to have, individually or in the aggregate, a SeaSpine Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine shall have performed in all material respects all of the covenants and agreements under this Agreement
that are required to be performed by it at or prior to the Closing Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;since the date of this Agreement,
there shall not have been or occurred any SeaSpine Material Adverse Effect; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine shall have delivered
to Orthofix a certificate of SeaSpine executed by a duly authorized officer thereof, dated as of the Closing Date, stating that the conditions in <U>Sections 7.02(a)</U>, <U>(b)</U> and <U>(c)</U>&nbsp;have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.03&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions to SeaSpine</U><U>&#146;</U><U>s Obligations</U>. The obligations of SeaSpine to consummate the
transactions contemplated by this Agreement are subject to the satisfaction (or waiver by SeaSpine), at or prior to the Closing, of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the representations and warranties contained in <U>Section</U><U></U><U>&nbsp;4.01(a)</U>,
<U>Section</U><U></U><U>&nbsp;4.02</U>, <U>Section</U><U></U><U>&nbsp;4.22</U> and <U>Section</U><U></U><U>&nbsp;4.24</U> shall be true and correct in all material respects as of the Closing Date as though made on the Closing Date (except to the
extent such representations and warranties expressly relate to a specific date or the date of this Agreement, in which case such representations and warranties, shall be true and correct in all material respects as of such date), (ii) the
representations and warranties contained in <U>Section</U><U></U><U>&nbsp;4.03</U> shall be true and correct in all respects as of the Closing Date as though made on the Closing Date (except to the extent such representations and warranties
expressly relate to a specific date or the date of this Agreement, in which case such representations and warranties, shall be true and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
correct in all respects as of such date), except where a failure of such representations and warranties to be true or correct is <I>de minimis</I> in nature, (iii)&nbsp;the representations and
warranties contained in <U>Section</U><U></U><U>&nbsp;4.09(a)</U> shall be true and correct in all respects as of the Closing Date as though made on the Closing Date and (iv)&nbsp;the representations and warranties contained in <U>ARTICLE 4</U> of
this Agreement (other than those contained in the sections set forth in the preceding clauses (i), (ii) and (iii)) shall be true and correct (without giving effect to any limitation as to &#147;materiality,&#148; &#147;Material Adverse Effect&#148;
or any similar limitation set forth therein) in all respects as of the Closing Date as though made on the Closing Date (except to the extent such representations and warranties expressly relate to a specific date or the date of this Agreement, in
which case such representations and warranties shall be true and correct in all respects as of such date), except where the failure to be so true and correct does not have, and would not reasonably be expected to have, individually or in the
aggregate, an Orthofix Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;each of Orthofix and Merger Sub shall have performed in all
material respects all of its respective covenants and agreements under this Agreement that are required to be performed by it at or prior to the Closing Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;since the date of this Agreement, there shall not have been or occurred any Orthofix Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix shall have delivered to SeaSpine a certificate of Orthofix executed by a duly authorized officer thereof,
dated as of the Closing Date, stating that the conditions in <U>Sections</U><U></U><U>&nbsp;7.03(a)</U>, <U>(b)</U> and <U>(c)</U>&nbsp;have been satisfied; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix shall have filed with NASDAQ the Listing of Additional Shares Notice with respect to the Orthofix Shares
issued or issuable pursuant to this Agreement, and such Orthofix Shares shall have been approved and authorized for listing on NASDAQ; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine shall have received the Merger Tax Opinion from SeaSpine Tax Counsel, and such opinion shall not have been
withdrawn or adversely modified. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 8 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>TERMINATION </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. This Agreement may be terminated and the transactions contemplated hereby, including the
Merger, may be abandoned at any time prior to the Effective Time: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;by the mutual written consent of Orthofix
and SeaSpine; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;by Orthofix, if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;at any time prior to the Effective Time, any of SeaSpine&#146;s covenants, obligations,
representations or warranties contained in this Agreement shall have been breached or any of SeaSpine&#146;s representations or warranties shall have become untrue, such that any of the conditions set forth in <U>Sections 7.02(a)</U> or
<U>7.02(b)</U> would not be satisfied, and any such breach or failure of a representation or warranty to be true is (A)&nbsp;is incapable of being cured by SeaSpine or (B)&nbsp;shall not have been cured within forty-five (45)&nbsp;days of receipt by
SeaSpine of written notice from Orthofix of such breach or failure to be true describing in reasonable detail such breach or failure to be true; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the SeaSpine Board or any committee thereof
(A)&nbsp;shall make a SeaSpine Adverse Recommendation Change, (B)&nbsp;shall not include the SeaSpine Recommendation in the Joint Proxy Statement or (C)&nbsp;shall publicly propose or allow SeaSpine to publicly propose to take any of the actions in
clause (A)&nbsp;or (B)&nbsp;of this <U>Section</U><U></U><U>&nbsp;8.01(b)(ii)</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;SeaSpine
materially breaches <U>Section</U><U></U><U>&nbsp;6.04</U>; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;at any time prior to obtaining
the Orthofix Stockholder Approval, Orthofix terminates in order to enter into a definitive agreement with respect to a Superior Proposal and Orthofix has otherwise complied with its obligations under <U>Section</U><U></U><U>&nbsp;6.04</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;by SeaSpine, if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;at any time prior to the Effective Time, any of Orthofix&#146;s or Merger Sub&#146;s covenants,
obligations, representations or warranties contained in this Agreement shall have been breached or any of Orthofix&#146;s or Merger Sub&#146;s representations or warranties shall have become untrue, such that any of the conditions set forth in
<U>Sections 7.03(a)</U> or <U>7.03(b)</U> would not be satisfied, and any such breach or failure of a representation or warranty to be true is (A)&nbsp;is incapable of being cured by Orthofix or Merger Sub or (B)&nbsp;shall not have been cured
within forty-five (45)&nbsp;days of receipt by Orthofix of written notice from SeaSpine of such breach or failure to be true describing in reasonable detail such breach or failure to be true; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Orthofix Board or any committee thereof (A)&nbsp;shall make an Orthofix Adverse Recommendation
Change, (B)&nbsp;shall not include the Orthofix Recommendation in the Joint Proxy Statement or (C)&nbsp;shall publicly propose to or allow Orthofix to publicly propose to take any of the actions in clause (A)&nbsp;or (B)&nbsp;of this
<U>Section</U><U></U><U>&nbsp;8.01(c)(ii)</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Orthofix materially breaches
<U>Section</U><U></U><U>&nbsp;6.04</U>; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;at any time prior to obtaining SeaSpine Stockholder
Approval, SeaSpine terminates in order to enter into a definitive agreement with respect to a Superior Proposal and SeaSpine has otherwise complied with its obligations under <U>Section</U><U></U><U>&nbsp;6.04</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;by either Orthofix or SeaSpine, if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;(A) any Governmental Body of competent jurisdiction shall have issued or entered any Order after the
date of this Agreement that shall have become final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> or any applicable Law shall have been enacted or promulgated after the date of this Agreement, in each case, that has the effect of
permanently restraining, enjoining or otherwise prohibiting the Merger, or (B)&nbsp;any expiration, termination authorization or consent from a Governmental Body required to be obtained pursuant to <U>Section</U><U></U><U>&nbsp;7.01(d)</U> shall
have been denied and such denial shall have become final and <FONT STYLE="white-space:nowrap">non-appealable;</FONT> <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this <U>Section</U><U></U><U>&nbsp;8.01(d)(i)</U>
shall not be available to any party if a material breach by such party of its obligations under <U>Section</U><U></U><U>&nbsp;6.05</U> or any other provision of this Agreement has been a principal cause of, or principally resulted in, such Order or
Law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Merger contemplated hereby has not been consummated by the date that is five
(5)&nbsp;months following the date of this Agreement (the &#147;<U>Termination Date</U>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
<U>provided</U>, <U>however</U>, that if the Merger shall not have been consummated by the Termination Date but on that date the condition set forth in <U>Section</U><U></U><U>&nbsp;7.01(d)</U>
shall have not been satisfied or waived, but all other conditions to the parties&#146; obligations to consummate the transactions contemplated by this Agreement set forth in <U>ARTICLE 7</U> shall have been satisfied or waived (other than those
conditions that by their terms are to be fulfilled at the Closing, provided that each such condition would be capable of being fulfilled if the Closing were to occur on such date), then either Orthofix or SeaSpine may extend the Termination Date by
written notice to the other party up to a date not beyond the date that is eight (8)&nbsp;months after the date of this Agreement; <U>provided</U>, <U>further</U>, that the right to terminate this Agreement under this
<U>Section</U><U></U><U>&nbsp;8.01(d)(ii)</U> shall not be available to any party if a material breach by such party of its obligations under any provision of this Agreement has been the principal cause of, or principally resulted in, the failure of
the Merger to be consummated by the Termination Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the SeaSpine Stockholder Approval at a
vote take thereon at the SeaSpine Stockholders&#146; Meeting shall not have been obtained; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this <U>Section</U><U></U><U>&nbsp;8.01(d)(iii)</U> shall not be available
to SeaSpine if a material breach by SeaSpine of its obligations under any provision of this Agreement has been the principal cause of, or principally resulted in, the failure to obtain the SeaSpine Stockholder Approval; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;the Orthofix Stockholder Approval at a vote take thereon at the Orthofix Stockholders&#146; Meeting
shall not have been obtained; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this <U>Section</U><U></U><U>&nbsp;8.01(d)(iv)</U> shall not be available to Orthofix if a material breach by Orthofix of its obligations
under any provision of this Agreement has been the principal cause of, or principally resulted in, the failure to obtain the Orthofix Stockholder Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.02&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Termination</U>. In the event of the termination of this Agreement as provided in
<U>Section</U><U></U><U>&nbsp;8.01</U> of this Agreement, this Agreement shall be of no further force or effect; <U>provided</U>, <U>however</U>, that (a)<U>&nbsp;Section</U><U></U><U>&nbsp;6.01(b)</U>,&nbsp;this
<U>Section</U><U></U><U>&nbsp;8.02</U>, <U>Section</U><U></U><U>&nbsp;8.03</U> and <U>ARTICLE 9</U> of this Agreement shall survive the termination of this Agreement and shall remain in full force and effect, and (b)&nbsp;the termination of this
Agreement shall not relieve any party from any liability or damages for any Intentional and Material Breach or Fraud. The Confidentiality Agreement shall not be affected by a termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.03&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination Fees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;In the event that (i)&nbsp;this Agreement is terminated by SeaSpine pursuant to
<U>Section</U><U></U><U>&nbsp;8.01(c)(ii)</U> or <U>Section</U><U></U><U>&nbsp;8.01(c)(iii)</U> or (ii)&nbsp;this Agreement is terminated by Orthofix pursuant to <U>Section</U><U></U><U>&nbsp;8.01(b)(iv)</U>, then Orthofix shall pay to SeaSpine
(A)&nbsp;the Orthofix Termination Fee (1)&nbsp;as promptly as possible (but in any event within three (3)&nbsp;Business Days) following such termination in the case of a termination pursuant to clause (i)&nbsp;above or (2)&nbsp;upon termination of
this Agreement in the case of a termination pursuant to clause (ii)&nbsp;above and (B)&nbsp;the Expenses no later than three (3)&nbsp;Business Days after receipt by Orthofix of documentation supporting such Expenses from SeaSpine. Other than with
respect to claims for, or arising out of or in connection with an Intentional and Material Breach hereunder or Fraud, SeaSpine&#146;s right to receive the <FONT STYLE="white-space:nowrap">one-time</FONT> payment of the Orthofix Termination Fee and
the Expenses from Orthofix as provided in this <U>Section</U><U></U><U>&nbsp;8.03(a)</U> shall be the sole and exclusive remedy available to SeaSpine against Orthofix or any of its former, current or future equityholders, directors, officers,
Affiliates, agents or Representatives with respect to this Agreement and the transactions contemplated hereby in the event that this Agreement is terminated by SeaSpine pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;8.01(c)(ii)</U> or <U>Section</U><U></U><U>&nbsp;8.01(c)(iii)</U> or by Orthofix pursuant to <U>Section</U><U></U><U>&nbsp;8.01(b)(iv)</U> (including if terminated
or terminable pursuant to one or more of such provisions), and, upon such payment of the Orthofix Termination Fee and the Expenses, none of Orthofix&#146;s or any of its former, current or future equityholders, directors, officers, Affiliates,
agents or Representatives shall have any further liability or obligation relating to or arising out of this Agreement or the transactions contemplated hereby. The parties hereto acknowledge and agree that in no event shall Orthofix be required to
pay the Orthofix Termination Fee or the Expenses on more than one occasion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that (i)&nbsp;this
Agreement is terminated by Orthofix pursuant to <U>Section</U><U></U><U>&nbsp;8.01(b)(ii)</U> or <U>Section</U><U></U><U>&nbsp;8.01(b)(iii)</U> or (ii)&nbsp;this Agreement is terminated by SeaSpine pursuant to
<U>Section</U><U></U><U>&nbsp;8.01(c)(iv)</U>, then SeaSpine shall pay to Orthofix (A)&nbsp;the SeaSpine Termination Fee (1)&nbsp;as promptly as possible (but in any event within three (3)&nbsp;Business Days) following such termination in the case
of a termination pursuant to clause (i)&nbsp;above or (2)&nbsp;upon termination of this Agreement in the case of a termination pursuant to clause (ii)&nbsp;above and (B)&nbsp;the Expenses no later than three (3)&nbsp;Business Days after receipt by
SeaSpine of documentation supporting such Expenses from Orthofix. Other than with respect to claims for, or arising out of or in connection with an Intentional and Material Breach hereunder or Fraud, Orthofix&#146;s right to receive the <FONT
STYLE="white-space:nowrap">one-time</FONT> payment of the SeaSpine Termination Fee and the Expenses from SeaSpine as provided in this <U>Section</U><U></U><U>&nbsp;8.03(b)</U> shall be the sole and exclusive remedy available to Orthofix against
SeaSpine or any of its former, current or future equityholders, directors, officers, Affiliates, agents or Representatives with respect to this Agreement and the transactions contemplated hereby in the event that this Agreement is terminated by
Orthofix pursuant to <U>Section</U><U></U><U>&nbsp;8.01(b)(ii)</U> or <U>Section</U><U></U><U>&nbsp;8.01(b)(iii)</U> or by SeaSpine pursuant to <U>Section</U><U></U><U>&nbsp;8.01(c)(iv)</U> (including if terminated or terminable pursuant to one or
more of such provisions), and, upon such payment of the SeaSpine Termination Fee and the Expenses, none of SeaSpine&#146;s or any of its former, current or future equityholders, directors, officers, Affiliates, agents or Representatives shall have
any further liability or obligation relating to or arising out of this Agreement or the transactions contemplated hereby. The parties hereto acknowledge and agree that in no event shall SeaSpine be required to pay the SeaSpine Termination Fee or the
Expenses on more than one occasion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event that, prior to the SeaSpine Stockholders&#146; Meeting,
(i)&nbsp;an Acquisition Proposal with respect to SeaSpine is publicly proposed or publicly disclosed and this Agreement is terminated by Orthofix or SeaSpine pursuant to <U>Section</U><U></U><U>&nbsp;8.01(b)(i)</U> or
<U>Section</U><U></U><U>&nbsp;8.01(d)(iii)</U>, and such Acquisition Proposal is not irrevocably withdrawn at or prior to the SeaSpine Stockholders&#146; Meeting, in the case of termination pursuant to <U>Section</U><U></U><U>&nbsp;8.01(d)(iii)</U>,
or prior to the time of the relevant breach or failure to be true of a covenant, obligation, representation or warranty, in the case of termination pursuant to <U>Section</U><U></U><U>&nbsp;8.01(b)(i)</U>, then, in each case, SeaSpine shall pay to
Orthofix the Expenses no later than three (3)&nbsp;Business Days after receipt by SeaSpine following termination of documentation supporting such Expenses from Orthofix. If, concurrently with or within twelve (12)&nbsp;months after any such
termination described in the immediately preceding sentence, SeaSpine enters into a definitive agreement (which is ultimately consummated) with respect to, or otherwise consummates, any Acquisition Proposal with respect to SeaSpine (substituting
fifty percent (50%)&nbsp;for the twenty percent (20%)&nbsp;threshold set forth in the definition of &#147;<U>Acquisition Proposal</U>&#148; for all purposes under this <U>Section</U><U></U><U>&nbsp;8.03(c)</U>), then SeaSpine shall pay to Orthofix
the SeaSpine Termination Fee as promptly as possible (but in any event within three (3)&nbsp;Business Days) following the consummation of such Acquisition Proposal. Other than with respect to claims for, or arising out of or in connection with an
Intentional and Material Breach hereunder or Fraud, Orthofix&#146;s right to receive the <FONT STYLE="white-space:nowrap">one-time</FONT> payment of the SeaSpine Termination Fee (if and when due) and the Expenses from SeaSpine as provided in this
<U>Section</U><U></U><U>&nbsp;8.03(c)</U> shall be the sole and exclusive remedy available to Orthofix against SeaSpine or any of its former, current or future equityholders, directors, officers, Affiliates, agents or Representatives with respect to
this Agreement and the transactions contemplated hereby in the event that this Agreement is terminated by Orthofix or SeaSpine pursuant to <U>Section</U><U></U><U>&nbsp;8.01(b)(i)</U> or <U>Section</U><U></U><U>&nbsp;8.01(d)(iii)</U> (including if
terminated or terminable pursuant to one or more of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such provisions), and, upon such payment of the SeaSpine Termination Fee (if and when due) and the Expenses, none of SeaSpine&#146;s or any of its former, current or future equityholders,
directors, officers, Affiliates, agents or Representatives shall have any further liability or obligation relating to or arising out of this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;In the event that, prior to the Orthofix Stockholders&#146; Meeting, (i)&nbsp;an Acquisition Proposal with respect
to Orthofix is publicly proposed or publicly disclosed and this Agreement is terminated by Orthofix or SeaSpine pursuant to <U>Section</U><U></U><U>&nbsp;8.01(c)(i)</U> or <U>Section</U><U></U><U>&nbsp;8.01(d)(iv)</U>, and such Acquisition Proposal
is not irrevocably withdrawn at or prior to the Orthofix Stockholders&#146; Meeting, in the case of termination pursuant to <U>Section</U><U></U><U>&nbsp;8.01(d)(iv)</U>, or prior to the time of the relevant breach or failure to be true of a
covenant, obligation, representation or warranty, in the case of termination pursuant to <U>Section</U><U></U><U>&nbsp;8.01(c)(i)</U>, then, in each case, Orthofix shall pay to SeaSpine the Expenses no later than three (3)&nbsp;Business Days after
receipt by Orthofix following termination of documentation supporting such Expenses from SeaSpine. If, concurrently with or within twelve (12)&nbsp;months after any such termination described in the immediately preceding sentence, Orthofix enters
into a definitive agreement (which is ultimately consummated) with respect to, or consummates, any Acquisition Proposal with respect to Orthofix (substituting fifty percent (50%)&nbsp;for the twenty percent (20%)&nbsp;threshold set forth in the
definition of &#147;Acquisition Proposal&#148; for all purposes under this <U>Section</U><U></U><U>&nbsp;8.03(d)</U>), then Orthofix shall pay to SeaSpine the Orthofix Termination Fee as promptly as possible (but in any event within three
(3)&nbsp;Business Days) following the consummation of such Acquisition Proposal. Other than with respect to claims for, or arising out of or in connection with an Intentional and Material Breach hereunder or Fraud, SeaSpine&#146;s right to receive
the <FONT STYLE="white-space:nowrap">one-time</FONT> payment of the Orthofix Termination Fee (if and when due) and the Expenses from Orthofix as provided in this <U>Section</U><U></U><U>&nbsp;8.03(d)</U> shall be the sole and exclusive remedy
available to SeaSpine against Orthofix or any of its former, current or future equityholders, directors, officers, Affiliates, agents or Representatives with respect to this Agreement and the transactions contemplated hereby in the event that this
Agreement is terminated by Orthofix or SeaSpine pursuant to <U>Section</U><U></U><U>&nbsp;8.01(c)(i)</U> or <U>Section</U><U></U><U>&nbsp;8.01(d)(iv)</U> (including if terminated or terminable pursuant to one or more of such provisions), and, upon
such payment of the Orthofix Termination Fee (if and when due) and the Expenses, none of Orthofix&#146;s or any of its former, current or future equityholders, directors, officers, Affiliates, agents or Representatives shall have any further
liability or obligation relating to or arising out of this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;As used in this Agreement, &#147;<U>Orthofix Termination Fee</U>&#148; shall mean $13,744,149 and &#147;<U>SeaSpine
Termination Fee</U>&#148; shall mean $10,582,995. As used in this Agreement, &#147;<U>Expenses</U>&#148; shall mean reasonable, documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and
expenses, not to exceed $2,000,000 in the aggregate, incurred or paid by or on behalf of the party receiving payment thereof and its Affiliates in connection with the transactions contemplated by this Agreement, or related to the authorization,
preparation, negotiation, execution and performance of this Agreement, in each case including documented fees and expenses of law firms, commercial banks, investment banking firms, financing sources, accountants, experts and consultants to such
party and its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The parties acknowledge that the agreements contained in this
<U>Section</U><U></U><U>&nbsp;8.03</U> are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, neither SeaSpine nor Orthofix would enter into this Agreement. Accordingly, if either party fails
promptly to pay any amount due pursuant to this <U>Section</U><U></U><U>&nbsp;8.03</U> (such party, the &#147;<U>Defaulting Party</U>&#148;), and, in order to obtain such payment, the other party (the
&#147;<U><FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party</U>&#148;) commences a suit which results in a judgment against the Defaulting Party for any payments set forth in this <U>Section</U><U></U><U>&nbsp;8.03</U>, the Defaulting
Party shall pay to the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party its costs and expenses (including attorneys&#146; fees) in connection with such suit, together with interest on the Orthofix Termination Fee or the SeaSpine
Termination Fee, as applicable, and the Expenses to be reimbursed to the <FONT STYLE="white-space:nowrap">Non-Defaulting</FONT> Party under this <U>Section</U><U></U><U>&nbsp;8.03</U> from the date payment was required to be made until the date of
such payment at the prime </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rate published in the <I>Wall Street Journal</I> in effect on the date such payment was required to be made. If this Agreement is terminated pursuant to a provision that calls for a payment to be
made under this <U>Section</U><U></U><U>&nbsp;8.03</U>, it shall not be a defense to either party&#146;s obligation to pay hereunder that this Agreement could have been terminated under a different provision or could have been terminated at an
earlier or later time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 9 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>MISCELLANEOUS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.01&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. Except as otherwise expressly provided herein, Orthofix and Merger Sub, on the one hand, and
SeaSpine, on the other hand, shall each pay its own expenses (including attorneys&#146; and accountants&#146; fees and expenses) in connection with the negotiation of this Agreement, the performance of its obligations hereunder and the consummation
of the transactions contemplated by this Agreement (whether consummated or not). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.02&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>. At any
time prior to the Effective Time, any provision of this Agreement may be amended (whether before or after any required approval by SeaSpine Stockholders or Orthofix Stockholders) if, and only if, such amendment or waiver is in writing and signed by
Orthofix, SeaSpine and Merger Sub; <U>provided</U>, <U>however</U>, that after the receipt of SeaSpine Stockholder Approval or Orthofix Stockholder Approval, no amendment shall be made which by applicable Laws or the rules of NASDAQ requires further
approval of SeaSpine Stockholders or Orthofix Stockholders without the further approval of such shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.03&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy, and no single or partial exercise of any such power, right, privilege or
remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;No party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or
remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party, and any such waiver shall not be applicable or have
any effect except in the specific instance in which it is given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.04&nbsp;&nbsp;&nbsp;&nbsp;<U>No Survival of Representations and
Warranties</U>. None of the representations, warranties or agreements contained in this Agreement or in any certificate, document or instrument delivered pursuant to this Agreement shall survive the Effective Time, except for covenants and
agreements which contemplate performance after the Effective Time or otherwise expressly by their terms survive the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.05&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement; Counterparts</U>. This Agreement (including the exhibits and schedules hereto, the SeaSpine
Disclosure Letter and the Orthofix Disclosure Letter), the Confidentiality Agreement and the Clean Team Agreement constitute the entire agreement among the parties hereto and supersedes all other prior agreements and understandings, both written and
oral, among or between any of the parties hereto with respect to the subject matter hereof and thereof. This Agreement may be executed in several counterparts (including counterparts delivered by electronic transmission in .pdf format), each of
which shall be deemed an original and all of which shall constitute one and the same instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.06&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable Law; Jurisdiction</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware without
regard to the Laws of the State of Delaware or any other jurisdiction that would call for the application of the substantive Laws of any jurisdiction other than the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The parties agree that the appropriate, exclusive and convenient forum (the &#147;<U>Forum</U>&#148;) for any
disputes among any of the parties arising out of or related to this Agreement or the transactions contemplated by this Agreement shall be the Court of Chancery in the State of Delaware, except where such court lacks subject matter jurisdiction. In
such event, the Forum shall be the United States District Court for the District of Delaware or, in the event such federal district court lacks subject matter jurisdiction, then the Superior Court in the State of Delaware. The parties irrevocably
submit to the jurisdiction of such courts solely in respect of any disputes between them arising out of or related to this Agreement or the transactions contemplated by this Agreement. The parties further agree that no party shall bring suit with
respect to any disputes arising out of or related to this Agreement or the transactions contemplated by this Agreement in any court or jurisdiction other than the above specified courts. Notwithstanding the foregoing, nothing in this
<U>Section</U><U></U><U>&nbsp;9.06</U> shall limit the rights of any party to obtain execution of a judgment of any of the above specified courts in any other jurisdiction outside of those specified in this <U>Section</U><U></U><U>&nbsp;9.06</U>,
and the parties further agree, to the extent permitted by Law, that a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment against any party in any action, suit or proceeding contemplated above shall be conclusive and may be
enforced in any other jurisdiction within or outside the U.S. by suit on the judgment, a certified or exemplified copy of which shall be conclusive evidence of the fact and amount of such judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any party has or hereafter may acquire any immunity from jurisdiction of any court or from any
legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself or its property, each such party hereby irrevocably (i)&nbsp;waives such immunity in
respect of its obligations with respect to this Agreement and (ii)&nbsp;submits to the personal jurisdiction of each court described in <U>Section</U><U></U><U>&nbsp;9.06(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.07&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of Jury Trial</U>. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN
ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.08&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignability</U>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the
benefit of, the parties hereto and their respective successors and permitted assigns. <U>N</U>either this Agreement nor any rights, interests or obligations hereunder may be assigned by any party hereto without the prior written consent of all other
parties hereto, and any attempted assignment of this Agreement or any of such rights, interests or obligations without such consent shall be void and of no effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.09&nbsp;&nbsp;&nbsp;&nbsp;<U>No Third Party Beneficiaries</U>. Except for following the Effective Time, the right of the Indemnified Parties
to enforce the provisions of <U>Section</U><U></U><U>&nbsp;6.08</U> only, Orthofix, SeaSpine and Merger Sub agree that (a)&nbsp;their respective representations, warranties and covenants set forth herein are solely for the benefit of the other
parties hereto, in accordance with and subject to the terms of this Agreement, and (b)&nbsp;this Agreement is not intended to, and does not, confer upon any Person other than the parties hereto any rights or remedies hereunder, including the right
to rely upon the representations and warranties set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All notices, demands and other communications to
be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (a)&nbsp;when personally delivered, (b)&nbsp;the day following the day (except if not a Business Day then the
next Business Day) on which the same has been delivered prepaid to a reputable national overnight air courier service for overnight delivery, (c)&nbsp;the third (3rd)&nbsp;Business Day following the day on which the same is sent by certified or
registered mail, postage prepaid or (d)&nbsp;when sent by electronic mail, provided that the sender does not receive a written notification of delivery failure. Notices, demands and other communications, in each case to the respective parties, shall
be sent to the applicable address set forth below, unless another address has been previously specified in writing: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><U>Notices to Orthofix or Merger Sub prior to the Closing Date:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orthofix Medical Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">3451 Plano
Parkway</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Lewisville, TX 75056</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Attention: Kimberley Elting</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: KimElting@Orthofix.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">with copies (which shall not constitute notice) to:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hogan Lovells US LLP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">555
Thirteenth Street, NW</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Washington, DC 20004</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Joseph E. Gilligan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Brian C. O&#146;Fahey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">joseph.gilligan@hoganlovells.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">brian.ofahey@hoganlovells.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><U>Notices to SeaSpine:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SeaSpine Holdings Corporation</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">5770 Armada Drive</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Carlsbad, CA 92008</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Patrick L. Keran, Senior Vice President&nbsp;&amp; General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">patrick.keran@seaspine.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">with a copy (which shall not constitute notice) to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DLA Piper LLP (US)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">4365
Executive Drive, Suite 1100</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">San Diego, CA 92121</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Michael S. Kagnoff</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">David M. Clark</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">michael.kagnoff@dlapiper.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">david.clark@dlapiper.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, and only in such situation, without invalidating the remainder of such provision or the remaining provisions of this Agreement (or in any other situations), and the parties
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall amend or otherwise modify this Agreement to replace any prohibited or invalid provision with an effective and valid provision that gives effect to the intent of the parties to the maximum
extent permitted by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance</U>. The parties agree that irreparable damage
would occur in the event that any of the provisions of this Agreement were not performed by SeaSpine, Orthofix or Merger Sub in accordance with their specific terms or were otherwise breached by SeaSpine, Orthofix or Merger Sub. It is accordingly
agreed that (a)&nbsp;SeaSpine shall be entitled to an injunction or injunctions to prevent breaches of this Agreement by Orthofix or Merger Sub and to enforce specifically the terms and provisions hereof, in each case, without proof of actual
damages, against Orthofix or Merger Sub in any court having jurisdiction, this being in addition to any other remedy to which SeaSpine is entitled at law or in equity, without posting any bond or other undertaking, and (b)&nbsp;Orthofix and Merger
Sub shall be entitled to an injunction or injunctions to prevent breaches of this Agreement by SeaSpine and to enforce specifically the terms and provisions hereof, in each case, without proof of actual damages, against SeaSpine in any court having
jurisdiction, this being in addition to any other remedy to which Orthofix or Merger Sub is entitled at law or in equity, without posting any bond or other undertaking. The parties acknowledge that the agreements contained in this
<U>Section</U><U></U><U>&nbsp;9.12</U> are an integral part of the transactions contemplated by this Agreement and that, without these agreements, neither SeaSpine nor Orthofix would enter into this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(signature page follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>SEASPINE</U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SEASPINE HOLDINGS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Keith Valentine</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Keith Valentine</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>ORTHOFIX</U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ORTHOFIX MEDICAL INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jon C. Serbousek</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Jon C. Serbousek</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>MERGER SUB</U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ORCA MERGER SUB INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jon C. Serbousek</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Jon C. Serbousek</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;&nbsp;&nbsp;President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Agreement and Plan of Merger] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d345457dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORTHOFIX MEDICAL INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#0000ff"><B><U STYLE="border-bottom:1pt double; padding-bottom:1pt">AMENDED AND RESTATED</U> </B></FONT></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>B Y L A W S </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 1. </B><B><U>Offices</U></B><B>.</B> The registered office of the Corporation shall be in the State of Delaware. The
Corporation may have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or as may be necessary or convenient to the business of the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEETINGS OF
STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B><B><U>Annual Meeting</U></B><B>.</B> The annual meeting of the stockholders of the
Corporation shall be held on such date, at such time, and at such place (if any) within or without the State of Delaware as shall be designated from time to time by the Board of Directors and stated in the Corporation&#146;s notice of the meeting.
In lieu of holding an annual meeting of stockholders at a designated place, the Board of Directors may, in its sole discretion, determine that any annual meeting of stockholders may be held solely by means of remote communication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2. <U>Special Meetings</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Special meetings of the stockholders of the Corporation may be called only (i)&nbsp;by or at the direction of the Board of Directors,
pursuant to a resolution approved by a majority of the entire Board of Directors, or (ii)&nbsp;by the Secretary of the Corporation, following his or her receipt at the principal executive offices of the Corporation of one or more written demands to
call a special meeting of the stockholders submitted by or on behalf of the record holder or holders of at least 25% percent of the voting power of the issued and outstanding shares of the Corporation (the &#147;<I>Requisite Percentage</I>&#148;);
<I>provided</I>, <I>however</I>, that such stockholder demand or demands have been submitted in accordance with and in the form required by this Section&nbsp;2. Special meetings of the stockholders of the Corporation (including those called by the
Secretary following receipt of a written demand or demands from stockholders holding the Requisite Percentage in accordance with clause (ii)&nbsp;of the first sentence of this Section&nbsp;2(a)) shall be held on such date, at such time, and at such
place (if any) within or without the State of Delaware as shall be designated by the Board of Directors and stated in the Corporation&#146;s notice of the meeting. In the case of a special meeting called by the Secretary following receipt of a
written demand or demands from stockholders holding the Requisite Percentage in accordance with clause (ii)&nbsp;of the first sentence of this Section&nbsp;2(a), the date of such special meeting, as fixed by the Board of Directors in accordance with
this Section&nbsp;2(a), shall not be fewer than thirty (30)&nbsp;nor more than ninety (90)&nbsp;days after the date a demand or demands by stockholders holding the Requisite Percentage have </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been received by the Secretary of the Corporation at the principal executive offices of the Corporation in accordance with this Section&nbsp;2. In lieu of holding a special meeting of
stockholders at a designated place, the Board of Directors may, in its sole discretion, determine that any special meeting of stockholders may be held solely by means of remote communication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To be in proper form, a demand submitted by any stockholder or stockholders pursuant to clause (ii)&nbsp;of the first sentence of
Section&nbsp;2(a) (a &#147;<I>Special Meeting Demand</I>&#148;) shall be in writing and shall set forth: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) as to each
Demanding Person (as defined below), (A) the name and address of such Demanding Person (including, if applicable, the name and address that appear on the Corporation&#146;s books and records) and (B)&nbsp;the class or series and number of shares of
capital stock of the Corporation that are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by such Demanding Person (<I>provided</I> that
for purposes of this Section&nbsp;2 such Demanding Person shall in all events be deemed to beneficially own any shares of any class or series and number of shares of capital stock of the Corporation as to which such Demanding Person has a right to
acquire beneficial ownership at any time in the future); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) As to each Demanding Person, any Disclosable Interests (as
defined in Paragraph (A)(3)(b) of Section&nbsp;13 of this Article II, except that for purposes of this Section&nbsp;2, the term &#147;Demanding Person&#148; shall be substituted for the term &#147;Proposing Person&#148; in all places it appears in
Paragraph (A)(3)(b) of Section&nbsp;13 of this Article II and the disclosure required by clause (vi)&nbsp;of Paragraph (A)(3)(b) of Section&nbsp;13 of this Article II shall be made with respect to the business proposed to be conducted at the special
meeting); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The purpose or purposes for which the meeting is to be called; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) As to each purpose for which the meeting is to be called, (A)&nbsp;a reasonably brief description of such purpose,
(B)&nbsp;a reasonably brief description of the specific proposal to be made or business to be conducted at the special meeting in connection with such purpose, (C)&nbsp;the text of any proposal or business to be considered at the special meeting in
connection with such purpose (including the text of any resolutions proposed for consideration and if such business includes a proposal to amend the Bylaws of the Corporation, the language of the proposed amendment), (D) the reasons for calling a
special meeting of stockholders for such purpose, and (E)&nbsp;a reasonably brief description of any material interest of each Demanding Person in any proposal or business to be considered at the special meeting in connection with such purpose; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) If a purpose for which the special meeting is to be called is the election of one or more directors to the Board of
Directors, the name of each person the Demanding Persons propose to nominate at the special meeting for election to the Board of Directors (each, a &#147;<I>nominee</I>&#148;), and as to each such nominee, (A)&nbsp;the name, age, business and
residence address, and principal occupation or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
employment of the nominee, (B)&nbsp;all other information relating to the nominee that would be required to be disclosed about such nominee if proxies were being solicited for the election of the
nominee as a director in an election contest (whether or not such proxies are or will be solicited), or that is otherwise required, in each case pursuant to and in accordance with Regulation 14A under the Exchange Act, (C)&nbsp;such nominee&#146;s
written consent to being named in the proxy statement, if any, as a nominee and to serving as a director if elected, and (D)&nbsp;all information with respect to such nominee that would be required to be set forth in a stockholder&#146;s Special
Meeting Demand pursuant to this subsection (b)&nbsp;if such nominee were a Demanding Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporation may require any proposed nominee to furnish
such other information as it may reasonably require to determine (i)&nbsp;the eligibility of such proposed nominee to serve as a director of the Corporation, and (ii)&nbsp;whether such nominee qualifies as an &#147;independent director&#148; or
&#147;audit committee financial expert&#148; under applicable law, securities exchange rule or regulation, or any publicly disclosed corporate governance guideline or committee charter of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the case of a special meeting called by the Secretary following receipt of Special Meeting Demand(s) from stockholders holding the
Requisite Percentage in accordance with clause (ii)&nbsp;of the first sentence of Section&nbsp;2(a), each Demanding Person shall further update and supplement his or her Special Meeting Demand so that the information provided or required to be
provided in such Special Meeting Demand pursuant to subsection (b)&nbsp;of this Section&nbsp;2 shall be true and correct both as of the record date for the determination of stockholders entitled to notice of the special meeting and as of the date
that is ten (10)&nbsp;business days before the special meeting or any adjournment or postponement thereof, and such updated and supplemental information shall be delivered to, or mailed and received by, the Secretary at the principal executive
offices of the Corporation (i)&nbsp;in the case of information that is required to be updated and supplemented to be true and correct as of the record date for the determination of stockholders entitled to notice of the special meeting, not later
than the later of five (5)&nbsp;business days after such record date or five (5)&nbsp;business days after the public announcement of such record date, and (ii)&nbsp;in the case of information that is required to be updated and supplemented to be
true and correct as of ten (10)&nbsp;business days before the special meeting or any adjournment or postponement thereof, not later than eight (8)&nbsp;business days before the special meeting or any adjournment or postponement thereof (or if not
practicable to provide such updated and supplemental information not later than eight (8)&nbsp;business days before any adjournment or postponement, on the first practicable date before any such adjournment or postponement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Secretary shall not accept, and shall consider ineffective, a Special Meeting Demand from a stockholder (i)&nbsp;that does not comply
with this Section&nbsp;2, (ii) that relates to an item of business to be transacted at the proposed special meeting that is not a proper subject for stockholder action under applicable law, or (iii)&nbsp;if the business proposed to be conducted at
the special meeting as set forth in such Special Meeting Notice is identical to or substantially similar to an item of business that will be submitted for stockholder approval or consideration at any meeting of stockholders to be held on or before
the ninetieth (90th) day after the Secretary receives such Special Meeting Demand. In addition to the requirements of this Section&nbsp;2, each Demanding Person shall comply with all requirements of applicable law, including all requirements of the
Exchange Act, with respect to any Special Meeting Demand. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Nothing in this Section&nbsp;2 shall be deemed or construed to give any stockholder a
right to fix the date, time, or place of, or to fix any record date for, any special meeting of the stockholders of the Corporation. Except as expressly provided in, and in accordance with, this Section&nbsp;2, stockholders shall not be permitted
(i)&nbsp;to call or cause any officer of the Corporation to call a special meeting of stockholders or (ii)&nbsp;to propose business to be brought before a special meeting of the stockholders, other than the nomination of persons for election to the
Board of Directors at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation&#146;s notice of meeting, which nominations may be made only in accordance with, and subject to, this Section&nbsp;2 or
Section&nbsp;13(B) of this Article II. Anything in Section&nbsp;13(B) of this Article II to the contrary notwithstanding, in the case of a special meeting called by the Secretary following receipt of Special Meeting Demand(s) from stockholders
holding the Requisite Percentage in accordance with clause (ii)&nbsp;of the first sentence of Section&nbsp;2(a), if a purpose of such special meeting is to elect directors to the Board of Directors of the Corporation and a Demanding Person has
included in his or her Special Meeting Demand the names of each person the Demanding Person proposes to nominate at the special meeting for election to the Board of Directors, together with all other information required by subsection (b)&nbsp;of
this Section&nbsp;2, and so long as the Demanding Person has otherwise complied with this Section&nbsp;2, then the Demanding Person&#146;s Special Meeting Demand shall be deemed to be, and shall substitute for, the notice contemplated by Paragraph
(B)&nbsp;of Section&nbsp;13 of this Article II and such Demanding Person shall be deemed to have given timely notice of such nominations in the proper form for purposes of Paragraph (B)&nbsp;of Section&nbsp;13 of this Article II and otherwise to
have complied with the notice procedures set forth in Paragraph (B)(2) of Section&nbsp;13 of this Article II, so long as such Demanding Person provides any updates or supplements to such Special Meeting Demand at such times and in the forms required
by subsection (c)&nbsp;of this Section&nbsp;2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Anything in this Section&nbsp;2 to the contrary notwithstanding, in the case of a
special meeting called by the Secretary following receipt of Special Meeting Demand(s) from stockholders holding the Requisite Percentage in accordance with clause (ii)&nbsp;of the first sentence of Section&nbsp;2(a), the Board of Directors may
submit its own proposal or proposals for consideration at such special meeting, and at the direction of the Board of Directors, such proposal or proposals shall be included in the notice for the special meeting as a purpose or purposes for which the
meeting is called. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) A stockholder may revoke a Special Meeting Demand by written revocation delivered to, or mailed and received by,
the Secretary at the principal executive office of the Corporation at any time before the special meeting. If any such revocation(s) are delivered to or received by the Secretary after the Secretary&#146;s receipt of Special Meeting Demands from the
holders of the Requisite Percentage, and as a result of such revocation(s), there no longer are unrevoked demands from stockholders holding the Requisite Percentage, the Board of Directors shall have the discretion to determine whether or not to
proceed with the special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) For purposes of this Section&nbsp;2, (i) &#147;<I>Demanding Person</I>&#148; shall mean
(A)&nbsp;each stockholder making a demand pursuant to the first sentence of subsection (a)&nbsp;of this Section&nbsp;2, (B) the beneficial owner or beneficial owners, if different, on whose behalf such notice is given, and (C)&nbsp;any affiliates or
associates (each within the meaning of Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act) of such stockholder or beneficial owner, (ii) &#147;<I>Exchange Act</I>&#148; shall have the meaning provided in Section&nbsp;13 of
this Article II, and (iii) &#147;<I>publicly announce</I>&#148; shall mean making a public announcement (as defined in Section&nbsp;13 of this Article II). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3. </B><B><U>Notice of Meetings</U></B><B>.</B> (a)&nbsp;The
Corporation shall give notice of any annual or special meeting of stockholders. Notices of meetings of the stockholders shall state the place, if any, date, and hour of the meeting, the record date for determining stockholders entitled to vote at
the meeting, if such record date is different from the record date for determining stockholders entitled to notice of the meeting, and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in
person and vote at such meeting. In the case of a special meeting, the notice shall state the purpose or purposes for which the meeting is called. No business other than that specified in the notice thereof shall be transacted at any special
meeting. Unless otherwise provided by applicable law or the Certificate of Incorporation, notice shall be given to each stockholder entitled to receive notice of such meeting not fewer than ten (10)&nbsp;days or more than sixty (60)&nbsp;days before
the date of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Notice to stockholders may be given by personal delivery, mail, or, with the consent of the stockholder
entitled to receive notice, by facsimile or other means of electronic transmission. If mailed, such notice shall be delivered by postage prepaid envelope directed to each stockholder at such stockholder&#146;s address as it appears in the records of
the Corporation and shall be deemed given when deposited in the United States mail. Notice given by electronic transmission pursuant to this subsection shall be deemed given: (i)&nbsp;if by facsimile telecommunication, when directed to a facsimile
telecommunication number at which the stockholder has consented to receive notice, (ii)&nbsp;if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice, (iii)&nbsp;if by posting on an
electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A)&nbsp;such posting and (B)&nbsp;the giving of such separate notice, and (iv)&nbsp;if by any other form of electronic transmission,
when directed to the stockholder. An affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the Corporation that the notice has been given by personal delivery, by mail, or by a form of electronic
transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notice of any meeting of
stockholders need not be given to any stockholder if waived by such stockholder either in a writing signed by such stockholder or by electronic transmission, whether such waiver is given before or after such meeting is held. If such a waiver is
given by electronic transmission, the electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. </B><B><U>Quorum and Adjournment</U></B><B>.</B> Except as otherwise required by law, by the Certificate of
Incorporation of the Corporation, or by these Bylaws, the presence, in person or represented by proxy, of the holders of a majority of the aggregate voting power of the stock issued and outstanding, entitled to vote thereat, shall constitute a
quorum for the transaction of business at all meetings of the stockholders. If such majority shall not be present or represented at any meeting of the stockholders, a majority of the stockholders present, although less than a quorum, or the
presiding officer of such meeting shall have the power to adjourn the meeting to another time and place. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. </B><B><U>Adjourned Meetings</U></B><B>.</B> When a meeting
is adjourned to another time and place, if any, unless otherwise provided by these Bylaws, notice need not be given of the adjourned meeting if the date, time, and place, if any, thereof and the means of remote communication, if any, by which
stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the stockholders may transact any business that might
have been transacted at the original meeting. If an adjournment is for more than thirty (30)&nbsp;days or, if after an adjournment, a new record date is fixed for determining the stockholders entitled to vote at the adjourned meeting, a notice of
the adjourned meeting shall be given to each stockholder entitled to vote at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. </B><B><U>Vote
Required</U></B><B>.</B> Except as otherwise provided by law, the Certificate of Incorporation, or these Bylaws: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each director shall
be elected by a majority of the votes cast with respect to the director, provided, however, that the directors shall be elected by the vote of a plurality of the shares represented in person or by proxy at any such meeting and entitled to vote on
the election of directors if (i)(A) the Secretary of the Corporation receives a notice that a stockholder has nominated a person for election to the Board of Directors in compliance with the advance notice requirements for stockholder nominees for
directors set forth in Article II, Section&nbsp;13(A) of these Bylaws for annual meetings of the Corporation or Article II, Section&nbsp;13(B) of these Bylaws for special meetings of the Corporation or otherwise becomes aware that a stockholder has
nominated a person for election to the Board of Directors and (B)&nbsp;such nomination has not been withdrawn by such stockholder on or prior to the third business day next preceding the date the Corporation first mails its notice of meeting for
such meeting to the stockholders or (ii)&nbsp;the number of nominees for election to the Board of Directors at such meeting exceeds the number of directors to be elected; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Whenever any corporate action other than the election of directors is to be taken, it shall be authorized by a majority in voting power
of the shares present in person or represented by proxy at a meeting of stockholders and entitled to vote on the subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this
Section&nbsp;6 of Article II, a majority of the votes cast means that the number of shares voted &#147;for&#148; a director must exceed the number of votes cast &#147;against&#148; that director (with &#147;abstentions&#148; and &#147;broker
nonvotes&#148; not counted as a vote cast either &#147;for&#148; or &#147;against&#148; that director&#146;s election).&nbsp;If directors are to be elected by a plurality of the shares represented in person or by proxy at any such meeting and
entitled to vote on the election of directors, then the stockholders shall not be permitted to vote &#147;against&#148; a nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. </B><B><U>Manner of Voting; Proxies</U></B><B>.</B> (a)&nbsp;At each meeting of stockholders, each
stockholder having the right to vote shall be entitled to vote in person or by proxy. Each stockholder shall be entitled to vote each share of stock having voting power and registered in such stockholder&#146;s name on the books of the Corporation
on the record date fixed for determination of stockholders entitled to vote at such meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each person entitled to vote at a meeting of stockholders or to express consent or
dissent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a
longer period. A proxy shall be irrevocable if it states that it is irrevocable and if, and only so long as, it is coupled with an interest sufficient in law to support an irrevocable power. Proxies need not be filed with the Secretary of the
Corporation until the meeting is called to order, but shall be filed before being voted. Without limiting the manner in which a stockholder may authorize another person or persons to act for such stockholder as proxy, the following shall constitute
valid means by which a stockholder may grant such authority: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) A stockholder may execute a writing authorizing another
person or persons to act for such stockholder as proxy. Execution may be accomplished by the stockholder or the stockholder&#146;s authorized officer, director, employee, or agent signing such writing or causing such person&#146;s signature to be
affixed to such writing by any reasonable means including, but not limited to, by facsimile signature; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) A
stockholder may authorize another person or persons to act for such stockholder as proxy by transmitting or authorizing the transmission of a telegram, cablegram, or other means of electronic transmission to the person or persons who will be the
holder of the proxy or to a proxy solicitation firm, proxy support service organization, or like agent duly authorized by the person who will be the holder of the proxy to receive such transmission; <I>provided</I>, <I>however</I>, that any such
telegram, cablegram, or other means of electronic transmission must either set forth or be submitted with information from which it can be determined that the telegram, cablegram, or other electronic transmission was authorized by the stockholder.
If it is determined that any such telegram, cablegram, or other electronic transmission is valid, the inspectors or, if there are no inspectors, such other persons making that determination, shall specify the information upon which they relied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any copy, facsimile telecommunication, or other reliable reproduction of a writing or electronic transmission authorizing a person or persons to act as proxy
for a stockholder may be substituted or used in lieu of the original writing or electronic transmission for any and all purposes for which the original writing or electronic transmission could be used; <I>provided</I>, <I>however</I>, that such
copy, facsimile telecommunication, or other reproduction shall be a complete reproduction of the entire original writing or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. </B><B><U>Remote Communication</U></B><B>.</B> For the purposes of these Bylaws, if authorized by the Board
of Directors in its sole discretion, and subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxyholders may, by means of remote communication: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) participate in a meeting of stockholders; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) be deemed present in person and vote at a meeting of stockholders whether such meeting
is to be held at a designated place or solely by means of remote communication, <I>provided</I> that (i)&nbsp;the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means
of remote communication is a stockholder or proxyholder, (ii)&nbsp;the Corporation shall implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters
submitted to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (iii)&nbsp;if any stockholder or proxyholder votes or takes other action at the meeting by
means of remote communication, a record of such vote or other action shall be maintained by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 9. </B><B><U>No
Stockholder Action Without a Meeting</U></B><B>.</B> Stockholder action by written consent in lieu of a meeting is prohibited by the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10. </B><B><U>Presiding Officer and Secretary</U></B><B>.</B> (a) The Chief Executive Officer shall preside at
meetings of the stockholders. In the absence of the Chief Executive Officer, the President shall preside at meetings of the stockholders. In the absence of each of the Chief Executive Officer and the President, any director or officer designated by
the Board of Directors shall preside at meetings of the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Secretary of the Corporation shall act as secretary of all
meetings of the stockholders, but, in the absence of the Secretary, the Assistant Secretary designated in accordance with Section&nbsp;11(b) of Article IV of these Bylaws shall act as secretary of meetings of the stockholders. In the absence of the
Secretary and any designated Assistant Secretary, the presiding officer of the meeting may appoint any person to act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. </B><B><U>Conduct of Meetings</U></B><B>.</B> At each meeting of stockholders, the presiding officer of the
meeting shall fix and announce the date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at the meeting and shall determine the order of business and all other matters of procedure. The Board
of Directors may adopt by resolution such rules, regulations, and procedures for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with any such rules and regulations adopted by the Board of
Directors, the presiding officer of the meeting shall have the right and authority to convene and to adjourn the meeting and to establish rules, regulations, and procedures, which need not be in writing, for the conduct of the meeting and to
maintain order and safety. Without limiting the foregoing, he or she may: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) restrict attendance at any time to bona fide stockholders
of record and their proxies and other persons in attendance at the invitation of the presiding officer or Board of Directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) place
restrictions on entry to the meeting after the time fixed for the commencement thereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) restrict dissemination of solicitation materials and use of audio or visual recording
devices at the meeting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) adjourn the meeting without a vote of the stockholders, whether or not there is a quorum present; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) make rules governing speeches and debate, including time limits and access to microphones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presiding officer of the meeting shall act in his or her absolute discretion, and his or her rulings shall not be subject to appeal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12. </B><B><U>Inspectors of Election</U></B><B>.</B> The Corporation may, and shall if required by law, in
advance of any meeting of stockholders, appoint one or more inspectors of election, who may be employees of the Corporation, to act at the meeting or any adjournment thereof and to make a written report thereof. The Corporation may designate one or
more persons as alternate inspectors to replace any inspector who fails to act. If no inspector so appointed or designated is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act
at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath to execute faithfully the duties of inspector with strict impartiality and according to the best of his or her ability. The
inspector or inspectors so appointed or designated shall (a)&nbsp;ascertain the number of shares of capital stock of the Corporation outstanding and the voting power of each such share, (b)&nbsp;determine the shares of capital stock of the
Corporation represented at the meeting and the validity of proxies and ballots, (c)&nbsp;count all votes and ballots, (d)&nbsp;determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by
the inspectors, and (e)&nbsp;certify their determination of the number of shares of capital stock of the Corporation represented at the meeting and such inspectors&#146; count of all votes and ballots. Such certification and report shall specify
such other information as may be required by law. In determining the validity and counting of proxies and ballots cast at any meeting of stockholders of the Corporation, the inspectors may consider such information as is permitted by applicable law.
No person who is a candidate for an office at an election may serve as an inspector at such election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13. <U>Notice of
Stockholder Business and Nominations</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) <U>Annual Meetings of Stockholders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) Nominations of persons for election to the Board of Directors and the proposal of business to be considered by the stockholders may be
made at an annual meeting of stockholders only (a)&nbsp;pursuant to the Corporation&#146;s notice of meeting (or any supplement thereto), (b) by or at the direction of the Board of Directors, or (c)&nbsp;by any stockholder of the Corporation
(i)&nbsp;who was a stockholder of record of the Corporation (and, with respect to any beneficial owner, if different, on whose behalf such business is proposed or such nomination or nominations are made, only if such beneficial owner was the
beneficial owner of shares of the Corporation) both at the time the notice provided for in Paragraphs (A)(2) and (A)(3) of this Section&nbsp;13 is delivered to the Secretary of the Corporation and on the record date for the determination of
stockholders entitled to vote at the meeting, (ii)&nbsp;who is entitled to vote at the meeting upon such election of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors or upon such business, as the case may be, and (iii)&nbsp;who complies with the notice procedures set forth in Paragraphs (A)(2) and (A)(3) of this Section&nbsp;13. Except for proposals
properly made in accordance with Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (as so amended and inclusive of such rules and regulations, the
&#147;<I>Exchange Act</I>&#148;), and included in the notice of meeting given by or at the direction of the Board of Directors, the foregoing clause (c)&nbsp;shall be the exclusive means for a stockholder to propose business to be brought before an
annual meeting of stockholders. In addition, for business (other than the nomination of persons for election to the Board of Directors) to be properly brought before an annual meeting by a stockholder, such business must be a proper matter for
stockholder action pursuant to the Certificate of Incorporation, these Bylaws, and applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) For nominations or other business
to be properly brought before an annual meeting of stockholders by a stockholder pursuant to clause (c)&nbsp;of Paragraph (A)(1) of this Section&nbsp;13, the stockholder (a)&nbsp;must have given timely notice thereof in writing and in proper form to
the Secretary at the principal executive offices of the Corporation, and (b)&nbsp;must provide any updates or supplements to such notice at such times and in the forms required by this Section&nbsp;13. To be timely, a stockholder&#146;s notice
relating to an annual meeting shall be delivered to, or mailed to and received by, the Secretary at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90th) day and not earlier than the close of
business on the one hundred twentieth (120th) day before the date of the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the immediately preceding year&#146;s annual meeting (<I>provided</I>, <I>however</I>, that if the date of the
annual meeting is more than thirty (30)&nbsp;days before or more than sixty (60)&nbsp;days after such anniversary date, notice by the stockholder must be so delivered, or mailed and received, not earlier than the close of business on the one hundred
twentieth (120th) day before such annual meeting and not later than the close of business on the later of the ninetieth (90th) day before such annual meeting or the tenth (10th) day following the day on which public announcement (as defined below)
of the date of such meeting is first made by the Corporation). In no event shall the public announcement of an adjournment or postponement of an annual meeting of stockholders commence a new time period (or extend any time period) for the giving of
a stockholder&#146;s notice as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) To be in proper form for purposes of this Section&nbsp;13, a stockholder&#146;s
notice to the Secretary (whether pursuant to this Paragraph (A)&nbsp;or Paragraph (B)&nbsp;of this Section&nbsp;13) must set forth: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) as to each Proposing Person (as defined below), (i) the name and address of such Proposing Person (including, if
applicable, the name and address that appear on the Corporation&#146;s books and records) and (ii)&nbsp;the class or series and number of shares of capital stock of the Corporation that are, directly or indirectly, owned of record or beneficially
owned (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by such Proposing Person (<I>provided</I> that for purposes of this Section&nbsp;13, such Proposing Person shall in all events be deemed to
beneficially own any shares of any class or series and number of shares of capital stock of the Corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) as to each Proposing Person, (i)&nbsp;any derivative, swap, or other
transaction or series of transactions engaged in, directly or indirectly, by such Proposing Person, the purpose or effect of which is to give such Proposing Person economic risk similar to ownership of shares of any class or series of capital stock
of the Corporation, including due to the fact that the value of such derivative, swap, or other transactions are determined by reference to the price, value, or volatility of any shares of any class or series of capital stock of the Corporation, or
which derivative, swap, or other transactions provide, directly or indirectly, the opportunity to profit from any increase in the price or value of shares of any class or series of capital stock of the Corporation (&#147;<I>Synthetic Equity
Interests</I>&#148;), which Synthetic Equity Interests shall be disclosed without regard to whether (x)&nbsp;the derivative, swap, or other transactions convey any voting rights in such shares to such Proposing Person, (y)&nbsp;the derivative, swap,
or other transactions are required to be, or are capable of being, settled through delivery of such shares, or (z)&nbsp;such Proposing Person may have entered into other transactions that hedge or mitigate the economic effect of such derivative,
swap, or other transactions, (ii)&nbsp;any proxy (other than a revocable proxy or consent given in response to a solicitation made pursuant to, and in accordance with, Section&nbsp;14(a) of the Exchange Act by way of a solicitation statement filed
on Schedule 14A), agreement, arrangement, understanding, or relationship pursuant to which such Proposing Person has or shares a right to vote any shares of any class or series of capital stock of the Corporation (including the number of shares and
class or series of capital stock of the Corporation that are subject to such proxy, agreement, arrangement, understanding, or relationship), (iii) any agreement, arrangement, understanding, or relationship, including any repurchase or similar <FONT
STYLE="white-space:nowrap">so-called</FONT> &#147;stock borrowing&#148; agreement or arrangement, engaged in, directly or indirectly, by such Proposing Person, the purpose or effect of which is to mitigate loss to, reduce the economic risk (of
ownership or otherwise) of shares of any class or series of capital stock of the Corporation by, manage the risk of share price changes for, or increase or decrease the voting power of, such Proposing Person with respect to the shares of any class
or series of capital stock of the Corporation, or that provides, directly or indirectly, the opportunity to profit from any decrease in the price or value of the shares of any class or series of capital stock of the Corporation (&#147;<I>Short
Interests</I>&#148;), (iv) any rights to dividends on the shares of any class or series of capital stock of the Corporation owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the Corporation,
(v)&nbsp;any performance related fees (other than an asset based fee) to which such Proposing Person is entitled based on any increase or decrease in the price or value of shares of any class or series of the capital stock of the Corporation, or any
Synthetic Equity Interests or Short Interests, if any, and (vi)&nbsp;any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with
solicitations of proxies or consents by such Proposing Person in support of the nominations or business proposed to be brought before the meeting pursuant to Regulation 14A under the Exchange Act (the disclosures to be made pursuant to the foregoing
clauses (i)&nbsp;through (vi) are referred to as &#147;<I>Disclosable Interests</I>&#148;); <I>provided</I>, <I>however</I>, that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company, or other nominee who is
a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these Bylaws on behalf of a beneficial owner; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) if such notice pertains to the nomination by the stockholder of a person or persons for election to the Board of Directors
(each, a &#147;<I>nominee</I>&#148;), as to each nominee, (i)&nbsp;the name, age, business and residence address, and principal occupation or employment of the nominee, (ii)&nbsp;all other information relating to the nominee that would be required
to be disclosed about such nominee if proxies were being solicited for the election of the nominee as a director in an election contest (whether or not such proxies are or will be solicited), or that is otherwise required, in each case pursuant to
and in accordance with Regulation 14A under the Exchange Act, (iii)&nbsp;such nominee&#146;s written consent to being named in the proxy statement, if any, as a nominee and to serving as a director if elected, and (iv)&nbsp;all information with
respect to such nominee that would be required to be set forth in a stockholder&#146;s notice pursuant to this Section&nbsp;13 if such nominee were a Proposing Person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) if the notice relates to any business (other than the nomination of persons for election to the Board of Directors) that
the stockholder proposes to bring before the meeting, (i)&nbsp;a reasonably brief description of the business desired to be brought before the meeting, (ii)&nbsp;the text of the proposal or business (including the text of any resolutions proposed
for consideration and if such business includes a proposal to amend the Bylaws of the Corporation, the language of the proposed amendment), (iii) the reasons for conducting such business at the meeting, and (iv)&nbsp;any material interest in such
business of each Proposing Person; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) a representation that the stockholder giving the notice is a holder of record of
stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business or nomination; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) a representation whether any Proposing Person intends or is part of a group that intends (i)&nbsp;to deliver a proxy
statement and/or form of proxy to holders of at least the percentage of the Corporation&#146;s outstanding capital stock required to approve or adopt the proposal or elect the nominee and/or (ii)&nbsp;otherwise to solicit proxies from stockholders
in support of such proposal or nomination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporation may require any proposed nominee to furnish such other information as it may reasonably
require to determine (i)&nbsp;the eligibility of such proposed nominee to serve as a director of the Corporation, and (ii)&nbsp;whether such nominee qualifies as an &#147;independent director&#148; or &#147;audit committee financial expert&#148;
under applicable law, securities exchange rule or regulation, or any publicly disclosed corporate governance guideline or committee charter of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(4) Notwithstanding anything in the second sentence of paragraph (A)(2) of this
Section&nbsp;13 to the contrary, if the number of directors to be elected to the Board of Directors of the Corporation at an annual meeting is increased and there is no public announcement by the Corporation naming all of the Board of
Directors&#146; nominees for director or specifying the size of the increased Board of Directors at least one hundred (100)&nbsp;days before the first anniversary of the preceding year&#146;s annual meeting, a stockholder&#146;s notice required by
this Section&nbsp;13 shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to, or mailed to and received by, the Secretary at the principal executive offices of
the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(5) Only such persons who are nominated in accordance with the procedures set forth in Paragraph (A)&nbsp;of this Section&nbsp;13 (including
those persons nominated by or at the direction of the Board of Directors) shall be eligible to be elected at an annual meeting of stockholders of the Corporation to serve as directors. Only such business shall be conducted at an annual meeting of
stockholders as shall have been brought before the meeting in accordance with the procedures set forth in Paragraph (A)&nbsp;of this Section&nbsp;13. Except as otherwise provided by law, the chairman of an annual meeting of stockholders shall have
the power and duty (a)&nbsp;if the facts warrant, to determine that a nomination or any business proposed to be brought before the annual meeting was not made or was not proposed, as the case may be, in accordance with the procedures set forth in
Paragraph (A)&nbsp;of this Section&nbsp;13, and (b)&nbsp;if any proposed nomination or business was not made or was not proposed in compliance with Paragraph (A)&nbsp;of this Section&nbsp;13, to declare that such nomination shall be disregarded or
that such proposed business shall not be transacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) <U>Special Meetings of Stockholders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the
Corporation&#146;s notice of meeting pursuant to Section&nbsp;2 of these Bylaws. Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected pursuant to the
Corporation&#146;s notice of meeting only (a)&nbsp;by or at the direction of the Board of Directors or (b)&nbsp;if a purpose for such meeting as stated in the Corporation&#146;s notice for such meeting is the election of one or more directors, by
any stockholder of the Corporation (i)&nbsp;who was a stockholder of record of the Corporation (and, with respect to any beneficial owner, if different, on whose behalf such nomination or nominations are made, only if such beneficial owner was the
beneficial owner of shares of the Corporation) both at the time the notice provided for in Paragraph (B)(2) of this Section&nbsp;13 is delivered to the Secretary of the Corporation and on the record date for the determination of stockholders
entitled to vote at the special meeting, (ii)&nbsp;who is entitled to vote at the meeting and upon such election, and (iii)&nbsp;who complies with the notice procedures set forth in Paragraph (B)(2) of this Section&nbsp;13; <I>provided</I>,
<I>however</I>, that a stockholder may nominate persons for election at a special meeting only to such position(s) as specified in the Corporation&#146;s notice of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) If a special meeting has been called in accordance with Section&nbsp;2 of this Article II for the purpose of electing one or more
directors to the Board of Directors, then for nominations of persons for election to the Board of Directors to be properly brought before such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
special meeting by a stockholder pursuant to clause (b)&nbsp;of Paragraph (B)(1) of this Section&nbsp;13, the stockholder (a)&nbsp;must have given timely notice thereof in writing and in the
proper form to the Secretary of the Corporation at the principal executive offices of the Corporation, and (b)&nbsp;must provide any updates or supplements to such notice at such times and in the forms required by this Section&nbsp;13. To be timely,
a stockholder&#146;s notice relating to a special meeting shall be delivered to, or mailed to and received by, the Secretary at the principal executive offices of the Corporation not earlier than the close of business on the one hundred twentieth
(120th) day before such special meeting and not later than the close of business on the later of the ninetieth (90th) day before such special meeting or the tenth (10th) day following the day on which public announcement is first made of the date of
the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. In no event shall the public announcement of an adjournment or postponement of a special meeting commence a new time period (or extend any time
period) for the giving of a stockholder&#146;s notice as described above. To be in proper form for purposes of this Paragraph (B)&nbsp;of this Section&nbsp;13, such notice shall set forth the information required by clauses (a), (b), (c), (e), and
(f)&nbsp;of Paragraph (A)(3) of this Section&nbsp;13. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) Only such persons who are nominated in accordance with the procedures set forth
in Paragraph (B)&nbsp;of this Section&nbsp;13 (including those persons nominated by or at the direction of the Board of Directors) shall be eligible to be elected at a special meeting of stockholders of the Corporation to serve as directors. Except
as otherwise provided by law, the chairman of a special meeting of stockholders shall have the power and duty (a)&nbsp;if the facts warrant, to determine that a nomination proposed to be made at the special meeting was not made in accordance with
the procedures set forth in Paragraph (B)&nbsp;of this Section&nbsp;13, and (b)&nbsp;if any proposed nomination was not made in compliance with Paragraph (B)&nbsp;of this Section&nbsp;13, to declare that such nomination shall be disregarded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) <U>General</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) A
stockholder providing notice of nominations of persons for election to the Board of Directors at an annual or special meeting of stockholders or notice of business proposed to be brought before an annual meeting of stockholders shall further update
and supplement such notice so that the information provided or required to be provided in such notice pursuant to Paragraph (A)(3)(a) through Paragraph (A)(3)(f) of this Section&nbsp;13 shall be true and correct both as of the record date for the
determination of stockholders entitled to notice of the meeting and as of the date that is ten (10)&nbsp;business days before the meeting or any adjournment or postponement thereof, and such updated and supplemental information shall be delivered
to, or mailed and received by, the Secretary at the principal executive offices of the Corporation (a)&nbsp;in the case of information that is required to be updated and supplemented to be true and correct as of the record date for the determination
of stockholders entitled to notice of the meeting, not later than the later of five (5)&nbsp;business days after such record date or five (5)&nbsp;business days after the public announcement of such record date, and (b)&nbsp;in the case of
information that is required to be updated and supplemented to be true and correct as of ten (10)&nbsp;business days before the meeting or any adjournment or postponement thereof, not later than eight (8)&nbsp;business days before the meeting or any
adjournment or postponement thereof (or if not practicable to provide such updated and supplemental information not later than eight (8)&nbsp;business days before any adjournment or postponement, on the first practicable date before any such
adjournment or postponement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) Notwithstanding the foregoing provisions of this Section&nbsp;13, unless otherwise
required by law, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed business, such nomination shall be
disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section&nbsp;13, to be considered a qualified representative of the
stockholder, a person must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such
writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) For purposes of this Section&nbsp;13, (a) &#147;<I>public announcement</I>&#148; shall mean disclosure in a press release reported by the
Dow Jones News Service, Associated Press, or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14, or 15(d) of the Exchange Act, and (b)
&#147;<I>Proposing Person</I>&#148; shall mean (i)&nbsp;the stockholder giving the notice required by Paragraph (A)&nbsp;or Paragraph (B)&nbsp;of this Section&nbsp;13, (ii) the beneficial owner or beneficial owners, if different, on whose behalf
such notice is given, and (iii)&nbsp;any affiliates or associates (each within the meaning of Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act for purposes of these Bylaws) of such stockholder or beneficial owner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(4) Paragraph (A)&nbsp;of this Section&nbsp;13 is expressly intended to apply to any business proposed to be brought before an annual meeting
of stockholders other than any proposal made pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act. Nothing in this Section&nbsp;13 shall be deemed to (a)&nbsp;affect any rights of stockholders to request inclusion of
proposals in the Corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> (or any successor thereto) promulgated under the Exchange Act, (b)&nbsp;confer upon any stockholder a right to have a nominee or any
proposed business included in the Corporation&#146;s proxy statement, or (c)&nbsp;affect any rights of the holders of any class or series of preferred stock of the Corporation to nominate and elect directors pursuant to and to the extent provided in
any applicable provisions of the Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Record Dates</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof,
the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than sixty (60)&nbsp;or fewer
than ten (10)&nbsp;days before the date of such meeting. If the Board of Directors so fixes a record date for determining the stockholders entitled to notice of any meeting of stockholders, such date shall also be the record date for determining the
stockholders entitled to vote at such meeting, unless the Board of Directors determines, at the time it fixes the record date for determining the stockholders entitled to notice of such meeting, that a later date on or before the date of the meeting
shall be the record date for determining the stockholders entitled to vote at such meeting. If no record date is fixed by the Board of Directors, the record date for determining </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders entitled to notice of and to vote at any meeting of stockholders or any adjournment thereof shall be at the close of business on the day next preceding the day on which notice is
given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any
adjournment of such meeting; <I>provided</I>, <I>however</I>, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for
stockholders entitled to receive notice of such adjourned meeting the same or an earlier date as that fixed for determining the stockholders entitled to vote at such adjourned meeting in accordance with the foregoing provisions of this subsection
(a)&nbsp;of this Section&nbsp;14. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In order that the Corporation may determine the stockholders entitled to receive payment of any
dividend or other distribution, or allotment of any rights, or the stockholders entitled to exercise any rights in respect of any change, conversion, or exchange of capital stock, or for the purpose of any other lawful action, except as may
otherwise be provided in these Bylaws, the Board of Directors may fix a record date. Such record date shall not precede the date upon which the resolution fixing such record date is adopted, and shall not be more than sixty (60)&nbsp;days prior to
such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B><B><U>Number</U></B><B>.</B> The number of directors that shall constitute the whole Board of
Directors initially shall be nine (9), and thereafter shall be no fewer than six (6)&nbsp;and no greater than fifteen (15), the exact number of directors to be determined from time to time by resolution adopted by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. </B><B><U>Powers</U></B><B>.</B> Subject to any limitations set forth in the Certificate of Incorporation and
to any provision of the General Corporation Law of the State of Delaware relating to powers or rights conferred upon or reserved to the stockholders or the holders of any class or series of the Corporation&#146;s issued and outstanding stock, the
business and affairs of the corporation shall be managed, and all corporate powers shall be exercised, by or under the direction of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3. </B><B><U>Resignations and Removal</U></B><B>.</B> (a)&nbsp;Any director may resign at any time by giving
notice in writing or by electronic transmission to the Board of Directors or the Secretary; <I>provided</I>, <I>however</I>, that if such notice is given by electronic transmission, such electronic transmission must either set forth or be submitted
with information from which it can be determined that the electronic transmission was authorized by the director. Such resignation shall take effect at the date of receipt of such notice or at any later time specified therein. Acceptance of such
resignation shall not be necessary to make it effective unless the resignation specifies that it will not be effective unless accepted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise may be provided in the Certificate of Incorporation, any director
or the entire Board of Directors may be removed, with or without cause, by the holders of capital stock having a majority in voting power of the shares entitled to vote in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Without limiting the foregoing, any incumbent director who is nominated for election by the Board of Directors or a committee thereof
shall, as a condition to such nomination submit, (a)&nbsp;in the case of a contested election, a conditional letter of resignation and, (b)&nbsp;in the case of an uncontested election, a conditional and irrevocable letter of resignation, in each
case to the Chairman of the Board. If an incumbent director is not elected, the Nominating and Governance Committee will consider the conditional resignation of such nominee and make a recommendation to the Board of Directors on whether to accept or
reject the conditional resignation, or whether other action should be taken. The Board of Directors will act on the Nominating and Governance Committee&#146;s recommendation and publicly disclose its decision and the rationale behind it within 90
days from the date of the certification of the election results. The director whose conditional resignation is being considered will not participate in the Nominating and Governance Committee&#146;s recommendation or the Board of Directors&#146;
decision. In addition, if there are not at least two members of the Nominating and Governance Committee who either were elected at the meeting or did not stand for election, then each of the independent members of the Board of Directors who either
were elected at the meeting or did not stand for election shall appoint a committee amongst themselves to consider the resignation offer and recommend to the Board of Directors whether to accept it (which committee of the independent members shall
act in lieu of the Nominating and Governance Committee with respect to the resignation offer in such situation). Each director shall hold office for the term for which he is elected and until his successor shall have been duly elected and qualified
or until death, or until he or she shall have resigned or have been removed or disqualified in accordance with these Bylaws and the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. </B><B><U>Annual Meetings</U></B><B>.</B> The Board of Directors shall meet each year as soon as practicable
following the annual meeting of stockholders, at the place where such meeting of stockholders has been held, or at such other place as shall be fixed by the Board of Directors (or if not previously fixed by the Board of Directors, by the person
presiding over the meeting of the stockholders), for the purpose of election of officers and consideration of such other business as the Board of Directors considers relevant to the management of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. </B><B><U>Regular Meetings</U></B><B>.</B> Regular meetings of the Board of Directors shall be held on such
dates and at such times and places, within or without the State of Delaware, as shall from time to time be determined by the Board of Directors, such determination to constitute the only notice of such regular meetings to which any director shall be
entitled. In the absence of any such determination, such meetings shall be held, upon notice to each director in accordance with Section&nbsp;7 of this Article III, at such times and places, within or without the State of Delaware, as shall be
designated by the Chairman of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. </B><B><U>Special Meetings</U></B><B>.</B> Special meetings of
the Board of Directors shall be held at the call of the Chairman of the Board at such times and places, within or without the State of Delaware, as he or she shall designate, upon notice to each director in accordance with Section&nbsp;7 of this
Article III. Special meetings shall be called by the Chief Executive Officer, President or Secretary on like notice at the written request of any two directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. </B><B><U>Notice</U></B><B>.</B> Notice of any regular (if
required) or special meeting of the Board of Directors may be given by personal delivery, mail, telegram, courier service (including, without limitation, Federal Express), facsimile transmission (directed to the facsimile transmission number at
which the director has consented to receive notice), electronic mail (directed to the electronic mail address at which the director has consented to receive notice), or other form of electronic transmission pursuant to which the director has
consented to receive notice. If notice is given by personal delivery, by facsimile transmission, by telegram, by electronic mail, or by other form of electronic transmission pursuant to which the director has consented to receive notice, then such
notice shall be given on not less than twenty-four (24)&nbsp;hours&#146; notice to each director. If written notice is delivered by mail, then it shall be given on not less than four (4)&nbsp;calendar days&#146; notice to each director. If written
notice is delivered by courier service, then it shall be given on not less than two (2)&nbsp;calendar days&#146; notice to each director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. </B><B><U>Waiver of Notice</U></B><B>.</B> Notice of any meeting of the Board of Directors, or any committee
thereof, need not be given to any member if waived by him or her in writing or by electronic transmission, whether before or after such meeting is held, or if he or she shall sign the minutes of such meeting or attend the meeting, except that if
such director attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened, then such director shall not be deemed to have waived
notice of such meeting. If waiver of notice is given by electronic transmission, such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by
the director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9. </B><B><U>Quorum and Powers of a Majority</U></B><B>.</B> At all meetings of the Board of
Directors and of each committee thereof, a majority of the total number of directors constituting the whole Board of Directors or such committee shall be necessary and sufficient to constitute a quorum for the transaction of business. The act of a
majority of the members present at any meeting of the Board of Directors or a committee thereof at which a quorum is present shall be the act of the Board of Directors or such committee, unless by express provision of applicable law, the Certificate
of Incorporation, or these Bylaws, a different vote is required, in which case such express provision shall govern and control. In the absence of a quorum, a majority of the members present at any meeting may, without notice other than announcement
at the meeting, adjourn such meeting from time to time until a quorum is present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10. </B><B><U>Manner of
Acting</U></B><B>.</B> (a)&nbsp;Members of the Board of Directors, or any committee thereof, may participate in any meeting of the Board of Directors or such committee by means of conference telephone or other communications equipment by means of
which all persons participating therein can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Any action required or permitted to be taken at any meeting of the Board of Directors or any committee thereof may be taken without a
meeting if all members of the Board of Directors or such committee, as the case may be, consent thereto in writing or by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or such committee;
<I>provided</I>, <I>however</I>, that such electronic transmission or transmissions must either set forth or be submitted with information from which it can be determined that the electronic transmission or transmissions were authorized by the
director. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. </B><B><U>Organization</U></B><B>.</B> Meetings of the Board of Directors shall be presided over by the
Chairman of the Board, if any, or in his or her absence by a presiding person chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his or her absence the presiding person at the meeting may appoint any person to act as
secretary of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12. </B><B><U>Committees</U></B><B>.</B> The Board of Directors may designate one
or more committees, each committee to consist of one or more directors, which to the extent provided in said resolution or resolutions shall have and may exercise the powers and authority of the Board of Directors in the management of the business
and affairs of the Corporation (including the power and authority to designate other committees of the Board of Directors); <I>provided</I>, <I>however</I>, that no such committee shall have the power or authority in reference to the following
matters: (a)&nbsp;approving or adopting, or recommending to the stockholders, any action or matter expressly required by the General Corporation Law of the State of Delaware to be submitted to stockholders for approval (other than recommending the
election or removal of directors) or (b)&nbsp;adopting, amending, or repealing any Bylaw of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee to replace any absent or disqualified
member of the committee. In the absence or disqualification of a member of a committee, the member or members present at any meeting of such committee and not disqualified from voting, whether or not such member or members constitute a quorum, may
unanimously appoint another member of the Board of Directors to act at the meeting in place of such absent or disqualified director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13. </B><B><U>Committee Procedure</U></B><B>.</B> (a)&nbsp;Except as otherwise determined by the Board of
Directors or provided by these Bylaws, each committee shall adopt its own rules governing the time, place, and method of holding its meetings and the conduct of its proceedings and shall meet as provided by such rules or by resolution of the Board
of Directors. Unless otherwise provided by these Bylaws or any such rules or resolutions, notice of the time and place of each meeting of a committee shall be given to each member of such committee as provided in Section&nbsp;7 of this Article III
with respect to notices of meetings of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each committee shall keep regular minutes of its proceedings and
report the same to the Board of Directors when required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Any member of any committee may be removed from such committee either with
or without cause, at any time, by the Board of Directors at any meeting thereof. Any vacancy in any committee may be filled by the Board of Directors in the manner prescribed by the Certificate of Incorporation or these Bylaws for the original
appointment of the members of such committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14. </B><B><U>Vacancies and Newly-Created
Directorships</U></B><B>.</B> Unless otherwise provided in the Certificate of Incorporation or in these Bylaws, vacancies and newly-created directorships resulting from any increase in the authorized number of directors may be filled only by a
majority of the directors then in office (and not by stockholders), although less than a quorum, or by a sole remaining director, and directors so chosen shall serve for a term expiring at the annual meeting of stockholders at which the term of
office to which they have been elected expires and until such directors&#146; successors have been duly elected and qualified. Unless otherwise provided in the Certificate of Incorporation or these Bylaws, when one or more directors shall resign
from the Board, effective at a future date, a majority of directors then in office, including those who have resigned, shall have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations
shall become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15. </B><B><U>Director Compensation</U></B><B>.</B> (a)&nbsp;The Board of
Directors, by a resolution or resolutions, may fix, and from time to time change, the compensation of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each director shall
be entitled to reimbursement from the Corporation for his or her reasonable expenses incurred with respect to duties as a member of the Board of Directors or any committee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Nothing contained in these Bylaws shall be construed to preclude any director from serving the Corporation in any other capacity and from
receiving compensation from the Corporation for service rendered to it in such other capacity. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B><B><U>Number</U></B><B>.</B> The officers of the Corporation shall include a President and a Secretary.
The Board of Directors also shall elect a Chairman of the Board. The Board of Directors also may elect a Chief Executive Officer, a Chief Financial Officer, one or more Vice Presidents (who may have such additional descriptive designations as the
Board of Directors may determine), one or more Assistant Secretaries, one or more Treasurers, one or more Assistant Treasurers, and such other officers as the Board of Directors may from time to time deem appropriate or necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. </B><B><U>Election of Officers, Term, and Qualifications</U></B><B>.</B> The officers of the Corporation
shall be elected from time to time by the Board of Directors and shall hold office at the pleasure of the Board of Directors. A vacancy in any office because of death, resignation, removal, disqualification, or any other cause shall be filled in the
manner prescribed in this Section&nbsp;2 for the regular election to such office. Except for the Chairman of the Board, none of the officers of the Corporation needs to be a director of the Corporation. Any two or more offices may be held by the
same person to the extent permitted by the General Corporation Law of the State of Delaware and other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3. </B><B><U>Divisional or Departmental Vice Presidents.</U></B> The Board of Directors may delegate to the
President the power to appoint one or more employees of the Corporation as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
divisional or departmental vice presidents and fix the duties of such appointees. However, no such divisional or departmental vice president shall be considered to be an officer of the
Corporation, the officers of the Corporation being limited to those officers elected by the Board of Directors in accordance with this Article IV. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. </B><B><U>Removal</U></B><B>.</B> Any officer may be removed, either with or without cause, by the Board of
Directors at any meeting thereof, or to the extent delegated to the Chairman of the Board, by the Chairman of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. </B><B><U>Resignations</U></B><B>.</B> Any officer of the Corporation may resign at any time by giving notice
in writing or by electronic transmission to the Board of Directors or to the Chairman of the Board; <I>provided</I>, <I>however</I>, that if such notice is given by electronic transmission, such electronic transmission must either set forth or be
submitted with information from which it can be determined that the electronic transmission was authorized by the officer. Such resignation shall take effect at the date of the receipt of such notice or at any later time specified therein and,
unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective unless the resignation specifies that it will not be effective unless accepted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. </B><B><U>Compensation of Officers</U></B><B>.</B> The salaries and other compensation of all officers of the
Corporation shall be fixed by or in the manner directed by the Board of Directors from time to time, and no officer shall be prevented from receiving such salary by reason of the fact that he or she also is a director of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. </B><B><U>The Chairman of the Board</U></B><B>.</B> The Chairman of the Board shall have the powers and
duties customarily and usually associated with the office of the Chairman of the Board, as well as such additional powers and duties as may be from time to time assigned to him or her by the Board of Directors. The Chairman of the Board shall
preside at meetings of the stockholders and of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. </B><B><U>The Chief Executive
Officer</U></B><B>.</B> The Chief Executive Officer shall have responsibility for implementation of the policies of the Corporation, as determined by the Board of Directors, for the general management and administration of the business affairs of
the Corporation, and for the supervision of other officers, together with any other powers and duties as may be prescribed by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9. </B><B><U>The President</U></B><B>.</B> The President shall have, subject to the supervision, direction, and
control of the Board of Directors and the Chief Executive Officer, the general powers and duties of supervision, direction, and management of the affairs and business of the Corporation customarily and usually associated with the position of
President, including, without limitation, all powers necessary to direct and control the organizational and reporting relationships within the Corporation. The President shall have such additional powers and duties as may be from time to time
assigned to him or her by the Board of Directors or the Chief Executive Officer. In the absence or disability of the President, his or her duties shall be performed by the Chief Executive Officer or such persons as the Board of Directors or the
Chief Executive Officer may designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10. </B><B><U>The Vice Presidents</U></B><B>.</B> Each Vice
President shall have such powers and perform such duties as may from time to time be assigned to him or her by the Board of Directors, the Chairman of the Board, the Chief Executive Officer, or the President. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. </B><B><U>The Secretary and Assistant Secretaries</U></B><B>.</B> (a)&nbsp;The Secretary shall attend
meetings of the Board of Directors and meetings of the stockholders and record all votes and minutes of all such proceedings in a book or books kept for such purpose. The Secretary shall have all such further powers and duties as are customarily and
usually associated with the position of Secretary or as may from time to time be assigned to him or her by the Board of Directors, the Chairman of the Board, the Chief Executive Officer, or the President. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each Assistant Secretary shall have such powers and perform such duties as may from time to time be assigned to him or her by the Board
of Directors, the Chairman of the Board, the Chief Executive Officer, the President, or the Secretary. In the case of absence or disability of the Secretary, the Assistant Secretary designated by the Chief Executive Officer or the President (or, in
the absence of such designation, by the Secretary) shall perform the duties and exercise the powers of the Secretary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12. </B><B><U>The Chief Financial Officer</U></B><B>. </B>The Chief Financial Officer shall have all such powers
and duties as are customarily and usually associated with the position of Chief Financial Officer or as may from time to time be assigned to him or her by the Board of Directors, the Chairman of the Board, the Chief Executive Officer, or the
President. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13. </B><B><U>The Treasurer and Assistant Treasurers</U></B><B>.</B> (a)&nbsp;The Treasurer
shall have custody of the Corporation&#146;s funds and securities, shall be responsible for maintaining the Corporation&#146;s accounting records and statements, shall keep full and accurate accounts of receipts and disbursements in books belonging
to the Corporation, and shall deposit or cause to be deposited moneys or other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors. The Treasurer also shall maintain
adequate records of all assets, liabilities, and transactions of the Corporation and shall assure that adequate audits thereof are currently and regularly made. The Treasurer shall have all such further powers and duties as are customarily and
usually associated with the position of Treasurer or as may from time to time be assigned to him or her by the Board of Directors, the Chairman of the Board, the Chief Executive Officer, the President, or the Chief Financial Officer. In the absence
of a designation of a Chief Financial Officer by the Board of Directors, the Treasurer shall be the Chief Financial Officer of the Corporation unless the Board of Directors designates another person to be Treasurer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each Assistant Treasurer shall have such powers and perform such duties as may from time to time be assigned to him or her by the Board
of Directors, the Chief Executive Officer, the Chief Financial Officer, the President, or the Treasurer. In the case of absence or disability of the Treasurer, the Assistant Treasurer designated by the Chief Executive Officer or the President (or,
in the absence of such designation, by the Treasurer) shall perform the duties and exercise the powers of the Treasurer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B><B><U>Certificates</U></B><B>.</B> The shares of capital stock of the Corporation shall be represented by
certificates, unless the Certificate of Incorporation otherwise provides or unless the Board of Directors provides by resolution or resolutions that some or all of the shares of any class or classes, or series thereof, of the Corporation&#146;s
capital stock shall be uncertificated. Every holder of capital stock of the Corporation represented by certificates shall be entitled to a certificate representing such shares. Certificates for shares of stock of the Corporation shall be issued
under the seal of the Corporation, or a facsimile thereof, and shall be numbered and shall be entered in the books of the Corporation as they are issued. Each certificate shall bear a serial number, shall exhibit the holder&#146;s name and the
number of shares evidenced thereby, and shall be signed by the Chairman of the Board or the Chief Executive Officer, or the President or any Vice President, and by the Secretary or an Assistant Secretary, or the Chief Financial Officer, or the
Treasurer or an Assistant Treasurer. Any or all of the signatures on the certificate may be a facsimile. If any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to
be such officer, transfer agent, or registrar before such certificate is issued, the certificate may be issued by the Corporation with the same effect as if such person or entity were such officer, transfer agent, or registrar at the date of issue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. </B><B><U>Transfers</U></B><B>.</B> Transfers of stock of the Corporation shall be made on the books of
the Corporation only upon surrender to the Corporation (or a transfer agent designed to transfer shares of stock of the Corporation) of a certificate (if any) for the shares duly endorsed or accompanied by proper evidence of succession, assignment,
or authority to transfer; <I>provided</I>, <I>however</I>, that such succession, assignment, or transfer is not prohibited by the Certificate of Incorporation, these Bylaws, applicable law, or contract. Thereupon, the Corporation shall issue a new
certificate (if requested) to the person entitled thereto, cancel the old certificate (if any), and record the transaction upon its books. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3. </B><B><U>Lost, Stolen, or Destroyed Certificates</U></B><B>.</B> Any person claiming a certificate of stock
to be lost, stolen, or destroyed shall make an affidavit or an affirmation of that fact, and shall give the Corporation a bond of indemnity in satisfactory form and with one or more satisfactory sureties, whereupon a new certificate (if requested)
may be issued of the same tenor and for the same number of shares as the one alleged to be lost, stolen, or destroyed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. </B><B><U>Registered Stockholders</U></B><B>.</B> The names and addresses of the holders of record of the
shares of each class and series of the Corporation&#146;s capital stock, together with the number of shares of each class and series held by each record holder and the date of issue of such shares, shall be entered on the books of the Corporation.
Except as otherwise required by the General Corporation Law of the State of Delaware or other applicable law, the Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares of capital
stock of the Corporation as the person entitled to exercise the rights of a stockholder, including, without limitation, the right to vote in person or by proxy at any meeting of the stockholders of the Corporation. The Corporation shall not be bound
to recognize any equitable or other claim to or interest in any such shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise expressly required by the General Corporation Law of the
State of Delaware or other applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. </B><B><U>Fractional Shares</U></B><B>.</B> The Corporation
may, but shall not be required to, issue fractional shares of its capital stock if necessary or appropriate to effect authorized transactions. If the Corporation does not issue fractional shares, it shall (a)&nbsp;arrange for the disposition of
fractional interests on behalf of those that otherwise would be entitled thereto, (b)&nbsp;pay in cash the fair value of fractions of a share as of the time when those who otherwise would be entitled to receive such fractions are determined, or
(c)&nbsp;issue scrip or warrants in registered form (either represented by a certificate or uncertificated) or in bearer form (represented by a certificate), which scrip or warrants shall entitle the holder to receive a full share upon surrender of
such scrip or warrants aggregating a full share. Fractional shares shall, but scrip or warrants for fractional shares shall not (unless otherwise expressly provided therein), entitle the holder to exercise voting rights, to receive dividends
thereon, to participate in the distribution of any assets in the event of liquidation, and otherwise to exercise rights as a holder of capital stock of the class or series to which such fractional shares belong. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. </B><B><U>Additional Powers of the Board</U></B><B>.</B> (a)&nbsp;In addition to, and without limiting, those
powers set forth in Section&nbsp;2 of Article III, the Board of Directors shall have power and authority to make all such rules and regulations as it shall deem expedient concerning the issue, transfer, and registration of certificates for shares of
stock of the Corporation, including the use of uncertificated shares of stock, subject to the provisions of the General Corporation Law of the State of Delaware, other applicable law, the Certificate of Incorporation, and these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Board of Directors may appoint and remove transfer agents and registrars of transfers, and may require all stock certificates to bear
the signature of any such transfer agent and/or any such registrar of transfers. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 1. </B><B><U>Indemnification</U></B><B>.</B> (a)&nbsp;Subject to Section&nbsp;3 of this Article VI, the Corporation shall
indemnify, to the full extent that it shall have power under applicable law to do so and in a manner permitted by such law, any person who is made or threatened to be made a party to or is otherwise involved (as a witness or otherwise) in any
threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative (hereinafter, a &#147;<I>Proceeding</I>&#148;), by reason of the fact that such person is or was a director or officer of the
Corporation, or while serving as a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise,
including service with respect to an employee benefit plan (collectively, &#147;<I>Another Enterprise</I>&#148;), against expenses (including attorneys&#146; fees), judgments, fines (including ERISA excise taxes or penalties) and amounts paid in
settlement actually and reasonably incurred by him or her in connection with such Proceeding if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Corporation, and, with
respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Corporation may indemnify, to the full extent that it shall have power under
applicable law to do so and in a manner permitted by such law, any person who is made or threatened to be made a party to or is otherwise involved (as a witness or otherwise) in any threatened, pending, or completed Proceeding, by reason of the fact
that such person is or was an employee or agent of the Corporation, or while not serving as a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee, or agent of Another
Enterprise, against expenses (including attorneys&#146; fees), judgments, fines (including ERISA excise taxes or penalties) and amounts paid in settlement actually and reasonably incurred by him or her in connection with such Proceeding if he or she
acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was
unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) To the extent that a present or former director or officer of the Corporation has been successful on the merits or
otherwise in defense of any threatened, pending, or completed Proceeding referred to in Section&nbsp;145(a) or (b)&nbsp;of the General Corporation Law of the State of Delaware, or in defense of any claim, issue, or matter therein, he or she shall be
indemnified against expenses (including attorneys&#146; fees) actually and reasonably incurred by him or her in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendre or its equivalent, shall
not, of itself, create a presumption that the person seeking indemnification did not act in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal
action or proceeding, had reasonable cause to believe that his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 2. </B><B><U>Advancement of
Expenses</U></B><B>.</B> (a)&nbsp;Subject to Section&nbsp;3 of this Article VI, with respect to any person who is made or threatened to be made a party to or is otherwise involved (as a witness or otherwise) in any threatened, pending, or completed
Proceeding, by reason of the fact that such person is or was a director or officer of the Corporation or while serving as a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee,
or agent of Another Enterprise, the Corporation shall pay the expenses (including attorneys&#146; fees) incurred by such person in defending any such Proceeding in advance of its final disposition (hereinafter an &#147;<I>advancement of
expenses</I>&#148;); <I>provided</I>, <I>however</I>, that any advancement of expenses shall be made only upon receipt of an undertaking (hereinafter an &#147;<I>undertaking</I>&#148;) by such person to repay all amounts advanced if it shall
ultimately be determined by final judicial decision from which there is no further right to appeal that such person is not entitled to be indemnified for such expenses under this Article VI or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) With respect to any person who is made or threatened to be made a party to or is otherwise involved (as a witness or otherwise) in any
threatened, pending, or completed Proceeding, by reason of the fact that such person is or was an employee or agent of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Corporation, or while not serving as a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee, or agent of Another
Enterprise, the Corporation may, in its discretion and upon such terms and conditions, if any, as the Corporation deems appropriate, pay the expenses (including attorneys&#146; fees) incurred by such person in defending any such Proceeding in
advance of its final disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 3. </B><B><U>Actions Initiated Against The Corporation</U></B><B>.</B> Anything in
Section&nbsp;1(a) or Section&nbsp;2(a) of this Article VI to the contrary notwithstanding, except as provided in Section&nbsp;5(b) of this Article VI, with respect to a Proceeding initiated against the Corporation by a person who is or was a
director or officer of the Corporation (whether initiated by such person in or by reason of such capacity or in or by reason of any other capacity, including as a director, officer, employee, or agent of Another Enterprise), the Corporation shall
not be required to indemnify or to advance expenses (including attorneys&#146; fees) to such person in connection with prosecuting such Proceeding (or part thereof) or in defending any counterclaim, cross-claim, affirmative defense, or like claim of
the Corporation in such Proceeding (or part thereof) unless such Proceeding was authorized by the Board of Directors of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 4. </B><B><U>Contract Rights</U></B><B>.</B> The rights to indemnification and advancement of expenses conferred upon any current
or former director or officer of the Corporation pursuant to this Article VI (whether by reason of the fact that such person is or was a director or officer of the Corporation, or while serving as a director or officer of the Corporation, is or was
serving at the request of the Corporation as a director, officer, employee, or agent of Another Enterprise) shall be contract rights, shall vest when such person becomes a director or officer of the Corporation, and shall continue as vested contract
rights even if such person ceases to be a director or officer of the Corporation. Any amendment, repeal, or modification of, or adoption of any provision inconsistent with, this Article VI (or any provision hereof) shall not adversely affect any
right to indemnification or advancement of expenses granted to any person pursuant hereto with respect to any act or omission of such person occurring prior to the time of such amendment, repeal, modification, or adoption (regardless of whether the
Proceeding relating to such acts or omissions, or any proceeding relating to such person&#146;s rights to indemnification or to advancement of expenses, is commenced before or after the time of such amendment, repeal, modification, or adoption), and
any such amendment, repeal, modification, or adoption that would adversely affect such person&#146;s rights to indemnification or advancement of expenses hereunder shall be ineffective as to such person, except with respect to any threatened,
pending, or completed Proceeding that relates to or arises from (and only to the extent such Proceeding relates to or arises from) any act or omission of such person occurring after the effective time of such amendment, repeal, modification, or
adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 5. </B><B><U>Claims</U></B><B>.</B> (a)&nbsp;If (i) a claim under Section&nbsp;1(a) of this Article VI with respect
to any right to indemnification is not paid in full by the Corporation within sixty (60)&nbsp;days after a written demand has been received by the Corporation or (ii)&nbsp;a claim under Section&nbsp;2(a) of this Article VI with respect to any right
to the advancement of expenses is not paid in full by the Corporation within twenty (20)&nbsp;days after a written demand has been received by the Corporation, then the person seeking to enforce a right to indemnification or to an advancement of
expenses, as the case may be, may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If successful in whole or in part in any suit brought pursuant to Section&nbsp;5(a) of
this Article VI, or in a suit brought by the Corporation to recover an advancement of expenses (whether pursuant to the terms of an undertaking or otherwise), the person seeking to enforce a right to indemnification or an advancement of expenses
hereunder or the person from whom the Corporation sought to recover an advancement of expenses, as the case may be, shall be entitled to be paid by the Corporation the reasonable expenses (including attorneys&#146; fees) of prosecuting or defending
such suit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by a person seeking to enforce a right to indemnification hereunder (but not a suit brought by a
person seeking to enforce a right to an advancement of expenses hereunder), it shall be a defense that the person seeking to enforce a right to indemnification has not met any applicable standard for indemnification under applicable law. With
respect to any suit brought by a person seeking to enforce a right to indemnification or right to advancement of expenses hereunder or any suit brought by the Corporation to recover an advancement of expenses (whether pursuant to the terms of an
undertaking or otherwise), neither (i)&nbsp;the failure of the Corporation to have made a determination prior to commencement of such suit that indemnification of such person is proper in the circumstances because such person has met the applicable
standards of conduct under applicable law, nor (ii)&nbsp;an actual determination by the Corporation that such person has not met such applicable standards of conduct, shall create a presumption that such person has not met the applicable standards
of conduct or, in a case brought by such person seeking to enforce a right to indemnification, be a defense to such suit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) In any
suit brought by a person seeking to enforce a right to indemnification or to an advancement of expenses hereunder, or by the Corporation to recover an advancement of expenses (whether pursuant to the terms of an undertaking or otherwise), the burden
shall be on the Corporation to prove that the person seeking to enforce a right to indemnification or to an advancement of expenses or the person from whom the Corporation seeks to recover an advancement of expenses is not entitled to be
indemnified, or to such an advancement of expenses, under this Article VI or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.
</B><B><U>Determination of Entitlement to Indemnification</U></B><B>.</B> Any indemnification required or permitted under this Article VI (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a
determination that indemnification of the present or former director, officer, employee or agent is proper in the circumstances because he or she has met all applicable standards of conduct set forth in this Article VI and Section&nbsp;145 of the
General Corporation Law of the State of Delaware. Such determination shall be made, with respect to a person who is a director or officer of the Corporation at the time of such determination, (a)&nbsp;by a majority vote of the directors who are not
parties to such Proceeding, even though less than a quorum, (b)&nbsp;by a committee of such directors designated by majority vote of such directors, even though less than a quorum, (c)&nbsp;if there are no such directors, or if such directors so
direct, by independent legal counsel in a written opinion, or (d)&nbsp;by the stockholders. Such determination shall be made, with respect to any person who is not a director or officer of the Corporation at the time of such determination, in the
manner determined by the Board of Directors (including in such manner as may be set forth in any general or specific action of the Board of Directors applicable to indemnification claims by such person) or in the manner set forth in any agreement to
which such person and the Corporation are parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 7. </B><B><U><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT>
Rights</U></B><B>.</B> The indemnification and advancement of expenses provided in this Article VI shall not be deemed exclusive of any other rights to which any person may be entitled under any bylaw, agreement, vote of stockholders or
disinterested directors, or otherwise, both as to action in such person&#146;s official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be such director, officer, employee,
or agent and shall inure to the benefit of the heirs, executors, and administrators of such person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.
</B><B><U>Insurance</U></B><B>.</B> The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee, or agent of the Corporation, or is or was serving at the request of the Corporation as a
director, officer, employee, or agent of Another Enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#146;s status as such, whether or not the Corporation
would have the power to indemnify such person against such liability under the provisions of this Article VI or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9. </B><B><U>Severability</U></B><B>.</B> If any provision or provisions of this Article VI shall be held to be
invalid, illegal, or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality, and enforceability of the remaining provisions of this Article VI (including, without limitation, each portion of any paragraph or clause containing any
such provision held to be invalid, illegal, or unenforceable, that is not itself held to be invalid, illegal, or unenforceable) shall not in any way be affected or impaired thereby and (b)&nbsp;to the fullest extent possible, the provisions of this
Article VI (including, without limitation, each such portion of any paragraph or clause containing any such provision held to be invalid, illegal, or unenforceable) shall be construed so as to give effect to the intent manifested by the provision
held invalid, illegal, or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section 10. </B><B><U>Miscellaneous</U></B><B>.</B> For purposes of this Article VI:
(a)&nbsp;references to serving at the request of the Corporation as a director or officer of Another Enterprise shall include any service as a director or officer of the Corporation that imposes duties on, or involves services by, such director or
officer with respect to an employee benefit plan, (b)&nbsp;references to serving at the request of the Corporation as an employee or agent of Another Enterprise shall include any service as an employee or agent of the Corporation that imposes duties
on, or involves services by, such employee or agent with respect to an employee benefit plan, (c)&nbsp;a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an
employee benefit plan shall be deemed to have acted in a manner not opposed to the best interests of the Corporation, and (d)&nbsp;references to a director of Another Enterprise shall include, in the case of any entity that is not managed by a board
of directors, such other position, such as manager or trustee or member of the governing body of such entity, that entails responsibility for the management and direction of such entity&#146;s affairs, including, without limitation, general partner
of any partnership (general or limited) and manager or managing member of any limited liability company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1. </B><B><U>Books and Records</U></B><B>.</B> (a)&nbsp;Any books or records maintained by the Corporation in
the regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or by means of, or be in the form of, any information storage device or method; <I>provided</I>, <I>however</I>, that the books and
records so kept can be converted into clearly legible paper form within a reasonable time. The Corporation shall so convert any books or records so kept upon the request of any person entitled to inspect such records pursuant to the Certificate of
Incorporation, these Bylaws, or the provisions of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) It shall be the duty of the
Secretary or other officer of the Corporation who shall have charge of the stock ledger to prepare and make, at least ten (10)&nbsp;days before every meeting of the stockholders, a complete list of the stockholders entitled to vote thereat, arranged
in alphabetical order, and showing the address of each stockholder and the number of shares registered in the stockholder&#146;s name; <I>provided</I>, <I>however</I>, if the record date for determining the stockholders entitled to vote at the
meeting is fewer than ten (10)&nbsp;days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth day before the meeting date. Nothing contained in this subsection (b)&nbsp;shall require the Corporation to
include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least ten (10)&nbsp;days prior to the
meeting: (i)&nbsp;on a reasonably accessible electronic network, <I>provided</I> that the information required to gain access to such list is provided with the notice of the meeting, or (ii)&nbsp;during ordinary business hours, at the principal
place of business of the Corporation. If the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation.
If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by
means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible network, and the information required to access such list shall be provided with
the notice of the meeting. The stock ledger shall be the only evidence of the identity of the stockholders entitled to examine such list. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except to the extent otherwise required by law, or by the Certificate of Incorporation, or by these Bylaws, the Board of Directors shall
determine from time to time whether and, if allowed, when and under what conditions and regulations the stock ledger, books, records, and accounts of the Corporation, or any of them, shall be open to inspection by the stockholders and the
stockholders&#146; rights, if any, in respect thereof. Except as otherwise provided by law, the stock ledger shall be the only evidence of the identity of the stockholders entitled to examine the stock ledger, the books, records, or accounts of the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. </B><B><U>Voting Shares in Other Business Entities</U></B><B>.</B> The Chief Executive
Officer, the President, any Vice President, or any other officer or officers of the Corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designated by the Board of Directors, the Chief Executive Officer or the President may vote, and otherwise exercise on behalf of the Corporation any and all rights and powers incident to the
ownership of, any and all shares of stock or other equity interest held by the Corporation in any other corporation or other business entity. The authority herein granted may be exercised either by any such officer in person or by any other person
authorized to do so by proxy or power of attorney duly executed by any such officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. <U>Execution of Corporate
Instruments</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Board of Directors may in its discretion determine the method and designate the signatory officer or
officers, or other person or persons, to execute, sign, or endorse any corporate instrument or document, or to sign the corporate name without limitation, except where otherwise provided by law, and such execution or signature shall be binding upon
the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Unless otherwise specifically determined by the Board of Directors or otherwise required by law, formal contracts of
the Corporation, promissory notes, deeds of trust, mortgages, and other evidences of indebtedness of the Corporation, and other corporate instruments or documents requiring the corporate seal, shall be executed, signed, or endorsed by the Chairman
of the Board, the Chief Executive Officer, the President, any Vice President, the Secretary, the Chief Financial Officer, the Treasurer, or any Assistant Secretary or Assistant Treasurer. All other instruments and documents requiring a corporate
signature but not requiring the corporate seal may be executed as aforesaid or in such other manner and by such other person or persons as may be determined from time to time by the Board of Directors or the President. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All checks and drafts drawn on banks or other depositaries on funds to the credit of the Corporation or in special accounts of the
Corporation shall be executed, signed, or endorsed by the Chief Financial Officer, the Treasurer, any Assistant Treasurer, or in such other manner and by such other person or persons as may be determined from time to time by the Board of Directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Unless otherwise specifically determined by the Board of Directors or otherwise required by law, the execution, signing, or
endorsement of any corporate instrument or document may be effected manually, by facsimile, or (to the extent permitted by applicable law and subject to such policies and procedures as the Corporation may have in effect from time to time) by
electronic signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. </B><B><U>Fiscal Year</U></B><B>.</B> The fiscal year of the Corporation shall be
such fiscal year as the Board of Directors from time to time by resolution shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.
</B><B><U>Gender/Number</U></B><B>.</B> As used in these Bylaws, the masculine, feminine, or neuter gender, and the singular and plural number, shall each include the other whenever the context so indicates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. </B><B><U>Section Titles</U></B><B>.</B> The titles of the sections and subsections have been inserted as a
matter of reference only and shall not control or affect the meaning or construction of any of the terms and provisions hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. </B><B><U>Electronic Transmission</U></B><B>.</B> For
purposes of these Bylaws, &#147;electronic transmission&#148; means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and
that may be directly reproduced in paper form by such a recipient through an automated process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.
</B><B><U>Amendment</U></B><B>.</B> These Bylaws, or any of them, may be altered, amended, or repealed, and new Bylaws may be made, (a)&nbsp;at any annual or regular meeting of the Board of Directors or at any special meeting of the Board of
Directors if notice of the proposed alteration, amendment, or repeal be contained in written notice of such special meeting or (b)&nbsp;at any annual meeting of the stockholders (subject to Section&nbsp;13 of Article II of these Bylaws) or at any
special meeting of the stockholders of the Corporation if noticed of the proposed alteration, amendment, or repeal is contained in the Corporation&#146;s notice of such special meeting of stockholders (and subject to Section&nbsp;2 of Article II of
these Bylaws). Anything herein to the contrary notwithstanding, any alteration, amendment, or repeal of these Bylaws, or the making of any new Bylaw, by the stockholders shall require the affirmative vote of the holders of not less than a majority
of the voting power represented by the issued and outstanding shares of the Corporation entitled to vote thereon. Any Bylaws altered, amended, or made by the stockholders may be altered, amended, or repealed by either the Board of Directors or the
stockholders, in the manner set forth in this Section&nbsp;8, except a Bylaw amendment adopted by the stockholders that specifies the votes that shall be necessary for the election of directors shall not be amended or repealed by the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9. </B><B><U>Certificate of Incorporation</U></B><B>.</B> Anything herein to the contrary
notwithstanding, if any provision contained in these Bylaws is inconsistent with or conflicts with a provision of the Certificate of Incorporation, such provision of these Bylaws shall be superseded by the inconsistent provision in the Certificate
of Incorporation to the extent necessary to give effect to such provision in the Certificate of Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Forum</B><B>. </B><B><FONT
STYLE="font-family:Times New Roman" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(a)</U></FONT>&nbsp;</B>Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the
State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, the Superior Court of the State of Delaware, or, if and only if both the Court of Chancery of the State of Delaware and the
Superior Court of the State of Delaware lack subject matter jurisdiction, the United States District Court for the District of Delaware) and any state (or, if applicable, federal) appellate court therefrom shall, to the fullest extent permitted by
law, be the sole and exclusive forum for (<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>a</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">i</U>) any
derivative action, suit, or proceeding brought on behalf of the Corporation, (</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>b</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">ii</U></FONT><FONT STYLE="font-family:Times New Roman">) any action, suit, or proceeding asserting a claim of breach of
fiduciary duty owed by any </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">current or former</U></FONT><FONT STYLE="font-family:Times New Roman"> director,
officer, </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>or other </STRIKE></FONT><FONT STYLE="font-family:Times New Roman">employee</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">, or stockholder</U></FONT><FONT STYLE="font-family:Times New Roman"> of the Corporation to the Corporation or the
Corporation&#146;s stockholders </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">or any action asserting a claim for aiding and abetting any such breach of
fiduciary duty</U></FONT><FONT STYLE="font-family:Times New Roman">,
(</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>c</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">iii</U></FONT>
<FONT STYLE="font-family:Times New Roman">)&nbsp;any action, suit, or proceeding asserting a claim against the Corporation or any director, officer, or other employee of the Corporation arising pursuant to, or seeking to enforce any right,
obligation, or remedy under, any provision of the DGCL or the Certificate of Incorporation or the Corporation&#146;s Bylaws (in each case, as may be amended from time to time), (</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>d</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">iv</U></FONT><FONT
STYLE="font-family:Times New Roman">) any action, suit, or proceeding as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or
(</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff0000"><STRIKE>e</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U>v</U></FONT><FONT STYLE="font-family:Times New Roman">) any
action, suit, or proceeding asserting a claim </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">against the Corporation or its current or former directors,
officers, employees, or stockholders</U></FONT><FONT STYLE="font-family:Times New Roman"> governed by the internal affairs doctrine, in all cases subject to the court&#146;s having personal jurisdiction over the indispensable parties named as
defendants (including personal jurisdiction by reason of any such indispensable party&#146;s consent to personal jurisdiction in the State of Delaware or such court).
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">If any action, suit or proceeding the subject matter of which is within the scope of the immediately preceding
sentence is filed in a court other than the courts in the State of Delaware, (a &#147;Foreign Action&#148;) in the name of any stockholder, such stockholder shall be deemed to have consented to (x)&nbsp;the personal jurisdiction of the state and
federal courts in the State of Delaware in connection with any action brought in any such court to enforce the provisions of the immediately preceding sentence and (y)&nbsp;having service of process made upon such stockholders in any action by
service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(b) Unless the Corporation
consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act of 1933, as amended.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(c) Notwithstanding the foregoing, the provisions of this Section&nbsp;10 of Article VII shall not apply to suits brought to
enforce any liability or duty created by the Securities Exchange Act of 1934, as amended, or any claim for which the federal courts of the United States have exclusive jurisdiction.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0000ff"><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(d) If any provision of this
Section&nbsp;10 of Article VII shall be held to be invalid, illegal or unenforceable as applied to an person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability
of such provisions, in any other circumstance and of the remaining provisions of this Section&nbsp;10 of Article VII (including, without limitation, each portion of any sentence of this Section&nbsp;10 of Article VII containing any such provision
held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired
thereby.</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">END OF BYLAWS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d345457dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g345457g1011050223771.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g345457g1011050223975.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Highly complementary spine and orthopedics portfolios</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>One of the industry&#146;s broadest biologics and regenerative technology offerings</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Differentiated and synergistic enabling technologies</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Meaningful cross-selling revenue synergies and cost savings</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Financial strength to pursue growth investments without need for immediate equity financing </I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected to be adjusted EBITDA accretive to Orthofix by the second year following close including cost savings
</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Companies to host joint conference call and webcast today at 8:00 a.m. ET</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lewisville, Texas and Carlsbad, California &#151; October</B><B></B><B>&nbsp;11, 2022 &#151;</B> Orthofix (NASDAQ: OFIX), a global medical device company
with a spine and orthopedics focus, and SeaSpine (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced they have entered into a definitive agreement to combine in an <FONT
STYLE="white-space:nowrap">all-stock</FONT> merger of equals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined company, to be named prior to the transaction&#146;s closing, will be a
leading global spine and orthopedics company with highly complementary portfolios of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions and a leading surgical navigation system. With products distributed
in 68 countries world-wide, approximately 1,600 employees and a global R&amp;D and manufacturing footprint, the new company would have revenues of approximately $693&nbsp;million as of the twelve months ended September&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, which was unanimously approved by the Boards of Directors of both companies, SeaSpine shareholders will receive 0.4163
shares of Orthofix common stock for each share of SeaSpine common stock owned. Following the close of the transaction, Orthofix shareholders will own approximately 56.5&nbsp;percent of the combined company, and SeaSpine shareholders will own
approximately 43.5&nbsp;percent of the combined company, respectively, on a fully diluted basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This transaction significantly advances our
mission to deliver innovative, quality-driven solutions that make us a partner of choice for surgeons in their work to improve patient mobility,&#148; said Jon Serbousek, Orthofix President and Chief Executive Officer. &#147;The combined
company&#146;s broad portfolio of technology, expanded commercial capabilities and ability to make greater investments in innovative solutions provide a clear roadmap for sustainable, <FONT STYLE="white-space:nowrap">top-tier</FONT> growth and
increased competitiveness across a broad spectrum of products and services. We look forward to capitalizing on this merger&#146;s tremendous value creation opportunities.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Keith Valentine, SeaSpine President and Chief Executive Officer, said, &#147;This transaction brings together two complementary organizations to create an
industry leader with the immediate financial strength to self-fund investments that deliver both growth and better patient outcomes. We are excited about the value we can create for the combined company&#146;s shareholders, the new opportunities
opened for employees and our ability to now provide surgeons and hospital partners a complete procedural solution using cutting-edge technology at every level.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic and Financial Benefits of the Merger </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>An industry leader in spine and orthopedics portfolios. </B>The combination of Orthofix&#146;s and
SeaSpine&#146;s portfolios will create an innovative suite of offerings in growth segments of spine and orthopedics. The combined company&#146;s differentiated technologies will include: the <FONT STYLE="white-space:nowrap">M6-C</FONT><SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> artificial cervical disc, a next-generation artificial disc replacement alternative to spinal fusion; the FLASH<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Navigation System with
7D Technology, which is the only approved image guidance system that utilizes a novel and proprietary camera-based technology and machine-vision algorithms; the Fitbone<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform, which
includes the currently available intermedullary limb lengthening system; the under-development Fitspine<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> scoliosis solution; and a comprehensive offering of advanced interbody devices
featuring WaveForm<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> 3D and NanoMetalene<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> with Reef Topography<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technologies.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>One of the industry&#146;s broadest biologics and regenerative technology offerings. </B>Together, the
combined company&#146;s biologics portfolio will represent one of the broadest offerings available, extending the new company&#146;s reach to an even greater number of surgeons for use in spine and orthopedics procedures. These biologic solutions
include the recently launched Virtuos<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Lyograft, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-of-its-kind,</FONT></FONT></FONT>
shelf-stable and complete autograft substitute; the market-leading Trinity<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Elite allograft; the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT>
OsteoStrand<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Plus and OsteoSurge<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> 300 demineralized bone matrix (DBM) products with patented Accell<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Bone Matrix, and the future commercialization of Novosis<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, a next generation <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">rh-BMP-2</FONT></FONT> technology via our recent license agreement with CGBio. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The combined
company&#146;s regenerative technologies will include the CervicalStim<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> bone growth therapy device, the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> PEMF system for cervical
treatment; SpinalStim<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> for spine fusion; PhysioStim<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> for the treatment of nonunion fractures; and the recently launched AccelStim<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> bone healing therapy. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Differentiated and synergistic enabling technologies.</B> The combined company will have a&nbsp;complementary
portfolio of technologies that enables it to service the full continuum of surgical care from preoperative planning through surgical&nbsp;navigation. Flagship enabling technologies include the unique FLASH<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Navigation System with 7D Technology, which is designed to provide visibility during surgery to improve accuracy of screw placement and provide a cost-effective, rapid, radiation-free solution
to surgical navigation, and the OrthoNext<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> preoperative planning system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Premier offering in high-growth pediatrics market. </B>The combined company will have a complementary
portfolio of specialized hardware and enabling technologies, including specialized spine, limb deformity, limb reconstruction and software planning and imaging solutions, that enable it to service the full patient continuum of care for pediatric
orthopedic surgeons. Currently an $800&nbsp;million annual market, pediatrics is among the fastest growing markets in orthopedics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strengthened commercial reach in the United States and internationally. </B>With its broader product and
services portfolio, increased resources and deep pipeline, the combined company will be able to attract and support larger, dedicated distribution partners. It will also be able to invest in direct sales representatives in select markets to engage
even more surgeon users. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Revenue synergies, cost savings and economies of scale. </B>The companies have identified meaningful
cross-selling revenue synergies as a result of cross-selling the complementary portfolios in the United States, the ability to sell SeaSpine&#146;s biologics and 7D technology into Orthofix&#146;s international established channels, the greater
breadth of bag to support large distributor conversions and increased product offerings per procedure. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, the
combination is expected to generate at least $40&nbsp;million in annualized cost savings not including stock-based compensation within three years following the close of the transaction. Cost savings will be primarily from reductions in redundant
overhead and public company costs as well as supply chain efficiencies. Working capital and capital expenditure efficiencies are expected to be driven through economies of scale via higher spinal implant set utilization. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strong financial profile with enhanced opportunities for investment</B>. The transaction is expected to be
accretive to Orthofix&#146;s standalone adjusted EBITDA by the second full year after close and is expected to be accretive to our existing return on invested capital after fully realizing synergies, including cost savings. The combined
company&#146;s strong capital structure will allow it to self-fund certain investments intended to maximize growth potential, including organic and inorganic innovation initiatives, sales force expansion, and field inventory and instrumentation,
without the need for equity financing. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leadership and Headquarters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined company will be led by an experienced Board of Directors and leadership team that leverages the talent within both organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon closing of the transaction, the combined company&#146;s Board of Directors will consist of nine directors, with five designated by Orthofix, including
Lead Independent Director, and four designated by SeaSpine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jon Serbousek will serve as Executive Chairman of the Board, and Keith Valentine will serve
as President and Chief Executive Officer and member of the Board. The remainder of the combined company&#146;s Board and leadership team will be named prior to closing and is expected to include representatives from both Orthofix and SeaSpine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined company will be headquartered in Lewisville, Texas. This location will conduct general business, product development, medical education and
manufacturing. The Company will retain primary offices in Carlsbad, CA, with a focus on spinal product innovation and surgeon education, and in Verona, Italy with an emphasis on product innovation, production, and medical education for Orthopedics.
Current facilities in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead UK, Munich, Germany, Paris, France and Sao Paulo, Brazil will also be retained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Timing and Approvals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction is expected to
close in the first quarter of 2023, subject to approval by both companies&#146; shareholders and customary closing conditions and regulatory approvals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advisors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Perella Weinberg Partners LP is serving as
financial advisor to Orthofix, and Hogan Lovells US LLP is serving as its legal counsel. Piper Sandler&nbsp;&amp; Co. is serving as financial advisor to SeaSpine, and DLA Piper LLP is serving as its legal counsel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and Webcast </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orthofix and SeaSpine will
host a joint conference call and webcast today at 8:00 a.m. ET to discuss the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conference call can be accessed by dialing +1 (833) <FONT
STYLE="white-space:nowrap">927-1758</FONT> within the U.S. and +1 (929) <FONT STYLE="white-space:nowrap">526-1599</FONT> for all other locations. The confirmation code is 867247. Participants should dial in 10 minutes prior to the scheduled start
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A live webcast of the conference call and associated presentation materials will be available on the investor relations section of each
company&#146;s website at <U>www.orthofix.com</U> and <U>www.seaspine.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Orthofix </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orthofix Medical Inc.&nbsp;is a global medical device company with a spine and orthopedics focus. The Company&#146;s mission is to deliver innovative,
quality-driven solutions while partnering with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix&#146;s spine and orthopedics products are distributed in more than 60 countries via the Company&#146;s
sales representatives and distributors. For more information, please visit&nbsp;<U>www.orthofix.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SeaSpine </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SeaSpine (<U>www.seaspine.com</U>) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for
the treatment of patients suffering from spinal disorders. SeaSpine&#146;s complete procedural solutions feature its market-leading FLASH<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Navigation, a system designed to improve accuracy of
screw placement and provide a cost-effective, rapid, radiation-free solution to surgical navigation, and a comprehensive portfolio of spinal implants and orthobiologics to meet the varying combinations of products that neurosurgeons and orthopedic
spine surgeons need to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures on the lumbar, thoracic and cervical spine. With product development expertise in advanced optics, software,
orthobiologic sciences and spinal implants, SeaSpine can offer its surgeon customers a complete solution to meet their patients&#146; evolving clinical needs. SeaSpine currently markets its products in the United States and in approximately 30
countries worldwide. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains statements which, to the extent they are not statements of historical or present fact, constitute &#147;forward-looking
statements&#148; under the securities laws. From time to time, oral or written forward-looking statements may also be included in other information released to the public. These forward-looking statements are intended to provide Orthofix&#146;s and
SeaSpine&#146;s respective management&#146;s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. Forward-looking statements can be identified by the use of words such
as &#147;believe,&#148; &#147;expect,&#148; &#147;expectations,&#148; &#147;plans,&#148; &#147;strategy,&#148; &#147;prospects,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;target,&#148; &#147;anticipate,&#148; &#147;will,&#148;
&#147;should,&#148; &#147;see,&#148; &#147;guidance,&#148; &#147;outlook,&#148; &#147;confident,&#148; &#147;on track&#148; and other words of similar meaning. Forward-looking statements may include, among other things, statements relating to future
sales, earnings, cash flow, results of operations, uses of cash, tax rates, R&amp;D spend, other measures of financial performance, potential future plans, strategies or transactions, credit ratings and net indebtedness, other anticipated benefits
of the proposed merger, including estimated synergies and cost savings resulting from the proposed merger, the expected timing of completion of the proposed merger, estimated costs associated with such transaction and other statements that are not
historical facts. All forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Such risks, uncertainties and other factors include, without limitation: (1)&nbsp;the effect of economic conditions
in the industries and markets in which Orthofix and SeaSpine operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, and
the levels of market demand in the health care segments in which our products are purchased and utilized; (2)&nbsp;challenges in the development, regulatory approval, commercialization, reimbursement, market acceptance, performance and realization
of the anticipated benefits of new products of the combined company; (3)&nbsp;the scope, nature, impact or timing of the proposed merger, including among other things the integration of the businesses and realization of synergies and opportunities
for growth and innovation and incurrence of related costs and expenses; (4)&nbsp;future levels of indebtedness, capital spending and research and development spending; (5)&nbsp;future availability of credit and factors that may affect such
availability, including credit market conditions and our capital structure; (6)&nbsp;delays and disruption in delivery of materials and services from suppliers; (7)&nbsp;cost reduction efforts and restructuring costs and savings; (8)&nbsp;new
business and investment opportunities; (9)&nbsp;the ability to realize the intended benefits of organizational changes; (10)&nbsp;the anticipated benefits of diversification and balance of operations across product lines, regions and industries;
(11)&nbsp;the effect of changes in political conditions in the U.S. and other countries in which Orthofix, SeaSpine and the businesses of each operate, including the effect of changes in U.S. healthcare policies, on general market conditions in the
near term and beyond; (12)&nbsp;the effect of changes in tax, regulatory and other laws and regulations in the U.S. and other countries in which Orthofix, SeaSpine and the businesses of each operate; (13)&nbsp;negative effects of the announcement or
pendency of the proposed merger on the market price of Orthofix and/or SeaSpine&#146;s respective common stock and/or on their respective financial performance; (14)&nbsp;the ability of the parties to receive the required regulatory approvals for
the proposed merger (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction) and approvals of Orthofix&#146;s and SeaSpine&#146;s
shareholders and to satisfy the other conditions to the closing of the merger on a timely basis or at all; (15)&nbsp;the occurrence of events that may give rise to a right of one or both of the parties to terminate the merger agreement;
(16)&nbsp;risks relating to the value of the Orthofix shares to be issued in the proposed merger, significant transaction costs and/or unknown liabilities; (17)&nbsp;the possibility that the anticipated benefits from the proposed merger cannot be
realized in full or at all or may take longer to realize than expected, including risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction; (18)&nbsp;risks associated
with transaction-related litigation; (19)&nbsp;the possibility that costs or difficulties related to the integration of Orthofix&#146;s and SeaSpine&#146;s operations will be greater than expected; (20)&nbsp;the ability of the combined company to
retain and hire key personnel; (21)&nbsp;the intended qualification of the merger as a <FONT STYLE="white-space:nowrap">tax-free</FONT> reorganization to Orthofix and SeaSpine shareholders for U.S. federal income tax purposes; and (22)&nbsp;the
impact of the proposed merger on the respective businesses of Orthofix and SeaSpine. There can be no assurance that the proposed merger will in fact be consummated in the manner described or at all. For additional information on identifying factors
that may cause actual results to vary materially from those stated in forward-looking statements, see the reports of Orthofix and SeaSpine on Forms <FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT>
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and <FONT STYLE="white-space:nowrap">8-K</FONT> filed with or furnished to the Securities and Exchange Commission (the &#147;SEC&#148;) from time to time. Any forward-looking statement speaks
only as of the date on which it is made, and Orthofix and SeaSpine assume no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information about the Proposed Transaction and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction, Orthofix intends to file with the SEC a registration statement on Form
<FONT STYLE="white-space:nowrap">S-4,</FONT> which will include a document that serves as a prospectus of Orthofix and a joint proxy statement of Orthofix and SeaSpine (the &#147;joint proxy statement/prospectus&#148;). Each party also plans to file
other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. A definitive joint proxy statement/prospectus will be sent to Orthofix&#146;s shareholders and SeaSpine&#146;s shareholders. Investors and securityholders may obtain a free copy of
the joint proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by Orthofix and SeaSpine with the SEC at the SEC&#146;s website at www.sec.gov. Copies of the documents filed by Orthofix with the SEC will be
available free of charge on Orthofix&#146;s website at http://ir.orthofix.com/ or by contacting Orthofix&#146;s Investor Relations at (214) <FONT STYLE="white-space:nowrap">937-3190.</FONT> Copies of the documents filed by SeaSpine with the SEC will
be available free of charge on SeaSpine&#146;s website at http://investor.seaspine.com/ or by contacting SeaSpine&#146;s Investor Relations at (415) <FONT STYLE="white-space:nowrap">937-5402.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orthofix and SeaSpine and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the
solicitation of proxies in respect of the proposed transaction. Information about directors and executive officers of Orthofix is available in the Orthofix proxy statement for its 2022 Annual Meeting, which was filed with the SEC on April&nbsp;27,
2022. Information about directors and executive officers of SeaSpine is available in the SeaSpine proxy statement for its 2022 Annual Meeting, which was filed with the SEC on April&nbsp;22, 2022. Other information regarding the participants in the
proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed
transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. Investors may obtain free copies of these documents from
Orthofix and SeaSpine as indicated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication and the information contained herein shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Orthofix Contact</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>SeaSpine Contact</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alexa Huerta</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel 214 937 3190</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denise Landry</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Tel 214 937 2529</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Bostjancic,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">760 216 5111</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LeAnn Burton</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">760 607 9703</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ofix-20221010.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/11/2022 1:12:17 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:ofix="http://www.orthofix.com/20221010"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.orthofix.com/20221010"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ofix-20221010_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ofix-20221010_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ofix-20221010_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/11/2022 1:12:17 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ofix-20221010_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/11/2022 1:12:17 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ofix-20221010.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g345457g1011050223771.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g345457g1011050223771.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ ,H# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g345457g1011050223975.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g345457g1011050223975.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E )0# 2(  A$! Q$!_\0
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M"'GF,S+Z X S^%=?:>%M(LY5ECM TB]"[%N?H>*N2:5:2ZDFH/&3<(NU6W'
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&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139889733374048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000884624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 10,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORTHOFIX MEDICAL INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1340767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3451 Plano Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lewisville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">937-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.10 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OFIX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d345457d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ofix-20221010.xsd" xlink:type="simple"/>
    <context id="duration_2022-10-10_to_2022-10-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000884624</identifier>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-10-10_to_2022-10-10">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-10-10_to_2022-10-10"
      id="Hidden_dei_EntityCentralIndexKey">0000884624</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="duration_2022-10-10_to_2022-10-10"
      id="Hidden_dei_CurrentFiscalYearEndDate_duration_2022-10-10_to_2022-10-10">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="duration_2022-10-10_to_2022-10-10">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-10-10_to_2022-10-10">2022-10-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-10-10_to_2022-10-10">ORTHOFIX MEDICAL INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-10-10_to_2022-10-10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-10-10_to_2022-10-10">0-19961</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-10-10_to_2022-10-10">98-1340767</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-10-10_to_2022-10-10">3451 Plano Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-10-10_to_2022-10-10">Lewisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-10-10_to_2022-10-10">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-10-10_to_2022-10-10">75056</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-10-10_to_2022-10-10">(214)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-10-10_to_2022-10-10">937-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-10-10_to_2022-10-10">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-10-10_to_2022-10-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-10-10_to_2022-10-10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-10-10_to_2022-10-10">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-10-10_to_2022-10-10">Common stock, $0.10 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-10-10_to_2022-10-10">OFIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-10-10_to_2022-10-10">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-10-10_to_2022-10-10">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MU,N>'3#2TO(I[MD?2:>V)!59RGWUBHG+W?.]T#L1AM@Z0,N%@)ZU$A1T^:P
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( *$S2U4'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ H3-+5=75M _M
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ H3-+59E<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "A,TM56SPF@F\$   H$0
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ H3-+59^@&_"Q @  X@P   T              ( !L0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "A,TM5EXJ[',     3 @  "P
M        @ &-#P  7W)E;',O+G)E;'-02P$"% ,4    " "A,TM5'#AEZC\!
M   \ @  #P              @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ H3-+520>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ H3-+5660>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d345457d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d345457d8k.htm">d345457d8k.htm</File>
    <File>d345457dex21.htm</File>
    <File>d345457dex31.htm</File>
    <File>d345457dex991.htm</File>
    <File>ofix-20221010.xsd</File>
    <File>ofix-20221010_lab.xml</File>
    <File>ofix-20221010_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d345457d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d345457d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ofix-20221010_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ofix-20221010_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ofix-20221010.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ofix",
   "nsuri": "http://www.orthofix.com/20221010",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d345457d8k.htm",
      "contextRef": "duration_2022-10-10_to_2022-10-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d345457d8k.htm",
      "contextRef": "duration_2022-10-10_to_2022-10-10",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.orthofix.com//20221010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-22-260149-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-260149-xbrl.zip
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M84>;?[BP2/[CYJW*K>T?T2&0N(6[-R)*/(?["KIRPY5/JG%Z]QA'K[GZE>*
M\#]J[9%^9,ZO17,<"?X%O;B>*P[Y30@8LC;@NG1T^7F9A4TLATZ'A$BLL!?
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MVW;0)APMP[-]4SJ6"M%Z3^?ZH["7S&_Y]Q_V>]V]HQC@X(OY- P$"TAA:S
MOY^B<&9@P'- 4T";>MZ O*@/SST(IS=[W>TW9<?G@^W)LQ!.[!/NYJ$FY-9>
ML]?I=%Y#@L\9$ER%VQO')U/A?*$(%I^#K  >@3;J.+QC8^&'M\R3X:WW(%M6
MHP^%?.D\V<3S$=&]&+ ^$8$K7(S@Q=XL]1,>B#"-_06+ 6OBR8)F4"^$8X"7
MLD#EU)9S/(5Q(L:#A;XW 4TVO,7W4,YY:*/%A[6XM/M@1?M1%6FC/6<:=5EU
M+ZCVZXF?HD11FO*/1Y4\MX[6?XV\!(X,S=XT4$9-_-7:R#@,_3&'XTH N1#*
M!WO;NT=E=K!* !7M3Y8_4?;5[+Z0GK5QK. ! + !PN969'J4 I)L]W84AA8"
MPA@'WNSNL9/W(];;ZK3@P?L8B*]HNQ;:7@(7=@#@P?5'8&' Q_PGP=GM[P)G
M,V# T!(:981=R<^[V[S9[6F6GN%V+L-!8_;*T7K;G98<\8TE]5^)X#&)X%,D
MD&]C"C E;J'DC2XFD_MK;'\B8EB)F0"UIF.!36/\*HZ_!@&YS=[F^,WCDI <
M\Y6(GHF(AG&<BNB5E%Z8E+9$<WO3>5Q24F.N34J/;GY96J*T<T0$EM*\*ND1
M:5[;/;#3>C/G.P@HO":]/*/;< V?1<UN*\CF10-M5U@XB#0@N#-ECL_C^+G<
MUP\%XDM#+.)(O&_'$6L?7RYF\-QF_&RAX^\4:.<J+9.P3"CI(D$(C!BH BYG
MW#HO-+[!..17);DI ;7H]L9$??=V_*(F%>+,H?.EP?X&0K?#YCQB-]Q/!9MC
M!>'T^\MGJP.7HC=):?=/7WX__.U/ @B--UHY>T@Z=TEO1EK4P<SS_N5I_W_8
MSWX(FC1H23[H2>PCC[Z(9&4L[SDTNV'@HK8KV'C!''*RPXA?@'L(2OXJ>+:]
MF &806/&2:_9=13>)E-4FN?H[>8Q<\7$"V1*N'0V=G98N?0DJSC98IN("'M'
MTN.HG_8HFWR.V>28X;6FZMT;-XT7:+UZ%S/[>GIX:0)KG:VOJYVYCXU#49B-
MXT'-,:P(1NO7?J:W3N1+SV8K/B6, )LG2_ 3(YN5R.Z5(CA30&4B54#E("0#
M)XT%/04P4G$B[&?AD=$CZ[,1)C27O\#);SV8&L\C@/7!G4C<>#&\!P3" P<]
MG=QQ, <;'\;.%BZ/W%A&B-QJZTJ5.&UM<F-BV5C=8@;L=3;7.E78:U19?\?E
MW#)6J2*6?_T+B)Y*=!2S$C;B)4M3&@LX;]"4_%N^B#=DN0XV$C%:%9B;873X
MPP']=Z0W-+_+^9/::A'+H\&/6Z/_U[^4/&;O+D:G@U'SY.+LK/_I<G"H__BV
M/68'E1XS1G\"'I5=067-8)B(F2*K5J?;JE!C[-%>RL&US!R0VQQ@+0<&L4/&
MF8XLL5,4QQZET/2O(T&NKA:[C_]H]S'8<OD,Z.]#+X$M.!O'9FW +UU*T4/V
M]A&X.*@@U:D7C[W$BZ!01ZK*-AOL0O5_@O6@]/#9,'!:#8"RKG%A=C[Z)B;6
M]#I'^BWZV3UZ0SN[B!RNMW69CI>/A"]P4,1"WU\TPUO4JN)T#"3A\8@R"\S"
M])S9R'K6!B,&0@H98D; EH)Z$R5*?C#SO-D(R;5+P2_GP*?9!\!&H.28G61+
M7PD<_;8>L\6N8.+BC%H4QB#H>-)@Z1R&P!7"CF8QK1\ \@<JU+ WO $ZC.M)
MSVTL$I3'L%1/OE0<O6$?Q*WG^PRU!J'%MH*8V6<9-!F,\Q!!1<H+4LJ?BFGJ
M.(UNO!N\8#3EM<\V2QVAG:/.P4D7:"VI#WTDIV\>N!G4+3 K+:0,7)Y(;6DR
M0=4%^$\"P\M]PR"@#,6IG^1?;TA/!MG9>,>Q3'+\;2#L8:3#I<'"-"'5B9)X
M9C.@4&!]_@*3"$'E4BLO+"*_9CKZ,1T;<G5-*J00(K_%02+A"'P=+)3N[I9<
M85RU1'UL+2!MAC)/D<-#@&%0@%;(8<\SP6S*H?0]<0<Z*^X>6Y,E* %09\ Y
MYD#;F-:$.PN4=YXPU9ZD"$,#8S4<TC HI1I(J#]@_S9@@P#D LC,@O/O;BJJ
MC=%==2/D:K$=DXM6'2U FII5^,75#E$?UD<:I^A5I;DQDTIQC^P" I*>J=A#
MZ( ]J,^#5J0=9XQX%!W(?(Z=!IA-_KF#SG$4"4-I&8C( 14?5^HH#-8 ,@,I
M5)G+[<FC]>-08F $F# /Z20 O-S](\6=/SVE?T;.2I:+L%/:2IA(BP>F!4J>
MAN=M(#/R[KR9I+R=W=;.CWH$&'-,_@#-^%"NL4F*V.-Z?HJ@&?/8D^>>!]**
M>;:W8)ZG!XW=V"/C@O5LS]Q;QG0:]/<X!+S$&ZX'#"8)H[@6; 0#P": %/&)
M@-@@( K(QQ3PQT[:G>"<UCT4,YC)"X;L#%X39I;J^<UAK\M.\>0F(5#5P^?,
M./MZ<];H"^3" "2&]Z7.P/X!^'8IHG$(UOL7"<581# *1W^0SBX_F7(OFG&#
M]^]PD9*N?Q'(,?_)?62J@2@,\0GHE=K$T;,G4T],K&$O*&D]ROC\3&!.<FZ6
MIT=@<Y[HT^ (*TIQ3?@7V(*4"B =1!RCY@$W?$0Q7%]&]=7B+B&FI63Q4C'#
ME 18X@M]>C@,4+>8\RA9&-EI)?'"9JB[(N&1M7+@3):.":>9<-PJ\&48-5I8
MHLHFP4WOC;0B3,+R#6QXO*CAI HA$)38WY3DEX&Y>:4H@NKA?00+R*W E?*F
MCFWARJIY[U1J]XB[_(\0'>5Z#%MIR!9;4D_L1=.R]+HX"CX4M ZY(6ZYS *4
MGK382IOX $?6O'3@V)LC[%0<LCZZ,2,X C:<(6AI#Y93>6\7<)W4;7$W]]#X
M 3XR%B(@YNT%/%'*(ZYAAGXWX$.+TA+(90<:1$1\.(AI$BNUFY06:PO<+$NY
M 4&6$M3!$(KK5A2.$:&$B["Y4:"!+<(K^@UZ3 2<?)%4[>P27A+9$9.+Q S&
M(%5/LDG:W%09'^H2Q@F#/T(OH.QU5=M]*[65<.J-Y=Z5$06JYHR7,086>6.A
M%6Q6F4H<M2KN9,A!L,D36R3F@"0 1)5:@^^!8H;N5E2V:JVT:Q&(B-1-BQ M
M%T??1;5/L('<YV8^"%$UYAOC;<4->1G4Z\8L[TH?#JF3>)XQZMWTE*OZ557-
M?$2[ACEMZ@1\(V<Z#@ KEDBI%H+Z(*P@1@HM+@'FP&?A'VJ^ W00<$11.A ]
MHTU)Q=4\$\^U>5A.RP,8"IC"%18_+6!)PT81:1KH;=8BC&'#(,&!]UQ+H,%0
MV;M$-H9)"R,9C)[EIG#L"-9Q"B>+A6FU)Z/6 60)G(4D0HJHHY0UY*[$G><\
M1H<&2EPX9S>--+EAW4GDS70,82R26V)5TJ! 56()X]:FQU*:]>HVBI$-$5SS
M:T(\+=R^@!XG95+F;"!N2"J#?DI?5SLA>TMN(<?F*V +AR"51A0NI!4)XCT*
MD7/R!R,J1"-I- ]C;5.ASF7@MTJX-?0).5P.H/&OH337T@Q28)OS>2RI7%J(
M'D-Q!<_FK0J]4(TDE3G.Z\P$2_A!&8R@JE;H*&#7BKDB(ND_*T&70/<0H)5'
M(I")9P+8<RJ+TCJW=&<5#LQ4O"JJ0"^%+&U \0J(A391), R(;0" >8#U8,F
M0@>L>8PT^Y1"6B"^C(I7G'6FA4H\<H0W)Q'&V65*%!J!W2+71-*22!<U(U1V
M5XE.Y5"6#A_7BX%SQWJ)8$!QVQ:#U07$AN&><N7BY8ELK VS>X'Y'$ %)C1(
MS<K AY1Z+["U=$C.BOA1Z.L_-^SW5"T>-HXK#?(97Z"-:*G=H,?,TB2%P[\U
MY6JD6M>J"36V/I$E&ORD^FI"T#,A*M#>XR7Z0.;B1>78LU0KM(_UFC$[(&?/
MJ:4 :U,BE/28,3)CVT^A-#92!TG? .HBU\SFCAJ,.H;&!0__,O4Q%X2XLK:*
M#4RS<$25P6J9J2;!@%:%(Q:'TN=F4AU@+R7X%/=&>,XV]Q^\.4_JLY;S-PDS
MQ4;8+RF( _;(TEQL0JF<R%,>Y$-!RH@C*]98:-HFCY63*M$N?E>?&X5- 4V+
ML"G:UC;.MH%#5=G1%=/9=E]N/%O#1X;C3-$X2JKMI[S23XQ<OL-NPQ24*Q58
MT&+4#V,9A#(0QJ6,!2EP&I!'4MIH982S:Y@D"O"(T(<1N@N%^G0()A2SH+P6
MGQ:R,ID*/^@#,!'<1\O99%2191M*\]HRK-$8MJ;,&<2$?0\V=24Z/;TZ4<_!
M<B'.#)EFB*1S;KEE>(ZW3031T=^Z6XV][>U&=_N S?T48R5S >PTUEH**@8
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M8Y9&O"%>&@:LU<*9)V8_H_PR0IY[L"6BF%ULI$?5D)@D'BI[F.+M(XSYL.C
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MCOQ^,_DZ_L(^%;GW4["&VL%N7BO7105V>N. 02S=A7-UF)GR4*$"6.)Y.F/
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M$D$%F7';!Y2RG[*GGF)D]_DZLKN8F=1LRWN/.KZ^YLD83/[]./AP?/';\45
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M2$ %+'P*5M@P!V4+3&0^%(0DDU+$6,#L1Y\'*L&X'/L-)N)*BP\JE4$*2Y>
MZ2)@3>'[""U1S9BP_!R7<M,3'O]]\?Y]OFN;/+J9N;FM:Z<>4O*2SET<ZH@Y
MQ[S!U6JPW."6^+$=R7LB.3I9N"V8A]D]/)V>H7X4FJYVI7ESB@@3@#XO=2M$
M"NI1XU%R7/L*IV5G^]GNBWW0= 1HC.(!A^W2+.5*3'JA>H4;AY5)X,G-H3_3
MBHJ.=>AK\"<R#@[:CU0O:R0S:MTI=]?RKKG 1WUU"$H^HCF@S?)5QPXZG]'U
M-985@%D@HW>.A88$S,],0M(5F6+(IMB"K] NM_/<V(AM.-<>E%^(I&M$OL0.
MZT%#4?R'KDHDLT#<[56J<6B)+3NQ$K?(1,;'[9]0H@^9F$0&-70I%[$?,/5,
M\NE]NAVW$Y(NE9C:1,]08T1D=IEF!-9<3J3-:F6@GD%<$B2,G,32H1C2B0D3
M(>#A<,<G#8J."K?YL/=R#WKST'M'L(=T"0X>UU,4@L=NLKNWO4>5P)L-BJ3Z
MB_B_VYWZN]GON!T<]"5)@78#FSASGB@U',7]QP:?:$_']JLW!V&!9%%B84M]
M9<1;*:K@O6'W$U ^](SJ=F,:_RV6<JE92QEE[!YAN.YWPO;F=.VHJUSCN!48
M'+2 EWKN5L-I#4O9/:-N"$6W<Z^=X02Y;A5W\75>8X/2X:'A"(ENLY@W!O+9
M956OU/:IB_*6AJ&PC;B&S2;4IO5=F[85:D1B89V+@R!0/ANQ=,'K=JP>W Q]
M$H49IZ%"%]W)L<+;8+5.5E&L< #N@/XR51$QSG(YTM0[AD3^<N#D#^REEG^Y
M;I8Y@=Z'KCRF?V;K@XUWSMOX-LR;Y6_\N7?^Y2=_LQ/$*PV6O=EMBY["$X>O
MW_1FP%^YSY]LH/7E.M Z?=L],/#ZY)4]'.M6VP<_IK)OV_%/7K_/J^ _2E?7
MJ=I] Z\/C?L#5NP%YE\1;%;O%KOYS8^"9@_:!N].24>&#CRH+RI'5C]FAK1]
MOZBYSD"5$0* ,+V09'>;81.0-^T0@5_?J=P%A#0%2Z9V7B?B>RN&;F=A9J"C
M&&1B_49%FW/;PF_$+10WS$%X38DY_V(U 0DV+4%-0IU<M\@#/5VZP [= #-+
MT1M_=T_7;8Z\T-.G/=BR3Q,0; 0S&H^3B09$/U!_>:LK3Q+,I:^(!+J"JI:8
MZQ^N:X73\-"9#;N':IM+"^[4V!?A1,V/-%1USCE#M@%3B7;?.Q!*Z5$3^5C$
M1NO\<T3&S#_%7FD[<=V[]^;5N'UIT"ZS>8(I8;/O=*K<3CU4W A3#2"F86%^
MAVR'CIVH#@R*#%M2JR+.1:?"EJ69K@2^W ;)?4!FPJJAK(<%C 179NKXG/I'
M(L"::VHU$U\TP%.'^2TC$.41TVM.BT?]_!#;RP&%.L5(-($",!Q8"6VM4=$7
MV;0;N4!4/XPS) 3I")Y"TE><U(QH'M%WFG",<\1$0&.2?L(.@6JLA+RGWHO=
M)1C2'1GT$D>&;\REBKQW 1^06WH4O/)!4GZ6E3B#QO[!5S:4BXRRGG% T]5Q
M#KL7Y4>?DP\8))7O>>7>IIY;@NVLF(2$5JAGW?RU83OB*+8VW/KFI!9"[1K+
MMJX%T5];.F==.2VT'(86EH/=;H-US *YW!@,F:0@$:EZ/2<K1=!37W"'4EY+
M:AOX/\VP:JHO/&D-PX"W<,\T1IY2[:Q1JG W.N"0"854(-*4QKW*5.+YRD%H
M6XW-Z;P)'XNF117=VH&N%&;]6G_H$$WPBSNT+-,?XO 32%<SK@2DUE$&Q:D[
MEO$AZAJOJ%.<*;0-2+<#)#)I;<(*IV-PEU6)PU-&U1&ZJYJ3WHS,JPL;LK]:
M7NK,V4C2&&1:#X^Z78'0"!#U.:W]GBP CV93PYA!3))85<8X\EY<4^"G4G)3
MD"FN<255,SON8;_SX%V6?=XZAMT],9XT\@9$,8MG5 @9+_'D"#5UL*$]]:G6
MR2;E=]C',RW":J6E3#4L9P+2]WI$Y].M8W\2Q,@Z0'[V:U63F. <[:CMX"QS
M9];*LRL99J^%NEV?B*)'QB^?22L3U3>LUW8G6+R+3#E9.76YI'(#@K 96Q@!
ML8[WVY8RY;H%;54YQ3[\D%H+$5H^'X7B"!,^%X<Y0V7=P2OA#M8%M"# S.K>
M[<S@=>^!HB8BB"W0*YK>W7\-1."/0"H2% %I<5L003D>.GA46!,Y&PX;F50Z
M9_51C UAL*>,<-XX[("PK&9(K:M R(BJL.6(M!AR1+=,C'3G+9XPN<.K=2SW
M.W!M4:%?TK<DO2I'KA80M/K)XK52:F?-DANQGB(^D@%85"-LUY!$",O?V-G>
MV=G974+WYQF$5@_#6#*\Z/ZX8#N6<%YL)3LS3OM5<'3PU&P2-SP&1N:18/EA
MRH$N4,1.GK<@LP.XE9A3W8Y%6;%7/T]S$PO#TBJ638':J*A)+C?J"/X3Q&37
M!DK"V6AL!^!H(2]DPB%Y8BW;UWSP/<4I%-F4F$RM(MWS@+^[0$^G_3JY!Z"R
M]V+/+?LC,QL\^SR*L2&;6 XV[FC(J0*7Y\*Q9XO9'L)2R@I?W\]/X 78KJ0#
M!QF:# 0''=>F&:BQLH&?,"&38ZN2]LQ=>T$[9C4#UVO9F-8@D9O!1K.=>\,P
M=M,7%.N,O=>J4N?%ZLA.YP'6ML:CEOQZNL2]_:*&54,B]WP8+ W"N\%D&E;4
MO(=PI+9A0QNP3\J$H+'IF)?4QFNZ;2D]Y7PNK_O#(08AS.AQQST67@+/239,
MHS:;9!LT4ZA8.P /@4HR5,L@\?1]';$7,]&5J:+5VZJO&S=:]MS@PNW5YSRC
MUEJ(<E.D=W73FZ"'6ZY9&$OG4T+=\AK]5UM\V(>=@T@+/F*/2Q=)F/<13ZG%
M*W5"#,3;E^G@4-N IM7.;0<GPQF%=1$?NYY2&2/;7585]^\_3%D$<H5U?'5H
M'\TVB@#-JH^4((<U8.YSSVO@;8W>MM[K%UU5Z992ZF+U)OO.$NJ,=G=F5>?K
MQ,A[\/3>V#P)R(F[<5:O>NC<%7V7,26<PN<@=!B:(Z6@@C60R%Z4?B:QR*O"
M$))I*AP)FU/JRFR!".5L6EHMY"PX\3&9PA+^A4=R5B,9,1-/0NR5P, H0HH
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M,Y )HF:G=SM)7+C6=6-!Y7,7S++0E?%HE=J6!L&G[EG); <8R8S'D? :>G-
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M0G5!UB EL+%M@NB-X\YBL^ 5@4WK+V<,0@QVV@@^E6IIPR7NJQ$"#JGT4&E
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MY:GNGQ;9KKGQ&H;I'KRWDEA&D79Q_5T>A4I1R1F8KZ%%QN'9#.XV3G%]D%B
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MP[A$$^^Q)[@Z^B?/G,ZU2M+TFICW*:=G9AA9[MSI >/"RV)5;+A:4,)ZOMD
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MH<:2.Z089*.)TYB0I.4>V\)<@*>:VD< 2*5-JR"3>(B4?']AC>^EH?P08QK
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MF%#&=B,7_;:J/R*^# ZSL;<R;@[J;(/<F"-<\'\)=[=)E^ > -CZVIUH"'0
MEKA&*U,M^57NS*N,:IX-E#,LH4-E.ONSNN1.,PB_]05IR'!(A=T_$@A#SWL(
M<,U+Z%J-_P('PYW@H_SQU>,6?R>D=!\1Z),:;=$_9"DM:7,RMF6X^_%&\ 88
MOH(_0%C N39:M4OW!437SP">HO-Q 2DC=^,:*/:PI=]^R%BXW1RWV2A2'[U
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M-Q82;H<%40/XZ6&14N]3NO<U,WNUM#NFR"]K@D\FEC77F#$J1+%_.@(UO@Z
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M^:X%E>*7!<1C:%Y4H)R,1Z!7EM-F4L,!^;+&8EB;$+1%TX)27B0PI+Q<R?^
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M$&_,\X\X/*&5Q[@#/GG? W6L$0X7%:'MC!"TT(+E)<Y$C>%_ 63V?8!:3P>
M6IV1L@,$:1F6.*"FV&#O26 0FY7.[&FP_S&(6I2\D ^&] )9*)+BP+\$7P3K
MB[DHT1KRV-8&&YD;?(&W21./2_ QTSN%%H]" =Q%U:5#[-T?%<4 G+A+&]#3
MIWMTS'1"2N;Q[&V92T0C<+T[)9=; @Z*(;BU838Q7-^$Z6Y(C%J\0Z8\-H+2
MAU%]@?CM$ 5-%P.-FS5\AOQY R+LCJ/K(!L,[7<DE^YZG#+C1O"WUD1C^K;N
MQVVYJ2@1$DD/M6JF?9 PQQBR*L9*IN/M'*@RZ3U,?'&Z!YLS4<JG842]Y]O=
MW(6D<=^V.!WF60UL 2JRW.*M#3ENW5^ B'VYE>2R7P2FO(7?,$P8X+U%M84N
MB0:<B^'61;5UUMAW++C /V_DK6#V!2^%/^ K\ZSKC=@%;S_'\EUN ;+ F02M
M4(A,)QTD1)XO6 K)SZ1:9A^/D&<,LH\YXQX#SO5<0L,="7(H]BDAFZD MB(U
ME9B4Q9TB)Y[SEK[?)QNEK:/*$^].[_LI<1]Y+@Q^M:TR?UMGP*1?E']N2Y[=
MG]OLBF!^63[G.LMZBYC,O$R)-Y2;]"![_VJ[O)*"6-0XW->G@P<$OE%?%E#_
M3P&[**@U0"MU6/U&ASE)]]&S(B.WRA'4&7MD1]1LM(_.5>NFY<;&%U;N:^=U
M'1#>>D>CU"T1H(;OO+.4Z'^O$^4]+QXAMD81J: O/N)AB3^76,^%S102BC !
M[6M"4@+NS I]&I%#'BRZ6FU+J30"^7$E2(R NGPZB;G+>?5Z6,P]SI4&AK(*
M#;I G-ITPFK;;$0=DX>_J,'PQ-S\MI%']9R$1;P56*B'7(/.W;JID%!FB(N]
M8S[3B4[H>(_)%+\^D?NC)!J1L#_J\>(DO!D(>_K-L>XF2.TM)'+M?A'=\!WF
MJ)-[""'6'Y<:0^J&]42^7A[1$AR6RB%<X(QT@GC5U49"!VON-\^"CAT2A'KU
MFG-W,P*&;2=XB^EBYDF)-, +#B_T8X7D-4UTCD>@3X]N30?[,;3<T8T#!JA.
M/ J^FDO ?(L>;FN!UFR/P])E-WNJ8[_H>"^@EIAO ,9[.!3SM0:MGYU\"UK?
MFXEVK02E[JY! U7V6$V(CEA^Z/QXBM)TZU[IA-@<A< -^+M!B=$06 NB1M93
MXL:M/N :ET?9*\I75JZP4Y!X:P1U-'@E#.^_2B&:7_<]-R#9.WES/0;9PT3'
MOAN(CKU*-ZF;;G&3S@\P*+8GDBRG17CV>_62-!:9A<R/$"E+:RD)U@[?._!B
M<$5\(R'"G!(\Z9VT$<#%TUA9EGLQ+=HO_"K94Z5O=L:ITX2>3%VY*$251!F(
M_'-31ET\PK. 'J@W9=3TL 2?OD@,C2 MO_/V# \G*:#8,>K:3 ZSK+=8E)$3
M&:$X?+Z;),2GE0,LF5VA0RE>]QVW;SK!33%Q46XYVYCG9O 5?AQ^%?\@;SJH
M]/RP"XJ;.)UT[R*P(MRE'!@\/#A,[A_8))48+<I%4:_RK/N$F_I$='@7&$X(
M>I'YWHP2F BN3Z)DZ7N/_36R:V<V(VJP!N'YCE-]RD=GJ+EWX9R<M*FW2H4
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MV$D,C["/"_"GY)UIJ8'^AIO?\ GG:&T3H)7Y1NT%+.^?,.*5D_W?0R14,@(
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MBUI%C/3M%.ZUMCE)M26JL<#O\G$.3,+,]*$Z^]11-+"U3G]%^VH,=QZA.>(
M>TD-2WM3'?WV2.:TJ4JH$@A6%0NDRL#0>R^-+S\1?0\&?E;!W4BFZXHJO%$9
MH5K&/HV77!4'K;0I3@:T0%CB"$."(RTF'B+J\QD^ XL=5@6WR,1B@'E)7]HX
M6'"0JLFS/_-\"<^R]Q-O&\%BX.X7NI!)CA0DQFDI*YJ"_4\*XU?<*82,3#-^
MF!:8^JS0L"++C+9>YS;>E^S]X^L7CM)ZWW.I3JK*M5__^&4?#8Y1 1UL8&0I
M/Y2>$@QW:?>=BU':KS(*69K_1$=&_NQ;1F6\>:</Q/;[@6+J%Q,0$S'>\+97
MZ&95  ].,3>BK2GKYLGYIEB(Y1J$5ZAT,=BZQD^@E)'4J^NFXE,"A^ANXOS?
M>/K*!1X2 ?*G&T]O"YC?\DL8%2K#M_6M>'M0V5_EG!TY*)+P"IE!5X[W2A&/
M:GT0J@IC^Y132*-0U19B!23X'UF8#6NB.[FGKCCZ+M1M>]. ABT=@[T.!UJQ
M2-(]'N?B_B+U>K0L\T66/MYX^YNG>/O.\7:*VBB$Q&5N.TP#:UNJ:OU2"(%4
M^!_<>YX!N<#RUD!\2Q]V#_K'+9/;(4OZ-D<+'->*SN1'O BJG(VA;+[\V9@G
M^&$Q$:)>U^X<<EY&GT':5*);I#?P&[]BA,K^Z#->(O"=$T*J [@=H3RSM.UI
M_US7E'R F>#?#QG=(8I0GEJ1PV+_[A[-QC1HGXR8B>F;@*:@3DRQ-;)M6;Q[
MR3;(<8@L>#S!O/K9.E:OB_4PHI8NBC)NJBP_APH)+[4'6<J& $*_-M=L8[B^
M!.GF>T=Q[4I39A\ &.W+&L"7C"=F7[C( >(%> K@8* Z7G0IV4*=0,2I7/:,
M>ABCLF&@HN4E=JZU3M45J W..@.8!)#65"L^N.8*<_^P/;WJBV)I([B.=M@S
M4FT2R%ZPA=\\K.8R9TAAA*O&&Z-:.35B^X 2E?MZSR639U=T1"FT8+PYN^%<
M=?F!09_P3PHV[-M[W;<WHE786$SN28T#Y?;IBXAT"-9(V 64&US_T_5L6IC9
M$X^"$2($7MGB<Y3KCKRG3R/#BR.P6ET<'?/2B V8D4L"8;9L*N%3V;;<&"(A
MYP2Y*HFF;"(EPP LY%H^I#)49/O9DH"%%!S&+<&OIUA9+LX559<+ EU'4%84
MP<&H&/.H"WF44ZX%9.,J4?EH4G.G9XX%@73DMD-B<P'ZR]DH;UW];7KTWKBX
MF?="*"U29:5[D):5Y]4Z2GV(K71G_$BZO"Z#\!5/+VK/O>=EUM=QC[K? #AV
MSK?UW$5C8B<[!/.*JV[[,5#** 6"!_-ZZ!I<Y;:V(5"?Y* JO]B(4<P/+JLV
M-YC/R:9& +,\LWW\J%&F2*Q.>2*/KHM22"1#8/-KZNIF@QI*B8N/H:B(-^_[
MP^K%>:B3I\#'NSBO)21B_L-2BC/D"6F-1US<4G,P A%/]/F*8=H!,8YY,-H'
MJF *;+UUM2 ^*-XCLWAI<O3Q+'7V8'P1;74>9;-+U(:S*S>&E%^9M+T1W=E<
MZJSRE1#88_2G/:M,"I1"X?@&S.OS@_"W%!ZAC-J2LCR !L2\NAE>#; !Y%Z'
MI=X/R>SM(JMJ/#^69;<F&M!R>P>2;L9C'JJ W6%42VY)J)"03;!FC*1&$9UC
M#/5\,;Z2IU,7-'6*ZM13A%"ZH 0EU4K3B9(=,PM>XOIA3*2K."!+9MPGVEPY
MJ(WQ#J,^\"OSR_\A=AKD\)),7DI;("+9!"R1 R/L-8SFJ+GNO6DHA(J]Y7 C
M1;,-P(;%_KH%=>4M-I(++-2 W8G8H$X<+4&)OI7<4@#2!5.Q*O$^P")#)&5%
M)@.\B"L,-H+ID5GYY\/0>@ "%B"P?=T^&ZD =)HU]K4B6"_A![4T\PF$$E2]
MWQ9!$*X=(I9<7\*4$FE9^K;;&XW!#/O:T-0F,K5)JG2!G1C"6.<8GMMIW:&R
ML\08F/P1$+)<=JB3JXK&'BTE9ZR0JI'S0UJJ1%>L9(6;J;L 0J^>WX9=8- 6
M5*^01^' BAIN7+/.#XJ-OE<049G8;:7S!''L8=@A@I&BO%0-9--K/LQ%61@]
MO5ZR4L2V<R9)6:D$S)0<PS5WNF=-(_9>PWG5LB/JB!CD?",-2K#$/\$8?-T>
M@=\4;-X3G25[\PR+9W#UJ>*0&'$AC0 CC"<#+$E)]]OV799>X]YBRGO/C\.9
MO=Y/ZHOU:F*&AZ<)0P94 ('_-9$V9*!JINN:HD_278@0]9'BY4W.(4$W=UI]
M#_6I%R;\4*V0F;ALR*.-A[]]BH?O' ^__BG<?.;WO5K>39DWD&+0M._-Y<7T
M83^^ZK2['%[$L:[ :1Q!:96C"A5C>EJ@ZV8L PJ@?<L(O4QM@NJ4X3GTQS6U
M!9S(7QVP1S Z01^DTF]6W\><X#!VRB/FU!50Y%6</%\T(E-0.-F1(%09/;%C
M:ZY;I9 Y('W'?V+]&2$^0;$1N)N)T+>(9_2*>FGL-]IWG!LAI2GTBM'<W<-B
ME?G*:R(VA:U5PM-BEYT\, T=<E>LKFE('#D%.VWN9G;G4Q;4GK2P0X-V.'@1
M#Y*SSI,6J2&0$>SQS:6),X@_AOZY#V9U3C$Z;9;3A\J\EU 2BNVDRKZ!ZXG.
M@1GZ6/Q</H+@.M*QFQCS!B(0QG3B$R>G4Z7=[%&K'6YYEE>Z3YI$*&!%QPWV
MI6QAJ0#\T^""63169\6Y<\B;).HNIOG($\V+_S'*$@8UR;EOD:@B]V1SFMD?
M6AE;>T%D[WU;1>U3BP[OJ/:C-.EGL_$CC=H7M@.*YV[&6DAZ!]2^,-VD&(GD
MH)"F P"--Q_- F8 8PG_B="34B@ 'A21D$.G05\*<R%"-Y[%9I+-ER_,0_NU
M)@ZJVUVN"VPZU3^X%VUO0F4^&KQ#8FK[:D$*U(%='Q)14%@CO'+<JDWLQQ;<
MO#YA@F4-\2D;O7.BSMMR7=7KS/7&1=NERM:3Y M4+UUUN &;4%@A"68J%)B5
MBZK[^"Y-@90850U5]XJ=:!HX^2VAIN$@<L5#XH;IXAEMVX@9!*%?A\KM'=+"
M<+MQORD<@S3WJY0GE'@T2VXXU*)6_14.1"I4-=PNS=@;BA#J&Z]2VL@C "FP
METAP;<Y<J4#/N9A?PY7Y9QZ5BQ#KO61IN?L#=]&9(E#2Y7K8-]F*F&5&_ 1@
M#I%^!U+E]$=9F-V!4#;>ARX>)\%1":$:3711+#E$[< =X[71_W,T FQW8/S'
MQ55M7L2=TNF1%\X@-CLXS3%4B&!.=7)PD*N";!#[4V$QP0#*Q)(\3_.JP@?X
M70&Y$)=294OC-"(R4X,:6+/"E-+D'(B=*1!?7IDA7BFV@-I&I[$K E6+8^B?
MX]INHNF&:=I2C FNT+F63;]HCQOEV<? 6@O3$9=7BG'GFF)OJ+L+O)'[D.FB
M5:8_!1Q4:4.\ V+>?JJ:62(5QSFK[UK57=46JBO_Y0I@2A(T5Q!1,%\XA&W1
M&6L<*#3*&#7E2X(1LSDE1D -YM4<GJ:*35Z_1 #7T0&XN6]_^'ES#/+%JY?/
MLV<_C(S58J'6^,Q15CDJL9<O_.<.!Z]>O<F(TA)" '#T)#CN&G%W3,]-*Y4.
M+EO5+ZG?R*AE>?!4%_.1N;^9687(&S53-+6Y22VCIQCPVEJ*F]L'P\'M2IH5
MKZ2G=#D[HF9#@K2>5HBN&MP'?3/GZ?C"G%/ JL!)+RNAHA/KB?!C!-43 )DB
M]6O/UCL@"C/D:\QDAX3#Z$$ 123<;5P;'TT1T[055)52114V>2\K5;9^X?5&
M;$+A&< %68(>DQ6+@MK<@#W!_+"6'!8]1$TA"V9M-A.U+'/CV"Y$'TKRT!%?
M5T.# ;60WB*U(1CK1TS!_<-3_/>FKLT_^J72;(QX0RA7Q4L07H2']B(3#F)"
MB,TD94GM R4(J6,M\E.J9<6,*J= %,OH%_[2/]8%->^&H_7%:*RYN136*W29
M/^J"DC1Y^V/R'N()I_GY0?+RU0^O7B1['[.KY W,X/FK_03A2!-Q]SI T_BR
M)F9Z.&B%8 =10-U;4LT<_Q. +!(UHYRVM"53U,**%T%YLVS8MCT\(/V[ITK%
MEQV5BK]4QH$"2"ZSS*TL9]07LWJS69;\GA<+(WSGV(EY ?;ZAR\(LI1Z>&#1
M&;%E.^-.X=1)@1^-) @.3@ ) DN00,2%7KQ?L;W%>S9L9+5!GCEN,0?TOQ6
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MY+Y4^3/F8I?Y&<^C*"<>HYN5H&CW8-HA!\/,?3.3(%R2'>Q\5"K.N?DE=)=
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MJ[WB0?L*@<T4#]ZF^:$=T?[>E2HQT<_RS)ZHW>+T,"$H$7#G_P13Q8(W: X
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M-U;NRG5RL2N$,P86L9B&M-1\G>%MXS AK $X3S@J2[XJJQSJ!>B_*7H!R #
MD-3CBWRRGBF813*QR#)PT2<,&LK-\A'*8M4H=N# AX6C^:AL?"O:!'2U3RC5
M:-:5;03( C)/ SJM$QE(MLIH=18 ^R1CR?F'Q:KE]LWJAD1X;M=P$$K%/+O2
MGA/,AV$487D@X45!G5[29B#4 LM.2MDC,.<$=C[+M<W8;A\V2L8/DD_E"EYI
MJV6"O.DB+W""]H@8875'9$%&4%$I&V8XB#!GC!2@'KU$!,#SI3&V@72W =%A
M=]\.H(NP"K^ ]6=/U5XZ?J5U45?K)=G(/G<'"D]D-T-_WEZ4U$;6N+&713GS
M0@]>2IP<@5Y/1Q^#O[4GI0(IN=_:PY<ML:*(Y5<@9"/SV87Y$)%1;:9@#HJ-
M, ?FA$PP4CLS%\X"I=5XEU>]=@JQ0[MNU3[3'' SW@SM;EP_M+L)N&[.P"P_
M1^._]^Z(#^[18#1WR-<@I2(O\!(5$*;+)1D$JP-DW#4X4+A4XLP]*%:+K^"-
M9*B[Q2UD_!/($9Q)?=QT18J9^3R)'NQ0H44UEU8OB?3UCKFV6Z@IIT6@=)^&
M:?YQ#+DA>J8$%_ PH)A@8KO@0T"9VHE[S@H3*)-(F5M*""ESW4T1:F@>"G$X
MI3*ON<N[&%E=C%JG^3F0)M ZG,&]8)?^2U5^OU*?@1N*I834$3XY7,+&9S,R
MS0[-G567Y8**I:RRY(@3U];.9@A4D/+#\=IM:<!%(G:7Y\7:>X1VX@]SRZSP
M'3D4\IM#BI^ /'ZGX"T-? ]>1X%",^-_XG>"R<$<*&RX#[MJG@@!WP7[ZH '
M)14L3$X81,C) J18G*N S"E/-W%Y8]< VO_;WGH!B2VJJ"@8D5ICX-0]3XA\
M@M\>V2R(:H+<^5V4;J>U2,LS/=%DG_$=HW#=:<IVB2$< 5D1RJQ@NOSX2-'?
M@/'C!,KM@?G'>[.0?9#3KU.Q0B%00Y$T\Y[HOKDS23E\CI@HGAR0!E1":Y#+
M&1EP;!2&%;*D&,KI-)?02VU$/; E"R/H31W%H;8]"@#%U\#GBL)+40HIR.Y%
MX*=4Q1"9!RH4)[SQXZJD]R 1OZ3KY,!]"3>?NM%'8$VJ:_TBX[R(?J4QS^QL
MF*5EPO YN,M<<?.9 Q8>CK& TG)^X7\[I4"H#5PV(UAB79L!(%HP'(#:>?=:
M\\1921D!<YV8 P7'EFFL\-[(M[TRTL2#A P'M+W;+JZ-S'6L\SPK9AWRS0Z8
M>E;M5'"]>6$[%K"H._?0[+6WB0>A<[NN.R<6<@IH$WZ4<W#<,04H<PI/C,:F
M&ONJ5DZ7;WFU6!*Z)GY3+;RW]<,!O EU.QF+--OINEH4]47#^#%O'N?$7^=L
M:D\\8"RR7R%'2VL  97UHPVSOGT*L^ZVDN;A^H;.:G;)(JZ_U*+K&$+D)%CP
M.1]#SCS0A<Y@'U:\I<^@):9V5#&![V]_1V43]C(CXB%[EPGXT6;,'-( T$QR
M&8,= =ZAT1Y& 4RG88(Z[=)EU@S 0B!%58AO#E/=K;-*FP^*'.JP-+<M?.&X
MWLA#$LO7BP-J%5HN(>:U7H#+@ R/ET5.L2DRYYCB"ZL#?_N[N%UP^Z?PP47Y
M#0H,Z=_HJ:%J<_Q'FK3.[,Y58V'\*)8SEC::F,;E<?9H7^.U<:-DDTMPFMV2
MN[L-+[-B)6&^6BJ 7=T.^X7F0$%YUZ)+6L#P'<&(<G7QE4+\8^56RS3_QCP7
M(X[LY^DKA@ CY9)B;22M];I><JJ4QT< !H4SB=FA^%C*1$9O-D%$E!49JP+8
MR6:YI*?_,'=G/2G&=,!Y;A(T'%W9$S?U)LGC:5DV3M_DV)J/)9%CMU1U9ZU6
M"LCBR^K&VUQP58E;/].*!<0>HFTEI&,1/',\HOJTZ:L6(KGQ=3@QPR3Z2)3E
M#H -?JGMR.HV)9XR;%%=R>$4U+F9(M0U,G<!EO=IBI :(UJNGC'V%NLK8PQU
ME/O<UXCIM,L<W!/B!7<+88<W6'*$BN:(]Y[+%5!0%[0?.XL$Y#"GS3U]BB .
MP9H -2]F'3AG29:I!__ KWAN!Y8"X.F7Q[(\0!S)K, ,T#4B81[5+YO#UN<U
M"MK\#*\B)$2&L<[R;(+!]17'Z*[X^[(Q','2<B$^/!\5IE;VKR()]2'$$! -
M"[@CJM+('\ZY9<\X68L47_'7CG+W9LK66#UFCH*&[>M[$=3M13;9\7[$8$:(
M<>C@RT5RNSHGH-)$":+3S&"M6RM>I33T'X((R_7SE;M$^UYU1/M4^*Z6F#JF
M\?@?YF;!BH7ZX:5;@YO >9>0?8"K@1U[=Q0C)&21K%_0C1>8T%I(+(Q43-9&
MB,]!6_+E O<*$NZQ^P9K"QJ$EE$.>8NPD".,7+VWZ,<'L9C4WG::,K,<K9C\
MI&V\-MP;A%.C<^N2+2]89<SE/]CV=$F?NB7K\UJ8LF&ES1_PH_$^V;N^?(!Z
M))R(-Y]?RJR:(&$'6:-@QF2K]CTB"I187J)7" 2JXL=010?0U?:70+R:\[33
M[!*-.C)'%/]*+#4B,19+.M\\ U0KQ^R,,"*0A5S".QV[?'-;8V,@50[PNTE>
MV?ELS/,)0;S:7O"'RP5$_<MZM63L9C;YHP0L?NL:2R=MED$%)W*[I PRV9'F
M44FV."DZTVM-S%&=B\-@G(&R6L]A@?X#TH>N+ 0N8<B5:.%2PT/#4)[HHJ;_
M@4ZV^.0$#'=7->'UI8!AXLCE\0C8B5P@60KA<\'/(?6#H=09 >!)E0)))N1V
M9_DYNO1K8_?.TFCO!%9T]O[EH%]3%T]+C@3W&34^T[NVR00'FR W)UM;I\%Q
M4Q9UA[2(PDIM@O,_3X#-Y>3O!&;OP^-N[8<],-]HS!Z80-C:54L(PK,PGSLD
MN:7\95%*K1.C5%#HV2@;#N1 X <ZP,D8.BZF*2AO3@193N2LL385+#0#M1?)
MW@MAX/I%4$;OLJM:%1:Y*%6;B97X#2C,J\(Y,&A(3:)V&1,7N*!D_TJX0R7]
MUF,?>?E=*=D4[LF]-[&Y^4(2(J%OY=Z:9U?J9MFDW< =;9WH>HDC_U:Z$O(5
MFEJPM_S']GVEV#?J&.S/0KK;ZB'QGY5T'\12(%&T2 J)P,QL70'5'UE=U!JI
MUC4HV1#:;MY[_P@_VG#Y#T_A\IW#Y5UZF\-%+J)4RXFVY:#)@LN+51Z&HW
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M5TH:HT&6B*.FK^T#T3(6X-6M>^_8^>Q8G./,IW?+VR'EF()6L/1[&"F".!R
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M7GC%-]Q$CYC',WD9-O1HUC]W6FH>POV] 'PORV(B]#&3<CV"M()M;^5;\A#
M]9YK!D)C6.1K<TE(3UVD_^TWIHWTS5$:DJUB713:L?C'T"A#]NF"4.I$*TO8
M0T'Z8*9P-Y-< )0;0.,$K P;QR?]PRHNK06V/2+UQ/!8L!M+E"/FM^L9 _V5
M!;E%S"YMBQ:2T]!SU_M21Q$U:6]$#QP9YFG'0X*\HKH%T\)8KJ";H'MN"T8X
MB&/3@GJ ROP[D%$+OR+RJ%BGJ>?\K[79MFLIM-^;=9H@A+QSQY>7O+:Q4Z$G
MTHV P%J$U7262H.>0'OTC B-3"%-8/#<*8LP&,Q70X$PXDQA%+GC+H\\AT)*
M[D'M&1>)37A/&@[LJE)24,)KXW(I;<?!B; E59"Z%@53MHSJYV3O2K V4T$%
M,X5HVXXD2VYI8->VJ*!_X)AIBM%>KBGHKIC,E?VM@X/4_7)BF;QL?$/BC' [
M:^/<7'RQ$]4='9:2"A6B\? (HWSU#31.'-*Z5_"N>K\17%S#*M[?;B'-_8EC
MPRP&;3QD=8Q?1]TI<5MMAZ64BS_H@CY?&TNDA#Q.ES"V;<-2"Y0+C!=SKF7Q
MZ,)=1=&,GD3-F<S7>H6Z];/$-Q%V#C<\K[6T/S[<[5!^]U78?^,L"[I:K#66
M^<%P?_.1/3$@B(T.@?(9_V/560_1C$0'H89H&]UKPXCMX4+'5EC? R5^.VP\
ML)7(^C9V9KURMB)(5=]PVTV85RUTGR?@9UWF^)3C2XP,W(3ED&J_(WB8C?9T
M)[J"V#*^GE3\C<E/CW"S#I1L'B]%O#%AC^+NKKA^8P:%"_(('9C%25M,L+1K
M)FQCND/S=@D+9CM7<9^-5L9>S'OY),7+38>%RT)[V26%#E)A@V+.5_1>+? 8
M6DP7H-H3;)%'P$S95_D^U0I9?(47-)/MQI]N-H6I&#A^=5_;&.ZP'E-G:;:<
M7&0#W/;XD-5*BFMJ!&KOS7^>_?;%Q>:<KOSAC5&=EX B'&>S9QB9^9M1N__G
M[ZN+__P/\YN_[R>>34"V %JDRY47:\.81*N8D?R*,;>E)6</:(.0I.E+L F4
M^Z=\.(AE><D#KVV4V+?Q/  :(:-(+5$9;C2"OMI%VZ6-'JXQ3?>P2G6<*W-7
MV/^PR/\)^_^$_;_ER/L/SY\B[X\%^R_JX1%A_WLV8M\)^]_GV0\&^Z\'^[\4
M^^^,]OO"_F]]OSYA_YL(<^VN;87]#\_K7Q3['Y3AWR'VOQ$]NPGLO]ZU6\;^
M!ROW5\'^]Y#[!XG]WT#RU.@+Y=.0W3;V?[(M]M\.;U?LOWW _R;L?["I]X?]
M=^&0 /OO,0G=*?:_I^F"Y"6%=#2AISN^BBIK*O!6S'RR(V3>8<+O'#*OM9_/
MU+$-9KY5(=T(9-Y5%%P?,F^4U\UBYI/M(?/!H;T+R/QPT"^)T=J$I(F9UX;1
M;4#F-80R#IGOZUH$.JD/7#[8(HO\Z-MO[(;@\KG Y7O=N=/;Q<OOI'/$$'!P
M^8#RMATN;]G&;A<O[P;H.,;O/LZ=]\++!V+Y4/#R[F*\#8"\??I-0.+#)52(
M>*@'V1T2[[?Q[>P(RYDY OO?"93>66=-*/UPT(&EWQI)W]:;?&<DO:Z<<DCZ
M&P$/=[&1W2ZJ^M&F(UX\I2-V[[9K"1(?(9)^.+@FE+Y]BO> I-]@Q$F+V9VA
M]&U:L -)W[^3[?6A]#$K?SAHQ=*'%MLF+/WNU:VW#:7W044,I3>^T=98^OZ&
M9=H6?-O.H=@!2]^#\A+:"O<$T[?S;0=QX2VQ]'T7X%K;'0'3#P>=:'K-8M &
M<W,!?0&M^:4:K;[^O8+IAX->:'H?OOL P/1V;;<%TYN=W@)-GW2!Z7N&6_N"
MZ>/]IWN"Z9W3%2YDBVAWH^F3QP6FWPA+Z@>G;Q_@[:/I&UQ@O=#T0%41A].W
M"V<K(+J_]MT%3G^W$91I7SQ]LC.</N\-IU=@P9O TU_;?-"]KX.'71=/'PZ@
M43ZZ*Z"^I6_5CH!Z[Y+K*?1;XNF!/N=V /7N;H@Y,1V ^BU,DU8\_489$W?I
M@2'JDP:@O@]_?G] ?9L%&2#J(V?71]3W%,861/W-X^D=B];4VWPK9MY^WQRB
MWO%]A!Y%'%$?I4V[-J"^$6*WO@KW-^JK</LCZN^T[.R\]9K\"IX[8VD0),,P
M[054Y9"1)ZI97?6MS3#,Y;J"@PQ37\"#S3.SY46=6#Y_:9)GK^XMJ; V]RT4
MJ9:TR![I'Y24_-+")<TGT-3(IKF]'C_[RO4HG6,8=(M(65;#/J!EI>3:Y;,
MQ&[>"IJ^<&W1Y#!,,5_C07=[A_H)Y(&0".MH4O2B%[YP."!<_56Z$:(<'KTM
MA^<ZB71Z$[PF:0O8K\]H4]^_PFSJ8PW OWP*P.\<@-]P=*TJV5)+P+6V+W&B
M$$S>=OA5&,6\12P^L994D,CG=^Z81(M'P3ZO#1#;4T<!HI7]QF:V!4L=UGDF
M*=F,IQ)!O7A37[ "ZM(I8&US0,(8?./\(#D6XI+X!:,*OQ""A;M8%W-H";G(
MRW5- 2+9%KRXJ KI^M449JG'QOUGA%8^F\9P#!Y8U15!=:RTMXE<,MBN6\F
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M\G:NC!=(I:"Y.4><,/1TZ7#0F [G]2-C#:UKB&)A@LO..S=V6\&$H;!6C8-
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M*!6O0Q/2C$!][ Y _>9*P.CF=:IO2YR5=+Z4M4*GE)Y)]&5V(0EM?K4Y"+$
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M8RZQ1H6[O5<)6,-4IFSCWW2*9LP<E:W<ZY#FDO!5QGK@FX'IX^,"3C:N7AH
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M^G"<_+!3P.0Z;P8XRN=/[TZ^GGS^=)9\_9P<??A\=O+I'PF&Z>XZ>@/MZ[J
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MR-6YW'TR$II[%:>T,+?-RK8<H/+' ,&&)911.B'=A8"1])!"XP-JTT3[=J6
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MN"K>H6:Z:YP 4DA>9V8C4>+/>9=NG8 CJ UY9D05(]QLNL-2NCTC#ZK()_>
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MG#G'<2*<OL*J4YF_Y-.?$T_+],G(8MU$ _&90%NHC3 ,*)EV1HFK(R 0E1Q
MAN_2 9@U+W)RXR%6^65037U*&[K$TKYYNI=6.T3RB(JA^?".2%]*")XE\09[
M60^W7M:5B;!J9:D(0Q572BM#1%L]RAP!\0/\)9A,]7HDC7(0MW/$ U-$4I&O
MDY!#G)_:?Y#92[&G*R6Q%OFGLJBB!9%T0EV*U\<2BK+YE%:*A1C4H$KIYCA#
M_I!K!0MZM(HBCT@.<*;G"<>NH6+!AQ5)??81C3IAH\7ACK@UE18AQ:PB;RC
ML_#SW8Q4$@%RQY@O.HOI%. > 4Q#A(\JBP3%9'*'?"K(\MB\(KE'!]+.YW X
M)]5YSI3SX_8B2I3'Q=/-4O(Y>]&,)C+AWAB1 ]$,=E8\+1A?7+2#%D(]1PM
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MPO_V)G<3K#*>3Q5+;_*W*-9275;RS5$U9KI)#1*5H3 WL1@S=K"H.$YHR"?
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MEKNI?OMTTFE<P<5F[ZQU_ ]02P,$%     @ H3-+5:ZWXM\+<0  ;%P" !
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M3X]5NOB Q@IW(6=K'LMVK&D3X/?ASECQAB>6E7$/,7@1WP&8BQU:, +EA1[
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M@7?8: H?E%<IK9==O!(WR7B0%WAI^FNYH(6$F>+-^$K)AI:*T,[V-GA0-&Q
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M%%,]$A>V^4Z;?]1^@D:G S(G^Y ;0^VHC:]3VM5>,&A1NZ@*?83Q"L"%C%9
M,[6+TS::T8AM)RL7#FWA!24Z5($<MZ!51YO(?P2HX=+(=A""(UK#,-+6F64D
MQ->W0ID+NY"SW)6V/<,Y^H7WEA ;5@;?:67P1]5*#5X-Y%4[&#GZ+*.1LSTT
M1A>B/?5#]&R?RKO()LEQIN"0M+% @6C1D%':8MA0B$XV;90O2!Z7VF5)$V;&
M39VE/ _RKOY+Y35DH*V7FSI;:@.$J+JT)>/9?F+OV5"G-C!  W7DLRI)VG71
MO!NB.90'Q43(Z ;9("WD/W.A6$*G!B$-0> !%I!'OB-1!C*: ')*4T?"0;W
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M0=$V4)P()35X@GH+\RV<987QZ?D95"8HCT$"3OG<M&EAP:NRD?>5,H9I77V
MG2ZK$I_/'Z!*PPUYZG"CX";ANSF&%4ZAJK>/2E(F(K*30UKBD\5@800*Z:W?
MQ'XN2@MA]$0I^/8.13+VD;$UL90N#R[T]E=MC?YJKE22O#]0*?R4_$8D//W
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M=?$<O)ILPPLB$%B@*>,:733 )@>=+O#.,_]\ZOKXA/3(B+14E.]>5B:V[E0
M07'3'1J@!@0@6S@>4J_'-2KQ+=\@D]33T3#JSS6D]<.7D-8U(PB:D:"JE5C(
MR4X%B8<LO*1U.U -$#KN,-/LWV%FCX-G<R*+2C78P+8 Y@9:7I%U&\EX[D@3
M_RQ[]'V7)OZ]:]6NR=YAD(]_>/H,ERA;0;?XN>-2CB=C\+J@)P,#._A/]$4J
ME8((4T,-*P92.BDIQ2T,])/4/;/;<T3=:I;G;\^KRTN0V,8N<IDY.F3,7<G$
M"(33A2[OWO,.8BZ#-[W7YI-20_:1!]?MA1=9@8EE7F+AZXPT-$FPL%L--0UN
M42Q 0(0R]X;BA"DQ270!.1TC9I 'I_7PO!@(\)V!N^^=\81Z9VC;P *N9%6,
M4[KG,H>67[CLWKJ%<EMYS;>,-GK<JXTZ)%?.O,2=[&T*)M$X54K*7:QT3S!(
M6/J&Q=8.-W&?$?7J5(],T(<[].#B(>_8<XML]9CB/B5V#ER'U-\/W^"&C!TH
M.B$=#'<W0G/M]PG";_FM@I);6,>P0[C '7+/>6$C+]ZWN*3<=9[5YJ:,/,88
MNL%S(!)Y;NX+G.4E6'7XS,=/[$-5TR)-K[[UKC-/?@1%PG+=F56&U6R4 5NL
M5OD<H C88E48<>!+MHK1WYJ#W0HY%(>>#;@%3S(2M(W"S3';;F&@5\2W>I)4
M$LWB':G=%&7<5$[2^MI1I</[VA$/M:WFC _MJPQ;+X[(T:[":.FR>R5SX&5"
MF&K&" .T7W&%Q;275XD%]6SK-S/-S3<GEFU'Y""D)A:&I7D>0=A.\)8OJ\3(
MED4YXJ&.O+SJT 2"^5@UK3%WO4\,WR." V""0/0L.08+D0$$Z,P=&H/^-+%.
MGF4A-]+>K_X27*AF5A=3$+)I=9'?P\5L3'!2V,&=%/:IC%^+L>D!Y8ZF?'?:
M^$#2Q!W2?N\BYNNY[NF-&1O)A ZQ=3L&BWUVJ4M^=N.ZY&R"#A43.?Z&)F]A
MVX!%C@DU#L.3FS'?J?#XRYGI/D45;A<@;M;.2^-/HEI1;.4@2B,2$".>%]9[
MT.9A(HZ@JH4P]E1#QH01?S85KI45H#%!#H>\D>45)9_DIQ1#07,=[]+-NI97
M1L'@!PYNU#GLZ?S1TVV=PX1MKKL1T5J8W0Y1_(F<C"XQ[8&ZK_&H8'6L#%;L
MLJ28HEUW3 ?=UAZ1*',SH.AXSZG_H# =93.T$[M-Y,Z+M0=E$^MR Y0"D\\7
M;?7XFR^QJ4^E2Z>#NC1U-6>4ZZR+BPQL?'.T+K.U*Q/FAA;"-FA/!<B[^P/$
M5,_,XH/CTZ^2^C0!HQ!<3ZI\L<@IA,3, 3B1,TN$T#E(1L6!FSPS9ZGYD&#Q
M<X9A$W=^O+,;.^?AD;8FF.<N.IS3?&.O:^C3D5@F@XMLN7$V6__2^@M(G5(M
M00$BK#&]X*P"XY(!CS8^'Q]S48$O*#QXVU79#EHK1?0*+?NN0V<EWK_Q:-4'
MM7EUM2BX8QMA7V:0O+>Z#>>*<[2K>=.I)0<V*/C^RACLQHZ=)<=&Y;97T/>!
MF)4:+T9(ZQ!^.K$?5OYVT:"+,;?8/^C=4,_I"B 3[N"C,@5V75R$C%/NB_$<
M>%\TCG^.UD5"$I&3?C7T6B/FO?)H Q?<9+ZB]K=FH:G<<D&<3BD8D910.<?P
MD^V98T\!#9(R>O_1;+6=HPQ1=(P-H:I%C0+GN#M /&_G^?R,W-RB+<Z$BM:J
M Z=(PK,X'@TLNLX98:T,TK'H\&B6*'XM89"1NC^*:A4E9A'A=\0M$T!>Y[FV
MZ24>'0;G0V;B9V DLVQ[\7:H/\Q(#_AO0A(R]..0C0MY!]_/S,*!B??XV1&$
MPL_J/&=Z][J&1](/:-*YIB)(\,IA=E"IVB799N9@>0 *:A90.]Z*VE)6?1QJ
M@QR?UWFP6-H=>@;F$;O>VDVX71AA$:_U"+\:&:X+LQ]&(.@*E3N0;/CQ:,"*
M;ZI'Q.(FECRI25J1:577&,D0NE(9*RD#-=H[L #L(3>:ML%#8Q3$9A8<>K0!
M#B"2H&Y_Q<D]N9W;9(K]#DMH'X@I+7BK/)BO+SJ>F#)):2GXDD,T(/\[@M3K
M\V]B-/>1B:!*W^_*)S$7QL,;W>1V8KTW><^PKW^;GYOQ]%WAT+J.S@==F]!$
MO< ^:W,; [SY8,B9]KS+7K_7:11NM4>H$/P![A/;Q1;/__**X_IQ/(>YR XN
M]%65UPAQ*Y%Z?XE/7P!"VKN]L)]>;BZ-K*&_3[;I< V;H&]5I6^X:9F^OA%'
MV?0=!-9\WVBU?LO,? 3EPOW*M9+!P,R%ON&[\$:=9QG8QTLA:_)M)64/(H,-
MT\?9J]B:'=#6'6PZ_]N2J3<JK>1,*YQ]8[2HFUW*-A$^Z<R/IE_RT&0D!CL)
M>/O)11L<MWBE:)I9@V6T$?#.IN'!L.B)""4'[;E='V'\D#F'25N;0L?+>P,Q
M(4660L8F["2;J\9AXD4T)H?5#Z_H77BX8DIB5XZMSS;,\OA+F*4_S+(G)"@J
M3*H&B"$EKO!82WKL L=J PCUSRHC_ KA <[(12'E"PA#1'Y^<SOGV1+^BSF7
M&@.%TZS\8,2TAI ^H(U0SUDMPQ3SC&*&%$LW=DH,1A21S)O-LK7^72?[I[NY
M8NODFFLRD#U'(VG\U+<B30 #BK"2Z+&$(<^?[C\9,9M8[*6 M:A(HY&=4_B8
M&+WM(LI4N!M\QMSJ$+>#;)%58[R)/HC)A?CXSZG/)@79#'!2H*.V!G(S%PFD
MU"C-(47EDO6O9K/-V@)4J=)*LH%V\KG7?=GQ"O1=I.J+/=>G %K<_9E-(9KB
M0+,YLFO+O7>96V9IOAM5;;*&;^I7HY!;_I6B])#[YAIMH>3G("C0M$X?)@4H
MN2X,KO;5$V=,%['VH\A:@MN%D$%UW4&6/\I'LM.EZG6?UFLEZ:F0FPA7&58-
M!&3N##;/3%$64^,:54B=')+@(EVYMYH+:=41MHZFW(P3#+)HE#;T]GC0NO*P
MDD/YXD[6M -67OBO17GJJL<'H(_F$\&&6-VZ)'IYQJA_(AC?.7 PA<J-[4.R
MW;".KVL:ZAR#J\R"6PQXDBB-O];'T[6:,LJIWL'X#*GF8('E8:YZ0B,<_2B1
M?)[")\)GXJQ?HI&58@L'5B\Z"'^Z]!L&)^)[6X:OTLKRK==3M+0TYWB3G>7^
MX$'YP1/@*-J $<8:<#%I#YG4HQ"6<]VMUUNJX#!":167W;NV AQ3UE"K13R!
M-%1L?S?GP?BLF:N."]JZ:UEE:(DZ.5C(%:D(81QIS,'?UG&%P[<MAA6D^+ON
M;T*D72@%[_6WT$-_;N4!N)ME7T2676Y*$*J(TTF+4F'C=:BV)=/HS!SK-5^5
M_!%GN5A8F?C.L#7B/)MU^+IBS V[P!B)TMVTVV290Q4AGB9C(\-8W?F*X#=T
M :T?@-!W#U(075#+>&1""E4-JE3?V*#1.DWEK *X\\ARL(8%!G]\=AK?:Q<S
MQ+[12<BG[Y!V>MZM?>?E23A10GK+WN)5LMC4)? 8]9>1%BT_2*X(L KHH2@(
M4N[K&;9&/,Z*J4U^JF7Q7^^*,!7C7A\.6!5M*#)8>=J_-\;Q7!1$P&PN5[+,
MX22M<SQ.7F\SKPV:N7/0+\-:4Z#0*8V!5R"X%KP*^OQX1,:=CSR'[)HML<C%
MYH/:!\H(B'4H43$&^2VOE WM^O00C0=:EY9?FH)',C8HPE>0R"YQY^<8 7GR
M)0)R6^C'9U#?VH+QK@@'K@!$=B9N1 .YF'F"5>M,_['VR@:>V+*!H+^BL<C9
M%@4WK$9Z0[%ZMS7I'"BIC:&S8F6Q16/CV98+C%AYRBH*GNUB;\&APC59+L/Z
M(,4JQW7Z7A-330C*Q?<V^ )-601X;@<8[W)*]Y[&QA\808N PS&^BC#B"+Q]
M%TC[8*6"#OV _Q#QO9A79-F$-<U2" %]=; (-HR;>>L&.@\@Q\+KT"2P0%S2
MSV7_M&2I].6ZHRH)\INN6R:Q#ZJ<KK^(@&Z#BM]'A?RWD^0M]CMS79FH30_U
M2I%6R)%8"%M;PR63"@_=4Z'LW$#8(5A^&85[^[XE?Q/=0!Q,DV78N72W0OP(
M D$9,5;U':HEM()C1\!.8?]+@QKJ3+Z+R!ML%SV0\OED&W.X>U=[8Z44D.;<
MK3C!38Z.I&OH.=^TBOB KQK \QF)1'A#F_I&*+?P]NOWO?C+]MQ9,-I+;M.-
M1[2J[<_RH'B9\7Z[,![MO@U!41QSS?O&M9VZG?:V6<3ZQ>\S)MR%V=*V40]I
M%#04C[!WF%B'#<_:P#\(3@QSMPD$3/HGW6E1R<_(:?*>^\L_0%*3W?4-62\#
MQW$_=1/DA#W^J7XZ$OTM3Y:>L(ZUN:C#&_*U, N2)5O9/OV6;^VA/M?7F[7/
MX[+O'8;P3'WL+23+]ONSX:Z&T@0V== _O,YWBZ:3G=&D<JK+-IB.VUE?D@=$
M^O*9\;I E9CRQNZ<RR4(=?4QLP0GZAJ<+D@LV^%UN66RCBVKV<69&"4>;=K8
M:5PG=FE<-\6U#DB9!:NR;W308%D(N9?%+J>WNN]F +"@)XO(! %6C'<']R#>
MULOAB=T7V\SAQ JFQ9X*U2BNH%5*F@JF]R9 RY2H",L;W2C#G ZXH9]M).[I
METC<M>F(PA.P$W?'U!G6OJ*Z4^X.O-%\ H\=+I/_+90>PT7M'J5'1\W=*Z7'
MM5@;'!G'>-3'VA#.\M/2-G3NQMOA;?"#:Y7'V,"8B<@T?3"2BA<$34@Z%X(*
M)&E[^O;)'CK#WH_< 7O(Q]D=!B/&,7*'W8D6=F<^2+V3SFRWUJ"C&+O&K[FC
M;C'(&7%:(G=Q"B3 *548'2SZF)*&>-ON@\'BEB.PF*;>?0M\),Y=1F"W>N>[
M1V I6&ET^W[1RJTC"'H)W6JP,@A.2M BIJN\@%Y7%#B2NHM/=$O1QG!  ]'$
MK>^\3C3Q/IR?EQ@6_'MN_/]LZ:)_=ZHMC*%XY%/LD9 C?-1ZB3=S>;P\A21
MATYIK5Z]8^A]USS!8E,C^(,L10+F*E9C[_*H'.9,7QI6"R!$P\.NVC]) 7<$
MJAI>'5#T*^4NG;\M^L,WCF>RWA!NUQQA6'*.%EEM%XG50)N=@6"-%W&)Q@J(
M1*?Q[")!1@,4V=A=$J>TP,\@/3W0M".T6]CUD%;J9EUI^^:)OWV9#T+N6M>
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MSL"CE@NV(7,P:297T>0NF/6Q[#&8&%#7=CC-0^16WDXTU^FWL76'/$LY=36
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M@88U&!3G;0/Y;,-DWWX)DUT?>K:+>O!$\7H7@+,>^>CV(H  G5,"@8<K5>R
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MDL:8[+5A=9[DCS$&YI*K.A%HP4C7304AGA67W@=$/K@S]M2WE0D^21W=7N6
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M4(@H0V+0K+0#,0)7Y@LC]NNE^>W!K%HNB;)A:4Z)W;,C'N"Q?8^W=]E95I1
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MVUHK *^#"VVR(!3I+X 14*U1>7FH_>D^TW-U4_"BHMP@@O8"RY;LN\<C%B.
M,8:UJ5A/&VN!-?1BJBC.C.#-*4YGG+@< !$0%*WF3DJYV4DVK]8Z F@A9J!U
M@0.KP6 T**NT*V0,:G)?$O7@0*7F))CI@&^8,:H:' WKWX6'!X<4/SMG@&+E
MBGWG']E#0!CG:$@(=AE631IG5$$1,)!P85-D(R.5K5)%F+-\-+*B>CG]M3P
MO&X]7S)]M!S%EMC95,A\2:A>N2>R6=OH@3:VH]MZX%LT"ZFPZM=+WBT6KBZ>
M1VBN2E7Y7)(-;U]P(/WZZS%APF]K5^ZUF*BJ"%3>D:5]Y]\G6EAOB-$!Q]=0
MJO;.3;#8UGZ+29MRHL>CK7D3G![N*9UU&"5H*NZ7@7W#,=SCMR4*+][>)TSV
M.P%NN]WT]]UX\!1H\^[5(_"*3EZ"N3,0=SY9&'-N G!_M(M(&"+V?]?4UR*
MY6*PWKWZ34JX.:>+V(,>^@*PPXJ/QE(^^.X;'N4\NVIXBS+LI]1"J_1\!4)B
M\WT,LX_2(D *KBBD_J1_LGU^34S><:Z6AK#OB.TW\?;2?-_,_,EMS1P-_S*6
M1(+J .C*!+T[^_>-E6>9],5[K<^._&)4E4P-PG5C++2?:1K3FHS^HNWUU+CV
M\()/Y*;$U:-@K*I2*%:?,>3INR\AM-N,))\L=+Z_0 ^?2E6A<A9<.%N7:@1O
M6E<;$'CM200Q"-0#X"0&00AZ8N8_)W*@E0QW3H]RI<5&\GV:G,-DW>R&%[].
M;W2N^X<U'CG#H*KU2SA]$6FPWM!*[#3MN,Z(EGE#MPHX_+$5UEGL?<(39B0Z
M_E#5+K0@Q6AF<^\)#',2$5,=N=IOF]T^'D!M'#HFW6>#N;;#PP?DV+YGH@H^
MR7UCQ$H?EF''>61TC:YR3A<Z/"+&%B'.@GV9@N_%:@0.,>W4P>?>THI7.HFW
MU>RNZNB[/YTR82*VN#8IN9ST0"PEBIL42]70.Q@60D4Y%R<94([2B$\IWI6,
MUYXP1IV&"[@( S3,2<25C[.BGFU6#;9/;&S/</T5$!80%#3+[-9#D1I)"G$\
M,( D)B'0(=<S&$N&/053C"JE(,"D)5<Z\H:BJP<D>K ?$-3W='^Z[N%(-2O3
M)5I^L/=!]2J1TT_=2^+3X)Q7R;VJT+FH4%#EMW6B=U1^*8?U[\\6F&YJLW#"
M"C^U=&7!:"!P=5.5O'59=K8<S&N;'=<H"G_P((W2RIC.VH )LBLJXN&PVGV'
M/'OBV;_* R#C,2T*SM0LP+8:/HB7AGMJTT"5AO+'5\I6S=?4#IQ( ZI-W4X"
MU$[,'R^1REWG3%B]<^?:&2DHRA:,1[[>[;LW4-QZ<<.1L+F+FN]XS3C\I%PR
M"!,:5NE^17BXCN#)AZAA6RZW+TZ8NQ_[R^7M1BR-ZB=%=T;=L?;PPF3>FU,7
M9T+I6&5_4@$[4AKQ$^<V-P;O!XH(<\*-10JL"+D+0&H #F8-H C_[#QAUE\X
MZ<F_-U6]62FZ#Y;)%0JR&F27KA[EMS,^_],[O-AR>"P8WD7SZ3P(3-7.8)I*
M\M"(,0(!AS JB"?T8E]BSK/)EW2!2S"H6A>E!(_-[6<GCH=),4%=2S0Z>"SR
M(&Y/0.BT =,-M5/>H4.J=O D9\M?=\TVO",'TY!VF7!\1<4(%+F_M9@[V)$;
M$$-036 \2;8:ZPUH5)VQ9&=U+GIZ/%+D&KS6MO^G7LN:"+2*O/F,HUY__1+U
MNOV O]<U^_GKMV].[5C/BS9_U*RS6?YC65W6V?JK%V^J\M&QT.4]_QH^;D8^
MD/'?)\^O03WA1>=Q6 &J*Y\KWCX/ ^.2670XE![B\VTM0/;?2NB+3K6&<KA2
MI\8]0KP:M&PC=0SY/-#+UOPS2KB"$@H<!ZN*PDN/2^X-52# ?"W(!]<H^**M
M)I</$8@ QF5A,*1,^[+HX64--HAEGTZ$?'I'5+I[A7E\G;LB#ZH[9Z5XGA=X
M\2'->"5L(8IE@$$M:E4>FMG\O6<VGY3-I@;9W<:^AI)F7+'9.1BBQ)%"'9C,
M@O$S?%:R[FW9@99LA6[$P";7A7<Z5-LU$",V.0.SDHY2Q$)5:Y1=>&\-("UM
M'MQ!W#AGB][LI@T$28X7-!/;()T1_+'#%AE,W5RHF#3'R!1Z!%C([ ';O$'K
MB;B)NGX%(?O0IX31?\K>YN^A[(*GUQ'^DQ &0_59 Q.WIB,2TEI'_,)<B<8)
M+Y9HLE*-7,GAA$P:RV'ZE-!9E\:7:RH8VH_.6X!EQP>AD."3\%_8ZT>>Y34N
MJO,5-ZH;'O7!%N959-7%!N(*&Y35YE+)UN<(9EBB(PAJF5_(L2;J'6OQ0$M7
MF[%M2;@,AJUKJ@C<[PD:>,0'[9(;)B":@3SZ8K7.".1)O2=P.:VOI%@!<JP(
M1;S%NFJP'V#:<Q3&HWT7EYMK[;G"R4T6V$>_F6L+*+.!O0"O5.3W9NI+7@0P
M#LSDS0DK%F0CL#=B!P ILN5\AW??*Q3$[Z+]:]',\N4R*_-JTS7U7E>U]#..
MG9P?QR-[/+'F.<? "+CGUT,Q!KYCY 82ZP1DBCB(A3AGG]I .ELKFA?W#).+
ME6J$&GDN^'*I;T11L3@_?5>^'A6!N,E2]50-[;U2N[%4Q!;*3'WK2G6?O<<R
MS2PD1QE.N[ PZ!M\L)19CG.M%MHR;@HU'HW*F/!"XPZ)LC@5D]4D[,%(#LP.
MV@[QVA74+HSC2X\6^>UB(+$5U_@/2+RIZ8N^;\QHLS.)WTYM;T+E%)%G0JD)
M+GGA7V*\!;Y.. %@OR)!6.5"9P\C.(.P/FKR*?>G)<G!P?#MEX.V7S:N!RU=
M[\(13*]9B>-"H]/I0GJ8;4N[ &;?9BO1ND2%F-2+FFW2A20D7\F!"AWA=X%!
ME_P!.W7\)TS039SL9ORX,BNIV<K59QS"^?Y+".<3T%#>&P_EKR?O7Q[_\LO1
MF^.WO[^_;Q;*K6T)?Z;.#>;PO:/>Q_W(5LAO<4N+VG9*%A<^CA*5?O7<SQBS
M68VM^YMN&N STDH%?T]4J<M\?@;^M>VBP9VMF5ZU*#<MM]A()8;U 9#4?,%"
M]B'/T*ZFG^WEA?3<U 8/<@+P(\?NC78VA\=<1'C3H]8U&FZ^:]D]7DBRG@"'
MH24R=C$.;):5;#!?D,=O5JXRQGF.C9Z-M8MMPM?96BC$&<*::5 6A/[[^DTT
ME3R<PG?A7LE , <8F$LJU*)SP<:17UM\O#PG3*?[?+_CT6#7J"H> ]B?P><^
ML!" BU1@+,RV;:S/C'6>KNT?7? #AC289KKMW;D9K\WBZ4- "(-\C>SY>$]^
M@) F9+$R0/OF97+PV ,X<]E%CBTO![J9I)3.PVH"<ZDZB\Z+\&J)P! PH8_A
M*%+G@3DV(<Z6Z_-L:MXUP[M]+KS7C3DJPE?-S8$PQHW.JWN/S=)T6O<HEGY)
M:KNOZ4:1.YS40L(;V.<'&_LL*I<GDW$.SY\.^W@D*VLLOT6.03%(7_;O!QI>
M_)TY5E[#;W#=21",?;I$(W_[$%P7!?,WXU^A"HR^Y3!Y4U$M,H< 5#JAV4P;
M-ORLBR5#(?+J+MI%F%>-?,%@ZZHL9G 1+'7K)\O8ZCZ";T=&):=SJU+BA$W+
M"56U'("W6>>E*UG)0J(IKPF01,+8ZS;&*#3[M)%X61/\&&B[HL+TY-!!TH5<
M=K]_=("^RM//4!^#S?<0/^MF7N;M955_2$/Q=/>&7A-=.PRQ5'ZHS=SC A4J
M-^2:7E$C'Q8,'FWJ%VO,-S5AG<Q]"YI*;N'D'"[G5%QI,_$2/+KE>(1-.^&A
M]J.Q<L%8+Q-)/N/8D6'?RGMV802&NA^5Z-!&5BM\'ESS+3Q%78A&+ZP;0E@U
MF'6QB#Z]I(#"4"^D*JAM;9W,3>8M)#R%W& ,51&K'JR-J@GQA=?LT'PSX]ZZ
M>/?J##[\TJZM=VAIB^!7A+IW)1_2OE>ZU=']S-ZF?QXD9\( 'KM#\=DTYCW@
M[U^!E)/=A-SW;8YXCTUIT8FQN6;+IMKOM/9,,EB)@>-EI42NC;XCQ*>GZ>H6
M[P"1I1H]061P>3>R9P.@0.D.GSB<.<<&MMVHM$ZYUH/W0!XTFR3<E,ZO#XSW
MIY.&GSNU#;6?4V9@#SZ$212LXB"4(XE_9?L%X<6"S'A <[)<FOM]GE*M-7*C
ME"3]6:LH49*PF4=H9*7B3+"9RXE9<CKBH26^;NA/J[1[:?'Q5-!F3PIL6VO]
M6ZZLD&)R(7+!9D4< 21%<)C$N@A:F99=ZAB3GT!TNVMI?2&UGE4=+J='7__0
MTMP> >$?U(2(^HS!9KQ%(?Q9;D3$BA9]+<C\SN+CD6WQ#<OD=1#O=A47(?.]
M"?O/:%?VSS86]L.76-BU>;!\Z&5<P;)-%>]T+[ZY:W0/5@9X&V$C+-L%J_*;
MR 4IEY)Q.^!-<+LL,'FHJQ.8E_/<1A'&(^P;B@%B"<[(ESL-NZUS 2TTKUPZ
M0EJY=N-0F@_(+V.F7UK3EC0?W?BN0111(%KF",%,\3+,$Z[S$2-,=7]/PD:C
M8;/.\4BW!Q0>>-N1%)*(B+= 1X6J[[CI..Z?,OW46^]3E[K&U;^_8!DC"U!V
M)(<0$22-D=4<-.:AC9/>Y9"A)/4T;H<0P7](O.;,$C(.(3A(V1,Y>G03XK^A
M$[53US;GJ3!Q2B[H7]3=CO<UQ>?@I[F]/-,T\2*"<<%KB!67U6SC&KU7^&7*
M5MDO0(0D#B-@#@H$6 ^8$AC,(29,NZVUZEQE+8MI0;Q2$&GL\$+=O6Q"W.[W
ML"6A@):1>WLGF+1&)G6M870^EI:1A]JX=4Q&LZ9 G5$1E1N4S<SS?,X-Q+#7
MS:JJVS-S;S5*Z5H+C=J0FF68FH/?XXKK[\6DI='BTO!$Q!5S7VB0DL/5$+.V
M(;'DLB 63*=SSS,@"BLQ[6=7<?#2V<D&P@"PQ%;UXUX;![-$I*CWN%-P&8U$
MUM9\.FJ @0B"UEZ,UOW:?N4P.3(SIN73BX;G/+)JF5LS8\C;LR#5P4/+J^X1
MTN0 +@ SI8$*;8*]JURQ8/)+AP7LT2,*MZ\DN^M+#<JZMR_W@,0#EQ2V8G:>
MSSA'-:^S!:CD.KO$T.$T*S^H6.,\QW0Z@PZ &Z2<-Y9"T1S6(HK3X(4&?8#-
M(/I=E+V/PVXRZ@NH+[SW)@((\KUC/3V_ SU-L0V^OVC[.$@Z'O$&"@I_E_O6
MGF'!!9J98#\'+#E:9+/&7+1+0@<?^*$5K[=/T!"(KEI+8<\8/_.)@ON2(I'7
M? -V<83C%0:%224C/HS$ZVS]!(-]*NYJE==#\\0]3L77QAXS9^E?>59'G>T%
M_?TJSZ))-]>V@[KOJD_S.D8D*GILS-)7RXUZJ!7.A[9^WWJ _;]CH^BOWV"6
MK5O%VD!/64FT!1&[5=;,-DLS0V/NY)@M(\$N\PTP$9WEI4WZD2%<4MZ?(MT;
M2.]2<D\,"\P!2C8)XU&HS2"4EPM;$7;_^-B"5P1F)?9.?7# \.]\8#C%_$XA
M4!8/"6$,S5IOG()KY-C;G_$,(R65T3Y<)X"%"-R7!H/T#&GC&F!;A0+6!UJC
MU9+X]Q:2680 /]>[,WS70K]</%,12ZMDO80>/]<(T]-OOD28[N1 >#5TQ^Z2
M.84NQ<P>&(-,CT<^9EJK(.H\H6ZL5CV,VD\PZ ?$F'$^8?H*C@6A';')$L!P
MQ3I?GU\U"%[0SX5'("B'43[$(])@7@HQ!/A;M@+ LRC0'#3_JA$Y*[V_+XK\
M4E"AYIO%&ON&ZZ0>M\83JTW&6.<VC8C46Q8?)!:@_SRDYT"BAHW99PP'HJW0
M#/:%OO\ZLB/A@XSI2Q] Y"5=>+FR)0)$4N*59(.<B"5E#THS,'J*?(F*M"W"
M35JGE&#!T??I_@H0-'&;D[\M?D3/=\8C]Z5B$>0;@3$!X<TX&_'F'5&FG9+P
M#ELPAQ2ON^<1:4PX&-4YS9_M $@H.6AZFBD]QFY*4M-P<A(>V8E;%V-OQ1=F
M2Q;>+=)\_U5"*EH/\N(]VT*'MBQ:4/!Z$!CG/N%E9T4P"N26Y-"U!N"H<KN-
MXQ^W:=M<.]K2 KT_\"3@,?8,I-&,9!?ZH[G?-<N$VC'0J)J\05@?;!3H@I)G
M%,<&=8: !.?#8;L]BJ16FU;FK<+^H4S$ 6E"6LUG/*H1-'^*-_-=U A\D2/]
M@V$3/Z%KZP9B[ 4(PO($Z'O7TX%FXK:;N(S=NGD3(. +.<MY(^N>RQ\D<%'F
M<!6 F$DE -ZG?-'-_4R\%)?S8H1KT:/7'MH]XQ5M#D$5^IMXQ$\J=GOPCVH1
MEGV&^L<>4%!.'6IT-LD7QM%O&_I-IFM(%SO +8+"OD O.$EH-A JRN?J'.KA
M: +W\*UXLKW7!J@1)V7=>L!@?-VG=^;T&;L;C[^X&W=3U/ -GECZH?N_YG.O
M@5%(3K=5"$CN,1[Q' :W%M?R;U_]US?F_Q8+,Z#?9>I3!#O+5!\;X9M7F^DR
MA_V:@UY0?\*T(RD:9 H1J?SY!4<^P[L.CB2F'-C*8T(Y"ALHU0U7+UQ>)=W5
M"R)0HJ=M:HQGOCP'CH5:X=5#4#UT8F EQFSQQ6+P&5U<?K+,(%PO]A$'*O[<
MU$4SESZO^,4-(G!K]^CHX](D,B+D$=ES6!9LM>.+<1[;I_%[B05I^/7&6 *-
M<?O,Y^G9<L7:7ZOG<V]N1$7"J^W*VT P!-GF4!,QP>Z%2R#F)T(XLG<P*HGJ
MW&M!KXO-581Y/"*KCW/4@+C$ZG]+&(,2@T,^\#AO!@Y%>(3=(5DLX)B80_+^
M]-W)?Q^_R)Y_S?]BN=_U%=<_9P6<L@GY'N9KQ04=C&PFUV1!]K-JB2'<ED.P
M%N,O[CF%W5=I&E^E7?13_TMNJJ^*0JFKW;?-]HOH76VB/N$<*G>12N!R0QS+
M>+0HYALH(;[B(AL)GYC'WMH.W'1QN.F28T>\UEHY.AN+$TEO;XZAE-E\Z?7/
MI)1R/R Q1>E2'M'U-B)6QE_%,L9A:MAQZRB?[,&(*0?-F#NK>_"P)*;@7G#F
M5IKF;>L1A?0>RVLMLQ'S3Z=$9]<5ZT^I0K4.-6;V[EI4"+/W5:5]K4!8$B)$
M5@Y5:0DH(IA.)I=2-:!T\")4Q]+2!93:U/@-#C5? ],#4T*E(4\2O?35WU_^
M(B&L(=_0?J9[%-GA/8 <>(8L6<!!YW 1$M7H9L;#._YFFBT4T/D#%-"+SCG>
MR2G:Z99WM(-V8ZE]8>/9TXY:>U>;GD ;GTZ3Y)]RHUYTEWSG!1^/]E,&#T;.
M!K028&T[UI1B3=$(6M%037CI-]>[]8E/10?"T)%>"NT)H'V, U<2!PRR2&)+
M194$H+B@D5S1/N<9YA4)CH6MZ[6H"[@!$ T-<'UF5/Q/',V U(5,/S@NT$@%
M>7442V_\H9W^MUP&&;[!DKIP: '+RZ-/Y-A<US>NF#"(Z,DQC_= )(QY]_3Y
M"(X'NK^^6U\M6$$5C6T<!I^:56M7%+4R>P(=BI=P6^6SG-O;0, ,T!=0 UXL
MA;*(W/2*<P59Z>2CZ5U5R$1RCOMU5>< X*;^TY3:GL@7$<<=JW^F[)6JL>SC
M5N*-I]\<?%0D@3WB*JDZ[* !F6J.3&R;4JQ5L3)$Q=_VN"PIP.'L"$[Y!701
MT>U([&X@Z],53XR/HE!X50O)B%,ZR/52]XQWX9:6P\7M96<]7W"'RG**PSC]
MG43T#G)Z+>0(J4<<7D][R3<^,=?- SC<"L@?W"#CT0WCI%OC9PX]*K(_EZ@>
M'P*63#\B"-E@<Y$9X]4OO(S%W>#W"E5H$:CFM@.:'?]B1TY'\,?$J6/+W/&L
MOL_-?8I5B2!]\+C'/SQ]BA8PF[XW%[@]LWS7D+?[C2H "/V-G^0C&3#'^JS"
ME%],/X5)W<??:%@ L%.IQL;K-?,1;) 5J9;&;X!'=JZ4HSP#]#$$Q B)9(T6
MM=W''V?GP,NB]OV9WG>+HG'>OS/0 ]4>E6J\19P(Z\OBBQ+;)E+S280=6-A?
M=Q(;CR2XPYG:I0C.N/."-+U6Y0)2Z5U[#5KZ286)_V$_A=EE'DZZQ,.84_9S
MPP2=4)6;>H28#]J!JWC+@EZ'O]A:&3N^8Y!YEXEO=]W*_9B-(\R] L[F/)/'
M^>CDT3Q.%Y8T5E2D_L!OY[,/6S+BH8 N^6'?/L=O7B5O7R<__^N7HW^^_WP!
M"$^& 0C/O_[Y[:M_F5_^X_377U[\_U!+ P04    " "A,TM5!<N3'/$D   S
MF@  $0   &0S-#4T-3=D97@Y.3$N:'1M[7UI4]M*NO!WJO@/7<R<J:1>VV$)
M$+)09< )S+!=["1S[C=9:MM](JM]M ">7_\^2W>K)<M 0D+=>RY3-8=8EEI/
M/_WLF]\?#\Y.]]\?][I'^ZLK[P<G@]/>?N_?[;V]SL;[5_P1KK\R-XCW!Q='
MOXN#3X<7IQ=7']:^'I\,>FO[8G4%;CJ422[3_?=')U]$?_#[:>_#VHV*\LG;
M-YUME:R)(%;CY,-:+$?Y&JUU:6^;!NE8)>U<S]ZNS_)WPGP>ZCS74[XTTDG>
MSM1_Y-N-\O,HF*IX_G:@IC(3Y_)&7.EI &_JGIY\.O^PEJKQ!%[U_F"_=SM1
M0Y4+W)9X_^I@__VKRWT/ &_U35B]!L\".&O[_TB&V>P=KD);'W0/3GOBL'=Z
MVK_L'IZ<?_JPMKY&GR^[1T?V\]>3H\'QA[6-]?7?UL3!Q=51[XJN&R#X2AM0
M>]J][/?>VG_<N=DZ9MSF0SJ--8)/((A7^^8?1Q:0K>W? #NO!D?E-U_,T[S7
M$F1[8VV!S<<NX*[#?ZX\6"U.9L%8MH>I#+ZU59*I2+X-KK6*Q/?A9+\&'!PL
M(P8NGYQ]$OVKPP]KXZW7VZ^W=\<;ZQL;Z]OKFYM;N[L;G3]F8T3IX,/:Z<6G
MBS5BAG(;M=T:LK#$L7@?O?C1"]P/^=[N]C+(#:+A#]+L?C,7;KQ9PH:YO,WA
M)"(@KK>O?_L^MD1&O$CSB1ZI6Q$DD>C+H#]3B12Y%H=Z.L1_JD2<R70L4Z%'
MHO=G$<09?0TDD$MQ*H-()6/Q*=;#(!;\-"Y%Z\YDI,(,EYH%R1SW> >C[WPG
MGPO'YC^773TY4)<7=7GBRX]]PR=9/H^E^""6<<I:C>->_U9N:H$=X<L*I5E9
MPB+['W_;>+W7]-A&[;&&%_@+5>_%PZE\:] KJH<CEFN%APJ!]R?[QZ 1XKD(
M@4)B.04B#M*YR!P5:8^*9O!AI&.EL_>O3@!*((&2?RSWP.:>2>N9M)"T+H"&
M0&3E$Y1A49'EZ1QWM?,N$\-4!Y',<C%4.M9CI"ZDME2.92+3(%?7( )E.$GP
MVSFL,I(I2+EGPGLFO <0WI%">@%9ID!#1D19V1SH:JRR7(5")L$P1IWI*$S)
M9\IZIJP'4-:9#!*@G%$1BS#56=;.9$RDE,IKF132TIED>19J$'%9</TLNIX)
M[&$$]E$E01(JL.1!7<IDG$_0UI\5:0;$-4[U#5Q0R36H3K35,G&CP#XK<I%(
M$'0CG0HUG8*UAIZ!_+-0^5R,>$6@4:1 = &:2/#9(7BF0*; WNU,AJ@V@>Z&
MX 1$?X#E!A][!R>#HZX(PC"5;)]IX7S7X9S,O$R&&L3>7 8I+!W'^@;I+HQU
MAB9@&!?DJOI2$>EQJ5Q\)LIGHF2BY  &JE6@N@G2SQ]:)3F04D*67BA%&,0Q
M*=T;.0P#N"/743 702[>O%U?%T%GVA&]P0.UL!_XV?P)\5<,])S*&Y5=JSB6
M+3&0MP&;"(=!&F?#(&K!OV(%$CQ1@8 3V]YX)R["7 ]E2D$;C-O0'SZCC8V6
MV%S?W#2WXG<E-[XX[_:/NO_U5EQ\//GWRY8(Q)BC0Z@: $\BDM<*46;#0JA%
MX*YFMW^DPR)K5<-3[@W]R_->TQL\Y\V\A=<!0:(3D16 3;PMTW&1*YUDI+M0
MA.08UD+=AJXC H3@JDRGD4P!"G.H2:(+./0('YF+20#BB(*[< 7(0@,\D03%
MITA0!>-44F@#B2<LHVI!(MY_O#@? *G;X/Q$Y;*=S8)0ODWT31H G0-9M;-<
MA]_>O\*;]V&+-A@G*1C7$;6(VD\GGL%$6K@CB\Z6D<]) "@7LU0A_K1!89!D
M08AXM?XVBF 0MRVP%X!+4*ROKL0F<FA.KOGP[>$1A4R:8D5E5 A1XOSY%F X
MT=?LRIMSG 1I=!.D0/]#G3AS!D &1 -OM^ ^B;8/H,6'PJ,2!"\0%G)'1@DH
MDW& MX !#MH*6/TK CQ+=52$8"8!!>6I&A:@R%97X.AWWL NB@2N :9O=!I'
M[1L0O4#(,WCF5DW!@(*=;K1V0'1(V*Z>2VE?;Q!V]8]@.GMW1!?AF(H1H+S
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MX#%PY22IO1!\[31H#\D6\64M>8#A! Z]?:W('@WBL4X!M&EF=JYR]'D?LW=
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M#\NA$8=V:,17,S3B"0ZY>> G2IW5%1IM$?SH< OJ@E49,!.;F]S$^%3S":K
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M;6[7=BRP=U^C^8Y[>MW 9A9:3";R;QO8,=8\?N'/0J6RN?BA#%[7]_K"C6\
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MP]).U/WDI?W['O+?$K]5W'I(\G!TW#OY=#R $]NIGIAW'5Q+I', :?,[[FF
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MYY=7G\"#>9(LY6@P>'Q\[$?WE$D>KQ(E*?LA7PS \XKX\>0+_):E&\%G$I-
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MP+O MEBZD6/K^C$FX\]D1O4[0I9\"A;61)O7=CH75QCAU3'N4[%)#W<H?LH
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MFWF&4V_Y&U!+ 0(4 Q0    ( *$S2U6$4?D#%BD  +_3   .
M  "  0    !D,S0U-#4W9#AK+FAT;5!+ 0(4 Q0    ( *$S2U7-NHJ:H'L!
M -G0"  0              "  4(I  !D,S0U-#4W9&5X,C$N:'1M4$L! A0#
M%     @ H3-+5:ZWXM\+<0  ;%P" !               ( !$*4! &0S-#4T
M-3=D97@S,2YH=&U02P$"% ,4    " "A,TM5!<N3'/$D   SF@  $0
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7;%!+!08     !P ' +P!  "<2@(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
